PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bieri, C; Ernst, OP; Heyse, S; Hofmann, KP; Vogel, H				Bieri, C; Ernst, OP; Heyse, S; Hofmann, KP; Vogel, H			Micropatterned immobilization of a G protein-coupled receptor and direct detection of G protein activation	NATURE BIOTECHNOLOGY			English	Article						G protein-coupled receptors; chip-based functional real-time assays; micropatterning	SUPPORTED MEMBRANES; LIGHT-SCATTERING; ALPHA-SUBUNIT; RHODOPSIN; TRANSDUCIN; GOLD	G protein-coupled receptors (GPCRs) constitute an abundant family of membrane receptors of high pharmacological interest. Cell-based assays are the predominant means of assessing GPCR activation, but are limited by their inherent complexity. Functional molecular assays that directly and specifically report G protein activation by receptors could offer substantial advantages. We present an approach to immobilize receptors stably and with defined orientation to substrates. By surface plasmon resonance (SPR), we were able to follow ligand binding, G protein activation, and receptor deactivation of a representative GPCR, bovine rhodopsin. Microcontact printing was used to produce micrometer-sized patterns with high contrast in receptor activity. These patterns can be used for local referencing to enhance the sensitivity of chip-based assays. The immobilized receptor was stable both for hours and during several activation cycles. A ligand dose-response curve with the photoactivatable agonist 11-cis-retinal showed a half-maximal signal at 120 nM. Our findings may be useful to develop novel assay formats for GPCRs based on receptor immobilization to solid supports, particularly to sensor surfaces.	Swiss Fed Inst Technol, Inst Phys Chem, Lab Phys Chem Polymers & Membranes, CH-1015 Lausanne, Switzerland; Humboldt Univ, Klinikum Charite, Inst Med Phys & Biophys, Berlin, Germany	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Vogel, H (corresponding author), Swiss Fed Inst Technol, Inst Phys Chem, Lab Phys Chem Polymers & Membranes, CH-1015 Lausanne, Switzerland.							ANTONNY B, 1993, BIOCHEMISTRY-US, V32, P8646, DOI 10.1021/bi00084a036; ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; Bain C. D., 1989, ANGEW CHEM, V101, P522; BRUCKERT F, 1988, EUR BIOPHYS J BIOPHY, V16, P207; Delamarche E, 1998, J PHYS CHEM B, V102, P3324, DOI 10.1021/jp980556x; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Fivash M, 1998, CURR OPIN BIOTECH, V9, P97, DOI 10.1016/S0958-1669(98)80091-8; Freissmuth M, 1999, TRENDS PHARMACOL SCI, V20, P237, DOI 10.1016/S0165-6147(99)01337-1; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; Hermanson G.T., 1992, IMMOBILIZED AFFINITY; Heyse S, 1998, BIOCHEMISTRY-US, V37, P507, DOI 10.1021/bi971564r; Hovius R, 1999, J RECEPT SIGNAL TR R, V19, P533, DOI 10.3109/10799899909036670; KUHN H, 1981, CURR TOP MEMBR TRANS, V15, P171; LANG H, 1994, LANGMUIR, V10, P197, DOI 10.1021/la00013a029; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; O'SHANNESSY D J, 1985, Journal of Applied Biochemistry, V7, P347; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P240; REMMERS AE, 1994, J BIOL CHEM, V269, P13771; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; SPINKE J, 1993, J CHEM PHYS, V99, P7012, DOI 10.1063/1.465447; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G	26	236	269	1	50	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1105	1108		10.1038/15090	http://dx.doi.org/10.1038/15090			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545918				2022-12-27	WOS:000083428000029
J	Fu, AY; Spence, C; Scherer, A; Arnold, FH; Quake, SR				Fu, AY; Spence, C; Scherer, A; Arnold, FH; Quake, SR			A microfabricated fluorescence-activated cell sorter	NATURE BIOTECHNOLOGY			English	Article						microchips; cell sorting; disposable chip; flow cytometry	CHIP	We have demonstrated a disposable microfabricated fluorescence-activated cell sorter (mu FACS) for sorting various biological entities. Compared with conventional FAGS machines, the mu FACS provides higher sensitivity, no cross-contamination, and lower cost. We have used mu FACS chips to obtain substantial enrichment of micron-sized fluorescent bead populations of differing colors. Furthermore, we have separated Escherichia coli cells expressing green fluorescent protein from a background of nonfluorescent E. coli cells and shown that the bacteria are viable after extraction from the sorting device. These sorters can function as stand-alone devices or as components of an integrated microanalytical chip.	CALTECH, Dept Appl Phys, Pasadena, CA 91125 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Quake, SR (corresponding author), CALTECH, Dept Appl Phys, Pasadena, CA 91125 USA.	quake@caltech.edu		Arnold, Frances H./0000-0002-4027-364X				BRODY JP, 1998, Patent No. 656155; Carlson RH, 1997, PHYS REV LETT, V79, P2149, DOI 10.1103/PhysRevLett.79.2149; Chou HP, 1999, P NATL ACAD SCI USA, V96, P11, DOI 10.1073/pnas.96.1.11; Coulter W.H, 1949, U.S. Patent, Patent No. [2,656,508, 2656508]; CROSLANDTAYLOR PJ, 1953, NATURE, V171, P37, DOI 10.1038/171037b0; Fiedler S, 1998, ANAL CHEM, V70, P1909, DOI 10.1021/ac971063b; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; FULWYLER MJ, 1965, SCIENCE, V150, P910, DOI 10.1126/science.150.3698.910; HARRISON DJ, 1993, SCIENCE, V261, P895, DOI 10.1126/science.261.5123.895; KAMENTSKY LA, 1965, SCIENCE, V150, P630, DOI 10.1126/science.150.3696.630; Kopp MU, 1998, SCIENCE, V280, P1046, DOI 10.1126/science.280.5366.1046; Li PCH, 1997, ANAL CHEM, V69, P1564, DOI 10.1021/ac9606564; Melamed M. R., 1990, FLOW CYTOMETRY SORTI; Shapiro H. M., 1995, PRACTICAL FLOW CYTOM; SWEET RG, 1965, REV SCI INSTRUM, V36, P131, DOI 10.1063/1.1719502; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G	16	767	1040	9	199	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1109	1111		10.1038/15095	http://dx.doi.org/10.1038/15095			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545919	Green Published			2022-12-27	WOS:000083428000030
J	Kent, A; Tambuyzer, E				Kent, A; Tambuyzer, E			Partnerships between patients, medicine, and the biotechnology industry	NATURE BIOTECHNOLOGY			English	Editorial Material									Genzyme Corp, Louvain, Belgium	Sanofi-Aventis									0	1	1	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					935	935		10.1038/13588	http://dx.doi.org/10.1038/13588			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biotechnology & Applied Microbiology	243UM	10504676	Bronze			2022-12-27	WOS:000083015700004
J	Ronn, LCB; Olsen, M; Ostergaard, S; Kiselyov, V; Berezin, V; Mortensen, MT; Lerche, MH; Jensen, PH; Soroka, V; Saffells, JL; Doherty, P; Poulsen, FM; Bock, E; Holm, A				Ronn, LCB; Olsen, M; Ostergaard, S; Kiselyov, V; Berezin, V; Mortensen, MT; Lerche, MH; Jensen, PH; Soroka, V; Saffells, JL; Doherty, P; Poulsen, FM; Bock, E; Holm, A			Identification of a neuritogenic ligand of the neural cell adhesion molecule using a combinatorial library of synthetic peptides	NATURE BIOTECHNOLOGY			English	Article						cell adhesion; combinatorial chemistry; drug discovery; neural cell adhesion molecule; neurite outgrowth; nuclear magnetic resonance spectroscopy; surface plasmon resonance; synthetic peptide	LONG-TERM POTENTIATION; N-CAM; NEURITE OUTGROWTH; NCAM; BINDING; FGF; RECEPTOR; RAT; PROLIFERATION; SPECTROSCOPY	The neural cell adhesion molecule (NCAM) plays a key role in neural development, regeneration, and learning. In this study, we identified a synthetic peptide-ligand of the NCAM Ig1 module by combinatorial chemistry and showed it could modulate NCAM-mediated cell adhesion and signal transduction with high potency. In cultures of dissociated neurons, this peptide, termed C3, stimulated neurite outgrowth by activating a signaling pathway identical to that activated by homophilic NCAM binding. A similar effect was shown for the NCAM Ig2 module, the endogenous ligand of NCAM Ig1, By nuclear magnetic resonance spectroscopy, the C3 binding site in the NCAM Ig1 module was mapped and shown to be different from the binding site of the NCAM Ig2 module. The C3 peptide may prove useful as a lead in development of therapies for neurodegenerative disorders, and the C3 binding site of NCAM Ig1 may represent a target for discovery of nonpeptide drugs.	Univ Copenhagen, Panum Inst 6 2, Inst Mol Pathol, Prot Lab, DK-2200 Copenhagen N, Denmark; Royal Vet & Agr Univ, Dept Chem, DK-1871 Frederiksberg, Denmark; Univ Copenhagen, Inst Mol Biol, Dept Prot Chem, DK-1353 Copenhagen, Denmark; Carlsberg Lab, Dept Chem, DK-2500 Valby, Denmark; Guys Hosp, GKT Sch Med, Dept Expt Pathol, London SE1 9RT, England	University of Copenhagen; University of Copenhagen; University of Copenhagen; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Ronn, LCB (corresponding author), Univ Copenhagen, Panum Inst 6 2, Inst Mol Pathol, Prot Lab, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.		Poulsen, Flemming M/E-6848-2010; Kiselyov, Vladislav/D-2273-2009; Doherty, Patrick/A-8752-2008; Ostergaard, Soren/B-8123-2019; Lerche, Mathilde Hauge/J-5487-2017	Ostergaard, Soren/0000-0002-9415-3352; Lerche, Mathilde Hauge/0000-0002-5899-2781				Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; COVAULT J, 1985, P NATL ACAD SCI USA, V82, P4544, DOI 10.1073/pnas.82.13.4544; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; DOYLE E, 1992, J NEUROSCI RES, V31, P513, DOI 10.1002/jnr.490310315; EDVARDSEN K, 1994, INT J CANCER, V58, P116, DOI 10.1002/ijc.2910580119; Fields RD, 1996, TRENDS NEUROSCI, V19, P473, DOI 10.1016/S0166-2236(96)30013-1; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; GEGELASHVILI G, 1996, TREATISE BIOMEMBRANE, V3, P33; Jensen PH, 1999, NAT STRUCT BIOL, V6, P486; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; Kiselyov VV, 1997, J BIOL CHEM, V272, P10125; KJAER M, 1994, METHODS ENZYMOL, V239, P288; Krushel LA, 1998, P NATL ACAD SCI USA, V95, P2592, DOI 10.1073/pnas.95.5.2592; KUMAR A, 1981, J AM CHEM SOC, V103, P3654, DOI 10.1021/ja00403a008; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; Maar TE, 1997, J NEUROSCI RES, V47, P163; MORAN N, 1988, FEBS LETT, V242, P121, DOI 10.1016/0014-5793(88)80998-0; OLSEN M, 1995, INT J DEV NEUROSCI, V13, P97, DOI 10.1016/0736-5748(95)00003-Y; OSTERGAARD S, 1995, FEBS LETT, V362, P306, DOI 10.1016/0014-5793(95)00262-8; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PROBSTMEIER R, 1989, J NEUROCHEM, V53, P1794, DOI 10.1111/j.1471-4159.1989.tb09245.x; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; RAO Y, 1994, J BIOL CHEM, V269, P27540; Ronn LCB, 1998, EXP GERONTOL, V33, P853, DOI 10.1016/S0531-5565(98)00040-0; RONN LCB, 1995, BRAIN RES, V677, P145, DOI 10.1016/0006-8993(95)00147-I; SCHOLEY AB, 1993, NEUROSCIENCE, V55, P499, DOI 10.1016/0306-4522(93)90519-L; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SPORNS O, 1995, P NATL ACAD SCI USA, V92, P542, DOI 10.1073/pnas.92.2.542; THIERY JP, 1977, J BIOL CHEM, V252, P6841; Thomsen NK, 1996, NAT STRUCT BIOL, V3, P581, DOI 10.1038/nsb0796-581; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WILLIAMS EJ, 1994, DEVELOPMENT, V120, P1685; WILLIAMS EJ, 1994, J CELL BIOL, V124, P1029, DOI 10.1083/jcb.124.6.1029; WILLIAMS EJ, 1995, J CELL SCI, V108, P3523; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458	41	119	124	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1000	1005		10.1038/13697	http://dx.doi.org/10.1038/13697			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504702				2022-12-27	WOS:000083015700027
J	Francisco, M				Francisco, M			Internet - Clinical trials	NATURE BIOTECHNOLOGY			English	Editorial Material																		Francisco M, 1998, NAT BIOTECHNOL, V16, P388, DOI 10.1038/nbt0498-388	1	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					202	202		10.1038/6211	http://dx.doi.org/10.1038/6211			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052361	Bronze			2022-12-27	WOS:000078508300033
J	Harper, BK; Mabon, SA; Leffel, SM; Halfhill, MD; Richards, HA; Moyer, KA; Stewart, CN				Harper, BK; Mabon, SA; Leffel, SM; Halfhill, MD; Richards, HA; Moyer, KA; Stewart, CN			Green fluorescent protein as a marker for expression of a second gene in transgenic plants	NATURE BIOTECHNOLOGY			English	Article						green fluorescent protein; transgene presence/expression; transgenic plants; Bacillus thuringiensis cry1Ac	THURINGIENSIS CRYLAC GENE; IN-VIVO; CELLS; HYBRIDIZATION; TRANSFORMATION; TOBACCO; CROPS	The use of transgenic crops has generated concerns about transgene movement to unintended hosts and the associated ecological consequences. Moreover, the in-field monitoring of transgene expression is of practical concern (e.g., the underexpression of an herbicide tolerance gene in crop plants that are due to be sprayed with herbicide). A solution to these potential problems is to monitor the presence and expression of an agronomically important gene by linking it to a marker gene, such as GFP. Here we show that GFP fluorescence can indicate expression of the Bacillus thuringiensus cry1Ac gene when co-introduced into tobacco and oilseed rape, as demonstrated by insect bioassays and western blot analysis. Furthermore we conducted two seasons of field experiments to characterize the performance of three different GFP genes in transgenic tobacco. The best gene tested was mGFP5er, a mutagenized GFP gene that is targeted to the endoplasmic reticulum. We also demonstrated that host plants synthesizing GFP in the field suffered no fitness costs.	Univ N Carolina, Dept Biol, Greensboro, NC 27402 USA	University of North Carolina; University of North Carolina Greensboro	Stewart, CN (corresponding author), Univ N Carolina, Dept Biol, Greensboro, NC 27402 USA.	nstewart@uncg.edu	Stewart, Neal/B-4709-2009	Stewart, Neal/0000-0003-3026-9193				Allen GC, 1996, PLANT CELL, V8, P899, DOI 10.1105/tpc.8.5.899; AN GH, 1985, PLANT PHYSIOL, V79, P568, DOI 10.1104/pp.79.2.568; Chevre AM, 1997, NATURE, V389, P924, DOI 10.1038/40054; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Grebenok RJ, 1997, PLANT J, V11, P573, DOI 10.1046/j.1365-313X.1997.11030573.x; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; HELM R, 1996, CURR BIOL, V8, P178; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; JORGENSEN RB, 1994, AM J BOT, V81, P1620, DOI 10.2307/2445340; Kohler RH, 1997, PLANT J, V11, P613, DOI 10.1046/j.1365-313X.1997.11030613.x; Leffel SM, 1997, BIOTECHNIQUES, V23, P912, DOI 10.2144/97235bi01; Mikkelsen TR, 1996, NATURE, V380, P31, DOI 10.1038/380031a0; Plautz JD, 1996, GENE, V173, P83, DOI 10.1016/0378-1119(95)00700-8; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; RAYBOULD AF, 1993, J APPL ECOL, V30, P199, DOI 10.2307/2404623; Reichel C, 1996, P NATL ACAD SCI USA, V93, P5888, DOI 10.1073/pnas.93.12.5888; ROGERS HJ, 1995, J EXP BOT, V46, P467, DOI 10.1093/jxb/46.5.467; Siemering KR, 1996, CURR BIOL, V6, P1653, DOI 10.1016/S0960-9822(02)70789-6; SOKAL RR, 1981, BIOMETRY, V2, P372; Stewart CN, 1996, PLANT PHYSIOL, V112, P115, DOI 10.1104/pp.112.1.121; Stewart CN, 1997, MOL ECOL, V6, P773, DOI 10.1046/j.1365-294X.1997.00239.x; Stewart CN, 1996, PLANT PHYSIOL, V112, P121, DOI 10.1104/pp.112.1.121; Stewart CN, 1996, NAT BIOTECHNOL, V14, P682, DOI 10.1038/nbt0696-682; Whitton J, 1997, THEOR APPL GENET, V95, P33, DOI 10.1007/s001220050529; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246	26	93	98	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1125	1129		10.1038/15114	http://dx.doi.org/10.1038/15114			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545923	Bronze			2022-12-27	WOS:000083428000034
J	McElroy, D				McElroy, D			Moving agbiotech downstream - Companies must turn to effective process develpment as a competitive weapon in agricultural biotechnology	NATURE BIOTECHNOLOGY			English	News Item							GENE INTROGRESSION; BREEDING PROGRAMS; PLANTS; PRODUCTS		Maxygen, Agr Business Operat, Redwood City, CA 94063 USA		McElroy, D (corresponding author), Maxygen, Agr Business Operat, 515 Galveston Dr, Redwood City, CA 94063 USA.							COOK ML, 1994, FOOD AGR MARKETS QUI; Diehn S H, 1996, Genet Eng (N Y), V18, P83; Duke S. O., 1996, HERBICIDE RESISTANT; Gebhardt C, 1997, TRENDS PLANT SCI, V2, P243, DOI 10.1016/S1360-1385(97)86340-6; Herbers K, 1996, TRENDS BIOTECHNOL, V14, P198, DOI 10.1016/0167-7799(96)10027-5; HILL WG, 1993, J HERED, V84, P212, DOI 10.1093/oxfordjournals.jhered.a111319; HILLEL J, 1990, GENETICS, V124, P783; HORNER HT, 1995, CROP SCI, V35, P1527, DOI 10.2135/cropsci1995.0011183X003500060002x; HOSPITAL F, 1992, GENETICS, V132, P1199; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; MAZUR BJ, 1995, TRENDS BIOTECHNOL, V13, P319, DOI 10.1016/S0167-7799(00)88975-1; MONSANTO AA, 1997, SEED CROP DIGEST, V6, P23; OHLROGGE JB, 1994, PLANT PHYSIOL, V104, P821, DOI 10.1104/pp.104.3.821; PISANO GP, 1997, DEV FACTORY; Register JC, 1997, TRENDS BIOTECHNOL, V15, P141, DOI 10.1016/S0167-7799(97)01008-1	15	20	23	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1071	1074		10.1038/15054	http://dx.doi.org/10.1038/15054			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545911				2022-12-27	WOS:000083428000022
J	Meyer, DE; Chilkoti, A				Meyer, DE; Chilkoti, A			Purification of recombinant proteins by fusion with thermally-responsive polypeptides	NATURE BIOTECHNOLOGY			English	Article						elastin-like polypeptide; inverse phase transition; environmentally responsive; fusion protein; protein purification	INVERSE TEMPERATURE TRANSITION; ESCHERICHIA-COLI EXPRESSION; FREE-ENERGY TRANSDUCTION; MONOCLONAL-ANTIBODY; LOCAL HYPERTHERMIA; SYSTEM; THIOREDOXIN; SEPARATION; POLYMER; PEPTIDE	Elastin-like polypeptides (ELPs) undergo a reversible, inverse phase transition. Below their transition temperature (T-t), ELPs are soluble in water, but when the temperature is raised above ft, phase transition occurs, leading to aggregation of the polypeptide. We demonstrate a method for purification of soluble fusion proteins incorporating an ELF tag. Advantages of this method, termed "inverse transition cycling," include technical simplicity, low cost, ease of scale-up, and capacity for multiplexing. More broadly, the ability to environmentally modulate the physicochemical properties of recombinant proteins by fusion with ELPs will allow diverse applications in bioseparation, immunoassays, biocatalysis, and drug delivery.	Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA	Duke University	Chilkoti, A (corresponding author), Duke Univ, Dept Biomed Engn, Box 90281, Durham, NC 27708 USA.			Meyer, Dan/0000-0002-1574-1704	NIGMS NIH HHS [1R21-GM-057373-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM057373] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN JP, 1990, BIOMATERIALS, V11, P631, DOI 10.1016/0142-9612(90)90020-Q; CHILKOTI A, 1994, BIOCONJUGATE CHEM, V5, P504, DOI 10.1021/bc00030a004; COLLGAN JE, 1995, CURRENT PROTOCOLS PR; COPE DA, 1990, CANCER RES, V50, P1803; DEWHIRST MW, 1988, CURRENT CONCEPTS HYP; Diamandis E.P., 1996, IMMUNOASSAY; Hartmeier W., 1988, IMMOBILIZED BIOCATAL; Hauck ML, 1997, CLIN CANCER RES, V3, P63; HOFFMAN A S, 1987, Journal of Controlled Release, V6, P297, DOI 10.1016/0168-3659(87)90083-6; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; KIM JS, 1993, PROTEIN SCI, V2, P348; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; McPherson DT, 1996, PROTEIN EXPRES PURIF, V7, P51, DOI 10.1006/prep.1996.0008; Moore DD, 1995, GLOB MOB SURV; NILSSON B, 1992, CURR OPIN STRUC BIOL, V2, P569; NISSON J, 1997, PROTEIN EXPRES PURIF, V11, P1; ONG E, 1989, TRENDS BIOTECHNOL, V7, P239, DOI 10.1016/0167-7799(89)90014-0; PORATH J, 1992, PROT EXPR PURIF, V3, P262; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MC, 1988, J BIOL CHEM, V263, P7211; Smith PA, 1998, NUCLEIC ACIDS RES, V26, P1414, DOI 10.1093/nar/26.6.1414; SU XZ, 1992, BIOTECHNIQUES, V13, P756; Tsao KL, 1996, GENE, V169, P59, DOI 10.1016/0378-1119(95)00762-8; UHLEN M, 1990, METHOD ENZYMOL, V185, P129; URRY DW, 1992, PROG BIOPHYS MOL BIO, V57, P23, DOI 10.1016/0079-6107(92)90003-O; URRY DW, 1991, J AM CHEM SOC, V113, P4346, DOI 10.1021/ja00011a057; URRY DW, 1985, BIOPOLYMERS, V24, P2345, DOI 10.1002/bip.360241212; URRY DW, 1988, J PROTEIN CHEM, V7, P1, DOI 10.1007/BF01025411; Urry DW, 1997, J PHYS CHEM B, V101, P11007, DOI 10.1021/jp972167t; VERTESY L, 1984, EUR J BIOCHEM, V141, P505, DOI 10.1111/j.1432-1033.1984.tb08221.x	31	662	718	8	225	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1112	1115		10.1038/15100	http://dx.doi.org/10.1038/15100			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545920				2022-12-27	WOS:000083428000031
J	Kim, BS; Nikolovski, J; Bonadio, J; Mooney, DJ				Kim, BS; Nikolovski, J; Bonadio, J; Mooney, DJ			Cyclic mechanical strain regulates the development of engineered smooth muscle tissue	NATURE BIOTECHNOLOGY			English	Article						smooth muscle; tissue engineering; elastin; collagen; mechanical stimulation	VASCULAR CELLS; BLOOD-VESSEL; GROWTH; COLLAGEN; INVITRO; RAT; STRETCH; ARTERY; PROLIFERATION; COMPONENTS	We show that the appropriate combinations of mechanical stimuli and polymeric scaffolds can enhance the mechanical properties of engineered tissues. The mechanical properties of tissues engineered from cells and polymer scaffolds are significantly lower than the native tissues they replace. We hypothesized that application of mechanical stimuli to engineered tissues would alter their mechanical properties. Smooth muscle tissue was engineered on two different polymeric scaffolds and subjected to cyclic mechanical strain. Short-term application of strain increased proliferation of smooth muscle cells (SMCs) and expression of collagen and elastin, but only when SMCs were adherent to specific scaffolds. Long-term application of cyclic strain upregulated elastin and collagen gene expression and led to increased organization in tissues. This resulted in more than an order of magnitude increase in the mechanical properties of the tissues.	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biomed Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Select Genet, San Diego, CA 92121 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Mooney, DJ (corresponding author), Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.		; Byung-Soo, Kim/O-2352-2013	Mooney, David/0000-0001-6299-1194; Byung-Soo, Kim/0000-0001-5210-7430	NICHD NIH HHS [5T32 HD07505-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007505] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BIRUKOV KG, 1995, MOL CELL BIOCHEM, V144, P131, DOI 10.1007/BF00944392; BUCK RC, 1983, ATHEROSCLEROSIS, V46, P217, DOI 10.1016/0021-9150(83)90112-0; Choi RS, 1998, J PEDIATR SURG, V33, P991, DOI 10.1016/S0022-3468(98)90520-6; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; COSTA KA, 1991, FASEB J, V5, pA1609; Fung YC, 1990, BIOMECHANICS MOTION; Hirai J, 1996, CELL TRANSPLANT, V5, P93, DOI 10.1016/0963-6897(95)02002-0; HUME WR, 1980, HYPERTENSION, V2, P738, DOI 10.1161/01.HYP.2.6.738; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; KANDA K, 1993, CELL TRANSPLANT, V2, P475, DOI 10.1177/096368979300200606; KANDA K, 1994, CELL TRANSPLANT, V3, P481, DOI 10.1177/096368979400300605; Kim BS, 1998, J BIOMED MATER RES, V41, P322, DOI 10.1002/(SICI)1097-4636(199808)41:2<322::AID-JBM18>3.0.CO;2-M; Kim BS, 1998, BIOTECHNOL BIOENG, V57, P46; KOLPAKOV V, 1995, CIRC RES, V77, P823, DOI 10.1161/01.RES.77.4.823; KULIK TJ, 1993, J CELL PHYSIOL, V157, P615, DOI 10.1002/jcp.1041570322; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; LEUNG DYM, 1976, SCIENCE, V191, P475; LEUNG DYM, 1977, EXP CELL RES, V109, P285, DOI 10.1016/0014-4827(77)90008-8; Mills I, 1997, J CELL PHYSIOL, V170, P228, DOI 10.1002/(SICI)1097-4652(199703)170:3<228::AID-JCP2>3.0.CO;2-Q; MILLS I, 1993, HEMODYNAMIC FORCES V, P66; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Oberpenning F, 1999, NAT BIOTECHNOL, V17, P149, DOI 10.1038/6146; PARK J B, 1992, BIOMATERIALS INTRO, V2; PREDEL HG, 1992, LANCET, V340, P878; Reusch P, 1996, CIRC RES, V79, P1046, DOI 10.1161/01.RES.79.5.1046; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; STANISLAWSKI L, 1995, J BIOMED MATER RES, V29, P315, DOI 10.1002/jbm.820290306; SUMPIO BE, 1988, J SURG RES, V44, P696, DOI 10.1016/0022-4804(88)90103-5; Tranquillo RT, 1996, BIOMATERIALS, V17, P349, DOI 10.1016/0142-9612(96)85573-6; VANDERLEI B, 1987, SURGERY, V101, P459; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; ZIEGLER T, 1994, J CELL BIOCHEM, V56, P204, DOI 10.1002/jcb.240560215	35	356	367	5	72	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					979	983		10.1038/13671	http://dx.doi.org/10.1038/13671			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504698				2022-12-27	WOS:000083015700023
J	Nordhoff, E; Krogsdam, AM; Jorgensen, HF; Kallipolitis, BH; Clark, BFC; Roepstorff, P; Kristiansen, K				Nordhoff, E; Krogsdam, AM; Jorgensen, HF; Kallipolitis, BH; Clark, BFC; Roepstorff, P; Kristiansen, K			Rapid identification of DNA-binding proteins by mass spectrometry	NATURE BIOTECHNOLOGY			English	Article						protein-DNA interactions; matrix-assisted laser desorption/ionization time-of-flight mass spectrometry	POLY(ADP-RIBOSE) POLYMERASE; ESCHERICHIA-COLI; RECEPTOR PROTEIN; RETINOIC ACID; TRANSCRIPTION; SPECIFICITIES; PROMOTER; SYSTEM; YEAST; GELS	We report a protocol for the rapid identification of DNA-binding proteins. Immobilized DNA probes harboring a specific sequence motif are incubated with cell or nuclear extract. Proteins are analyzed directly off the solid support by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The determined molecular masses are often sufficient for identification. If not, the proteins are subjected to mass spectrometric peptide mapping followed by database searches. Apart from protein identification, the protocol also yields information on posttranslational modifications. The protocol was validated by the identification of known prokaryotic and eukaryotic DNA-binding proteins, and its use provided evidence that poly(ADP-ribose) polymerase exhibits DNA sequence-specific binding to DNA.	Univ Aarhus, Inst Mol & Struct Biol, Dept Biostruct Biol, Aarhus, Denmark; Odense Univ, Dept Mol Biol, DK-5230 Odense, Denmark	Aarhus University; University of Southern Denmark	Nordhoff, E (corresponding author), Max Planck Inst Mol Genet, Berlin, Germany.		Kristiansen, Karsten/J-5148-2014; Krogsdam, Anne/AAM-7278-2020	Kristiansen, Karsten/0000-0002-6024-0917; Kallipolitis, Birgitte H./0000-0003-1233-9776; Jorgensen, Helle/0000-0002-7909-2977; Krogsdam, Anne/0000-0002-5478-0511				ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; Dent C, 1993, TRANSCRIPTION FACTOR; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Gobom J, 1997, INT J MASS SPECTROM, V169, P153, DOI 10.1016/S0168-1176(97)00216-4; HENRY K, 1995, TOXICOL APPL PHARM, V132, P317, DOI 10.1006/taap.1995.1113; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Lechler A, 1998, J MOL BIOL, V278, P897, DOI 10.1006/jmbi.1998.1744; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Um S, 1998, J BIOL CHEM, V273, P20728, DOI 10.1074/jbc.273.33.20728; VALENTINHANSEN P, 1978, MOL GEN GENET, V159, P191, DOI 10.1007/BF00270893; WAKABAYASHIITO N, 1994, J BIOL CHEM, V269, P29831; ZHANG XP, 1991, J BIOMOL STRUCT DYN, V9, P463, DOI 10.1080/07391102.1991.10507929	23	56	58	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					884	888		10.1038/12873	http://dx.doi.org/10.1038/12873			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471930				2022-12-27	WOS:000082365800030
J	Koivunen, E; Arap, W; Valtanen, H; Rainisalo, A; Medina, OP; Heikkila, P; Kantor, C; Gahmberg, CG; Salo, T; Konttinen, YT; Sorsa, T; Ruoslahti, E; Pasqualini, R				Koivunen, E; Arap, W; Valtanen, H; Rainisalo, A; Medina, OP; Heikkila, P; Kantor, C; Gahmberg, CG; Salo, T; Konttinen, YT; Sorsa, T; Ruoslahti, E; Pasqualini, R			Tumor targeting with a selective gelatinase inhibitor	NATURE BIOTECHNOLOGY			English	Article						phage display; matrix metalloproteinase; tumor targeting; angiogenesis; cancer therapy	MATRIX METALLOPROTEINASE INHIBITOR; EXTRACELLULAR-MATRIX; CYCLIC-PEPTIDES; IV COLLAGENASE; PHAGE DISPLAY; STROMAL CELLS; CANCER; ANGIOGENESIS; METASTASIS; CARCINOMA	Several lines of evidence suggest that tumor growth, angiogenesis, and metastasis are dependent on matrix metalloproteinase (MMP) activity, However, the lack of inhibitors specific for the type IV collagenase/gelatinase family of MMPs has thus far prevented the selective targeting of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) for therapeutic intervention in cancer, Here, we describe the isolation of specific gelatinase inhibitors from phage display peptide libraries. We show that cyclic peptides containing the sequence HWGF are potent and selective inhibitors of MMP-2 and MMP-9 but not of several other MMP family members, Our prototype synthetic peptide, CTTHWGFTLC, inhibits the migration of human endothelial cells and tumor cells, Moreover, it prevents tumor growth and invasion in animal models and improves survival of mice bearing human tumors. Finally, we show that CTTHWGFTLC-displaying phage specifically target angiogenic blood vessels in vivo. Selective gelatinase inhibitors may prove useful in tumor targeting and anticancer therapies.	Univ Helsinki, Dept Biosci, Div Biochem, FIN-00014 Helsinki, Finland; Burnham Inst, La Jolla, CA 92037 USA; Univ Helsinki, Dept Periodontol, FIN-00014 Helsinki, Finland; Univ Oulu, Dept Diagnost & Oral Med, FIN-90401 Oulu, Finland; Univ Helsinki, Dept Anat, FIN-00014 Helsinki, Finland	University of Helsinki; Sanford Burnham Prebys Medical Discovery Institute; University of Helsinki; University of Oulu; University of Helsinki	Koivunen, E (corresponding author), Univ Helsinki, Dept Biosci, Div Biochem, Viikinkaari 5, FIN-00014 Helsinki, Finland.	erkki.koivunen@helsinki.fi; pasqualini@burnham-inst.org	Gahmberg, Carl/AAE-1876-2019; , tuula/ABG-2051-2021; Penate-Medina, oula/ABB-8198-2021; medina, oula penate/G-5136-2012	Penate-Medina, oula/0000-0001-9878-5309; medina, oula penate/0000-0001-9878-5309; Salo, Tuula/0000-0001-6039-0088; Koivunen, Erkki/0000-0002-6443-9595; Gahmberg, Carl/0000-0001-9892-9296; Heikkila, Pia/0000-0002-5925-1993	NCI NIH HHS [CA30199, CA74238] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074238, P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson IC, 1996, CANCER RES, V56, P715; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap Wadih, 1998, Current Opinion in Oncology, V10, P560, DOI 10.1097/00001622-199811000-00014; Beckett RP, 1996, DRUG DISCOV TODAY, V1, P16, DOI 10.1016/1359-6446(96)89115-X; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; DAVIES B, 1993, CANCER RES, V53, P2087; DOMINGO GJ, 1995, INT J PEPT PROT RES, V46, P79; Eccles SA, 1996, CANCER RES, V56, P2815; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Ferry G, 1997, MOL DIVERS, V2, P135, DOI 10.1007/BF01682201; Goetzl EJ, 1996, J IMMUNOL, V156, P1; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Heppner KJ, 1996, AM J PATHOL, V149, P273; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; Itoh T, 1998, CANCER RES, V58, P1048; Karakiulakis George, 1997, Invasion and Metastasis, V17, P158; Ke SH, 1997, J BIOL CHEM, V272, P16603, DOI 10.1074/jbc.272.26.16603; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; KOIVUNEN E, 1991, INT J CANCER, V47, P592, DOI 10.1002/ijc.2910470419; Krook M, 1998, MOL DIVERS, V3, P149; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MURPHY G, 1995, METHOD ENZYMOL, V248, P470; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; PASQUALINI R, 1999, IN RPESS PHAGE DISPL; PASQUALINI R, 1997, NAT BIOTECHNOL, V245, P346; Pulli T, 1997, J BIOL CHEM, V272, P21176, DOI 10.1074/jbc.272.34.21176; PYKE C, 1993, AM J PATHOL, V142, P359; Rajotte D, 1999, J BIOL CHEM, V274, P11593, DOI 10.1074/jbc.274.17.11593; RUI F, 1996, BIOCHEM BIOPH RES CO, V220, P53; Santos O, 1997, CLIN EXP METASTAS, V15, P499, DOI 10.1023/A:1018418725453; Seftor REB, 1998, CLIN EXP METASTAS, V16, P217, DOI 10.1023/A:1006588708131; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; SORSA T, 1994, ANN NY ACAD SCI, V732, P112, DOI 10.1111/j.1749-6632.1994.tb24729.x; Sorsa T, 1997, J BIOL CHEM, V272, P21067, DOI 10.1074/jbc.272.34.21067; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STOCKER W, 1995, CURR OPIN STRUC BIOL, V5, P383, DOI 10.1016/0959-440X(95)80101-4; Sugiura Y, 1998, CANCER RES, V58, P2209; Talbot DC, 1996, EUR J CANCER, V32A, P2528; TARABOLETTI G, 1995, J NATL CANCER I, V87, P293, DOI 10.1093/jnci/87.4.293; Teronen O, 1997, J DENT RES, V76, P1529, DOI 10.1177/00220345970760090401; Volpert OV, 1996, J CLIN INVEST, V98, P671, DOI 10.1172/JCI118838; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Wojtowicz-Praga S, 1998, J CLIN ONCOL, V16, P2150, DOI 10.1200/JCO.1998.16.6.2150	52	490	556	2	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					768	774		10.1038/11703	http://dx.doi.org/10.1038/11703			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429241				2022-12-27	WOS:000081751400025
J	Sturniolo, T; Bono, E; Ding, JY; Raddrizzani, L; Tuereci, O; Sahin, U; Braxenthaler, M; Gallazzi, F; Protti, MP; Sinigaglia, F; Hammer, J				Sturniolo, T; Bono, E; Ding, JY; Raddrizzani, L; Tuereci, O; Sahin, U; Braxenthaler, M; Gallazzi, F; Protti, MP; Sinigaglia, F; Hammer, J			Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices	NATURE BIOTECHNOLOGY			English	Article						HLA matrix; epitope prediction; DNA microarrays; tumor immunology; genomics	MHC CLASS-II; PEPTIDE BINDING-SPECIFICITY; HUMAN-GENOME-PROJECT; CD4(+) T-CELLS; CRYSTAL-STRUCTURE; TUMOR-ANTIGENS; IDENTIFICATION; PREDICTION; PROTEIN; HLA-DR1	Most pockets in the human leukocyte antigen-group DR (HLA-DR) groove are shaped by clusters of polymorphic residues and, thus, have distinct chemical and size characteristics in different HLA-DR alleles, Each HLA-DR pocket can be characterized by "pocket profiles," a quantitative representation of the interaction of all natural amino acid residues with a given pocket. In this report we demonstrate that pocket profiles are nearly independent of the remaining HLA-DR cleft. A small database of profiles was sufficient to generate a large number of HLA-DR matrices, representing the majority of human HLA-DR peptide-binding specificity. These virtual matrices were incorporated in software (TEPITOPE) capable of predicting promiscuous HLA class II ligands, This software, in combination with DNA microarray technology, has provided a new tool for the generation of comprehensive databases of candidate promiscuous T-cell epitopes in human disease tissues. First, DNA microarrays are used to reveal genes that are specifically expressed or upregulated in disease tissues. Second, the prediction software enables the scanning of these genes for promiscuous HLA-DR binding sites. In an example, we demonstrate that starting from nearly 20,000 genes, a database of candidate colon cancer-specific and promiscuous T-cell epitopes could be fully populated within a matter of days. Our approach has implications for the development of epitope-based vaccines.	Roche Milano Ric, I-20132 Milan, Italy; Hoffmann La Roche Inc, Dept Genom & Informat Sci, Nutley, NJ 07110 USA; Univ Saarlandes, Dept Internal Med, D-66421 Homburg, Germany; San Raffaele Sci Inst, Lab Tumor Immunol, I-20132 Milan, Italy	Roche Holding; Roche Holding; Saarland University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Hammer, J (corresponding author), Roche Milano Ric, I-20132 Milan, Italy.		Protti, Maria Pia/J-7899-2016; Sahin, Ugur/L-4818-2017	Protti, Maria Pia/0000-0001-9079-2336; Sahin, Ugur/0000-0003-0363-1564				ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; BENMAHREZ K, 1988, BRIT J CANCER, V57, P529, DOI 10.1038/bjc.1988.123; Blackwell JM, 1997, T ROY SOC TROP MED H, V91, P107, DOI 10.1016/S0035-9203(97)90187-5; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Brusic V, 1998, BIOINFORMATICS, V14, P121, DOI 10.1093/bioinformatics/14.2.121; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Degrave W, 1997, MEM I OSWALDO CRUZ, V92, P859, DOI 10.1590/S0074-02761997000600023; Dessen A, 1997, IMMUNITY, V7, P473, DOI 10.1016/S1074-7613(00)80369-6; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; Hammer J, 1997, ADV IMMUNOL, V66, P67, DOI 10.1016/S0065-2776(08)60596-9; HAMMER J, 1995, J EXP MED, V181, P1847, DOI 10.1084/jem.181.5.1847; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HAMMER J, 1994, J EXP MED, V180, P2353, DOI 10.1084/jem.180.6.2353; HAMMER J, 1995, CURR OPIN IMMUNOL, V7, P263, DOI 10.1016/0952-7915(95)80013-1; HAMMER J, 1998, MHC, V2, P197; Harwood CR, 1996, FEBS LETT, V389, P84, DOI 10.1016/0014-5793(96)00524-8; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Manici S, 1999, J EXP MED, V189, P871, DOI 10.1084/jem.189.5.871; Marsh SGE, 1998, TISSUE ANTIGENS, V51, P582, DOI 10.1111/j.1399-0039.1998.tb02998.x; MARSHALL KW, 1995, J IMMUNOL, V154, P5927; Ossendorp F, 1998, J EXP MED, V187, P693, DOI 10.1084/jem.187.5.693; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; Raddrizzani L, 1997, J IMMUNOL, V159, P703; RAMMENSEE HG, 1998, SYFPEITHI INTERNET D; Sahin U, 1997, CURR OPIN IMMUNOL, V9, P709, DOI 10.1016/S0952-7915(97)80053-2; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SINIGAGLIA F, 1994, CURR OPIN IMMUNOL, V6, P52, DOI 10.1016/0952-7915(94)90033-7; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Topalian SL, 1996, J EXP MED, V183, P1965, DOI 10.1084/jem.183.5.1965; TOPALIAN SL, 1994, CURR OPIN IMMUNOL, V6, P741, DOI 10.1016/0952-7915(94)90078-7; Tsuji K, 1992, P 11 INT HIST WORKSH; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	36	581	701	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					555	561		10.1038/9858	http://dx.doi.org/10.1038/9858			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385319				2022-12-27	WOS:000080716500026
J	Baggot, B				Baggot, B			Have you bargained away patent rights? Inventors and entrepreneurs need to consider a recent Supreme Court ruling in their patent strategies.	NATURE BIOTECHNOLOGY			English	Article																			0	0	0	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					297	298		10.1038/7050	http://dx.doi.org/10.1038/7050			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096300				2022-12-27	WOS:000078977500034
J	Reineke, U; Sabat, R; Misselwitz, R; Welfle, H; Volk, HD; Schneider-Mergener, J				Reineke, U; Sabat, R; Misselwitz, R; Welfle, H; Volk, HD; Schneider-Mergener, J			A synthetic mimic of a discontinuous binding site on interleukin-10	NATURE BIOTECHNOLOGY			English	Article						interleukin-10; protein mimics; antibody epitope; peptide library; mini-protein	BOUND PEPTIDE LIBRARIES; CRYSTAL-STRUCTURE; RECEPTOR; IDENTIFICATION; ERYTHROPOIETIN; ANTIBODY; COMPLEX; HORMONE	We synthetically reconstructed a discontinuous binding site on interleukin-10 (IL-10) that recognizes the neutralizing anti-IL-10 antibody CB/RS/1. To design the 32-mer IL-10 mimic, a discontinuous interaction site on IL-10 was mapped, and binding studies with epitope-derived peptides led to specific replacement of several amino acids. Both parts of the interaction site were combined by addition of a linker molecule. Systematic analoging of the combined molecule then led to introduction of several additional substitutions in both regions and the linker. All possible disulfide bridge-containing variants of the 32-mer were tested by binding studies. Parallel syntheses were performed on continuous cellulose membranes by spot synthesis. As a result, a conformationally stabilized IL-10-derived molecule was obtained that both binds to and neutralizes the biological activity of CB/RS/1 in the low nanomolar range. This synthetic approach is a powerful alternative to phage display methods for the design of protein mimics.	Humboldt Univ, Klinikum Charite, Inst Med Immunol, D-10098 Berlin, Germany; Humboldt Univ, Klinikum Charite, Inst Biochem, D-10098 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Sabat, R (corresponding author), Humboldt Univ, Klinikum Charite, Inst Med Immunol, D-10098 Berlin, Germany.		volk, hans-dieter/AAV-8053-2021	volk, hans-dieter/0000-0002-7743-6668				ATASSI MZ, 1977, J BIOL CHEM, V252, P8784; Ballinger MD, 1998, NAT STRUCT BIOL, V5, P938, DOI 10.1038/2911; Braisted AC, 1996, P NATL ACAD SCI USA, V93, P5688, DOI 10.1073/pnas.93.12.5688; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FRANK R, 1996, COMBINATORIAL PEPTID, P363; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Kramer A, 1998, METH MOL B, V87, P25; Kramer Achim, 1994, Methods (Orlando), V6, P388, DOI 10.1006/meth.1994.1039; LI B, 1995, SCIENCE, V270, P1657, DOI 10.1126/science.270.5242.1657; MALIN R, 1995, J AM CHEM SOC, V117, P11821, DOI 10.1021/ja00152a031; Peters KP, 1996, J MOL BIOL, V256, P201, DOI 10.1006/jmbi.1996.0077; Reineke U, 1998, PROTEIN SCI, V7, P951; Reineke U, 1996, MOL DIVERS, V1, P141, DOI 10.1007/BF01544952; Reineke U, 1998, ANGEW CHEM INT EDIT, V37, P769, DOI 10.1002/(SICI)1521-3773(19980403)37:6<769::AID-ANIE769>3.0.CO;2-B; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Sabat R, 1996, MOL IMMUNOL, V33, P1103, DOI 10.1016/S0161-5890(96)00072-7; Takasaki W, 1997, NAT BIOTECHNOL, V15, P1266, DOI 10.1038/nbt1197-1266; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; Tian SS, 1998, SCIENCE, V281, P257, DOI 10.1126/science.281.5374.257; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Wrighton NC, 1997, NAT BIOTECHNOL, V15, P1261, DOI 10.1038/nbt1197-1261; Zdanov A, 1997, J MOL BIOL, V268, P460, DOI 10.1006/jmbi.1997.0990; Zdanov A, 1996, PROTEIN SCI, V5, P1955, DOI 10.1002/pro.5560051001; Zhang HJ, 1997, MULTIMED TOOLS APPL, V4, P5	27	51	65	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					271	275		10.1038/7018	http://dx.doi.org/10.1038/7018			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096295				2022-12-27	WOS:000078977500029
J	Zozulya, S; Lioubin, M; Hill, RJ; Abram, C; Gishizky, ML				Zozulya, S; Lioubin, M; Hill, RJ; Abram, C; Gishizky, ML			Mapping signal transduction pathways by phage display	NATURE BIOTECHNOLOGY			English	Article						signal transduction; tyrosine phosphorylation; protein interaction screening; phage display	EPIDERMAL GROWTH-FACTOR; PHOSPHOTYROSINE INTERACTION DOMAIN; RECEPTOR TYROSINE KINASES; ACTIVATED PROTEIN-KINASE; BACTERIOPHAGE-LAMBDA; ADAPTER MOLECULE; CAPSID PROTEIN; EGF-RECEPTOR; SH3 DOMAIN; RAS	Rapid identification of proteins that interact with a novel gene product is an important element of functional genomics. Here we describe a phage display-based technique for interaction screening of complex cDNA libraries using proteins or synthetic peptides as baits. Starting with the epidermal growth factor receptor (EGFR) cytoplasmic tail, we identified known protein interactions that link EGFR to the Ras/MAP kinase signal transduction cascade and several novel interactions. This approach can be used as a rapid and efficient tool for elucidating protein networks and mapping intracellular signal transduction pathways.	Sugen Inc, S San Francisco, CA USA	Pfizer	Zozulya, S (corresponding author), Sugen Inc, 230 E Grand Ave, S San Francisco, CA USA.		Zozulya, Sergey A/F-2986-2015	Zozulya, Sergey A/0000-0002-1179-2993				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERNARD DJ, 1992, BRIT J CANCER, V66, P88, DOI 10.1038/bjc.1992.222; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; CRAMERI R, 1993, GENE, V137, P69, DOI 10.1016/0378-1119(93)90253-Y; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DUNN IS, 1995, J MOL BIOL, V248, P497, DOI 10.1006/jmbi.1995.0237; EFIMOV VP, 1995, VIRUS GENES, V10, P172; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Griffiths AD, 1998, CURR OPIN BIOTECH, V9, P102, DOI 10.1016/S0958-1669(98)80092-X; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; Kay B. K, 1996, PHAGE DISPLAY PEPTID; Kishi T, 1997, BIOCHEM BIOPH RES CO, V232, P5, DOI 10.1006/bbrc.1997.6218; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lin JW, 1998, J NEUROSCI, V18, P2017; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mandiyan V, 1996, J BIOL CHEM, V271, P4770; MARUYAMA IN, 1994, P NATL ACAD SCI USA, V91, P8273, DOI 10.1073/pnas.91.17.8273; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; *NOV, 1999, T7 SEL SYST MAN TB17; Nutt JE, 1996, EUR J CANCER, V32A, P2127, DOI 10.1016/S0959-8049(96)00261-4; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; Ren ZJ, 1996, PROTEIN SCI, V5, P1833, DOI 10.1002/pro.5560050909; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; Rosenbrock H, 1996, J PROCESS CONTR, V6, P1, DOI 10.1016/0959-1524(96)81787-2; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sakaguchi K, 1998, MOL ENDOCRINOL, V12, P536, DOI 10.1210/me.12.4.536; Santini C, 1998, J MOL BIOL, V282, P125, DOI 10.1006/jmbi.1998.1986; Satoh T, 1996, FEBS LETT, V386, P230, DOI 10.1016/0014-5793(96)00449-8; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SOLER C, 1994, CELL GROWTH DIFFER, V5, P519; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; STERNBERG N, 1995, P NATL ACAD SCI USA, V92, P1609, DOI 10.1073/pnas.92.5.1609; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; TODA M, 1993, BIOCHEM BIOPH RES CO, V196, P468, DOI 10.1006/bbrc.1993.2273; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	52	66	82	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1193	1198		10.1038/70736	http://dx.doi.org/10.1038/70736			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585717				2022-12-27	WOS:000084170700027
J	Knoblauch, M; Hibberd, JM; Gray, JC; van Bel, AJE				Knoblauch, M; Hibberd, JM; Gray, JC; van Bel, AJE			A galinstan expansion femtosyringe for microinjection of eukaryotic organelles and prokaryotes	NATURE BIOTECHNOLOGY			English	Article						microinjection; galinstan expansion femtosyringe; green fluorescent protein; chloroplast; cyanobacteria; transformation	GREEN-FLUORESCENT PROTEIN; PLASTID TRANSFORMATION; NICOTIANA-TABACUM; PLANTS; DNA; PROTOPLASTS; CONNECTIONS; EXPRESSION; TRANSIENT; COMPLEX	A galinstan expansion femtosyringe enables femtoliter to attoliter samples to be introduced into prokaryotes and subcellular compartments of eukaryotes. The method uses heat-induced expansion of galinstan (a liquid metal alloy of gallium, indium, and tin) within a glass syringe to expel samples through a tip diameter of about 0.1 mu m. The narrow tip inflicts less damage than conventional capillaries, and the heat-induced expansion of the galinstan allows fine control over the rate of injection. We demonstrate injection of Lucifer Yellow and Lucifer Yellow-dextran conjugates into cyanobacteria, and into nuclei and chloroplasts of higher organisms. Injection of a plasmid containing the bla gene into the cyanobacterium Phormidium laminosum resulted in transformed ampiciltin-resistant cultures. Green fluorescent protein was expressed in attached leaves of tobacco and Vicia faba following injection of DNA cantaining its gene into individual chloroplasts.	Univ Giessen, Inst Gen Bot & Plant Physiol, D-35390 Giessen, Germany; Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England	Justus Liebig University Giessen; University of Cambridge	Knoblauch, M (corresponding author), Univ Giessen, Inst Gen Bot & Plant Physiol, Senckenbergstr 17, D-35390 Giessen, Germany.			Knoblauch, Michael/0000-0003-0391-9891				DANIELL H, 1991, PLANT CELL REP, V9, P615, DOI 10.1007/BF00231800; DANIELL H, 1990, P NATL ACAD SCI USA, V87, P88, DOI 10.1073/pnas.87.1.88; GOLDS T, 1993, BIO-TECHNOL, V11, P95, DOI 10.1038/nbt0193-95; Grebenok RJ, 1997, PLANT J, V11, P573, DOI 10.1046/j.1365-313X.1997.11030573.x; HANDLER JS, 1981, AM J PHYSIOL, V240, P103; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hibberd JM, 1998, PLANT J, V16, P627, DOI 10.1046/j.1365-313x.1998.00328.x; HONER B, 1988, J CELL BIOL, V107, P2181, DOI 10.1083/jcb.107.6.2181; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kempers R, 1997, PLANTA, V201, P195, DOI 10.1007/BF01007704; KHAN MS, 1999, NAT BIOTECHNOL, V17; Knoblauch M, 1998, PLANT CELL, V10, P35, DOI 10.1105/tpc.10.1.35; Kohler R, 1997, TRENDS CELL BIOL, V7, P392; Kohler RH, 1997, SCIENCE, V276, P2039, DOI 10.1126/science.276.5321.2039; KOST B, 1995, J EXP BOT, V46, P1157, DOI 10.1093/jxb/46.9.1157; MALIGA P, 1993, TRENDS BIOTECHNOL, V11, P101, DOI 10.1016/0167-7799(93)90059-I; Nguyen L, 1996, P NATL ACAD SCI USA, V93, P12643, DOI 10.1073/pnas.93.22.12643; OKA MT, 1990, CELL STRUCT FUNCT, V15, P373, DOI 10.1247/csf.15.373; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; STAIGER CJ, 1994, CURR BIOL, V4, P215, DOI 10.1016/S0960-9822(00)00050-6; SVAB Z, 1993, P NATL ACAD SCI USA, V90, P913, DOI 10.1073/pnas.90.3.913; TAKESHIMA Y, 1996, DNA RES, V1, P181; VANDERSCHOOT C, 1989, THESIS U UTRECHT; WALTON PA, 1992, J CELL BIOL, V118, P499, DOI 10.1083/jcb.118.3.499	26	122	145	1	49	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					906	909		10.1038/12902	http://dx.doi.org/10.1038/12902			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471935				2022-12-27	WOS:000082365800035
J	Ilyin, SE; Plata-Salaman, CR				Ilyin, SE; Plata-Salaman, CR			Probe generation by PCR coupled with ligation - An approach for the efficient production of RNA probes.	NATURE BIOTECHNOLOGY			English	Article									Univ Delaware, Newark, DE 19716 USA	University of Delaware	Ilyin, SE (corresponding author), RW Johnson Pharmaceut Res Inst, Welsh & McKean Rd, Spring House, PA 19477 USA.							Ilyin SE, 1998, MOL CHEM NEUROPATHOL, V33, P125, DOI 10.1007/BF02870186; Ilyin SE, 1998, J NEUROSCI METH, V84, P139, DOI 10.1016/S0165-0270(98)00108-3; Plata-Salaman CR, 1998, INT J MOL MED, V1, P387; URRUTIA R, 1993, J BIOCHEM BIOPH METH, V26, P113, DOI 10.1016/0165-022X(93)90041-L; YANG HH, 1995, METH NEUROSCI, V26, P227	5	2	3	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					608	609		10.1038/9928	http://dx.doi.org/10.1038/9928			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385329				2022-12-27	WOS:000080716500036
J	Blezinger, P; Wang, JJ; Gondo, M; Quezada, A; Mehrens, D; French, M; Singhal, A; Sullivan, S; Rolland, A; Ralston, R; Min, W				Blezinger, P; Wang, JJ; Gondo, M; Quezada, A; Mehrens, D; French, M; Singhal, A; Sullivan, S; Rolland, A; Ralston, R; Min, W			Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene	NATURE BIOTECHNOLOGY			English	Article						angiogenesis; endostatin; gene therapy; cancer; intramuscular delivery	IN-VIVO; SKELETAL-MUSCLE; THERAPY; ANGIOGENESIS; ANGIOSTATIN; CANCER; SUPPRESSION; RESISTANCE; PLASMID; PROLIFERATION	Tumors require ongoing angiogenesis to support their growth, Inhibition of angiogenesis by production of angiostatic factors should be a viable approach for cancer gene therapy. Endostatin, a potent angiostatic factor, was expressed in mouse muscle and secreted into the bloodstream for up to 2 weeks after a single intramuscular administration of the endostatin gene. The biological activity of the expressed endostatin was demonstrated by its ability to inhibit systemic angiogenesis. Moreover, the sustained production of endostatin by intramuscular gene therapy inhibited both the growth of primary tumors and the development of metastatic lesions. These results demonstrate the potential utility of intramuscular delivery of an antiangiogenic gene for treatment of disseminated cancers.	GeneMed Inc, The Woodlands, TX 77381 USA		Min, W (corresponding author), GeneMed Inc, 8301 New Trails Dr, The Woodlands, TX 77381 USA.	minw@genemedicine.com	Ralston, Robert O/A-6924-2009	Rolland, Alain/0000-0002-7995-0548				Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867; Alila H, 1997, HUM GENE THER, V8, P1785, DOI 10.1089/hum.1997.8.15-1785; Anderson WF, 1998, NATURE, V392, P25; Anwer K, 1998, HUM GENE THER, V9, P659, DOI 10.1089/hum.1998.9.5-659; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; DAVIS HL, 1993, HUM GENE THER, V4, P733, DOI 10.1089/hum.1993.4.6-733; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1998, P NATL ACAD SCI USA, V95, P9064, DOI 10.1073/pnas.95.16.9064; Griscelli F, 1998, P NATL ACAD SCI USA, V95, P6367, DOI 10.1073/pnas.95.11.6367; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1998, NAT MED, V4, P13, DOI 10.1038/nm0198-013; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; Kerbel RS, 1997, NATURE, V390, P335, DOI 10.1038/36978; Kong HL, 1998, J NATL CANCER I, V90, P273, DOI 10.1093/jnci/90.4.273; Kong HL, 1998, HUM GENE THER, V9, P823, DOI 10.1089/hum.1998.9.6-823; Lannutti BJ, 1997, CANCER RES, V57, P5277; Li H, 1998, GENE THER, V5, P1105, DOI 10.1038/sj.gt.3300742; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Mumper RJ, 1996, PHARMACEUT RES, V13, P701, DOI 10.1023/A:1016039330870; Mumper RJ, 1998, J CONTROL RELEASE, V52, P191, DOI 10.1016/S0168-3659(97)00215-0; O'Reilly Michael, 1993, Surgical Forum, V44, P474; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; OREILLY MS, 1996, NAT MED, V2, P889; PREHN RT, 1993, CANCER RES, V53, P3266; PREHN RT, 1991, CANCER RES, V51, P2; Rolland AP, 1998, CRIT REV THER DRUG, V15, P143, DOI 10.1615/CritRevTherDrugCarrierSyst.v15.i2.20; SCHOFIELD JP, 1995, BRIT MED BULL, V51, P56, DOI 10.1093/oxfordjournals.bmb.a072953; Sim BKL, 1997, CANCER RES, V57, P1329; SUGARBAKER EV, 1977, PROGR CANC RES THERA, P227; Tanaka T, 1998, CANCER RES, V58, P3362; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; WARREN BA, 1977, PROGR CANC RES THERA, P185; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	37	268	318	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					343	348		10.1038/7895	http://dx.doi.org/10.1038/7895			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207881				2022-12-27	WOS:000079574400021
J	Trivedi, B				Trivedi, B			Encapsulating the right chemistry	NATURE BIOTECHNOLOGY			English	Article								Chemists are turning to biological systems to increase the efficiency and sophistication of molecular syntheses and separations.										Douglas T, 1998, NATURE, V393, P152, DOI 10.1038/30211	1	3	3	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					339	341		10.1038/7892	http://dx.doi.org/10.1038/7892			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207880				2022-12-27	WOS:000079574400020
J	Persidis, A				Persidis, A			Industry trends - Xenotransplantation	NATURE BIOTECHNOLOGY			English	Editorial Material							TO-RAT; TRANSPLANTATION; REJECTION		Argonex Inc, Charlottesville, VA 22901 USA		Persidis, A (corresponding author), Argonex Inc, 2044 India Rd, Charlottesville, VA 22901 USA.	apersidis@argonex.com						Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; Bracy JL, 1998, SCIENCE, V281, P1845, DOI 10.1126/science.281.5384.1845; Cooper DKC, 1998, XENOTRANSPLANTATION, V5, P6, DOI 10.1111/j.1399-3089.1998.tb00003.x; Groth CG, 1996, TRANSPLANT P, V28, P538; HITCHCOCK CR, 1964, JAMA-J AM MED ASSOC, V189, P934; Ildstad ST, 1996, LANCET, V347, P761, DOI 10.1016/S0140-6736(96)90112-9; Persidis A, 1998, NAT BIOTECHNOL, V16, P882, DOI 10.1038/nbt0998-882; REEMTSMA K, 1964, JAMA-J AM MED ASSOC, V187, P691; REEMTSMA K, 1964, SCIENCE, V143, P700, DOI 10.1126/science.143.3607.700; STARZL TE, 1964, TRANSPLANTATION, V2, P752; STARZL TE, 1993, LANCET, V341, P65, DOI 10.1016/0140-6736(93)92553-6; XIAO F, 1994, TRANSPLANTATION, V58, P828	12	4	4	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					205	206		10.1038/6222	http://dx.doi.org/10.1038/6222			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052362				2022-12-27	WOS:000078508300034
J	Bingham, C				Bingham, C			Using outsourcing to enhance core capabilities: Winning strategy or dangerous manuever? Inherent risks in sharing your core technology, if not properly managed, can destroy any value a deal might bring.	NATURE BIOTECHNOLOGY			English	Article											Bingham, C (corresponding author), 5 Chancery Lane,Cliffords Inn,Dent Hall, London EC4A 1BU, England.								0	0	0	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1229	1230		10.1038/70789	http://dx.doi.org/10.1038/70789			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585725				2022-12-27	WOS:000084170700035
J	Latham, PW				Latham, PW			Therapeutic peptides revisited	NATURE BIOTECHNOLOGY			English	Article								After a roller coaster ride of successes and failures, new discovery technologies and advances in manufacturing promise a brighter future for peptides in human therapy.	New Venture Advisors, Boston, MA 02130 USA		Latham, PW (corresponding author), New Venture Advisors, Boston, MA 02130 USA.		Minkiewicz, Piotr/G-6765-2011; Iwaniak, Anna/N-3589-2018	Minkiewicz, Piotr/0000-0003-0481-1196; Iwaniak, Anna/0000-0001-5068-0428				Kelley WS, 1996, BIO-TECHNOL, V14, P28, DOI 10.1038/nbt0196-28	1	165	179	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					755	757		10.1038/11686	http://dx.doi.org/10.1038/11686			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429238				2022-12-27	WOS:000081751400022
J	Hodson-de-Jaramillo, E; Aramendis, RH				Hodson-de-Jaramillo, E; Aramendis, RH			New confrontations	NATURE BIOTECHNOLOGY			English	Editorial Material									COLCIENCIAS, Inst Colombiano Desarrollo Ciencia & Tecnol Franc, Programa Nacl Biotecnol, Bogota, Colombia		Hodson-de-Jaramillo, E (corresponding author), COLCIENCIAS, Inst Colombiano Desarrollo Ciencia & Tecnol Franc, Programa Nacl Biotecnol, Transversal 9A 133-28, Bogota, Colombia.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					512	513		10.1038/9773	http://dx.doi.org/10.1038/9773			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385297				2022-12-27	WOS:000080716500003
J	Alexander, TD				Alexander, TD			The patentability of algorithms	NATURE BIOTECHNOLOGY			English	Editorial Material							SEQUENCE		Foley & Lardner, Madison, WI 53706 USA		Alexander, TD (corresponding author), Foley & Lardner, 150 E Gilman St, Madison, WI 53706 USA.	talexander@foleylaw.com						Agris CH, 1998, NAT BIOTECHNOL, V16, P702; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4	4	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					395	395		10.1038/7955	http://dx.doi.org/10.1038/7955			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207891	Bronze			2022-12-27	WOS:000079574400033
J	Serakinci, N; Koch, J				Serakinci, N; Koch, J			In the laboratory - Detection and sizing of telomeric repeat DNA in situ - A performance comparison of PRINS and PNA assays.	NATURE BIOTECHNOLOGY			English	Editorial Material							HUMAN-CHROMOSOMES; IN-SITU; LABELING PRINS; HYBRIDIZATION; PRIMERS; PROBES; INSITU		Danish Canc Soc, Dept Cytogenet, DK-8000 Aarhus C, Denmark	Danish Cancer Society		Jorn.Koch@aas.auh.dk		SERAKINCI, Nedime/0000-0002-1884-0839				Azzalin CM, 1997, CYTOGENET CELL GENET, V78, P112, DOI 10.1159/000134640; DELANGE T, 1995, TELOMERES, P264; GOSS SJ, 1977, J CELL SCI, V25, P17; KOCH J, 1995, CYTOGENET CELL GENET, V71, P142, DOI 10.1159/000134094; KOCH J, 1991, GENET ANAL-BIOMOL E, V8, P171, DOI 10.1016/1050-3862(91)90058-Y; KOCH J, 1999, NONRADIOACTIVE LABEL; KOCH JE, 1989, CHROMOSOMA, V98, P259, DOI 10.1007/BF00327311; Krejci K, 1998, CHROMOSOMA, V107, P198, DOI 10.1007/s004120050297; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; LEE TNH, 1982, J MOL BIOL, V161, P323, DOI 10.1016/0022-2836(82)90156-5; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; SLIJEPCEVIC P, 1995, CYTOGENET CELL GENET, V69, P87, DOI 10.1159/000133944; Slijepcevic P, 1997, CHROMOSOMA, V106, P413, DOI 10.1007/s004120050263; THERKELSEN AJ, 1995, CYTOGENET CELL GENET, V68, P115, DOI 10.1159/000133903; WALDREN C, 1984, CYTOMETRY, V5, P584, DOI 10.1002/cyto.990050606; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	17	24	26	1	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					200	201		10.1038/6209	http://dx.doi.org/10.1038/6209			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052360				2022-12-27	WOS:000078508300032
J	Bolin, F				Bolin, F			Leveling land mines with biotechnology	NATURE BIOTECHNOLOGY			English	Editorial Material																		1999, NATURE BIOTECHNOLOGY, V17, P491	1	2	2	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					732	732		10.1038/11615	http://dx.doi.org/10.1038/11615			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429219				2022-12-27	WOS:000081751400006
J	Agris, CH				Agris, CH			Patenting plants: What to claim	NATURE BIOTECHNOLOGY			English	Editorial Material									Baker & Botts LLP, Houston, TX 77002 USA		Agris, CH (corresponding author), Baker & Botts LLP, Houston, TX 77002 USA.							Agris CH, 1999, NAT BIOTECHNOL, V17, P197, DOI 10.1038/6205; BAGGOT B, 1999, GEN ENG NEWS, V2, P1; HOLZMAN D, 1999, GEN ENG NEWS, V2, P8; Moffat AS, 1998, SCIENCE, V282, P2176, DOI 10.1126/science.282.5397.2176; *OJEPO, 1995, T35693 OJEPO, P345; SEIDE RK, 1998, 8 ANN PAT PROS WORKS, P337; 5900525; 5639947; 5066830; 5783394; 5843782; 5436395; 5844118	13	6	6	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					717	718		10.1038/10938	http://dx.doi.org/10.1038/10938			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10409355				2022-12-27	WOS:000081296900035
J	Persidis, A				Persidis, A			Arthritis drug discovery	NATURE BIOTECHNOLOGY			English	Editorial Material									Argonex Inc, Business Dev, Charlottesville, VA 22901 USA		Persidis, A (corresponding author), Argonex Inc, Business Dev, 2044 India Rd, Charlottesville, VA 22901 USA.							Bernacka K, 1969, Reumatologia, V7, P207; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BRANEMARK PI, 1969, ACTA ORTHOP SCAND, V40, P153, DOI 10.3109/17453676908989496; BRANEMARK PI, 1969, ACTA ORTHOP SCAND, V40, P279, DOI 10.3109/17453676908989508; BUCHHOLZ HW, 1969, LANGENBECKS ARCH CHI, V325, P77; Evans CH, 1999, INTERNAL MED, V38, P233, DOI 10.2169/internalmedicine.38.233; Fernandez-Herlihy L, 1970, Lahey Clin Found Bull, V19, P124; GASTON JSH, 1986, ANN RHEUM DIS, V45, P932, DOI 10.1136/ard.45.11.932; Geis GS, 1999, J RHEUMATOL, V26, P31; Golden BD, 1999, RHEUM DIS CLIN N AM, V25, P359, DOI 10.1016/S0889-857X(05)70073-9; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; Kirwan JR, 1999, RHEUMATOLOGY, V38, P100, DOI 10.1093/rheumatology/38.2.100; Laan RFJM, 1999, RHEUMATOLOGY, V38, P6, DOI 10.1093/rheumatology/38.1.6; Lotz M, 1999, RHEUM DIS CLIN N AM, V25, P269, DOI 10.1016/S0889-857X(05)70067-3; Mandell BF, 1999, CLEV CLIN J MED, V66, P285; Mottonen T, 1999, LANCET, V353, P1568, DOI 10.1016/S0140-6736(98)08513-4; NILAS L, 1986, CLIN ENDOCRINOL, V25, P711, DOI 10.1111/j.1365-2265.1986.tb03627.x; PALOSUO T, 1978, CLIN IMMUNOL IMMUNOP, V10, P355, DOI 10.1016/0090-1229(78)90193-9; Persidis A, 1998, NAT BIOTECHNOL, V16, P882, DOI 10.1038/nbt0998-882; Shin H, 1999, ANN RHEUM DIS, V58, P55, DOI 10.1136/ard.58.1.55; Ushiyama T, 1999, ANN RHEUM DIS, V58, P7, DOI 10.1136/ard.58.1.7; Verhoef CM, 1999, ANN RHEUM DIS, V58, P49, DOI 10.1136/ard.58.1.49; WEDUM BG, 1970, ANN RHEUM DIS, V29, P516, DOI 10.1136/ard.29.5.516; Wendling D, 1999, REV RHUM, V66, P187	24	4	4	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					726	728		10.1038/10954	http://dx.doi.org/10.1038/10954			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10409361				2022-12-27	WOS:000081296900037
J	Waldo, GS; Standish, BM; Berendzen, J; Terwilliger, TC				Waldo, GS; Standish, BM; Berendzen, J; Terwilliger, TC			Rapid protein-folding assay using green fluorescent protein	NATURE BIOTECHNOLOGY			English	Article						protein folding; solubility; reporter; aggregation directed evolution; green fluorescent protein; inclusion body	MOLECULAR EVOLUTION; DIRECTED EVOLUTION; ESCHERICHIA-COLI; IN-VITRO; EXPRESSION; IDENTIFICATION; CHROMOPHORE; MUTATIONS; FERRITIN; MUTANTS	Formation of the chromophore of green fluorescent protein (GFP) depends on the correct folding of the protein. We constructed a "folding reporter" vector, in which a test protein is expressed as an N-terminal fusion with GFP. Using a test panel of 20 proteins, we demonstrated that the fluorescence of Escherichia coli cells expressing such GFP fusions is related to the productive folding of the upstream protein domains expressed alone. We used this fluorescent indicator of protein folding to evolve proteins that are normally prone to aggregation during expression in E. coli into closely related proteins that ford robustly and are fully soluble and functional. This approach to improving protein folding does not require functional assays for the protein of interest and provides a simple route to improving protein folding and expression by directed evolution.	Univ Calif Los Alamos Natl Lab, Struct Biol Grp, Los Alamos, NM 87545 USA; Univ Calif Los Alamos Natl Lab, Biophys Grp, Los Alamos, NM 87545 USA; Univ New Mexico, Albuquerque, NM 87131 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; University of New Mexico	Waldo, GS (corresponding author), Univ Calif Los Alamos Natl Lab, Struct Biol Grp, MS-M888, Los Alamos, NM 87545 USA.		Wood, David W/B-2992-2012; Terwilliger, Thomas/AEF-4827-2022; Terwilliger, Thomas/AAM-4079-2020; Terwilliger, Thomas C/K-4109-2012	Terwilliger, Thomas/0000-0001-6384-0320; Terwilliger, Thomas C/0000-0001-6384-0320; Berendzen, Joel/0000-0002-9454-9074				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Arnold FH, 1996, CHEM ENG SCI, V51, P5091, DOI 10.1016/S0009-2509(96)00288-6; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; DICKEY LF, 1987, J BIOL CHEM, V262, P7901; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; FitzGibbon S, 1997, EXTREMOPHILES, V1, P36, DOI 10.1007/s007920050013; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; JAPPELLI R, 1992, J MOL BIOL, V227, P532, DOI 10.1016/0022-2836(92)90905-Y; King J, 1996, FASEB J, V10, P57, DOI 10.1096/fasebj.10.1.8566549; MacBeath G, 1998, SCIENCE, V279, P1958, DOI 10.1126/science.279.5358.1958; Makino Y, 1997, J BIOL CHEM, V272, P12468, DOI 10.1074/jbc.272.19.12468; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; Martineau P, 1998, J MOL BIOL, V280, P117, DOI 10.1006/jmbi.1998.1840; MOOS T, 1993, HISTOCHEMISTRY, V99, P471; Neidhardt FC., 1987, ESCHERICHIA COLI SAL, V2nd ed, P3; Plaxco KW, 1998, J MOL BIOL, V277, P985, DOI 10.1006/jmbi.1998.1645; Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457; Reid BG, 1997, BIOCHEMISTRY-US, V36, P6786, DOI 10.1021/bi970281w; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; TERWILLIGER TC, 1994, J MOL BIOL, V236, P556, DOI 10.1006/jmbi.1994.1165; Terwilliger TC, 1998, PROTEIN SCI, V7, P1851, DOI 10.1002/pro.5560070901; WALDO GS, 1996, FERRITIN IRON BIOMIN, P65; Ward WW., 1981, BIOLUMINESCENCE CHEM, DOI 10.1016/b978-0-12-208820-9.50035-5; WILKINSON DL, 1991, BIO-TECHNOL, V9, P443, DOI 10.1038/nbt0591-443; Zhang Y, 1998, PROTEIN EXPRES PURIF, V12, P159, DOI 10.1006/prep.1997.0834; Zhao HM, 1997, NUCLEIC ACIDS RES, V25, P1307, DOI 10.1093/nar/25.6.1307; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	31	691	736	7	143	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					691	695		10.1038/10904	http://dx.doi.org/10.1038/10904			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404163				2022-12-27	WOS:000081296900030
J	de Bruin, R; Spelt, K; Mol, J; Koes, R; Quattrocchio, F				de Bruin, R; Spelt, K; Mol, J; Koes, R; Quattrocchio, F			Selection of high-affinity phage antibodies from phage display libraries	NATURE BIOTECHNOLOGY			English	Editorial Material							FLOWERS		Free Univ Amsterdam, BioCentrum Amsterdam, Inst Mol Biol Sci, Dept Dev Genet, NL-1081 HV Amsterdam, Netherlands	University of Amsterdam; Vrije Universiteit Amsterdam	Quattrocchio, F (corresponding author), Free Univ Amsterdam, BioCentrum Amsterdam, Inst Mol Biol Sci, Dept Dev Genet, Boelelaan 1087, NL-1081 HV Amsterdam, Netherlands.		Quattrocchio, Francesca M./N-6658-2019	Quattrocchio, Francesca M./0000-0001-8040-4061				Aida M, 1997, PLANT CELL, V9, P841, DOI 10.1105/tpc.9.6.841; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; Griffiths AD, 1998, CURR OPIN BIOTECH, V9, P102, DOI 10.1016/S0958-1669(98)80092-X; Kay B. K, 1996, PHAGE DISPLAY PEPTID; Mol J, 1998, TRENDS PLANT SCI, V3, P212, DOI 10.1016/S1360-1385(98)01242-4; Souer E, 1996, CELL, V85, P159, DOI 10.1016/S0092-8674(00)81093-4	6	81	97	1	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					397	399		10.1038/7959	http://dx.doi.org/10.1038/7959			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207892				2022-12-27	WOS:000079574400035
J	Gaensler, KML; Tu, GH; Bruch, S; Liggitt, D; Lipshutz, GS; Metkus, A; Harrison, M; Heath, TD; Debs, RJ				Gaensler, KML; Tu, GH; Bruch, S; Liggitt, D; Lipshutz, GS; Metkus, A; Harrison, M; Heath, TD; Debs, RJ			Fetal gene transfer by transuterine injection of cationic liposome-DNA complexes	NATURE BIOTECHNOLOGY			English	Article						gene therapy; gene transfer; cationic liposomes; fetus; in utero	HEMATOPOIETIC STEM-CELLS; IN-VIVO; TRANSGENIC MICE; HUMAN ALPHA-1-ANTITRYPSIN; ADENOVIRAL VECTOR; IMMUNE-RESPONSE; ADULT MICE; EXPRESSION; THERAPY; DELIVERY	In utero injection of cationic liposome-DNA complexes (CLDCs) containing chloramphenicol acetyltransferase, beta-galactosidase (beta-gal), or human granulocyte colony-stimulating factor (hG-CSF) expression plasmids produced high-level gene expression in fetal rats. Tissues adjacent to the injection site exhibited the highest levels of gene expression. Chloramphenicol acetyltransferase expression persisted for at least 14 days and was reexpressed following postnatal reinjection of CLDCs. Intraperitoneal administration of the hG-CSF gene produced high serum hG-CSF levels. X-gal staining demonstrated widespread beta-gal expression in multiple fetal tissues and cell types. No toxic or inflammatory responses were observed, nor was there evidence of fetal-maternal or maternal-fetal gene transfer, suggesting that CLDCs may provide a useful alternative to viral vectors for in utero gene transfer.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Calif Pacific Med Ctr, Inst Res, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA; Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA	University of California System; University of California San Francisco; California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; University of Wisconsin System; University of Wisconsin Madison	Gaensler, KML (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.			Lipshutz, Gerald/0000-0001-7876-6776	NHLBI NIH HHS [HL53762] Funding Source: Medline; NIDDK NIH HHS [DK49550, DK45917] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049550, R01DK045917] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTON EWFW, 1993, NAT GENET, V5, P135, DOI 10.1038/ng1093-135; BARTKE A, 1994, P SOC EXP BIOL MED, V206, P345, DOI 10.3181/00379727-206-43771; BOUT A, 1993, EXP LUNG RES, V19, P193, DOI 10.3109/01902149309031719; CANONICO AE, 1994, J APPL PHYSIOL, V77, P415, DOI 10.1152/jappl.1994.77.1.415; CANONICO AE, 1994, AM J RESP CELL MOL, V10, P24, DOI 10.1165/ajrcmb.10.1.8292378; CLAPP DW, 1991, BLOOD, V78, P1132, DOI 10.1182/blood.V78.4.1132.bloodjournal7841132; Cooper MJ, 1997, P NATL ACAD SCI USA, V94, P6450, DOI 10.1073/pnas.94.12.6450; DEBS R, 1992, AM J RESP CELL MOL, V7, P406, DOI 10.1165/ajrcmb/7.4.406; FLEISCHMAN RA, 1982, CELL, V30, P351, DOI 10.1016/0092-8674(82)90233-1; GAENSLER KML, 1993, P NATL ACAD SCI USA, V90, P11381, DOI 10.1073/pnas.90.23.11381; GILGENKRANTZ H, 1995, HUM GENE THER, V6, P1265, DOI 10.1089/hum.1995.6.10-1265; Halbert CL, 1997, J VIROL, V71, P5932, DOI 10.1128/JVI.71.8.5932-5941.1997; HATZOGLOU M, 1990, J BIOL CHEM, V265, P17285; HATZOGLOU M, 1995, SOMAT CELL MOLEC GEN, V21, P265, DOI 10.1007/BF02255781; HOITZMAN DM, 1996, ANN NEUROL, V39, P114; Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; ICHIKAWA T, 1995, EXP HEMATOL, V23, P192; Iwamoto HS, 1999, GENE THER, V6, P98, DOI 10.1038/sj.gt.3300804; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; Kafri T, 1998, P NATL ACAD SCI USA, V95, P11377, DOI 10.1073/pnas.95.19.11377; KAWAKAMI M, 1990, BLOOD, V76, P1962; KAY MA, 1992, HUM GENE THER, V3, P641, DOI 10.1089/hum.1992.3.6-641; Ketteler M, 1994, Curr Opin Nephrol Hypertens, V3, P446, DOI 10.1097/00041552-199407000-00011; Kurth R, 1995, ANN NY ACAD SCI, V772, P140, DOI 10.1111/j.1749-6632.1995.tb44739.x; Larson JE, 1997, LANCET, V349, P619, DOI 10.1016/S0140-6736(05)61567-X; LEDLEY FD, 1993, OBSTET GYN CLIN N AM, V3, P611; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; LOW JA, 1993, CLIN OBSTET GYNECOL, V36, P82, DOI 10.1097/00003081-199303000-00011; Mason CAE, 1999, NAT MED, V5, P176, DOI 10.1038/5538; MCCRAY PB, 1995, J CLIN INVEST, V95, P2620, DOI 10.1172/JCI117964; Mounkes LC, 1997, J LIPOS RES, V7, P161, DOI 10.3109/08982109709035493; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3; PANETH N, 1983, AM J OBSTET GYNECOL, V147, P960, DOI 10.1016/0002-9378(83)90254-5; PHILIP R, 1993, J BIOL CHEM, V268, P16087; PITT BR, 1995, GENE THER, V2, P344; Sambrook J., MOL CLONING LAB MANU; SEKHON HS, 1995, NAT MED, V1, P1201, DOI 10.1038/nm1195-1201; SOLODIN I, 1995, BIOCHEMISTRY-US, V34, P13537, DOI 10.1021/bi00041a033; SORSCHER EJ, 1994, HUM GENE THER, V5, P1259, DOI 10.1089/hum.1994.5.10-1259; STEWART MJ, 1992, HUM GENE THER, V3, P267, DOI 10.1089/hum.1992.3.3-267; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; THIERRY AR, 1995, P NATL ACAD SCI USA, V92, P9742, DOI 10.1073/pnas.92.21.9742; TOLES JF, 1989, P NATL ACAD SCI USA, V86, P7456, DOI 10.1073/pnas.86.19.7456; TSUKAMOTO M, 1995, NAT GENET, V9, P243, DOI 10.1038/ng0395-243; VINCENT MC, 1995, HUM GENE THER, V6, P1019, DOI 10.1089/hum.1995.6.8-1019; Walter J, 1996, P NATL ACAD SCI USA, V93, P3056, DOI 10.1073/pnas.93.7.3056; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	50	30	30	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1188	1192		10.1038/70729	http://dx.doi.org/10.1038/70729			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585716				2022-12-27	WOS:000084170700026
J	Persidis, A				Persidis, A			Antibacterial and antifungal drug discovery	NATURE BIOTECHNOLOGY			English	Editorial Material									RHeoGene, Charlottesville, VA 22903 USA		Persidis, A (corresponding author), RHeoGene, 706 Forest St, Charlottesville, VA 22903 USA.							Fleming A, 1929, BRIT J EXP PATHOL, V10, P226; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Ghannoum MA, 1999, CLIN MICROBIOL REV, V12, P501, DOI 10.1128/CMR.12.4.501; Hiemstra PS, 1999, J LEUKOCYTE BIOL, V66, P423, DOI 10.1002/jlb.66.3.423; Kirjavainen PV, 1999, ANN MED, V31, P288, DOI 10.3109/07853899908995892; Ma ZK, 1999, J MED CHEM, V42, P4202, DOI 10.1021/jm990191k; Moore PA, 1999, J AM DENT ASSOC, V130, P1341, DOI 10.14219/jada.archive.1999.0404; MOVAHED PV, 1999, J S C MED ASS, V95, P303; Ouellette AJ, 1999, AM J PHYSIOL-GASTR L, V277, pG257, DOI 10.1152/ajpgi.1999.277.2.G257; Sreenan C, 1999, ARCH PEDIAT ADOL MED, V153, P984, DOI 10.1001/archpedi.153.9.984	10	14	16	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1141	1142		10.1038/15141	http://dx.doi.org/10.1038/15141			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545930				2022-12-27	WOS:000083428000038
J	Ramirez, OT; Quintero, R				Ramirez, OT; Quintero, R			Pharmaceutical biotechnology emerges in Mexico	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Nacl Autonoma Mexico, Inst Biotechnol, Cuernavaca, Morelos, Mexico; Univ Nacl Autonoma Mexico, Inst Engn, Mexico City, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Ramirez, OT (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotechnol, Cuernavaca, Morelos, Mexico.	tonatiuh@ibt.unam.mx; quintero@ibt.unam.mx							0	1	1	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					934	934		10.1038/13587	http://dx.doi.org/10.1038/13587			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504675				2022-12-27	WOS:000083015700003
J	Halford, WP				Halford, WP			The essential prerequisites for quantitative RT-PCR	NATURE BIOTECHNOLOGY			English	Editorial Material							POLYMERASE CHAIN-REACTION; MESSENGER-RNA; EXPRESSION		Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Halford, WP (corresponding author), Univ Penn, Dept Microbiol, 221 Johnson Pavil, Philadelphia, PA 19104 USA.							Chandler DP, 1998, J IND MICROBIOL BIOT, V21, P128, DOI 10.1038/sj.jim.2900546; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GREEMAN WM, 1999, BIOTECHNIQUES, V26, P112; Haberhausen G, 1998, J CLIN MICROBIOL, V36, P628, DOI 10.1128/JCM.36.3.628-633.1998; Halford WP, 1999, ANAL BIOCHEM, V266, P181, DOI 10.1006/abio.1998.2913; Halford WP, 1997, VIROLOGY, V238, P53, DOI 10.1006/viro.1997.8806; Hill JM, 1996, ANAL BIOCHEM, V235, P44, DOI 10.1006/abio.1996.0089; Martell M, 1999, J CLIN MICROBIOL, V37, P327, DOI 10.1128/JCM.37.2.327-332.1999; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; SYKES PJ, 1992, BIOTECHNIQUES, V13, P444; VANDEVYVER C, 1995, CELL MOL BIOL, V41, P683; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WIESNER RJ, 1993, NATURE, V366, P416, DOI 10.1038/366416b0; Zhang CF, 1996, BIOCHEM BIOPH RES CO, V223, P450, DOI 10.1006/bbrc.1996.0914	14	49	53	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					835	835		10.1038/12783	http://dx.doi.org/10.1038/12783			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471906				2022-12-27	WOS:000082365800006
J	Greiner, S; Rausch, T; Sonnewald, U; Herbers, K				Greiner, S; Rausch, T; Sonnewald, U; Herbers, K			Ectopic expression of a tobacco invertase inhibitor homolog prevents cold-induced sweetening of potato tubers	NATURE BIOTECHNOLOGY			English	Article						potato; cold sweetening; vacuolar invertase; invertase inhibitor	CELL-WALL INVERTASE; SOLANUM-TUBEROSUM; STARCH; PROTEIN	We have transformed potato with Nt-inhh cDNA, encoding a putative vacuolar homolog of a tobacco cell wall invertase inhibitor, under the control of the CaMV 35S promoter. In transgenic tubers, cold-induced hexose accumulation was reduced by up to 75%, without any effect on potato tuber yield. Processing quality of tubers was greatly improved without changing starch quantity or quality, an important prerequisite for the biotechnological use of Nt-inhh for potato transformation.	Inst Bot, D-69120 Heidelberg, Germany; IPK Gatersleben, D-06466 Gatersleben, Germany	Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung	Rausch, T (corresponding author), Inst Bot, INF 360, D-69120 Heidelberg, Germany.	trausch@botanik1.bot.uni-heidelberg.de	Greiner, Steffen/D-3423-2014; Sonnewald, Uwe/J-7875-2012	Sonnewald, Uwe/0000-0003-1835-5339				BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Burton W.G., 1989, POTATO, V3rd ed.; Greiner S, 1998, PLANT PHYSIOL, V116, P733, DOI 10.1104/pp.116.2.733; GREINER S, 1995, PLANT PHYSIOL, V108, P825, DOI 10.1104/pp.108.2.825; GREINER S, Y12806 EMBL NUCL SEQ; HERBERS K, 1994, PLANTA, V194, P230, DOI 10.1007/BF01101682; HOFGEN R, 1990, PLANT SCI, V66, P221, DOI 10.1016/0168-9452(90)90207-5; ISHERWOO.FA, 1973, PHYTOCHEMISTRY, V12, P2579, DOI 10.1016/0031-9422(73)85060-5; Krausgrill S, 1998, PLANT J, V13, P275, DOI 10.1046/j.1365-313X.1998.00026.x; Lorberth R, 1998, NAT BIOTECHNOL, V16, P473, DOI 10.1038/nbt0598-473; Muller-Thurgau H., 1882, LANDW JB, V11, P751; POLLOCK CJ, 1975, PHYTOCHEMISTRY, V14, P613, DOI 10.1016/0031-9422(75)83003-2; ROCHASOSA M, 1989, EMBO J, V8, P23, DOI 10.1002/j.1460-2075.1989.tb03344.x; STARK DM, 1992, SCIENCE, V258, P287, DOI 10.1126/science.258.5080.287; Stark DM, 1996, ANN NY ACAD SCI, V792, P26, DOI 10.1111/j.1749-6632.1996.tb32487.x; STITT M, 1989, METHOD ENZYMOL, V174, P518; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEIL M, 1990, PLANT PHYSIOL, V94, P1575, DOI 10.1104/pp.94.4.1575; Zrenner R, 1996, PLANTA, V198, P246, DOI 10.1007/BF00206250; ZRENNER R, 1993, THESIS FREIE U BERLI	20	146	175	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					708	711		10.1038/10924	http://dx.doi.org/10.1038/10924			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404166				2022-12-27	WOS:000081296900033
J	Galvez, AF; de Lumen, BO				Galvez, AF; de Lumen, BO			A soybean cDNA encoding a chromatin-binding peptide inhibits mitosis of mammalian cells	NATURE BIOTECHNOLOGY			English	Article						antimitosis; chromatin-binding; soybean peptide; DNA endoreduplication	HUMAN CENTROMERE; CENP-B; PROTEINS; HOMOLOG; SEED; DNA; IDENTIFICATION; KINETOCHORE; EXPRESSION; METAPHASE	A soybean cDNA encoding the small subunit peptide of a cotyledon-specific 2S albumin (Gm2S-1) is thought to play a role in arresting mitosis during the DNA endoreduplication and cell expansion phase of seed development. The peptide (termed lunasin) contains the cell adhesion motif Arg-Gly-Asp (RGD) followed by eight aspartic acid residues at its C-terminal end. A chimeric gene encoding the lunasin peptide tagged with green fluorescent protein (GFP) arrested cell division, caused abnormal spindle fiber elongation, chromosomal fragmentation, and cell lysis when transiently transfected into murine embryo fibroblast, murine hepatoma, and human breast cancer cells. Deletion of the polyaspartyl end abolished the antimitotic effect. Subcellular localization of lunasin and immunobinding assay using synthetic peptides revealed the preferential adherence of lunasin to chromatin. Immunofluorescence showed that kinetochore proteins were displaced from the centromere in lunasin-transfected cells. These observations suggest that lunasin binds to the chromatin, leading to disruption of kinetochore formation and inhibition of mitosis.	Univ Calif Berkeley, Div Nutr Sci & Toxicol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	de Lumen, BO (corresponding author), Univ Calif Berkeley, Div Nutr Sci & Toxicol, Berkeley, CA 94720 USA.							AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; BENSASSON SA, 1995, METHOD CELL BIOL, V46, P29; CALVEZ AF, 1997, PLANT PHYSIOL, V114, P1567; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CONCEICAO AD, 1994, PLANT J, V5, P493, DOI 10.1046/j.1365-313X.1994.05040493.x; EARNSHAW WC, 1984, J CELL BIOL, V98, P352, DOI 10.1083/jcb.98.1.352; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; Erickson HP, 1997, TRENDS CELL BIOL, V7, P362, DOI 10.1016/S0962-8924(97)01108-2; GOLDBERG RB, 1994, SCIENCE, V266, P605, DOI 10.1126/science.266.5185.605; GOODWIN GH, 1978, CELL NUCLEUS, V6, P181; HAUXWELL AJ, 1990, DEVELOPMENT, V110, P283; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Higgins T. J. V., 1981, COMMENTARIES PLANT S, V2, P175; KENNEDY AR, 1995, J NUTR, V125, pS733, DOI 10.1093/jn/125.3_Suppl.733S; Lee JK, 1997, P NATL ACAD SCI USA, V94, P8427, DOI 10.1073/pnas.94.16.8427; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MANIATIS T, 1982, MOL CLONING LABORATO, P368; Margolin W, 1996, J BACTERIOL, V178, P1320, DOI 10.1128/jb.178.5.1320-1327.1996; ODANI S, 1987, J BIOL CHEM, V262, P10502; PLUTA AF, 1990, TRENDS BIOCHEM SCI, V15, P181, DOI 10.1016/0968-0004(90)90158-8; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SCHWEIZER L, 1995, P NATL ACAD SCI USA, V92, P7070, DOI 10.1073/pnas.92.15.7070; Ulitzur N, 1997, P NATL ACAD SCI USA, V94, P5084, DOI 10.1073/pnas.94.10.5084; Wilson Leslie, 1994, V13, P59; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	30	108	119	1	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					495	500		10.1038/8676	http://dx.doi.org/10.1038/8676			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331812				2022-12-27	WOS:000080074500037
J	Dove, AQ				Dove, AQ			Proteomics: translating genomics into products?	NATURE BIOTECHNOLOGY			English	Article							PROTEINS											BARRETT T, 1973, BIOCHIM BIOPHYS ACTA, V294, P165, DOI 10.1016/0005-2787(73)90323-7; Dongre AR, 1997, TRENDS BIOTECHNOL, V15, P418, DOI 10.1016/S0167-7799(97)01110-4; OFARREL PH, 1975, J BIOL CHEM, V250, P400; Oliver SG, 1998, TRENDS BIOTECHNOL, V16, P373, DOI 10.1016/S0167-7799(98)01214-1; Persidis A, 1998, NAT BIOTECHNOL, V16, P393, DOI 10.1038/nbt0498-393	5	109	126	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					233	236		10.1038/6972	http://dx.doi.org/10.1038/6972			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096288				2022-12-27	WOS:000078977500022
J	Oberpenning, F; Meng, J; Yoo, JJ; Atala, A				Oberpenning, F; Meng, J; Yoo, JJ; Atala, A			De novo reconstitution of a functional mammalian urinary bladder by tissue engineering	NATURE BIOTECHNOLOGY			English	Article						augmentation; cystoplasty; neo-bladder; cystectomy; cell culture	SMOOTH-MUSCLE; IN-VIVO; UROTHELIUM; URETEROCYSTOPLASTY; AUTOAUGMENTATION; REPLACEMENT; DETRUSOR; MEMBRANE; RABBIT; SYSTEM	Human organ replacement is limited by a donor shortage, problems with tissue compatibility, and rejection. Creation of an organ with autologous tissue would be advantageous. In this study, transplantable urinary bladder neo-organs were reproducibly created in vitro from urothelial and smooth muscle cells grown in culture from canine native bladder biopsies and seeded onto preformed bladder-shaped polymers. The native bladders were subsequently excised from canine donors and replaced with the tissue-engineered neo-organs. In functional evaluations for up to 11 months, the bladder neo-organs demonstrated a normal capacity to retain urine, normal elastic properties, and histologic architecture. This study demonstrates, for the first time, that successful reconstitution of an autonomous hollow organ is possible using tissue-engineering methods.	Childrens Hosp, Dept Urol, Lab Tissue Engn & Cellular Therapeut, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Atala, A (corresponding author), Childrens Hosp, Dept Urol, Lab Tissue Engn & Cellular Therapeut, 300 Longwood Ave, Boston, MA 02115 USA.		Sano, Michael/E-1715-2011	Atala, Anthony/0000-0001-8186-2160	NIDDK NIH HHS [R01 DK 49484] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049484] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atala A, 1998, J UROLOGY, V159, P2, DOI 10.1016/S0022-5347(01)63994-6; ATALA A, 1992, J UROLOGY, V148, P658, DOI 10.1016/S0022-5347(17)36685-5; ATALA A, 1993, J UROLOGY, V150, P608, DOI 10.1016/S0022-5347(17)35561-1; ATALA A, 1995, J UROLOGY, V156, P338; ATALA A, 1994, CLIN UROLOGY, P507; Atala Anthony, 1997, P149; BAKER R, 1958, JAMA-J AM MED ASSOC, V168, P1178, DOI 10.1001/jama.1958.03000090008002; BELLINGER MF, 1993, J UROLOGY, V149, P811, DOI 10.1016/S0022-5347(17)36215-8; BONA AV, 1966, UROLOGY, V18, P43; CARTWRIGHT PC, 1989, J UROLOGY, V142, P1050, DOI 10.1016/S0022-5347(17)38985-1; CHENG E, 1994, J UROLOGY, V152, P2252, DOI 10.1016/S0022-5347(17)31652-X; CILENTO BG, 1994, J UROLOGY, V152, P655; DEBOER WI, 1994, AM J PATHOL, V145, P1199; DEWAN PA, 1994, BRIT J UROL, V74, P460, DOI 10.1111/j.1464-410X.1994.tb00423.x; Freeman MR, 1997, J CLIN INVEST, V99, P1028, DOI 10.1172/JCI119230; FUJITA K, 1978, UROLOGY, V15, P355; GLEESON MJ, 1992, J UROLOGY, V148, P1377, DOI 10.1016/S0022-5347(17)36916-1; GONZALEZ R, 1995, UROLOGY, V45, P124, DOI 10.1016/S0090-4295(95)97364-8; GORHAM SD, 1989, EUR UROL, V16, P440; KELAMI A, 1970, EUR SURG RES, V2, P195, DOI 10.1159/000127514; Kropp BP, 1996, J UROLOGY, V156, P599, DOI 10.1016/S0022-5347(01)65761-6; KUDISH HG, 1957, J UROLOGY, V78, P232, DOI 10.1016/S0022-5347(17)66428-0; Lailas NG, 1996, J UROLOGY, V156, P1151, DOI 10.1016/S0022-5347(01)65740-9; MCDOUGAL WS, 1992, J UROLOGY, V147, P1199, DOI 10.1016/S0022-5347(17)37517-1; MONSOUR MJ, 1987, UROL RES, V15, P235; NEUHOF H, 1917, SURG GYNECOL OBSTET, V25, P383; Probst M, 1997, BRIT J UROL, V79, P505, DOI 10.1046/j.1464-410X.1997.00103.x; Rohrmann D, 1996, J UROLOGY, V156, P2094, DOI 10.1016/S0022-5347(01)65442-9; SALLE JLP, 1990, J UROLOGY, V144, P454, DOI 10.1016/S0022-5347(17)39487-9; Tobin Matthew S., 1994, Surgical Forum, V45, P786; TSUJI I, 1967, J UROLOGY, V98, P91, DOI 10.1016/S0022-5347(17)62828-3; TSUJI I, 1961, J UROLOGY, V85, P42, DOI 10.1016/S0022-5347(17)65279-0; WU XR, 1994, J BIOL CHEM, V269, P13716; Yoo JJ, 1997, J UROLOGY, V158, P1066, DOI 10.1016/S0022-5347(01)64390-8; Yoo JJ, 1998, UROLOGY, V51, P221, DOI 10.1016/S0090-4295(97)00644-4	35	588	658	2	68	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					149	155		10.1038/6146	http://dx.doi.org/10.1038/6146			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052350				2022-12-27	WOS:000078508300022
J	Hodgson, J				Hodgson, J			Scientists avert new GMO crisis	NATURE BIOTECHNOLOGY			English	News Item																			0	16	17	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					13	13		10.1038/71838	http://dx.doi.org/10.1038/71838			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625373	Bronze			2022-12-27	WOS:000084699900007
J	Dyck, MK; Gagne, D; Ouellet, M; Senechal, JF; Belanger, E; Lacroix, D; Sirard, MA; Pothier, F				Dyck, MK; Gagne, D; Ouellet, M; Senechal, JF; Belanger, E; Lacroix, D; Sirard, MA; Pothier, F			Seminal vesicle production and secretion of growth hormone into seminal fluid	NATURE BIOTECHNOLOGY			English	Article						transgenic mice; agriculture; genetic engineering; bioreactor	BINDING-PROTEINS; TRANSGENE EXPRESSION; REGULATED EXPRESSION; PROTEASE INHIBITOR; ACROSIN INHIBITOR; BOAR SPERMATOZOA; HEPARIN-BINDING; MAMMARY-GLAND; PLASMA; PROMOTER	Production of foreign proteins in the tissues of transgenic animals represents an efficient and economical method of producing therapeutic and pharmaceutical proteins. In this study, we demonstrate that the mouse P12 gene promoter specific to the male accessory sex gland can be used to generate transgenic mice that express human growth hormone (hGH) in their seminal vesicle epithelium. The hGH is secreted into the ejaculated seminal fluids with the seminal vesicle lumen contents containing concentrations of up to 0.5 mg/ml. As semen is a body fluid that can be collected easily on a continuous basis, the production of transgenic animals expressing pharmaceutical proteins into their seminal fluid could prove to be a viable alternative to use of the mammary gland as a bioreactor.	Univ Laval, Ctr Rech Biol Reprod, Dept Anim Sci, St Foy, PQ G1K 7P4, Canada	Laval University	Pothier, F (corresponding author), Univ Laval, Ctr Rech Biol Reprod, Dept Anim Sci, Pavillon Paul Comtois, St Foy, PQ G1K 7P4, Canada.		Sirard, Marc/A-9112-2011	Sirard, Marc Andre/0000-0001-8667-6682				Anderson L. L., 1993, P343; BREM G, 1989, MOL BIOL MED, V6, P531; Calvete JJ, 1997, FEBS LETT, V407, P201, DOI 10.1016/S0014-5793(97)00344-X; CECHOVA D, 1981, METHOD ENZYMOL, V80, P729; CECIM M, 1995, BIOL REPROD, V52, P1144, DOI 10.1095/biolreprod52.5.1144; Cerdan MG, 1998, MOL REPROD DEV, V49, P236, DOI 10.1002/(SICI)1098-2795(199803)49:3&lt;236::AID-MRD3&gt;3.0.CO;2-P; Chen LL, 1998, BIOL REPROD, V59, P1498, DOI 10.1095/biolreprod59.6.1498; EVANGELLSTA DJ, 1997, J CHROMATOGR B, V699, P383; Eyestone WH, 1999, TRANSGENIC ANIMALS IN AGRICULTURE, P177; Fink E, 1976, Methods Enzymol, V45, P825; Fritz H, 1976, Methods Enzymol, V45, P834; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; GUERIN SL, 1990, J BIOL CHEM, V265, P22035; Hogan B, 1994, MANIPULATING MOUSE E; Houdebine LM, 1995, REPROD NUTR DEV, V35, P609, DOI 10.1051/rnd:19950601; HUHTALA ML, 1984, H-S Z PHYSIOL CHEM, V365, P819, DOI 10.1515/bchm2.1984.365.2.819; JANNE J, 1994, INT J BIOCHEM, V26, P859, DOI 10.1016/0020-711X(94)90078-7; Kerr DE, 1998, NAT BIOTECHNOL, V16, P75, DOI 10.1038/nbt0198-75; MELOUN B, 1983, H-S Z PHYSIOL CHEM, V364, P1665, DOI 10.1515/bchm2.1983.364.2.1665; MILLS JS, 1987, NUCLEIC ACIDS RES, V15, P7709, DOI 10.1093/nar/15.19.7709; MILLS JS, 1987, EMBO J, V6, P3711, DOI 10.1002/j.1460-2075.1987.tb02705.x; MOOS J, 1992, MOL REPROD DEV, V33, P165, DOI 10.1002/mrd.1080330208; NEEDHAM M, 1988, NUCLEIC ACIDS RES, V16, P6229, DOI 10.1093/nar/16.13.6229; PARRY RV, 1992, MOL REPROD DEV, V33, P108, DOI 10.1002/mrd.1080330115; Pursel V G, 1990, J Reprod Fertil Suppl, V40, P235; Rosen Jeffrey M., 1996, American Journal of Clinical Nutrition, V63, p627S; SANZ L, 1993, MOL REPROD DEV, V35, P37, DOI 10.1002/mrd.1080350107; Setchell B.P., 1988, P753; SWANSON ME, 1992, BIO-TECHNOL, V10, P557, DOI 10.1038/nbt0592-557; TSCHESCHE H, 1982, EUR J BIOCHEM, V126, P99, DOI 10.1111/j.1432-1033.1982.tb06752.x; Wall RJ, 1997, J DAIRY SCI, V80, P2213, DOI 10.3168/jds.S0022-0302(97)76170-8; WILKINSON HA, 1992, CLIN J PAIN, V8, P49, DOI 10.1097/00002508-199203000-00010; 1999, SPERMNOTES MINITUBE, V3, P1	33	25	29	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1087	1090		10.1038/15067	http://dx.doi.org/10.1038/15067			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545914				2022-12-27	WOS:000083428000025
J	Miller, HI				Miller, HI			Substantial equivalence: Its uses and abuses	NATURE BIOTECHNOLOGY			English	Editorial Material																		[Anonymous], 1992, Nature, V356, P1; [Anonymous], 1992, FED REG, V57, p[22, 984, 988, 991]; [Anonymous], 1993, SAFETY EVALUATION FO; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; MACKENZIE D, 1999, NEWS SCI        0417; Masood E, 1999, NATURE, V398, P98, DOI 10.1038/18086; Millstone E, 1999, NATURE, V401, P525, DOI 10.1038/44006; 1986, RECOMBINANT DNA SAFE; 1989, FIELD TESTING GENETI; 1998, OECD WORKSH TOX NUTR	10	24	26	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1042	1043		10.1038/14987	http://dx.doi.org/10.1038/14987			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545866				2022-12-27	WOS:000083428000003
J	Rangel-Aldao, R				Rangel-Aldao, R			International agbio consortium takes shape in Beijing	NATURE BIOTECHNOLOGY			English	Editorial Material									Empresas Polar, Ctr Tecnol Polar, Caracas, Venezuela		Rangel-Aldao, R (corresponding author), Empresas Polar, Ctr Tecnol Polar, Caracas, Venezuela.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1044	1044		10.1038/14988	http://dx.doi.org/10.1038/14988			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545867	Bronze			2022-12-27	WOS:000083428000004
J	Syvanen, M				Syvanen, M			In search of horizontal gene transfer	NATURE BIOTECHNOLOGY			English	Editorial Material							DNA; TRANSFORMATION; MICE		Univ Calif Davis, Sch Med, Dept Microbiol & Immunol, Davis, CA 95616 USA	University of California System; University of California Davis	Syvanen, M (corresponding author), Univ Calif Davis, Sch Med, Dept Microbiol & Immunol, Davis, CA 95616 USA.							de Vries J, 1998, MOL GEN GENET, V257, P606, DOI 10.1007/s004380050688; Gebhard F, 1998, APPL ENVIRON MICROB, V64, P1550; SCHLUTER K, 1995, BIO-TECHNOL, V13, P1094, DOI 10.1038/nbt1095-1094; Schubbert R, 1998, MOL GEN GENET, V259, P569, DOI 10.1007/s004380050850; Schubbert R, 1997, P NATL ACAD SCI USA, V94, P961, DOI 10.1073/pnas.94.3.961; *US FOOD DRUG ADM, 1995, FDAS POL FOODS DEV B	6	18	19	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					833	833		10.1038/12781	http://dx.doi.org/10.1038/12781			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471904				2022-12-27	WOS:000082365800004
J	Chaerle, L; Van Caeneghem, W; Messens, E; Lambers, H; Van Montagu, M; Van Der Straeten, D				Chaerle, L; Van Caeneghem, W; Messens, E; Lambers, H; Van Montagu, M; Van Der Straeten, D			Presymptomatic visualization of plant-virus interactions by thermography	NATURE BIOTECHNOLOGY			English	Article						infrared thermography; plant-pathogen interaction; respiration; salicylic acid; TMV tobacco; transpiration	TOBACCO MOSAIC-VIRUS; SYSTEMIC ACQUIRED-RESISTANCE; SALICYLIC-ACID; INFECTED TOBACCO; GENE-EXPRESSION; INDUCTION; SIGNAL; HYDROXYLASE; TEMPERATURE; RESPIRATION	Salicylic acid (SA), produced by plants as a signal in defense against pathogens, induces metabolic heating mediated by alternative respiration in flowers of thermogenic plants, and, when exogenously applied, increases leaf temperature in nonthermogenic plants. We have postulated that the latter phenomenon would be detectable when SA is synthesized locally in plant leaves. Here, resistance to tobacco mosaic virus (TMV) was monitored thermographically before any disease symptoms became visible on tobacco leaves. Spots of elevated temperature that were confined to the place of infection increased in intensity from 8 h before the onset of visible cell death, and remained detectable as a halo around the ongoing necrosis. Salicylic acid accumulates during the prenecrotic phase in TMV-infected tobacco and is known to induce stomatal closure in certain species. We show that the time course of SA accumulation correlates with the evolution of both localized thermal effect and stomatal closure. Since the contribution of leaf respiration is marginal, we concluded that the thermal effect results predominantly from localized, SA-induced stomatal closure. The presymptomatic temperature increase could be of general significance in incompatible plant-pathogen interactions.	State Univ Ghent VIB, Dept Plantengenet, Genet Lab, B-9000 Ghent, Belgium; Univ Western Australia, Fac Agr, Nedlands, WA 6907, Australia; Univ Utrecht, Dept Plant Ecol & Evolutionary Biol, NL-3584 CA Utrecht, Netherlands	Flanders Institute for Biotechnology (VIB); Ghent University; University of Western Australia; Utrecht University	Van Der Straeten, D (corresponding author), State Univ Ghent VIB, Dept Plantengenet, Genet Lab, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	dostr@gengenp.rug.ac.be	Lambers, Hans/A-1544-2008; Van Der Straeten, Dominique/E-7385-2016	Lambers, Hans/0000-0002-4118-2272; Van Der Straeten, Dominique/0000-0002-7755-1420				Bachem CWB, 1996, PLANT J, V9, P745, DOI 10.1046/j.1365-313X.1996.9050745.x; BI YM, 1995, PLANT J, V8, P235, DOI 10.1046/j.1365-313X.1995.08020235.x; Breidenbach RW, 1997, PLANT PHYSIOL, V114, P1137, DOI 10.1104/pp.114.4.1137; Chivasa S, 1997, PLANT CELL, V9, P547, DOI 10.1105/tpc.9.4.547; Chivasa S, 1998, PLANT CELL, V10, P1489, DOI 10.1105/tpc.10.9.1489; Day DA, 1996, PLANT PHYSIOL, V110, P1, DOI 10.1104/pp.110.1.1; DECAROLIS C, 1975, P 10 INT S REM SENS, P659; ENYEDI AJ, 1992, P NATL ACAD SCI USA, V89, P2480, DOI 10.1073/pnas.89.6.2480; Friedrich L, 1995, PLANT MOL BIOL, V29, P959, DOI 10.1007/BF00014969; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; LARQUESAAVEDRA A, 1979, Z PFLANZENPHYSIOL, V93, P371, DOI 10.1016/S0044-328X(79)80271-8; Lennon AM, 1997, PLANT PHYSIOL, V115, P783, DOI 10.1104/pp.115.2.783; Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199; LIANG P, 1997, METHODS MOL BIOL, V85; MALAMY J, 1992, PLANT CELL, V4, P359, DOI 10.1105/tpc.4.3.359; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MANTHE B, 1992, J CHEM ECOL, V18, P1525, DOI 10.1007/BF00993226; MCNULTY AK, 1987, PLANT CELL ENVIRON, V10, P319, DOI 10.1111/j.1365-3040.1987.tb01612.x; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; Mur LAJ, 1997, PLANT J, V12, P1113, DOI 10.1046/j.1365-313X.1997.12051113.x; NILLSSON HE, 1995, ANNU REV PHYTOPATHOL, V15, P489; RASKIN I, 1989, P NATL ACAD SCI USA, V86, P2214, DOI 10.1073/pnas.86.7.2214; RASKIN I, 1988, PLANTA, V173, P73, DOI 10.1007/BF00394490; *SAS I INC, 1992, P229 SAS I INC; UKNES S, 1993, PLANT CELL, V5, P159, DOI 10.1105/tpc.5.2.159; Van Der Straeten D, 1995, PLANTA, V196, P412, DOI 10.1007/BF00203637; Weyers J. D. B., 1990, METHODS STOMATAL RES; WHENHAM RJ, 1981, PHYSIOL PLANT PATHOL, V18, P267; YALPANI N, 1991, PLANT CELL, V3, P809, DOI 10.1105/tpc.3.8.809	29	116	127	0	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					813	816		10.1038/11765	http://dx.doi.org/10.1038/11765			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429250				2022-12-27	WOS:000081751400034
J	Chowdhury, PS; Pastan, I				Chowdhury, PS; Pastan, I			Improving antibody affinity by mimicking somatic hypermutation in vitro	NATURE BIOTECHNOLOGY			English	Article						phage display; single-chain antibody; hot spots; affinity improvement	SINGLE-CHAIN FV; PHAGE DISPLAY; RECOMBINANT IMMUNOTOXIN; PSEUDOMONAS EXOTOXIN; ANTITUMOR-ACTIVITY; BREAST-CANCER; MATURATION; SELECTION; MUTATION; MUTAGENESIS	In vivo affinity maturation of antibodies involves mutation of hot spots in the DNA encoding the variable regions. We have used this information to develop a strategy to improve antibody affinity in vitro using phage display technology. In our experiment with the antimesothelin scFv, SS(scFv), we identified DNA sequences in the variable regions that are naturally prone to hypermutations, selected a few hot spots encoding nonconserved amino acids, and introduced random mutations to make libraries with a size requirement between 10(3) and 10(4) independent clones. Fanning of the hot spot libraries yielded several mutants with a 15- to 55-fold increase in affinity compared with a single clone with a fourfold increased affinity from a library in which mutagenesis was done outside the hot spots. The strategy should be generally applicable for the rapid isolation of higher-affinity mutants of Fvs, Fabs, and other recombinant antibodies from antibody phage libraries that are small in size.	NCI, Mol Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pastan, I (corresponding author), NCI, Mol Biol Lab, Div Basic Sci, NIH, Bldg 37,Room 4E16, Bethesda, MD 20892 USA.	pasta@helix.nih.gov	pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				Adams GP, 1998, CANCER RES, V58, P485; ADAMS GP, 1993, CANCER RES, V53, P4026; BARBAS CF, 1993, J MOL BIOL, V230, P812, DOI 10.1006/jmbi.1993.1203; Baselga J, 1998, CANCER RES, V58, P2825; BRINKMANN U, 1991, P NATL ACAD SCI USA, V88, P8616, DOI 10.1073/pnas.88.19.8616; Chang K, 1996, P NATL ACAD SCI USA, V93, P136, DOI 10.1073/pnas.93.1.136; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; Chowdhury PS, 1998, J MOL BIOL, V281, P917, DOI 10.1006/jmbi.1998.1980; Chowdhury PS, 1998, P NATL ACAD SCI USA, V95, P669, DOI 10.1073/pnas.95.2.669; CLAUSS MA, 1990, CANCER RES, V50, P3487; DEKRUIF J, 1995, J MOL BIOL, V248, P97, DOI 10.1006/jmbi.1995.0204; Goldhirsch A, 1998, ANN ONCOL, V9, P973, DOI 10.1023/A:1008436810268; GOLDING GB, 1987, GENETICS, V115, P169; GONZALEZFERNANDEZ A, 1994, P NATL ACAD SCI USA, V91, P12614, DOI 10.1073/pnas.91.26.12614; Goyenechea B, 1996, P NATL ACAD SCI USA, V93, P13979, DOI 10.1073/pnas.93.24.13979; GRAM H, 1992, P NATL ACAD SCI USA, V89, P3576, DOI 10.1073/pnas.89.8.3576; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; INSEL RA, 1994, INT IMMUNOL, V6, P1437, DOI 10.1093/intimm/6.9.1437; JAIN RK, 1990, CANCER RES, V50, pS814; JOHNSON G, 1996, WEIRS HDB EXPT IMMUN, V1, pCH6; Jolly C J, 1996, Semin Immunol, V8, P159, DOI 10.1006/smim.1996.0020; KOLCHANOV NA, 1987, FEBS LETT, V214, P87, DOI 10.1016/0014-5793(87)80018-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; Maloney DG, 1997, BLOOD, V90, P2188; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; Osterborg A, 1997, J CLIN ONCOL, V15, P1567, DOI 10.1200/JCO.1997.15.4.1567; Pai LH, 1996, NAT MED, V2, P350, DOI 10.1038/nm0396-350; Pini A, 1998, J BIOL CHEM, V273, P21769, DOI 10.1074/jbc.273.34.21769; Reiter Y, 1996, NAT BIOTECHNOL, V14, P1239, DOI 10.1038/nbt1096-1239; ROGOZIN IB, 1991, BIOCHIM BIOPHYS ACTA, V1089, P175, DOI 10.1016/0167-4781(91)90005-7; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; WAGNER SD, 1995, NATURE, V376, P732, DOI 10.1038/376732a0; WALDMANN TA, 1995, BLOOD, V86, P4063, DOI 10.1182/blood.V86.11.4063.bloodjournal86114063; Wu HR, 1998, P NATL ACAD SCI USA, V95, P6037, DOI 10.1073/pnas.95.11.6037; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626; YELTON DE, 1995, J IMMUNOL, V155, P1994; YOKOTA T, 1992, CANCER RES, V52, P3402	38	201	287	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					568	572		10.1038/9872	http://dx.doi.org/10.1038/9872			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385321				2022-12-27	WOS:000080716500028
J	Gilles, PN; Wu, DJ; Foster, CB; Dillon, PJ; Chanock, SJ				Gilles, PN; Wu, DJ; Foster, CB; Dillon, PJ; Chanock, SJ			Single nucleotide polymorphic discrimination by an electronic dot blot assay on semiconductor microchips	NATURE BIOTECHNOLOGY			English	Article						single nucleotide polymorphism; mannose binding protein; microarray; chip	MANNOSE-BINDING PROTEIN; HUMAN GENOME; DNA; HYBRIDIZATION; INFECTION; GENE; MUTATIONS; ALLELE; CHIPS	We have developed a rapid assay for single nucleotide polymorphism (SNP) detection that utilizes electronic circuitry on silicon microchips. The method was validated by the accurate discrimination of blinded DNA samples for the complex quadra-allelic SNP of mannose binding protein. The microchip directed the transport, concentration, and attachment of amplified patient DNA to selected electrodes (test sites) creating an array of DNA samples. Through control of the electric field, the microchip enabled accurate genetic identification of these samples using fluorescently labeled DNA reporter probes. The accuracy of this approach was established by internal controls of dual labeled reporters and by using mismatched sequences in addition to the wild-type and variant reporter sequences to validate the SNP-genotype. The ability to customize this assay for multiple genes has advantages over other existing approaches.	Nanogen Inc, San Diego, CA 92121 USA; NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wu, DJ (corresponding author), Nanogen Inc, 10398 Pacific Ctr Ct, San Diego, CA 92121 USA.	dwu@nanogen.com						Cheng J, 1998, NAT BIOTECHNOL, V16, P541, DOI 10.1038/nbt0698-541; Cheng J, 1998, ANAL CHEM, V70, P2321, DOI 10.1021/ac971274g; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; COOPER DN, 1985, HUM GENET, V69, P201, DOI 10.1007/BF00293024; Edman CF, 1997, NUCLEIC ACIDS RES, V25, P4907, DOI 10.1093/nar/25.24.4907; Epstein J, 1996, CURR OPIN IMMUNOL, V8, P29, DOI 10.1016/S0952-7915(96)80101-4; Ezekowitz A, 1996, LANCET, V348, P1396, DOI 10.1016/S0140-6736(05)67498-3; Foster CB, 1998, J CLIN INVEST, V102, P2146, DOI 10.1172/JCI5084; Fu DJ, 1998, NAT BIOTECHNOL, V16, P381, DOI 10.1038/nbt0498-381; Garred P, 1997, LANCET, V349, P236, DOI 10.1016/S0140-6736(96)08440-1; Hilsum, 1993, HDB SEMICONDUCTORS; Housman D, 1998, NAT BIOTECHNOL, V16, P492, DOI 10.1038/nbt0698-492; JEFFREYS AJ, 1979, CELL, V18, P1, DOI 10.1016/0092-8674(79)90348-9; Kornman KS, 1997, J CLIN PERIODONTOL, V24, P72, DOI 10.1111/j.1600-051X.1997.tb01187.x; LIVAK KJ, 1995, NAT GENET, V9, P341, DOI 10.1038/ng0495-341; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; Malmgren H, 1996, CLIN GENET, V50, P202; Marshall A, 1998, NAT BIOTECHNOL, V16, P27, DOI 10.1038/nbt0198-27; Marshall E, 1998, SCIENCE, V279, P317, DOI 10.1126/science.279.5349.317; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; Pennisi E, 1998, SCIENCE, V280, P814, DOI 10.1126/science.280.5365.814; Piatek AS, 1998, NAT BIOTECHNOL, V16, P359, DOI 10.1038/nbt0498-359; Schafer AJ, 1998, NAT BIOTECHNOL, V16, P33, DOI 10.1038/nbt0198-33; Sosnowski RG, 1997, P NATL ACAD SCI USA, V94, P1119, DOI 10.1073/pnas.94.4.1119; Sullivan KE, 1996, ARTHRITIS RHEUM, V39, P2046, DOI 10.1002/art.1780391214; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; Summerfield JA, 1997, BRIT MED J, V314, P1229, DOI 10.1136/bmj.314.7089.1229; Thomas HC, 1996, LANCET, V348, P1417, DOI 10.1016/S0140-6736(96)05409-8; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; VANZANT P, 1997, MICROCHIP FABRICATIO; Vesell ES, 1997, ANN INTERN MED, V126, P653, DOI 10.7326/0003-4819-126-8-199704150-00012; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Weiler J, 1997, NUCLEIC ACIDS RES, V25, P2792, DOI 10.1093/nar/25.14.2792; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; Yates CR, 1997, ANN INTERN MED, V126, P608, DOI 10.7326/0003-4819-126-8-199704150-00003; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P3929, DOI 10.1093/nar/19.14.3929	37	194	233	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					365	370		10.1038/7921	http://dx.doi.org/10.1038/7921			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207885				2022-12-27	WOS:000079574400025
J	Beck, S; Olek, A; Walter, J				Beck, S; Olek, A; Walter, J			From genomics to epigenomics: a loftier view of life	NATURE BIOTECHNOLOGY			English	Editorial Material									Sanger Ctr, Cambridge, England; Epigen GMBH, Berlin, Germany; Max Planck Inst Mol Genet, Berlin, Germany	Wellcome Trust Sanger Institute; Max Planck Society	Beck, S (corresponding author), Sanger Ctr, Cambridge, England.							Gasser SM, 1998, CELL MOL LIFE SCI, V54, P1, DOI 10.1007/s000180050120; Heinrich R, 1998, BIOSYSTEMS, V47, P61, DOI 10.1016/S0303-2647(98)00013-6; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Rasnick D, 1999, BIOCHEM J, V340, P621, DOI 10.1042/0264-6021:3400621; Reik W, 1999, NAT GENET, V23, P380, DOI 10.1038/70476; Reik W, 1998, CURR OPIN GENET DEV, V8, P154, DOI 10.1016/S0959-437X(98)80136-6; Strohman RC, 1999, NAT BIOTECHNOL, V17, P112, DOI 10.1038/6074	7	59	64	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1144	1144		10.1038/70651	http://dx.doi.org/10.1038/70651			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585673	Bronze			2022-12-27	WOS:000084170700003
J	Driver, SE; Robinson, GS; Flanagan, J; Shen, W; Smith, LEH; Thomas, DW; Roberts, PC				Driver, SE; Robinson, GS; Flanagan, J; Shen, W; Smith, LEH; Thomas, DW; Roberts, PC			Oligonucleotide-based inhibition of embryonic gene expression	NATURE BIOTECHNOLOGY			English	Article						gene function; knockout; antisense; oligonucleotide; angiogenesis; development	ENDOTHELIAL GROWTH-FACTOR; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; TARGETED MUTATIONS; VEGF; TRANSCRIPTION; INJECTION; LETHALITY; RECEPTORS; MOLECULE; BINDING	We describe a technique to define gene function using antisense oligonucleotide (AS-ODN) inhibition of gene expression in mice. A single intravenous injection of an AS-ODN targeting vascular endothelial growth factor (VEGF) into pregnant mice between E7.5-8.5 resulted in a lack of primary angiogenesis. This enabled us to define the critical window required to inhibit VEGF expression and recapitulate the primary loss of function phenotype observed in VEGF (-/-) embryos. This phenotype was sequence-specific and time- and dose-dependent. Injection of an AS-ODN targeting a second gene, E-cadherin, into pregnant mice at E10 confirmed a hypothesized secondary phenotype. This is the first report of AS-ODN inhibition of gene expression in utero and provides a new strategy for target validation in functional genomics.	QIK Technol Inc, Boston, MA USA; Ontogeny Inc, Cambridge, MA USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA; Tanox Biosyst Inc, Houston, TX 77025 USA; Genzyme Corp, Cambridge, MA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Sanofi-Aventis; Genzyme Corporation	Driver, SE (corresponding author), QIK Technol Inc, Boston, MA USA.							Aiello LP, 1994, NEW ENGL J MED, V331, P480; ANDERSON H, 1990, EXPERIENTIA, V46, P2, DOI 10.1007/BF01955407; Baumgartner I, 1998, VASA-J VASCULAR DIS, V27, P201; BOURQUE AJ, 1994, J CHROMATOGR B, V662, P343, DOI 10.1016/0378-4347(94)00207-X; Bramlage B, 1998, TRENDS BIOTECHNOL, V16, P434, DOI 10.1016/S0167-7799(98)01236-0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHEN BY, 1995, BIOL REPROD, V53, P1229, DOI 10.1095/biolreprod53.5.1229; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Christoffersen RE, 1997, NAT BIOTECHNOL, V15, P483, DOI 10.1038/nbt0697-483; Dickinson LA, 1998, P NATL ACAD SCI USA, V95, P12890, DOI 10.1073/pnas.95.22.12890; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Gaudette M F, 1993, Antisense Res Dev, V3, P391; Grunstein J, 1999, CANCER RES, V59, P1592; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Hynes RO, 1997, THROMB HAEMOSTASIS, V78, P83; Jones DA, 1999, CURR OPIN CHEM BIOL, V3, P71, DOI 10.1016/S1367-5931(99)80013-1; Juliano RL, 1999, PHARM RES-DORDR, V16, P494, DOI 10.1023/A:1011958726518; Kitamoto Y, 1997, J CLIN INVEST, V99, P2351, DOI 10.1172/JCI119416; Lai LW, 1999, EXP NEPHROL, V7, P11; Mei HY, 1997, BIOORGAN MED CHEM, V5, P1173, DOI 10.1016/S0968-0896(97)00064-3; Nyce JW, 1999, TRENDS PHARMACOL SCI, V20, P79, DOI 10.1016/S0165-6147(99)01305-X; Osterrieder N, 1998, REV SCI TECH OIE, V17, P351, DOI 10.20506/rst.17.1.1100; PACIFICI GM, 1995, CLIN PHARMACOKINET, V28, P235, DOI 10.2165/00003088-199528030-00005; Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851; Rockwell P, 1997, P NATL ACAD SCI USA, V94, P6523, DOI 10.1073/pnas.94.12.6523; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; Smyth AP, 1997, J INVEST DERMATOL, V108, P523, DOI 10.1111/1523-1747.ep12289740; Takeichi M, 1997, COLD SPRING HARB SYM, V62, P505; Tatton WG, 1997, J NEURAL TRANSM-SUPP, P245; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yu D, 1996, BIOORGAN MED CHEM, V4, P1685, DOI 10.1016/0968-0896(96)00160-5; Zhao QY, 1998, ANTISENSE NUCLEIC A, V8, P451, DOI 10.1089/oli.1.1998.8.451	35	23	27	1	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1184	1187		10.1038/70724	http://dx.doi.org/10.1038/70724			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585715				2022-12-27	WOS:000084170700025
J	Grossel, MJ; Wang, HM; Gadea, B; Yeung, W; Hinds, PW				Grossel, MJ; Wang, HM; Gadea, B; Yeung, W; Hinds, PW			A yeast two-hybrid system for discerning differential interactions using multiple baits	NATURE BIOTECHNOLOGY			English	Article							PROTEIN-PROTEIN INTERACTIONS; REVERSE 2-HYBRID; PHOSPHATASE; ACTIVATOR; INHIBITOR		Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Hinds, PW (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.				NIGMS NIH HHS [GM55684] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Inouye C, 1997, GENETICS, V147, P479; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; MA J, 1988, CELL, V55, P443, DOI 10.1016/0092-8674(88)90030-X; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Xu CW, 1997, P NATL ACAD SCI USA, V94, P12473, DOI 10.1073/pnas.94.23.12473	12	11	14	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1232	1233		10.1038/70792	http://dx.doi.org/10.1038/70792			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585727				2022-12-27	WOS:000084170700037
J	Lanza, RP; Cibelli, JB; West, MD				Lanza, RP; Cibelli, JB; West, MD			Prospects for the use of nuclear transfer in human transplantation	NATURE BIOTECHNOLOGY			English	Review						therapeutic cloning; nuclear transfer; transplantation; tissue engineering; stem cell	CELLS; EXPRESSION; CLEAVAGE; EMBRYOS; FETAL	The successful application of nuclear transfer techniques to a range of mammalian species has brought the possibility of human therapeutic cloning significantly closer The objective of therapeutic cloning is to produce pluripotent stem cells that carry the nuclear genome of the patient and then induce them to differentiate into replacement cells, such as cardiomyocytes to replace damaged heart tissue or insulin-producing beta cells for patients with diabetes. Although cloning would eliminate the critical problem of immune incompatibility, there is also the task of reconstituting the cells into more complex tissues and organs in vitro. In the review, we discuss recent progress that has been made in this field as well as the inherent dangers and scientific challenges that remain before these techniques can be used to harness genetically matched cells and tissues for human transplantation.	Adv Cell Technol, Worcester, MA 01605 USA		Lanza, RP (corresponding author), Adv Cell Technol, Worcester, MA 01605 USA.	rlanza@advancedcell.com		Cibelli, Jose/0000-0002-2176-3854; West, Michael/0000-0002-4842-5468				Baguisi A, 1999, NAT BIOTECHNOL, V17, P456, DOI 10.1038/8632; BONDIOLI KR, 1993, MOL REPROD DEV, V36, P274, DOI 10.1002/mrd.1080360229; BRAUDE P, 1988, NATURE, V332, P459, DOI 10.1038/332459a0; BRIGGS R, 1952, P NATL ACAD SCI USA, V38, P455, DOI 10.1073/pnas.38.5.455; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; Cibelli JB, 1998, NAT BIOTECHNOL, V16, P642, DOI 10.1038/nbt0798-642; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; CROSBY IM, 1988, J REPROD FERTIL, V82, P769, DOI 10.1530/jrf.0.0820769; Cummins J, 1998, REV REPROD, V3, P172, DOI 10.1530/ror.0.0030172; Dominko T, 1999, BIOL REPROD, V60, P1496, DOI 10.1095/biolreprod60.6.1496; Galton DJ, 1998, NAT MED, V4, P644, DOI 10.1038/nm0698-644a; JONES JM, 1995, ZYGOTE, V3, P133, DOI 10.1017/S0967199400002501; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; Kenyon L, 1997, P NATL ACAD SCI USA, V94, P9131, DOI 10.1073/pnas.94.17.9131; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Lanza RP, 1999, NAT MED, V5, P975, DOI 10.1038/12404; Lanza RP, 1999, SCIENCE, V283, P1849; LANZA RP, 1996, YB CELL TISSUE TRANS; LANZA RP, IN PRESS PRINCIPLES; MCGRATH J, 1983, SCIENCE, V220, P1300, DOI 10.1126/science.6857250; MCKINNELL RG, 1962, J HERED, V53, P199, DOI 10.1093/oxfordjournals.jhered.a107171; Meirelles FV, 1999, THERIOGENOLOGY, V51, P209, DOI 10.1016/S0093-691X(99)91768-5; Meng L, 1997, BIOL REPROD, V57, P454, DOI 10.1095/biolreprod57.2.454; PASTERNAK RC, 1991, HARRISONS PRINCIPLES, P953; Pennisi E, 1998, SCIENCE, V279, P646, DOI 10.1126/science.279.5351.646; PRATHER RS, 1993, J REPROD FERTIL, P17; Renard JP, 1999, LANCET, V353, P1489, DOI 10.1016/S0140-6736(98)12173-6; ROBL J, 1998, Patent No. 07841; Shiels PG, 1999, NATURE, V399, P316, DOI 10.1038/20580; Solter D, 1999, SCIENCE, V283, P1468, DOI 10.1126/science.283.5407.1468; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Vogel G, 1999, SCIENCE, V283, P1432, DOI 10.1126/science.283.5407.1432; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 1999, NAT GENET, V22, P127, DOI 10.1038/9632; Walker SK, 1996, THERIOGENOLOGY, V45, P111, DOI 10.1016/0093-691X(95)00360-K; WEISS R, 1999, WASHINGTON POST 0721, P1; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Zawada WM, 1998, NAT MED, V4, P569, DOI 10.1038/nm0598-569	38	107	125	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1171	1174		10.1038/70709	http://dx.doi.org/10.1038/70709			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585712				2022-12-27	WOS:000084170700022
J	Raab, A; Han, WH; Badt, D; Smith-Gill, SJ; Lindsay, SM; Schindler, H; Hinterdorfer, P				Raab, A; Han, WH; Badt, D; Smith-Gill, SJ; Lindsay, SM; Schindler, H; Hinterdorfer, P			Antibody recognition imaging by force microscopy	NATURE BIOTECHNOLOGY			English	Article						force microscopy; molecular recognition; antibody-antigen; receptor-ligand; lysozyme	DNA; RESOLUTION; BIOLOGY; EVENTS	We have developed a method that combines dynamic force microscopy with the simultaneous molecular recognition of an antigen by an antibody, during imaging. A magnetically oscillated atomic force microscopy tip carrying a tethered antibody was scanned over a surface to which lysozyme was bound. By oscillating the probe at an amplitude of only a few nanometers, the antibody was kept in close proximity to the surface, allowing fast and efficient antigen recognition and gentle interaction between tip and sample. Antigenic sites were evident from reduction of the oscillation amplitude, as a result of antibody-antigen recognition during the lateral scan. Lysozyme molecules bound to the surface were recognized by the antibody on the scanning tip with a few nanometers lateral resolution. In principle, any ligand can be tethered to the tip; thus, this technique could potentially be used for nanometer-scale epitope mapping of biomolecules and localizing receptor sites during biological processes.	Univ Linz, Inst Biophys, A-4040 Linz, Austria; Mol Imaging Corp, Phoenix, AZ USA; NCI, Basic Res Lab, Div Basic Sci, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA; Arizona State Univ, Dept Phys & Astron, Tempe, AZ 85287 USA	Johannes Kepler University Linz; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Arizona State University; Arizona State University-Tempe	Hinterdorfer, P (corresponding author), Univ Linz, Inst Biophys, A-4040 Linz, Austria.	peter.hinterdorfer@jk.uni-linz.ac.at	Hinterdorfer, Peter/C-4235-2013	Hinterdorfer, Peter/0000-0003-2583-1305	DIVISION OF BASIC SCIENCES - NCI [Z01BC008950] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen S, 1997, BIOCHEMISTRY-US, V36, P7457, DOI 10.1021/bi962531z; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BOLAND T, 1995, P NATL ACAD SCI USA, V92, P5297, DOI 10.1073/pnas.92.12.5297; Dammer U, 1996, BIOPHYS J, V70, P2437, DOI 10.1016/S0006-3495(96)79814-4; DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794; Evans E, 1997, BIOPHYS J, V72, P1541, DOI 10.1016/S0006-3495(97)78802-7; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRISBIE CD, 1994, SCIENCE, V265, P2071, DOI 10.1126/science.265.5181.2071; Fritz J, 1998, P NATL ACAD SCI USA, V95, P12283, DOI 10.1073/pnas.95.21.12283; HAN W, 1996, APPL PHYS LETT, V69, P1; Han WH, 1997, P NATL ACAD SCI USA, V94, P10565, DOI 10.1073/pnas.94.20.10565; Han WH, 1997, NATURE, V386, P563, DOI 10.1038/386563a0; HASELGRUBLER T, 1995, BIOCONJUGATE CHEM, V6, P242, DOI 10.1021/bc00033a002; HINTERDORFER P, 1998, NANOBIOLOGY, V4, P39; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; Ludwig M, 1997, BIOPHYS J, V72, P445, DOI 10.1016/S0006-3495(97)78685-5; MULLER DJ, 1995, BIOPHYS J, V68, P1681, DOI 10.1016/S0006-3495(95)80345-0; PHILLIPS DC, 1967, P NATL ACAD SCI USA, V57, P484; RADMACHER M, 1994, SCIENCE, V265, P1577, DOI 10.1126/science.8079171; Ros R, 1998, P NATL ACAD SCI USA, V95, P7402, DOI 10.1073/pnas.95.13.7402; SHAO ZF, 1995, Q REV BIOPHYS, V28, P195, DOI 10.1017/S0033583500003061; Willemsen OH, 1998, BIOPHYS J, V75, P2220, DOI 10.1016/S0006-3495(98)77666-0; Wong SS, 1998, NATURE, V394, P52, DOI 10.1038/27873	24	199	208	3	39	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					902	905		10.1038/12898	http://dx.doi.org/10.1038/12898			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471934				2022-12-27	WOS:000082365800034
J	Adlakha-Hutcheon, G; Bally, MB; Shew, CR; Madden, TD				Adlakha-Hutcheon, G; Bally, MB; Shew, CR; Madden, TD			Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity	NATURE BIOTECHNOLOGY			English	Article						mitoxantrone; programmable fusogenic vesicles; cationic liposomes; polyethylene glycol; antitumor efficacy	STERICALLY STABILIZED LIPOSOMES; PH-SENSITIVE IMMUNOLIPOSOMES; INTERBILAYER TRANSFER; PHARMACOKINETICS; BIODISTRIBUTION; STEALTH; TUMORS; MICE	Programmable fusogenic vesicles (PFVs) are lipid-based drug-delivery systems that exhibit time-dependent destabilization. The rate at which this destabilization occurs is determined by the exchange rate of a bilayer-stabilizing component, polyethylene glycol-phosphatidylethanolamine (PEG-PE) from the vesicle surface. This exchange rate is controlled, in turn, by the acyl chain composition of the PEG-PE. We describe in vitro and in vivo studies using PFVs as delivery vehicles far the anticancer drug mitoxantrone. We demonstrate that the PEG-PE acyl composition determined the rate at which PFVs are eliminated from plasma after intravenous administration, and the rate of mitoxantrone leakage from PFV, The nature of the PEG-PE component also determined the antitumor efficacy of mitoxantrone-loaded PFV in murine and human in murine and human xenograft tumor models. Increased circulation time and improved activity were obtained for PN containing PEG-PE with an 18-carbon acyl chain length, as a result of slower vesicle destabilization.	Univ British Columbia, Dept Pharmacol & Therapeut, Vancouver, BC V6T 1Z3, Canada; British Columbia Canc Agcy, Div Med Oncol Adv Therapeut, Vancouver, BC V5Z 4E6, Canada	University of British Columbia; British Columbia Cancer Agency	Madden, TD (corresponding author), Univ British Columbia, Dept Pharmacol & Therapeut, Vancouver, BC V6T 1Z3, Canada.							ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1068, P133, DOI 10.1016/0005-2736(91)90201-I; Allen TM, 1997, DRUGS, V54, P8, DOI 10.2165/00003495-199700544-00004; BALLY MB, 1994, CANCER CHEMOTH PHARM, V34, P137, DOI 10.1007/BF00685931; Chang CW, 1997, BRIT J CANCER, V75, P169, DOI 10.1038/bjc.1997.28; CONNOR J, 1985, J CELL BIOL, V101, P582, DOI 10.1083/jcb.101.2.582; CONNOR J, 1986, BIOCHIM BIOPHYS ACTA, V884, P474, DOI 10.1016/0304-4165(86)90197-2; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; Gaber MH, 1996, INT J RADIAT ONCOL, V36, P1177, DOI 10.1016/S0360-3016(96)00389-6; GABIZON AA, 1992, CANCER RES, V52, P891; Holland JW, 1996, BIOCHEMISTRY-US, V35, P2618, DOI 10.1021/bi952000v; Holland JW, 1996, BIOCHEMISTRY-US, V35, P2610, DOI 10.1021/bi951999j; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V852, P123; Lim HJ, 1997, J PHARMACOL EXP THER, V281, P566; OGIHARA I, 1986, J NUCL MED, V27, P1300; OSTRO MJ, 1989, AM J HOSP PHARM, V46, P1576, DOI 10.1093/ajhp/46.8.1576; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; PRESANT C A, 1986, Proceedings of the American Association for Cancer Research Annual Meeting, V27, P158; PROFFITT RT, 1983, SCIENCE, V220, P502, DOI 10.1126/science.6836294; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; SILVIUS JR, 1993, BIOCHEMISTRY-US, V32, P3153, DOI 10.1021/bi00063a030; SILVIUS JR, 1993, BIOCHEMISTRY-US, V32, P13318, DOI 10.1021/bi00211a045; STEIN Y, 1980, FEBS LETT, V111, P104, DOI 10.1016/0014-5793(80)80771-X; WEINSTEIN JN, 1980, CANCER RES, V40, P1388; WU NZ, 1993, CANCER RES, V53, P3765; YATVIN MB, 1980, SCIENCE, V210, P1253, DOI 10.1126/science.7434025	25	99	105	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					775	779		10.1038/11710	http://dx.doi.org/10.1038/11710			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429242				2022-12-27	WOS:000081751400026
J	Hu, WJ; Harding, SA; Lung, J; Popko, JL; Ralph, J; Stokke, DD; Tsai, CJ; Chiang, VL				Hu, WJ; Harding, SA; Lung, J; Popko, JL; Ralph, J; Stokke, DD; Tsai, CJ; Chiang, VL			Repression of lignin biosynthesis promotes cellulose accumulation and growth in transgenic trees	NATURE BIOTECHNOLOGY			English	Article						plant generic engineering; lignin biosynthesis; 4CL; transgenic; Populus tremuloides	CINNAMYL ALCOHOL-DEHYDROGENASE; PHENYLALANINE AMMONIA-LYASE; ASPEN POPULUS-TREMULOIDES; O-METHYLTRANSFERASE GENE; DOWN-REGULATION; TOBACCO PLANTS; 4-COUMARATE-COENZYME-A LIGASE; CORRELATION SPECTROSCOPY; AUXIN TRANSPORT; EXPRESSION	Because lignin limits the use of wood for fiber, chemical, and energy production, strategies for its downregulation are of considerable interest, We have produced transgenic aspen (Populus tremuloides Michx,) trees in which expression of a lignin biosynthetic pathway gene Pt4CL1 encoding 4-coumarate:coenzyme A ligase (4CL) has been downregulated by antisense inhibition. Trees with suppressed Pt4CL1 expression exhibited up to a 45% reduction of lignin, but this was compensated for by a 15% increase in cellulose. As a result, the total lignin-cellulose mass remained essentially unchanged, Leaf, root, and stem growth were substantially enhanced, and structural integrity was maintained both at the cellular and whole-plant levels in the transgenic lines. Our results indicate that lignin and cellulose deposition could be regulated in a compensatory fashion, which may contribute to metabolic flexibility and a growth advantage to sustain the long-term structural integrity of woody perennials.	Michigan Technol Univ, Sch Forestry & Wood Prod, Plant Biotechnol Res Ctr, Houghton, MI 49931 USA; Univ Wisconsin, USDA ARS, US Dairy Forage Res Ctr, Madison, WI 53706 USA; Univ Wisconsin, Dept Forestry, Madison, WI 53706 USA; Iowa State Univ, Dept Forestry, Ames, IA 50011 USA	Michigan Technological University; United States Department of Agriculture (USDA); University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Iowa State University	Chiang, VL (corresponding author), Michigan Technol Univ, Sch Forestry & Wood Prod, Plant Biotechnol Res Ctr, Houghton, MI 49931 USA.		Ralph, John/C-3161-2009; Tsai, CJ/C-2450-2009	Ralph, John/0000-0002-6093-4521; Tsai, CJ/0000-0002-9282-7704				Arioli T, 1998, SCIENCE, V279, P717, DOI 10.1126/science.279.5351.717; ATANASSOVA R, 1995, PLANT J, V8, P465, DOI 10.1046/j.1365-313X.1995.8040465.x; BATE NJ, 1994, P NATL ACAD SCI USA, V91, P7608, DOI 10.1073/pnas.91.16.7608; Baucher M, 1996, PLANT PHYSIOL, V112, P1479, DOI 10.1104/pp.112.4.1479; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BUGOS RC, 1995, BIOTECHNIQUES, V19, P734; CHIANG VL, 1983, WOOD SCI TECHNOL, V17, P217, DOI 10.1007/BF00372320; CHIANG VL, 1990, HOLZFORSCHUNG, V44, P147, DOI 10.1515/hfsg.1990.44.2.147; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Creelman RA, 1997, PLANT CELL, V9, P1211, DOI 10.1105/tpc.9.7.1211; DATLA RSS, 1993, PLANT SCI, V94, P139, DOI 10.1016/0168-9452(93)90015-R; Davis MW, 1998, J WOOD CHEM TECHNOL, V18, P235, DOI 10.1080/02773819809349579; DWIVEDI UN, 1994, PLANT MOL BIOL, V26, P61, DOI 10.1007/BF00039520; ELKIND Y, 1990, P NATL ACAD SCI USA, V87, P9057, DOI 10.1073/pnas.87.22.9057; FREUDENBERG K, 1965, SCIENCE, V148, P595, DOI 10.1126/science.148.3670.595; HAHLBROCK K, 1979, ANNU REV PLANT PHYS, V30, P105, DOI 10.1146/annurev.pp.30.060179.000541; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HALPIN C, 1994, PLANT J, V6, P339, DOI 10.1046/j.1365-313X.1994.06030339.x; HARTLEY RD, 1971, J CHROMATOGR, V54, P335, DOI 10.1016/S0021-9673(01)80289-2; HIBINO T, 1995, BIOSCI BIOTECH BIOCH, V59, P929, DOI 10.1271/bbb.59.929; Hu WJ, 1998, P NATL ACAD SCI USA, V95, P5407, DOI 10.1073/pnas.95.9.5407; JACOBS M, 1988, SCIENCE, V241, P346, DOI 10.1126/science.241.4863.346; Kajita S, 1996, PLANT CELL PHYSIOL, V37, P957, DOI 10.1093/oxfordjournals.pcp.a029045; Kajita S, 1997, PLANT PHYSIOL, V114, P871, DOI 10.1104/pp.114.3.871; Lee D, 1997, PLANT CELL, V9, P1985, DOI 10.1105/tpc.9.11.1985; LEE TT, 1965, PHYSIOL PLANTARUM, V18, P386, DOI 10.1111/j.1399-3054.1965.tb06902.x; Logemann E, 1995, PLANT J, V8, P865, DOI 10.1046/j.1365-313X.1995.8060865.x; MOCK HP, 1993, PHYTOCHEMISTRY, V32, P575, DOI 10.1016/S0031-9422(00)95139-2; NITSCH J. P., 1962, ANN PHYSIOL VEG [PARIS], V4, P211; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; Pear JR, 1996, P NATL ACAD SCI USA, V93, P12637, DOI 10.1073/pnas.93.22.12637; Piquemal J, 1998, PLANT J, V13, P71, DOI 10.1046/j.1365-313X.1998.00014.x; RALPH J, 1994, J AM CHEM SOC, V116, P9448, DOI 10.1021/ja00100a006; Rolando C., 1992, METHODS LIGNIN CHEM, P334, DOI DOI 10.1007/978-3-642-74065-7_23; Ruegger M, 1997, PLANT CELL, V9, P745, DOI 10.1105/tpc.9.5.745; RUIZCABELLO J, 1992, J MAGN RESON, V100, P282, DOI 10.1016/0022-2364(92)90262-6; Sewalt VJH, 1997, PLANT PHYSIOL, V115, P41, DOI 10.1104/pp.115.1.41; Shirley BW, 1996, TRENDS PLANT SCI, V1, P377, DOI 10.1016/1360-1385(96)10040-6; TAN KS, 1992, J PLANT PHYSIOL, V140, P460, DOI 10.1016/S0176-1617(11)80825-4; Timell T. E, 1986, COMPRESSION WOOD GYM; TSAI CJ, 1994, PLANT CELL REP, V14, P94, DOI 10.1007/BF00233768; Tsai CJ, 1998, PLANT PHYSIOL, V117, P101, DOI 10.1104/pp.117.1.101; VanDoorsselaere J, 1995, PLANT J, V8, P855, DOI 10.1046/j.1365-313X.1995.8060855.x; Whetten RW, 1998, ANNU REV PLANT PHYS, V49, P585, DOI 10.1146/annurev.arplant.49.1.585; ZENK MH, 1963, NATURE, V200, P761, DOI 10.1038/200761a0	46	555	658	1	127	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					808	812		10.1038/11758	http://dx.doi.org/10.1038/11758			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429249	Green Published			2022-12-27	WOS:000081751400033
J	Squirrell, JM; Wokosin, DL; White, JG; Bavister, BD				Squirrell, JM; Wokosin, DL; White, JG; Bavister, BD			Long-term two-photon fluorescence imaging of mammalian embryos without compromising viability	NATURE BIOTECHNOLOGY			English	Article						two-photon microscopy; laser scanning confocal microscopy; live cell fluorescence imaging; embryo; mitochondrial dynamics; mammal; hamster	VISIBLE-LIGHT; PROBE 2',7'-DICHLOROFLUORESCIN; PREIMPLANTATION EMBRYOS; ACTIVE MITOCHONDRIA; HYDROGEN-PEROXIDE; HAMSTER EMBRYOS; MOUSE EMBRYOS; CELLS; MICROSCOPY; CULTURE	A major challenge for fluorescence imaging of living mammalian cells is maintaining viability following prolonged exposure to excitation illumination. We have monitored the dynamics of mitochondrial distribution in hamster embryos at frequent intervals over 24 h using two-photon microscopy (1,047 nm) while maintaining blastocyst, and even fetal, developmental competence. In contrast, confocal imaging for only 8 h inhibits development, even without fluorophore excitation, Photo-induced production of H2O2 may account, in part, for this inhibition, Thus, two-photon microscopy, but not confocal microscopy, has permitted long-term fluorescence observations of the dynamics of three-dimensional cytoarchitecture in highly photosensitive specimens such as mammalian embryos.	Univ Wisconsin, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Squirrell, JM (corresponding author), Univ Wisconsin, Madison, WI 53706 USA.	jsquirre@students.wisc.edu			NCRR NIH HHS [RR00570, P41 RR000570] Funding Source: Medline; NICHD NIH HHS [HD22023] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD022023] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000570] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AUBIN JE, 1979, J HISTOCHEM CYTOCHEM, V27, P36, DOI 10.1177/27.1.220325; Barnett DK, 1996, DEV DYNAM, V205, P64, DOI 10.1002/(SICI)1097-0177(199601)205:1<64::AID-AJA6>3.0.CO;2-3; Barnett DK, 1997, MOL REPROD DEV, V48, P227, DOI 10.1002/(SICI)1098-2795(199710)48:2&lt;227::AID-MRD10&gt;3.0.CO;2-V; BATTEN BE, 1987, AM J ANAT, V178, P204, DOI 10.1002/aja.1001780212; Bavister BD, 1995, HUM REPROD UPDATE, V1, P91, DOI 10.1093/humupd/1.2.91; BAVISTER BD, 1988, IN VITRO CELL DEV B, V24, P759; CAPCO DG, 1993, CELL MOTIL CYTOSKEL, V24, P85, DOI 10.1002/cm.970240202; CATHCART R, 1984, METHOD ENZYMOL, V105, P352; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DANIEL JC, 1964, NATURE, V201, P316, DOI 10.1038/201316a0; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; HAUGLAND RP, 1995, BIOTECH HISTOCHEM, V70, P243, DOI 10.3109/10520299509108201; HEGELEHARTUNG C, 1991, ANAT EMBRYOL, V183, P559; HILLMAN N, 1969, AM J ANAT, V126, P151, DOI 10.1002/aja.1001260203; HIRAO Y, 1978, J EXP ZOOL, V206, P365, DOI 10.1002/jez.1402060308; Hockberger PE, 1999, P NATL ACAD SCI USA, V96, P6255, DOI 10.1073/pnas.96.11.6255; Hockberger PE, 1996, P SOC PHOTO-OPT INS, V2678, P129, DOI 10.1117/12.239502; HOLY J, 1991, J ELECTRON MICR TECH, V17, P384, DOI 10.1002/jemt.1060170403; Konig K, 1996, CELL MOL BIOL, V42, P1181; Konig K, 1997, OPT LETT, V22, P135, DOI 10.1364/OL.22.000135; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Ludwig TE, 1998, BIOL REPROD, V58, P167; McKiernan SH, 1998, THERIOGENOLOGY, V49, P209, DOI 10.1016/S0093-691X(98)90562-3; MOHLER W, IN PRESS IMAGING NEU; NAKAYAMA T, 1994, THERIOGENOLOGY, V41, P499, DOI 10.1016/0093-691X(94)90086-X; NASRESFAHANI MH, 1990, DEVELOPMENT, V109, P501; NASRESFAHANI MM, 1991, DEVELOPMENT, V113, P551; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; Takada T, 1997, NAT BIOTECHNOL, V15, P458, DOI 10.1038/nbt0597-458; Terasaki M., 1995, P327; WANG RJ, 1978, IN VITRO CELL DEV B, V14, P715; WILLEKENS P, 1994, DSP APPL, V3, P8; Wokosin DL, 1996, IEEE J SEL TOP QUANT, V2, P1051, DOI 10.1109/2944.577337; WOKOSIN DL, 1997, 3 DIMENSIONAL MICROS, P24; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; ZHU H, 1994, ARCH TOXICOL, V68, P582, DOI 10.1007/s002040050118; [No title captured]	38	463	482	3	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					763	767		10.1038/11698	http://dx.doi.org/10.1038/11698			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429240	Green Accepted			2022-12-27	WOS:000081751400024
J	Pelletier, JN; Arndt, KM; Pluckthun, A; Michnick, SW				Pelletier, JN; Arndt, KM; Pluckthun, A; Michnick, SW			An in vivo library-versus-library selection of optimized protein-protein interactions	NATURE BIOTECHNOLOGY			English	Article						library screening; library-versus-library; protein-fragment complementation assay; selection strategy; protein-protein interaction; leucine zipper; coiled coil; dihydrofolate reductase; trinucleotide	GCN4 LEUCINE-ZIPPER; HETERODIMERIC COILED-COIL; ELECTROSTATIC INTERACTIONS; DIHYDROFOLATE-REDUCTASE; DOMAIN; SYSTEM; PHAGE; STABILITY; SEQUENCE; PARALLEL	We describe a rapid and efficient in vivo library-versus-library screening strategy for identifying optimally interacting pairs of heterodimerizing polypeptides. Two leucine zipper libraries, semi-randomized at the positions adjacent to the hydrophobic core, were genetically fused to either one of two designed fragments of the enzyme murine dihydrofolate reductase (mDHFR), and cotransformed into Escherichia coli. Interaction between the library polypeptides reconstituted enzymatic activity of mDHFR, allowing bacterial growth. Analysis of the resulting colonies revealed important biases in the zipper sequences relative to the original libraries, which are consistent with selection for stable, heterodimerizing pairs. Using more weakly associating mDHFR fragments, we increased the stringency of selection. We enriched the best-performing leucine zipper pairs by multiple passaging of the pooled, selected colonies in liquid culture, as the best pairs allowed for better bacterial propagation. This competitive growth allowed small differences among the pairs to be amplified, and different sequence positions were enriched at different rates. We applied these selection processes to a library-versus-library sample of 2.0 x 10(6) combinations and selected a novel leucine zipper pair that may be appropriate for use in further in vivo heterodimerization strategies.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	Universite de Montreal; University of Zurich	Michnick, SW (corresponding author), Univ Montreal, Dept Biochim, 2900 Edouard Montpetit, Montreal, PQ H3C 3J7, Canada.		Plückthun, Andreas/C-2746-2009; Wood, David W/B-2992-2012	Plückthun, Andreas/0000-0003-4191-5306; Arndt, Katja/0000-0001-9220-0920				Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; BUCHWALDER A, 1992, BIOCHEMISTRY-US, V31, P1621, DOI 10.1021/bi00121a006; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Jelesarov I, 1996, J MOL BIOL, V263, P344, DOI 10.1006/jmbi.1996.0579; JOHN M, 1994, J BIOL CHEM, V269, P16247; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; Muller KM, 1998, FEBS LETT, V422, P259, DOI 10.1016/S0014-5793(98)00021-0; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Pelletier JN, 1998, P NATL ACAD SCI USA, V95, P12141, DOI 10.1073/pnas.95.21.12141; PELLETIER JN, J BIOMOL TECHNIQUES; Remy I, 1999, P NATL ACAD SCI USA, V96, P5394, DOI 10.1073/pnas.96.10.5394; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Rudert F, 1998, FEBS LETT, V440, P135, DOI 10.1016/S0014-5793(98)01413-6; SENGUPTA DJ, 1996, P NATL ACAD SCI USA, V93, P8495; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Spada S, 1997, NAT MED, V3, P694, DOI 10.1038/nm0697-694; Sydor JR, 1998, BIOCHEMISTRY-US, V37, P14292, DOI 10.1021/bi980764f; VIRNEKAS B, 1994, NUCLEIC ACIDS RES, V22, P5600, DOI 10.1093/nar/22.25.5600; Zeng X, 1997, P NATL ACAD SCI USA, V94, P3673, DOI 10.1073/pnas.94.8.3673; Zeng XG, 1997, PROTEIN SCI, V6, P2218; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365	29	162	208	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					683	690		10.1038/10897	http://dx.doi.org/10.1038/10897			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404162				2022-12-27	WOS:000081296900029
J	Draghia-Akli, R; Fiorotto, ML; Hill, LA; Malone, PB; Deaver, DR; Schwartz, RJ				Draghia-Akli, R; Fiorotto, ML; Hill, LA; Malone, PB; Deaver, DR; Schwartz, RJ			Myogenic expression of an injectable protease-resistant growth hormone-releasing hormone augments long-term growth in pigs	NATURE BIOTECHNOLOGY			English	Article						growth hormone-releasing hormone; gene therapy; muscle-specific promoter; electroporation	GENE-TRANSFER; PORCINE PLASMA; GH SECRETION; GRF ANALOGS; IN-VIVO; CHILDREN; BOVINE; ELECTROPORATION; DEGRADATION; STABILITY	Ectopic expression of a new serum protease-resistant porcine growth hormone-releasing hormone, directed by an injectable muscle-specific synthetic promoter plasmid vector (pSP-HV-GHRH), elicits growth in pigs. A single 10 mg intramuscular injection of pSP-HV-GHRH DNA followed by electroporation in three week-old piglets elevated serum GHRH levels by twofold to fourfold, enhanced growth hormone secretion, and increased serum insulin-like growth factor-I by threefold to sixfold over control pigs. After 65 days the average body weight of the pigs injected with pSP-HV-GHRH was similar to 37% greater than the placebo-injected controls and resulted in a significant reduction in serum urea concentration, indicating a decrease in amino acid catabolism. Evaluation of body composition indicated a uniform increase in mass, with no organomegaly or associated pathology.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA; Penn State Univ, University Pk, PA 16802 USA; Appl Vet Syst, Houston, TX 77030 USA; Natl Space Biol Res Inst, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; United States Department of Agriculture (USDA); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Draghia-Akli, R (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.			Draghia-Akli, Ruxandra/0000-0001-6372-4039				Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867; Albanese A, 1997, HORM RES, V48, P173, DOI 10.1159/000185509; Benfield MR, 1997, J PEDIATR-US, V131, pS28, DOI 10.1016/S0022-3476(97)70007-6; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; CAMPBELL RM, 1991, PEPTIDES, V12, P569, DOI 10.1016/0196-9781(91)90103-V; CORPAS E, 1993, J CLIN ENDOCR METAB, V76, P134, DOI 10.1210/jc.76.1.134; DAVIS HL, 1993, HUM GENE THER, V4, P151, DOI 10.1089/hum.1993.4.2-151; Draghia-Akli R, 1997, NAT BIOTECHNOL, V15, P1285, DOI 10.1038/nbt1197-1285; ELLIS KJ, 1993, BASIC LIFE SCI, P153; ETHERTON TD, 1986, J ANIM SCI, V63, P1389, DOI 10.2527/jas1986.6351389x; Etherton TD, 1998, PHYSIOL REV, V78, P745, DOI 10.1152/physrev.1998.78.3.745; FROHMAN LA, 1992, FRONT NEUROENDOCRIN, V13, P344; FROHMAN LA, 1984, J CLIN INVEST, V73, P1304, DOI 10.1172/JCI111333; FROHMAN LA, 1989, J CLIN INVEST, V83, P1533, DOI 10.1172/JCI114049; GESUNDHEIT N, 1995, ENDOCRINE THERAPY RE, P491; Heptulla RA, 1997, J CLIN ENDOCR METAB, V82, P3234, DOI 10.1210/jc.82.10.3234; JACOBS PA, 1990, ANN HUM GENET, V54, P209, DOI 10.1111/j.1469-1809.1990.tb00379.x; KUBIAK TM, 1989, DRUG METAB DISPOS, V17, P393; LAPIERRE H, 1991, J ANIM SCI, V69, P587; Li XY, 1999, NAT BIOTECHNOL, V17, P241, DOI 10.1038/6981; MARTIN RA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P252, DOI 10.1016/0167-4838(93)90256-Q; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; Muramatsu T, 1998, INT J MOL MED, V1, P55; PARK JS, 1995, GROWTH HORMONE DEFIC, P473; Savage MO, 1999, ACTA PAEDIATR, V88, P89, DOI 10.1111/j.1651-2227.1999.tb14360.x; SU CM, 1991, HORM METAB RES, V23, P15, DOI 10.1055/s-2007-1003601; Tanaka H, 1998, EUR J ENDOCRINOL, V138, P275, DOI 10.1530/eje.0.1380275; TANNER JW, 1990, J ENDOCRINOL, V125, P109, DOI 10.1677/joe.0.1250109; Thorner MO, 1997, RECENT PROG HORM RES, V52, P215; THORNER MO, 1984, J CLIN ENDOCR METAB, V59, P846, DOI 10.1210/jcem-59-5-846; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; Veldhuis JD, 1997, ENDOCRINE, V7, P41, DOI 10.1007/BF02778061; Watkins SL, 1996, KIDNEY INT, V49, pS126	33	87	112	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1179	1183		10.1038/70718	http://dx.doi.org/10.1038/70718			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585714				2022-12-27	WOS:000084170700024
J	Gollin, MA				Gollin, MA			New rules for natural products research	NATURE BIOTECHNOLOGY			English	Article									Venable Baetjer Howard & Civiletti LLP, Washington, DC 20005 USA		Gollin, MA (corresponding author), Venable Baetjer Howard & Civiletti LLP, 1201 New York Ave NW,Suite 1000, Washington, DC 20005 USA.							[Anonymous], 1995, U. S. Patent, Patent No. [5,401,504, 5401504]; MILLER LS, Patent No. 5751; WILSON EO, 1992, BIODIVERSITY LIFE	3	12	12	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					921	923		10.1038/12921	http://dx.doi.org/10.1038/12921			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471938				2022-12-27	WOS:000082365800038
J	Falcioni, F; Ito, K; Vidovic, D; Belunis, C; Campbell, R; Berthel, SJ; Bolin, DR; Gillespie, PB; Huby, N; Olson, GL; Sarabu, R; Guenot, J; Madison, V; Hammer, J; Sinigaglia, F; Steinmetz, M; Nagy, ZA				Falcioni, F; Ito, K; Vidovic, D; Belunis, C; Campbell, R; Berthel, SJ; Bolin, DR; Gillespie, PB; Huby, N; Olson, GL; Sarabu, R; Guenot, J; Madison, V; Hammer, J; Sinigaglia, F; Steinmetz, M; Nagy, ZA			Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules	NATURE BIOTECHNOLOGY			English	Article						peptidomimetics; antigen presentation; autoimmune disease	MHC CLASS-II; RHEUMATOID-ARTHRITIS; CRYSTAL-STRUCTURE; BINDING PEPTIDES; SELF-PEPTIDES; T-CELLS; COMPLEX; HLA; SUSCEPTIBILITY; HLA-DR1	We have identified a heptapeptide with high affinity to rheumatoid arthritis-associated class II major histocompatibility (MHC) molecules. Using a model of its interaction with the class II binding site, a variety of mimetic substitutions were introduced into the peptide. Several unnatural amino acids and dipeptide mimetics were found to be appropriate substituents and could be combined into compounds with binding affinities comparable to that of the original peptide. Compounds were designed that were several hundred-fold to more than a thousand-fold more potent than the original peptide in inhibiting T-cell responses to processed protein antigens presented by the target MHC molecules. Peptidomimetic compounds of this type could find therapeutic use as MHC-selective antagonists of antigen presentation in the treatment of autoimmune diseases.	Hoffmann La Roche Inc, Dept Inflammat & Autoimmune Dis, Nutley, NJ 07110 USA; Hoffmann La Roche Inc, Dept Phys Chem, Nutley, NJ 07110 USA; Hoffmann La Roche Inc, Dept Preclin Res, Nutley, NJ 07110 USA; Hoffmann La Roche Inc, Dept Immunol, Nutley, NJ 07110 USA; Roche Milano Ric, I-20132 Milan, Italy	Roche Holding; Roche Holding; Roche Holding; Roche Holding; Roche Holding	Nagy, ZA (corresponding author), Genome Pharmaceut Corp, D-82152 Martinsried, Germany.		Berthel, Steven/AAQ-7526-2020	Berthel, Steven/0000-0003-1250-0208				ADORINI L, 1988, NATURE, V334, P623, DOI 10.1038/334623a0; ATTWOOD MR, 1986, J CHEM SOC P1, V1, P1011, DOI DOI 10.1039/P19860001011; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BENNETT K, 1992, EUR J IMMUNOL, V22, P1519, DOI 10.1002/eji.1830220626; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CHO JH, 1987, J ORG CHEM, V52, P4517, DOI 10.1021/jo00229a016; CHUNG JYL, 1990, J ORG CHEM, V55, P270, DOI 10.1021/jo00288a045; DELOMBAERT S, 1994, TETRAHEDRON LETT, V35, P7513, DOI 10.1016/S0040-4039(00)78331-6; Dessen A, 1997, IMMUNITY, V7, P473, DOI 10.1016/S1074-7613(00)80369-6; DORROW RL, 1995, J ORG CHEM, V60, P4986; EVANS DA, 1989, J AM CHEM SOC, V111, P1063, DOI 10.1021/ja00185a042; Falcioni F, 1996, HUM IMMUNOL, V50, P79, DOI 10.1016/0198-8859(96)00121-8; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GORDON T, 1993, BIOORG MED CHEM LETT, V3, P915, DOI 10.1016/S0960-894X(00)80692-7; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; HAMMER J, 1994, P NATL ACAD SCI USA, V91, P4456, DOI 10.1073/pnas.91.10.4456; HAMMER J, 1995, J EXP MED, V181, P1847, DOI 10.1084/jem.181.5.1847; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HAMMER J, 1994, J EXP MED, V180, P2353, DOI 10.1084/jem.180.6.2353; HURTENBACH U, 1993, J EXP MED, V177, P1499, DOI 10.1084/jem.177.5.1499; ISHIOKA GY, 1994, J IMMUNOL, V152, P4310; Ito K, 1996, J EXP MED, V183, P2635, DOI 10.1084/jem.183.6.2635; LANCHBURY JSS, 1991, HUM IMMUNOL, V32, P56, DOI 10.1016/0198-8859(91)90117-R; LAPATSANIS L, 1983, SYNTHESIS-STUTTGART, P671, DOI 10.1055/s-1983-30468; MCMICHAEL AJ, 1977, ARTHRITIS RHEUM, V20, P1037, DOI 10.1002/art.1780200501; NEPOM BS, 1993, CLIN IMMUNOL IMMUNOP, V67, pS50, DOI 10.1006/clin.1993.1084; NEPOM GT, 1989, ARTHRITIS RHEUM, V32, P15, DOI 10.1002/anr.1780320104; OHTA N, 1982, HUM IMMUNOL, V5, P123, DOI 10.1016/0198-8859(82)90057-X; SAKAI K, 1989, P NATL ACAD SCI USA, V86, P9470, DOI 10.1073/pnas.86.23.9470; SCHIFF B, 1982, ANN RHEUM DIS, V41, P403, DOI 10.1136/ard.41.4.403; Siklodi B, 1998, HUM IMMUNOL, V59, P463, DOI 10.1016/S0198-8859(98)00038-X; SINIGAGLIA F, 1988, NATURE, V336, P778, DOI 10.1038/336778a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STORK G, 1976, J ORG CHEM, V41, P3491, DOI 10.1021/jo00883a044; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; WEISS GA, 1995, CHEM BIOL, V2, P401, DOI 10.1016/1074-5521(95)90221-X; WORDSWORTH P, 1992, AM J HUM GENET, V51, P585; Woulfe SL, 1997, J PHARMACOL EXP THER, V281, P663; WUCHERPFENNIG KW, 1995, P NATL ACAD SCI USA, V92, P11935, DOI 10.1073/pnas.92.25.11935	40	50	60	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					562	567		10.1038/9865	http://dx.doi.org/10.1038/9865			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385320				2022-12-27	WOS:000080716500027
J	Rangel-Aldao, R				Rangel-Aldao, R			"BioSafety" to assure underdevelopment	NATURE BIOTECHNOLOGY			English	Editorial Material									Venezuelan Presidential Commiss Biotechnol, Caracas, Venezuela		Rangel-Aldao, R (corresponding author), Venezuelan Presidential Commiss Biotechnol, Caracas, Venezuela.								0	2	2	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					515	516		10.1038/9776	http://dx.doi.org/10.1038/9776			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385300				2022-12-27	WOS:000080716500006
J	Suzuki, M; Saxena, SK; Boix, E; Prill, RJ; Vasandani, VM; Ladner, JE; Sung, C; Youle, RJ				Suzuki, M; Saxena, SK; Boix, E; Prill, RJ; Vasandani, VM; Ladner, JE; Sung, C; Youle, RJ			Engineering receptor-mediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction	NATURE BIOTECHNOLOGY			English	Article						ribonuclease inhibitor; eosinophil-derived neurotoxin; site-directed mutagenesis; receptor-mediated endocytosis; immunotoxin	EOSINOPHIL-DERIVED NEUROTOXIN; HUMAN PLACENTAL RIBONUCLEASE; BOVINE SEMINAL RIBONUCLEASE; TRANSFERRIN RECEPTOR; CATIONIC PROTEIN; SOLID TUMORS; MECHANISM; INVITRO; RNASE; ANGIOGENIN	Several nonmammalian members of the RNase A superfamily exhibit anticancer activity that appears to correlate with resistance to the cytosolic ribonuclease inhibitor (RI). We mutated two human ribonucleases-pancreatic RNase (hRNAse) and eosinophil-derived neurotoxin (EDN)-to incorporate cysteine residues at putative sites of close contact to RI, but distant from the catalytic sites. Coupling of Cys89 of RNase and Cys87 of EDN to proteins at these sites via a thioether bond produced enzymatically active conjugates that were resistant to RI. To elicit cellular targeting as well as to block RI binding, transferrin was conjugated to a mutant human RNase, rhRNase(Gly89--->Cys) and a mutant EDN (Thr87-->Cys). The transferrin-rhRNase(Gly89-->Cys) thioether conjugate was 5000-fold more toxic to U251 cells than recombinant wild-type hRNase. In addition, transferrin-targeted EDN exhibited tumor cell toxicities similar to those of hRNase, Thus, we endowed two human RI-sensitive RNases with greater cytotoxicity by increasing their resistance to RI. This strategy has the potential to generate a novel set of recombinant human proteins useful for targeted therapy of cancer.	NINCDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Natl Inst Stand & Technol, Rockville, MD 20850 USA; NIH, Drug Delivery & Kinet Resource Bioengn & Phys Sci, Off Res Serv, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institute of Standards & Technology (NIST) - USA; National Institutes of Health (NIH) - USA	Youle, RJ (corresponding author), NINCDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA.		Saxena, Shailendra K/ABK-6489-2022; Saxena, Shailendra K/X-4252-2019; Boix, Ester/B-9038-2012	Saxena, Shailendra K/0000-0003-2856-4185; Saxena, Shailendra K/0000-0003-2856-4185; Boix, Ester/0000-0003-1790-2142; Suzuki, Motoshi/0000-0002-4346-7677	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002674, ZIANS002674] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; D'Alessio G., 1997, RIBONUCLEASES STRUCT; Domachowske JB, 1997, J LEUKOCYTE BIOL, V62, P363, DOI 10.1002/jlb.62.3.363; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; JOHNSON VG, 1988, J NEUROSURG, V68, P1295; Kim JS, 1995, J BIOL CHEM, V270, P31097, DOI 10.1074/jbc.270.52.31097; Kobe B, 1996, J MOL BIOL, V264, P1028, DOI 10.1006/jmbi.1996.0694; LACCETTI P, 1992, CANCER RES, V52, P4582; Laske DW, 1997, NAT MED, V3, P1362, DOI 10.1038/nm1297-1362; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; LEHRER RI, 1989, J IMMUNOL, V142, P4428; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; MIKULSKI SM, 1993, INT J ONCOL, V3, P57; MURTHY BS, 1992, BIOCHEM J, V281, P343, DOI 10.1042/bj2810343; NEWTON DL, 1994, J BIOL CHEM, V269, P26739; NEWTON DL, 1992, J BIOL CHEM, V267, P19572; NEWTON DL, 1994, J NEUROSCI, V14, P538; NITTA K, 1994, CANCER RES, V54, P920; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; RECHT L, 1990, J NEUROSURG, V72, P941, DOI 10.3171/jns.1990.72.6.0941; ROSENBERG HF, 1995, J BIOL CHEM, V270, P7876, DOI 10.1074/jbc.270.14.7876; RYBAK SM, 1991, J BIOL CHEM, V266, P21202; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; SHAPIRO R, 1991, BIOCHEMISTRY-US, V30, P2246, DOI 10.1021/bi00222a030; VESCIA S, 1980, CANCER RES, V40, P3740; WU YN, 1995, J BIOL CHEM, V270, P17476, DOI 10.1074/jbc.270.29.17476; WU YN, 1993, J BIOL CHEM, V268, P10686; Yakovlev G, 1997, J BIOMOL STRUCT DYN, V15, P243, DOI 10.1080/07391102.1997.10508189	31	69	79	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					265	270		10.1038/7010	http://dx.doi.org/10.1038/7010			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096294				2022-12-27	WOS:000078977500028
J	Bartlett, JS; Kleinschmidt, J; Boucher, RC; Samulski, RJ				Bartlett, JS; Kleinschmidt, J; Boucher, RC; Samulski, RJ			Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab 'gamma)(2) antibody	NATURE BIOTECHNOLOGY			English	Article						gene therapy vector; targeted transduction; parvovirus; adeno-associated virus (AAV); bispecific antibody	HUMAN HEMATOPOIETIC-CELLS; GLYCOPROTEIN-IIB-IIIA; GAMMA-GLOBIN GENE; ADENOASSOCIATED VIRUS; RETROVIRAL VECTORS; PHENOTYPIC CORRECTION; NONDIVIDING CELLS; ERYTHROID-CELLS; HIGH-LEVEL; EXPRESSION	We have developed a system for the targeted delivery of adeno-associated virus (AAV) vectors. Targeting is achieved via a bispecific F(ab')(2) antibody that mediates a novel interaction between the AAV vector and a specific cell surface receptor expressed on human megakaryocytes. Targeted AAV vectors were able to transduce megakaryocyte cell lines, DAMI and MO7e, which were nonpermissive for normal AAV infection, 70-fold above background and at levels equivalent to permissive K562 cells. Transduction was shown to occur through the specific interaction of the AAV vector-bispecific F(ab')(2) complex and cell-associated targeting receptor. Importantly, targeting appeared both selective and restrictive as the endogenous tropism of the AAV vector was significantly reduced. Binding and internalization through the alternative receptor did not alter subsequent steps (escape from endosomes, migration to nucleus, or uncoating) required to successfully transduce target cells. These results demonstrate that AAV vectors can be targeted to a specific cell population and that transduction can be achieved by circumventing the normal virus receptor.	Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Pulm & Cyst Fibrosis Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Helmholtz Association; German Cancer Research Center (DKFZ)	Bartlett, JS (corresponding author), Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA.	jbart@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 533016, HL 42384, HL 51818] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER IE, 1994, J VIROL, V68, P8282, DOI 10.1128/JVI.68.12.8282-8287.1994; Bartlett JS, 1998, HUM GENE THER, V9, P1181, DOI 10.1089/hum.1998.9.8-1181; BARTLETT JS, 1996, PROTOCOLS GENE TRANS, P115; Bodey B, 1996, ANTICANCER RES, V16, P661; CHU THT, 1994, GENE THER, V1, P292; Conrad CK, 1996, GENE THER, V3, P658; Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; FLOTTE TR, 1994, AM J RESP CELL MOL, V11, P517, DOI 10.1165/ajrcmb.11.5.7946381; Goldman CK, 1997, CANCER RES, V57, P1447; GOODMAN S, 1994, BLOOD, V84, P1492; HALBERT CL, 1995, J VIROL, V69, P1473, DOI 10.1128/JVI.69.3.1473-1479.1995; HANDAGAMA P, 1993, BLOOD, V82, P135, DOI 10.1182/blood.V82.1.135.bloodjournal821135; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Imai K, 1997, Int Rev Immunol, V14, P213, DOI 10.3109/08830189709116853; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; KUMAR S, 1991, J MOL BIOL, V222, P45, DOI 10.1016/0022-2836(91)90736-P; Malik P, 1997, J VIROL, V71, P1776, DOI 10.1128/JVI.71.3.1776-1783.1997; McCown TJ, 1996, BRAIN RES, V713, P99, DOI 10.1016/0006-8993(95)01488-8; MILLER JL, 1994, P NATL ACAD SCI USA, V91, P10183, DOI 10.1073/pnas.91.21.10183; Mizukami H, 1996, VIROLOGY, V217, P124, DOI 10.1006/viro.1996.0099; MONTGOMERY RR, 1983, J CLIN INVEST, V71, P385, DOI 10.1172/JCI110780; PIDARD D, 1983, J BIOL CHEM, V258, P2582; Ponnazhagan S, 1996, J GEN VIROL, V77, P1111, DOI 10.1099/0022-1317-77-6-1111; PONNAZHAGAN S, 1994, BLOOD, V84, pA742; RUSSELL DW, 1994, P NATL ACAD SCI USA, V91, P8915, DOI 10.1073/pnas.91.19.8915; RUSSELL DW, 1995, P NATL ACAD SCI USA, V92, P5719, DOI 10.1073/pnas.92.12.5719; RUSSELL SJ, 1993, NUCLEIC ACIDS RES, V21, P1081, DOI 10.1093/nar/21.5.1081; SAMULSKI RJ, 1993, CURR OPIN GENET DEV, V3, P74, DOI 10.1016/S0959-437X(05)80344-2; SAMULSKI RJ, 1989, J VIROL, V63, P3822, DOI 10.1128/JVI.63.9.3822-3828.1989; SAMULSKI RJ, 1983, CELL, V33, P135, DOI 10.1016/0092-8674(83)90342-2; SAMULSKI RJ, 1987, J VIROL, V61, P3096, DOI 10.1128/JVI.61.10.3096-3101.1987; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SOMIA NV, 1995, P NATL ACAD SCI USA, V92, P7570, DOI 10.1073/pnas.92.16.7570; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Teramoto S, 1998, J VIROL, V72, P8904, DOI 10.1128/JVI.72.11.8904-8912.1998; WALSH CE, 1992, P NATL ACAD SCI USA, V89, P7257, DOI 10.1073/pnas.89.15.7257; WALSH CE, 1994, J CLIN INVEST, V94, P1440, DOI 10.1172/JCI117481; Wickham TJ, 1996, J VIROL, V70, P6831, DOI 10.1128/JVI.70.10.6831-6838.1996; Wickham TJ, 1995, GENE THER, V2, P750; WISTUBA A, 1995, J VIROL, V69, P5311, DOI 10.1128/JVI.69.9.5311-5319.1995; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996	45	170	197	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					181	186		10.1038/6185	http://dx.doi.org/10.1038/6185			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052356				2022-12-27	WOS:000078508300028
J	Fears, R; Tambuyzer, E				Fears, R; Tambuyzer, E			Core ethical values for European bioindustries	NATURE BIOTECHNOLOGY			English	Editorial Material									SmithKline Beecham, Harlow, Essex, England; Genzyme Corp, Corp Affairs Europe, Louvain, Belgium; EuropaBio, EuropaBio Task Force Eth, B-1040 Brussels, Belgium	GlaxoSmithKline; Sanofi-Aventis	Fears, R (corresponding author), SmithKline Beecham, Harlow, Essex, England.								0	3	3	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					114	115		10.1038/6076	http://dx.doi.org/10.1038/6076			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052333				2022-12-27	WOS:000078508300005
J	Fan, HR; Lin, Q; Morrissey, GR; Khavari, PA				Fan, HR; Lin, Q; Morrissey, GR; Khavari, PA			Immunization via hair follicles by topical application of naked DNA to normal skin	NATURE BIOTECHNOLOGY			English	Article						gene transfer; DNA vaccine; skin; immunization; hair follicle	DRUG-DELIVERY; GENE-TRANSFER; VACCINATION; VACCINES; IMMUNITY; ANTIGEN; HUMANS	In order to test the immune response generated to small amounts of foreign protein in skin, we applied naked DNA in aqueous solution to untreated normal skin. Topical application of plasmid expression vectors for lacZ and the hepatitis B surface antigen (HBsAg) to intact skin induced antigen-specific immune responses that displayed T-H2 features. For HBsAg, specific antibody and cellular responses were induced to the same order of magnitude as those produced by intramuscular injection of the commercially available recombinant HBsAS polypeptide vaccine. Finally, topical gene transfer was dependent on the presence of normal hair follicles.	Stanford Univ, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Dermatol, Sch Med, Stanford, CA 94305 USA; VA Palo Alto Hlth Care Syst, Palo Alto, CA 94305 USA	Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Khavari, PA (corresponding author), Stanford Univ, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA.							ALEXANDER MY, 1995, HUM MOL GENET, V4, P2279, DOI 10.1093/hmg/4.12.2279; Barry MA, 1997, VACCINE, V15, P788, DOI 10.1016/S0264-410X(96)00265-4; Beard CW, 1998, NAT BIOTECHNOL, V16, P1325, DOI 10.1038/4298; BERTI JJ, 1995, MAYO CLIN PROC, V70, P581, DOI 10.4065/70.6.581; BERTI JJ, 1999, MAYO CLIN P, V112, P370; Davis HL, 1998, J IMMUNOL, V160, P870; Domashenko A, 1999, J INVEST DERMATOL, V112, P552; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Janda JM, 1997, EUR J CLIN MICROBIOL, V16, P189, DOI 10.1007/BF01709581; LAUER AC, 1995, PHARM RES-DORDR, V12, P179, DOI 10.1023/A:1016250422596; LI LN, 1995, NAT MED, V1, P705, DOI 10.1038/nm0795-705; Livingston BD, 1997, J IMMUNOL, V159, P1383; Lu B, 1997, J INVEST DERMATOL, V108, P803, DOI 10.1111/1523-1747.ep12292254; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Tang DC, 1997, NATURE, V388, P729, DOI 10.1038/41917; Tuting T, 1998, J INVEST DERMATOL, V111, P183, DOI 10.1046/j.1523-1747.1998.00261.x; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; WYU WH, 1999, J INVEST DERMATOL, V112, P370; Zierhut M, 1996, IMMUNOL TODAY, V17, P448, DOI 10.1016/0167-5699(96)30056-X	19	147	156	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					870	872		10.1038/12856	http://dx.doi.org/10.1038/12856			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471927				2022-12-27	WOS:000082365800027
J	Kunkel, T; Niu, QW; Chan, YS; Chua, NH				Kunkel, T; Niu, QW; Chan, YS; Chua, NH			Inducible isopentenyl transferase as a high-efficiency marker for plant transformation	NATURE BIOTECHNOLOGY			English	Article						inducible ipt expression; selective regeneration; plant transformation marker	TRANSGENIC TOBACCO; LEAF SENESCENCE; CYTOKININ; GENE; EXPRESSION; RESISTANCE; PROMOTER; MUTANT	Overexpression of the isopentenyltransferase gene (ipt) from the Ti-plasmid of Agrobacterium tumefaciens increases cytokinin levels, leading to generation of shoots from transformed plant cells. When combined with a dexamethasone-inducible system for controlling expression, ipt expression can be used to select for transgenic regenerants without using an antibiotic-resistance marker. The combined system allows efficient cointroduction of multiple genes (in addition to ipt) and produces transgenic plants without morphological or developmental defects.	Rockefeller Univ, Plant Mol Biol Lab, New York, NY 10021 USA; Natl Univ Singapore, Inst Mol Agrobiol, Singapore 117604, Singapore	Rockefeller University; National University of Singapore	Chua, NH (corresponding author), Rockefeller Univ, Plant Mol Biol Lab, 1230 York Ave, New York, NY 10021 USA.	chua@rockefeller.rockvax.edu						AKIYOSHI DE, 1984, P NATL ACAD SCI-BIOL, V81, P5994, DOI 10.1073/pnas.81.19.5994; Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; BARRY GF, 1984, P NATL ACAD SCI-BIOL, V81, P4776, DOI 10.1073/pnas.81.15.4776; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BEVAN MW, 1982, ANNU REV GENET, V16, P357, DOI 10.1146/annurev.ge.16.120182.002041; CHAUDHURY AM, 1993, PLANT J, V4, P907, DOI 10.1046/j.1365-313X.1993.04060907.x; CLINE MG, 1994, PHYSIOL PLANTARUM, V90, P230, DOI 10.1034/j.1399-3054.1994.900133.x; Coenen C, 1997, TRENDS PLANT SCI, V2, P351, DOI 10.1016/S1360-1385(97)84623-7; CURTIS IS, 1994, J EXP BOT, V45, P1441, DOI 10.1093/jxb/45.10.1441; Davies P.J., 1995, PLANT HORMONES THEIR; Ebinuma H, 1997, P NATL ACAD SCI USA, V94, P2117, DOI 10.1073/pnas.94.6.2117; Faiss M, 1997, PLANT J, V12, P401, DOI 10.1046/j.1365-313X.1997.12020401.x; FRALEY RT, 1986, CRC CR REV PLANT SCI, V4, P1, DOI 10.1080/07352688609382217; GAN SS, 1995, SCIENCE, V270, P1986, DOI 10.1126/science.270.5244.1986; GATZ C, 1992, PLANT J, V2, P397, DOI 10.1046/j.1365-313X.1992.t01-37-00999.x; Goliber T, 1999, CURR TOP DEV BIOL, V43, P259; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Ishige F, 1999, PLANT J, V18, P443, DOI 10.1046/j.1365-313X.1999.00456.x; Kakimoto T, 1996, SCIENCE, V274, P982, DOI 10.1126/science.274.5289.982; KLEE H, 1987, ANNU REV PLANT PHYS, V38, P467, DOI 10.1146/annurev.pp.38.060187.002343; Kuraishi F., 1956, BOT MAG TOKYO, P300; Lotan T, 1998, CELL, V93, P1195, DOI 10.1016/S0092-8674(00)81463-4; McKenzie MJ, 1998, PLANT PHYSIOL, V116, P969, DOI 10.1104/pp.116.3.969; MEDFORD JI, 1989, PLANT CELL, V1, P403, DOI 10.1105/tpc.1.4.403; Michelet B, 1996, PLANT MOL BIOL REP, V14, P320, DOI 10.1007/BF02673364; MIklashevichs E, 1997, PHYSIOL PLANTARUM, V100, P528, DOI 10.1034/j.1399-3054.1997.1000314.x; Millar AJ, 1992, PLANT MOL BIOL REP, V10, P324, DOI 10.1007/BF02668909; MOK DWS, 1994, CYTOKININS CHEM ACTI, P155; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; Redig P, 1996, PLANT PHYSIOL, V112, P141, DOI 10.1104/pp.112.1.141; SACHS T, 1967, AM J BOT, V54, P136, DOI 10.2307/2440896; SKOOG F, 1957, Symp Soc Exp Biol, V11, P118; SMIGOCKI AC, 1988, P NATL ACAD SCI USA, V85, P5131, DOI 10.1073/pnas.85.14.5131; VAN KMTT, 1981, ANNU REV PLANT PHYS, V32, P291, DOI 10.1146/annurev.pp.32.060181.001451; WALDRON C, 1985, PLANT MOL BIOL, V5, P103, DOI 10.1007/BF00020092; Wingler A, 1998, PLANT PHYSIOL, V116, P329, DOI 10.1104/pp.116.1.329	36	103	121	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					916	919		10.1038/12914	http://dx.doi.org/10.1038/12914			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471937				2022-12-27	WOS:000082365800037
J	Flores, MA				Flores, MA			Taking the profit out of biomedical research tools - A National Institutes of Health proposal will restrict the licensing of Federally funded biomedical research tools for commercial gain.	NATURE BIOTECHNOLOGY			English	Editorial Material								A National Institutes of Health proposal will restrict the licensing of Federally funded biomedical research tools for commercial gain.	Campbell & Flores LLP, San Diego, CA 92122 USA		Flores, MA (corresponding author), Campbell & Flores LLP, 4370 La Jolla Village Dr,Suite 700, San Diego, CA 92122 USA.							Adler R G, 1990, New Biol, V2, P495; EISENBERG R, 1994, RISK HLTH SAFETY ENV, V5, P163; EISENBERG RS, 1989, U CHICAGO LAW REV, V56, P1017, DOI 10.2307/1599761; Marshall E, 1997, SCIENCE, V278, P212, DOI 10.1126/science.278.5336.212; *NAT AC SCI, 1996, INT PROP RIGHTS RES; *NAT AC STUD, CAS STUD PROT DNA SE, pCH5; *NIH WORK GROUP, 1998, REP NIH WORK GROUP R, P4	7	4	4	2	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					819	820		10.1038/11774	http://dx.doi.org/10.1038/11774			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429252				2022-12-27	WOS:000081751400035
J	Mir, KU; Southern, EM				Mir, KU; Southern, EM			Determining the influence of structure on hybridization using oligonucleotide arrays	NATURE BIOTECHNOLOGY			English	Article						antisense; DNA chips; microarray; spatially addressable array; combinatorial library; RNA secondary structure	TRANSFER-RNA; COMPLEMENTARY OLIGONUCLEOTIDES; DUPLEX STABILITY; HYBRID DUPLEXES; ANTICODON LOOP; ANTISENSE RNA; DNA PROBES; BINDING; EXPRESSION; SEQUENCE	We have studied the effects of structure on nucleic acid heteroduplex formation by analyzing hybridization of tRNA(phe) to a complete set of complementary oligonucleotides, ranging from single nucleotides to dodecanucleotides. The analysis points to features in tRNA that determine heteroduplex yield. All heteroduplexes that give high yield include both double-stranded stems as well as single-stranded regions. Bases in the single-stranded regions are stacked onto the stems, and heteroduplexes terminate at potential interfaces for coaxial stacking. Heteroduplex formation is disfavored by sharp turns or a lack of helical order in single-stranded regions, competition from bases displaced from a stem, and stable tertiary interactions. The study is relevant to duplex formation on oligonucleotide microarrays and to antisense technologies.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Mir, KU (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	kalim@bioch.ox.ac.uk						[Anonymous], 1994, PRINCIPLES NUCL ACID; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P1303; CRAIG ME, 1971, J MOL BIOL, V62, P383, DOI 10.1016/0022-2836(71)90434-7; DOTY P., 1959, PROC NATL ACAD SCI, V45, P482, DOI 10.1073/pnas.45.4.482; Draper DE, 1996, NAT STRUCT BIOL, V3, P397, DOI 10.1038/nsb0596-397; ECKER DJ, 1992, SCIENCE, V257, P958, DOI 10.1126/science.1502560; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; EISINGER J, 1973, J MOL BIOL, V73, P131, DOI 10.1016/0022-2836(73)90165-4; ENGLAND IE, 1977, METHOD ENZYMOL, V65, P65; Fountain MA, 1996, BIOCHEMISTRY-US, V35, P6539, DOI 10.1021/bi952697k; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FREIER SM, 1975, BIOCHEMISTRY-US, V14, P3310, DOI 10.1021/bi00686a004; Huang SG, 1996, J MOL BIOL, V258, P308, DOI 10.1006/jmbi.1996.0252; KALLENBACH NR, 1968, J MOL BIOL, V37, P445, DOI 10.1016/0022-2836(68)90114-9; KIELECZAWA J, 1992, SCIENCE, V258, P1787, DOI 10.1126/science.1465615; KUMAZAWA Y, 1992, NUCLEIC ACIDS RES, V20, P2223, DOI 10.1093/nar/20.9.2223; LAPTEV AV, 1994, BIOCHEMISTRY-US, V33, P11033, DOI 10.1021/bi00202a024; LEROY JL, 1977, EUR J BIOCHEM, V74, P567, DOI 10.1111/j.1432-1033.1977.tb11426.x; LEWIS JB, 1970, NATURE, V225, P510, DOI 10.1038/225510a0; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MASKOS U, 1992, NUCLEIC ACIDS RES, V20, P1679, DOI 10.1093/nar/20.7.1679; MASKOS U, 1993, NUCLEIC ACIDS RES, V21, P2267, DOI 10.1093/nar/21.9.2267; MASKOS U, 1992, NUCLEIC ACIDS RES, V20, P1675, DOI 10.1093/nar/20.7.1675; Matveeva O, 1997, NUCLEIC ACIDS RES, V25, P5010, DOI 10.1093/nar/25.24.5010; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; Milner N, 1997, NAT BIOTECHNOL, V15, P537, DOI 10.1038/nbt0697-537; MIR KU, 1995, THESIS U OXFORD; MURPHY FL, 1994, SCIENCE, V265, P1709, DOI 10.1126/science.8085157; PERSSON C, 1990, EMBO J, V9, P3767, DOI 10.1002/j.1460-2075.1990.tb07590.x; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; PONGS O, 1973, EUR J BIOCHEM, V32, P117, DOI 10.1111/j.1432-1033.1973.tb02586.x; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; RATMEYER L, 1994, BIOCHEMISTRY-US, V33, P5298, DOI 10.1021/bi00183a037; RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; SMITH M, 1983, METHODS DNA RNA SEQU, P23; Southern E, 1999, NAT GENET, V21, P5, DOI 10.1038/4429; SOUTHERN EM, 1994, NUCLEIC ACIDS RES, V22, P1368, DOI 10.1093/nar/22.8.1368; STEIN A, 1976, BIOCHEMISTRY-US, V15, P160, DOI 10.1021/bi00646a025; STUDIER FW, 1969, J MOL BIOL, V41, P199, DOI 10.1016/0022-2836(69)90385-4; STULL RA, 1992, NUCLEIC ACIDS RES, V20, P3501, DOI 10.1093/nar/20.13.3501; SUDDATH FL, 1974, SCIENCE, V185, P435; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; UHLENBEC.OC, 1970, NATURE, V225, P508, DOI 10.1038/225508a0; VESNAVER G, 1991, P NATL ACAD SCI USA, V88, P3569, DOI 10.1073/pnas.88.9.3569; Wagner RW, 1996, NAT BIOTECHNOL, V14, P840, DOI 10.1038/nbt0796-840; WALTER AE, 1994, P NATL ACAD SCI USA, V91, P9218, DOI 10.1073/pnas.91.20.9218; WETMUR JG, 1968, J MOL BIOL, V31, P349, DOI 10.1016/0022-2836(68)90414-2; WETMUR JG, 1991, CRIT REV BIOCHEM MOL, V26, P227, DOI 10.3109/10409239109114069; WILLIAMS JC, 1994, NUCLEIC ACIDS RES, V22, P1365, DOI 10.1093/nar/22.8.1365; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; WREDE P, 1978, J MOL BIOL, V120, P83, DOI 10.1016/0022-2836(78)90296-6; WU R, 1972, NATURE-NEW BIOL, V236, P198, DOI 10.1038/newbio236198a0	56	151	165	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					788	792		10.1038/11732	http://dx.doi.org/10.1038/11732			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429245				2022-12-27	WOS:000081751400029
J	Singh, M; O'Hagan, D				Singh, M; O'Hagan, D			Advances in vaccine adjuvants	NATURE BIOTECHNOLOGY			English	Review						adjuvant; recombinant vaccine delivery; mucosal delivery; vaccine targeting	B SURFACE-ANTIGEN; ADP-RIBOSYLTRANSFERASE ACTIVITY; IMMUNODEFICIENCY-VIRUS TYPE-1; MEDIATED IMMUNE-RESPONSES; CYTOTOXIC T-LYMPHOCYTES; BIODEGRADABLE MICROPARTICLES; ANTIBODY-RESPONSES; PROTECTIVE IMMUNITY; MF59 ADJUVANT; CPG-DNA	Currently, aluminum salts and MF59 are the only vaccine adjuvants approved for human use. With the development of new-generation vaccines (including recombinant subunit and mucosal vaccines) that are less immunogenic, the search for more potent vaccine adjuvants has intensified. Of the novel compounds recently evaluated in human trials, immunostimulatory molecules such as the lipopolysaccharide derived MPL and the saponin derivative QS21 appear most promising, although doubts have been raised as to their safety in humans. Preclinical work with particulate adjuvants, such as the MF59 microemulsion and lipid-particle immune-stimulating complexes (Iscoms), suggest that these molecules are also potent elicitors of humoral and cellular immune responses. In addition, preclinical data on CpG oligonucleotides appear to be encouraging, particularly with respect to their ability to selectively manipulate immune responses. While all these adjuvants show promise, further work is needed to better define the mechanisms of adjuvant action. Ultimately, the development of more potent adjuvants may allow vaccines to be used as therapeutic, rather than prophylactic, agents.	Chiron Corp, Emeryville, CA 94608 USA	Novartis	Singh, M (corresponding author), Chiron Corp, 5300 Chiron Way, Emeryville, CA 94608 USA.	Manmohan_Singh@cc.chiron.com	O'Hagan, Derek/AAV-1850-2021					Agrawal B, 1998, NAT MED, V4, P43, DOI 10.1038/nm0198-043; Agren LC, 1999, J IMMUNOL, V162, P2432; Agren LC, 1997, J IMMUNOL, V158, P3936; AllaouiAttarki K, 1997, INFECT IMMUN, V65, P853, DOI 10.1128/IAI.65.3.853-857.1997; ALLISON AC, 1986, J IMMUNOL METHODS, V95, P157, DOI 10.1016/0022-1759(86)90402-3; ALVING CR, 1992, BIOCHIM BIOPHYS ACTA, V1113, P307, DOI 10.1016/0304-4157(92)90004-T; Ambrosch F, 1997, VACCINE, V15, P1209, DOI 10.1016/S0264-410X(97)00015-7; Ando S, 1999, J PHARM SCI, V88, P126, DOI 10.1021/js9801687; ANDREW WH, 1995, VACCINE DESIGN SUBUN, P645; BANGHAM AD, 1962, NATURE, V196, P952, DOI 10.1038/196952a0; Barr IG, 1998, ADV DRUG DELIVER REV, V32, P247, DOI 10.1016/S0169-409X(98)00013-1; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; Broide D, 1998, J IMMUNOL, V161, P7054; CAHILL ES, 1995, VACCINE, V13, P455, DOI 10.1016/0264-410X(94)00008-B; Cataldo DM, 1997, VACCINE, V15, P1710, DOI 10.1016/S0264-410X(97)00115-1; Challacombe SJ, 1997, VACCINE, V15, P169, DOI 10.1016/S0264-410X(96)00159-4; CHALLACOMBE SJ, 1992, IMMUNOLOGY, V76, P164; Chen HM, 1996, PHARMACEUT RES, V13, P1378, DOI 10.1023/A:1016030202104; CHEN SC, 1996, TZU CHI MED J, V8, P263; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; Davis HL, 1998, J IMMUNOL, V160, P870; DICKINSON BL, 1995, INFECT IMMUN, V63, P1617, DOI 10.1128/IAI.63.5.1617-1623.1995; DiTommaso A, 1996, INFECT IMMUN, V64, P974, DOI 10.1128/IAI.64.3.974-979.1996; Douce G, 1997, INFECT IMMUN, V65, P2821, DOI 10.1128/IAI.65.7.2821-2828.1997; DOUCE G, 1995, P NATL ACAD SCI USA, V92, P1644, DOI 10.1073/pnas.92.5.1644; Dupuis M, 1998, CELL IMMUNOL, V186, P18, DOI 10.1006/cimm.1998.1283; EDELMAN R, 1997, NEW GENERATION VACCI, P173; ELDRIDGE JH, 1991, INFECT IMMUN, V59, P2978, DOI 10.1128/IAI.59.9.2978-2986.1991; ELDRIDGE JH, 1990, J CONTROL RELEASE, V11, P205, DOI 10.1016/0168-3659(90)90133-E; Foster N, 1998, VACCINE, V16, P536, DOI 10.1016/S0264-410X(97)00222-3; Ghiara P, 1997, INFECT IMMUN, V65, P4996, DOI 10.1128/IAI.65.12.4996-5002.1997; Giannasca PJ, 1997, INFECT IMMUN, V65, P4288, DOI 10.1128/IAI.65.10.4288-4298.1997; Giannelli V, 1997, INFECT IMMUN, V65, P331, DOI 10.1128/IAI.65.1.331-334.1997; Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280; Giuliani MM, 1998, J EXP MED, V187, P1123, DOI 10.1084/jem.187.7.1123; Glenn GM, 1998, NATURE, V391, P851, DOI 10.1038/36014; Goletz TJ, 1997, P NATL ACAD SCI USA, V94, P12059, DOI 10.1073/pnas.94.22.12059; Gould-Fogerite S, 1998, ADV DRUG DELIVER REV, V32, P273, DOI 10.1016/S0169-409X(98)00014-3; Granoff DM, 1997, INFECT IMMUN, V65, P1710, DOI 10.1128/IAI.65.5.1710-1715.1997; GREGORIADIS G, 1990, IMMUNOL TODAY, V11, P89, DOI 10.1016/0167-5699(90)90034-7; Gupta RK, 1998, ADV DRUG DELIVER REV, V32, P155, DOI 10.1016/S0169-409X(98)00008-8; GUSTAFSON GL, 1992, RES IMMUNOL, V143, P483, DOI 10.1016/0923-2494(92)80058-S; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hedley ML, 1998, NAT MED, V4, P365, DOI 10.1038/nm0398-365; Higgins DA, 1996, VACCINE, V14, P478, DOI 10.1016/0264-410X(95)00240-2; Hussain N, 1997, PHARM RES-DORDR, V14, P613, DOI 10.1023/A:1012153011884; Jakob T, 1998, J IMMUNOL, V161, P3042; Jones DH, 1996, INFECT IMMUN, V64, P489, DOI 10.1128/IAI.64.2.489-494.1996; Jones DH, 1997, VACCINE, V15, P814, DOI 10.1016/S0264-410X(96)00266-6; KAHN JO, 1994, J INFECT DIS, V170, P1288, DOI 10.1093/infdis/170.5.1288; Kensil C R, 1998, Expert Opin Investig Drugs, V7, P1475, DOI 10.1517/13543784.7.9.1475; Kensil CR, 1996, CRIT REV THER DRUG, V13, P1; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Klavinskis LS, 1996, J IMMUNOL, V157, P2521; Klinman DM, 1999, VACCINE, V17, P19, DOI 10.1016/S0264-410X(98)00151-0; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; LANG J, 1999, CLIN TRIALS ADJUVANT; LANGENBERG AGM, 1995, ANN INTERN MED, V122, P889, DOI 10.7326/0003-4819-122-12-199506150-00001; Levine MM, 1998, LANCET, V351, P1375, DOI 10.1016/S0140-6736(05)79439-3; Ling IT, 1997, VACCINE, V15, P1562, DOI 10.1016/S0264-410X(97)00076-5; LIVINGSTON PO, 1994, VACCINE, V12, P1275, DOI 10.1016/S0264-410X(94)80052-2; LONGENECKER BM, 1993, ANN NY ACAD SCI, V690, P276; MALOY KJ, 1994, IMMUNOLOGY, V81, P661; Marchetti M, 1998, VACCINE, V16, P33, DOI 10.1016/S0264-410X(97)00153-9; MARTIN SJ, 1993, AIDS, V7, P1315, DOI 10.1097/00002030-199310000-00003; MARX PA, 1993, SCIENCE, V260, P1323, DOI 10.1126/science.8493576; McCluskie MJ, 1998, J IMMUNOL, V161, P4463; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MESSINA JP, 1991, J IMMUNOL, V147, P1759; Moldoveanu Z, 1998, VACCINE, V16, P1216, DOI 10.1016/S0264-410X(98)80122-9; Moore A, 1995, VACCINE, V13, P1741, DOI 10.1016/0264-410X(95)00184-3; MORRELL C, 1997, NATURE, V386, P410; MOSMANN TR, 1991, IMMUNOPARASITOL TOD, pA49; Newman MJ, 1998, ADV DRUG DELIVER REV, V32, P199, DOI 10.1016/S0169-409X(98)00011-8; Nixon DF, 1996, VACCINE, V14, P1523, DOI 10.1016/S0264-410X(96)00099-0; O'Hagan DT, 1998, ADV DRUG DELIVER REV, V34, P305, DOI 10.1016/S0169-409X(98)00045-3; O'Hagan DT, 1998, ADV DRUG DELIVER REV, V32, P225, DOI 10.1016/S0169-409X(98)00012-X; O'Hagan DT, 1994, NOVEL DELIVERY SYSTE, P175; OHagan DT, 1996, J ANAT, V189, P477; OHAGAN DT, 1993, VACCINE, V11, P965, DOI 10.1016/0264-410X(93)90387-D; OHAGAN DT, 1991, IMMUNOLOGY, V73, P239; OHAGAN DT, 1991, VACCINE, V9, P768, DOI 10.1016/0264-410X(91)90295-H; OHagan DT, 1997, MOL MED TODAY, V3, P69, DOI 10.1016/S1357-4310(96)10058-7; OHAGAN DT, 1997, NEW GENERATION VACCI, P215; OKADA H, 1995, CRIT REV THER DRUG, V12, P1; OTT G, 1995, VACCINE, V13, P1557, DOI 10.1016/0264-410X(95)00089-J; OTT G, 1995, VACCINE DESIGN SUBUN, P229; Payne LG, 1998, VACCINE, V16, P92, DOI 10.1016/S0264-410X(97)00149-7; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Powell M.F., 1995, VACCINE DESIGN SUBUN, P495; Putney SD, 1998, NAT BIOTECHNOL, V16, P153, DOI 10.1038/nbt0298-153; Ramon G, 1924, ANN I PASTEUR PARIS, V38, P1; RAPPUOLI R, 1999, IMMUNOL TODAY; Relyveld EH, 1998, VACCINE, V16, P1016, DOI 10.1016/S0264-410X(97)00288-0; Rimmelzwaan GF, 1997, J GEN VIROL, V78, P757, DOI 10.1099/0022-1317-78-4-757; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; Salgaller ML, 1998, J SURG ONCOL, V68, P122; Sasaki S, 1998, J VIROL, V72, P4931, DOI 10.1128/JVI.72.6.4931-4939.1998; Sasaki S, 1997, INFECT IMMUN, V65, P3520, DOI 10.1128/IAI.65.9.3520-3528.1997; SCHIRMBECK R, 1995, VACCINE, V13, P857, DOI 10.1016/0264-410X(94)00038-O; SHAHIN R, 1995, INFECT IMMUN, V63, P1195, DOI 10.1128/IAI.63.4.1195-1200.1995; Smith RE, 1999, J IMMUNOL, V162, P5536; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SOLTYSIK S, 1995, VACCINE, V13, P1403, DOI 10.1016/0264-410X(95)00077-E; Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; STRAUS SE, 1994, LANCET, V343, P1460, DOI 10.1016/S0140-6736(94)92581-X; Sun SQ, 1998, J EXP MED, V187, P1145, DOI 10.1084/jem.187.7.1145; Tacket CO, 1998, NAT MED, V4, P607, DOI 10.1038/nm0598-607; Thoelen S, 1998, VACCINE, V16, P708, DOI 10.1016/S0264-410X(97)00254-5; Toda S, 1997, IMMUNOLOGY, V92, P111, DOI 10.1046/j.1365-2567.1997.00307.x; TOKUNAGA T, 1984, J NATL CANCER I, V72, P955; Traquina P, 1996, J INFECT DIS, V174, P1168, DOI 10.1093/infdis/174.6.1168; TSENG JN, 1995, INFECT IMMUN, V63, P2880, DOI 10.1128/IAI.63.8.2880-2885.1995; Ugozzoli M, 1998, IMMUNOLOGY, V93, P563; VALENZUELA P, 1982, NATURE, V298, P347, DOI 10.1038/298347a0; Vogel F. R., 1995, VACCINE DESIGN SUBUN, P141; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0; WhittumHudson JA, 1996, NAT MED, V2, P1116, DOI 10.1038/nm1096-1116; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	120	365	437	0	89	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1075	1081		10.1038/15058	http://dx.doi.org/10.1038/15058			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545912	Bronze			2022-12-27	WOS:000083428000023
J	Taylor, JK; Zhang, QQ; Wyatt, JR; Dean, NM				Taylor, JK; Zhang, QQ; Wyatt, JR; Dean, NM			Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides	NATURE BIOTECHNOLOGY			English	Article						Bcl-x; antisense oligonucleotide; apoptosis; alternative splicing	MESSENGER-RNA; CELL-DEATH; APOPTOSIS; EXPRESSION; BCL-X(S); INHIBITION; DIFFERENTIATION; IDENTIFICATION; ACTIVATION; SURVIVAL	Resistance to apoptosis, which plays an important role in tumors that are refractory to chemotherapy, is regulated by the ratio of antiapoptotic to proapoptotic proteins. By manipulating levels of these proteins, cells can become sensitized to undergo apoptosis in response to chemotherapeutic agents. Alternative splicing of the bcl-x gene gives rise to two proteins with antagonistic functions: Bcl-xL, a well-characterized antiapoptotic protein, and Bcl-xS, a proapoptotic protein. We show here that altering the ratio of Bcl-xL to Bcl-xS in the cell using an antisense oligonucleotide permitted cells to be sensitized to undergo apoptosis in response to ultraviolet B radiation and chemotherapeutic drug treatment. These results demonstrate the ability of a chemically modified oligonucleotide to alter splice site selection in an endogenous gene and illustrate a powerful tool to regulate cell survival.	ISIS Pharmaceut, Dept Pharmacol, Carlsbad, CA 92008 USA; ISIS Pharmaceut, Dept Biol Struct, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc; Isis Pharmaceuticals Inc	Dean, NM (corresponding author), ISIS Pharmaceut, Dept Pharmacol, 2280 Faraday Ave, Carlsbad, CA 92008 USA.							Ban J, 1998, BIOCHEM BIOPH RES CO, V248, P147, DOI 10.1006/bbrc.1998.8907; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CLARKE MF, 1995, P NATL ACAD SCI USA, V92, P11024, DOI 10.1073/pnas.92.24.11024; Condon TP, 1996, J BIOL CHEM, V271, P30398, DOI 10.1074/jbc.271.48.30398; Dean NM, 1997, ANTISENSE NUCLEIC A, V7, P229, DOI 10.1089/oli.1.1997.7.229; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; Dunckley MG, 1998, HUM MOL GENET, V7, P1083, DOI 10.1093/hmg/7.7.1083; Ealovega MW, 1996, CANCER RES, V56, P1965; Fridman JS, 1998, ONCOGENE, V17, P2981, DOI 10.1038/sj.onc.1202224; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; HARRIS AL, 1992, ACTA ONCOL, V31, P205, DOI 10.3109/02841869209088904; HODGE D, 1995, MOL PHARMACOL, V48, P905; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kole R, 1997, ACTA BIOCHIM POL, V44, P231; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; MONIA BP, 1992, J BIOL CHEM, V267, P19954; NOBLE JR, 1992, EXP CELL RES, V203, P297, DOI 10.1016/0014-4827(92)90002-P; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Ray S, 1996, CELL GROWTH DIFFER, V7, P1617; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; Sierakowska H, 1996, P NATL ACAD SCI USA, V93, P12840, DOI 10.1073/pnas.93.23.12840; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; Tao WK, 1998, J BIOL CHEM, V273, P23704, DOI 10.1074/jbc.273.37.23704; Taylor J K, 1999, Curr Opin Drug Discov Devel, V2, P147; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yu K, 1997, CELL DEATH DIFFER, V4, P745, DOI 10.1038/sj.cdd.4400295	32	167	187	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1097	1100		10.1038/15079	http://dx.doi.org/10.1038/15079			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545916				2022-12-27	WOS:000083428000027
J	Ness, JE; Welch, M; Giver, L; Bueno, M; Cherry, JR; Borchert, TV; Stemmer, WPC; Minshull, J				Ness, JE; Welch, M; Giver, L; Bueno, M; Cherry, JR; Borchert, TV; Stemmer, WPC; Minshull, J			DNA shuffling of subgenomic sequences of subtilisin	NATURE BIOTECHNOLOGY			English	Article						directed evolution; DNA shuffling; molecular breeding; subtilisin; Savinase	DIRECTED EVOLUTION; IN-VITRO; RANDOM MUTAGENESIS; CRYPTIC GENES; STABILITY; PROTEASE; BPN'; IMPROVEMENT; RESISTANCE; BACILLUS	DNA family shuffling of 26 protease genes was used to create a library of chimeric proteases that was screened for four distinct enzymatic properties. Multiple clones were identified that were significantly improved over any of the parental enzymes for each individual property. Family shuffling, also known as molecular breeding, efficiently created all of the combinations of parental properties, producing a great diversity of property combinations in the progeny enzymes. Thus, molecular breeding, like classical breeding, is a powerful tool for recombining existing diversity to tailor biological systems for multiple functional parameters.	Novo Nordisk AS, Enzyme Design, DK-2880 Bagsvaerd, Denmark; Maxygen, Santa Clara, CA 95051 USA; Novo Nordisk Biotech, Davis, CA 95616 USA	Novo Nordisk; Novo Nordisk	Minshull, J (corresponding author), Novo Nordisk AS, Enzyme Design, DK-2880 Bagsvaerd, Denmark.							Beebe AM, 1997, IMMUNITY, V6, P551, DOI 10.1016/S1074-7613(00)80343-X; BOTT R, 1992, ENZYME ENG 11, V672; BRYAN P N, 1986, Proteins Structure Function and Genetics, V1, P326; CARTER P, 1989, PROTEINS, V6, P240, DOI 10.1002/prot.340060306; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Crow JF, 1999, NATURE, V397, P293, DOI 10.1038/16789; CUNNINGHAM BC, 1987, PROTEIN ENG, V1, P319, DOI 10.1093/protein/1.4.319; Darwin C, 1859, ORIGIN SPECIES MEANS; GRAYCAR TP, 1992, ANN NY ACAD SCI, V672, P71; HALL BG, 1983, MOL BIOL EVOL, V1, P109; Harwood C.R., 1990, MOL BIOL METHODS BAC; Jones LJ, 1997, ANAL BIOCHEM, V251, P144, DOI 10.1006/abio.1997.2259; Kano H, 1997, APPL MICROBIOL BIOT, V47, P46, DOI 10.1007/s002530050886; Kuchner O, 1997, TRENDS BIOTECHNOL, V15, P523, DOI 10.1016/S0167-7799(97)01138-4; LAMB CJ, 1992, BIO-TECHNOL, V10, P1436, DOI 10.1038/nbt1192-1436; LI WH, 1984, MOL BIOL EVOL, V1, P213; Mann CC, 1999, SCIENCE, V283, P310, DOI 10.1126/science.283.5400.310; Mansfeld J, 1997, J BIOL CHEM, V272, P11152, DOI 10.1074/jbc.272.17.11152; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; Naki D, 1998, APPL MICROBIOL BIOT, V49, P290, DOI 10.1007/s002530051171; PANTOLIANO MW, 1989, BIOCHEMISTRY-US, V28, P7205, DOI 10.1021/bi00444a012; Patkar S, 1998, CHEM PHYS LIPIDS, V93, P95, DOI 10.1016/S0009-3084(98)00032-2; Rao MB, 1998, MICROBIOL MOL BIOL R, V62, P597, DOI 10.1128/MMBR.62.3.597-635.1998; RUSSELL AJ, 1987, NATURE, V328, P496, DOI 10.1038/328496a0; Schellenberger V, 1998, ASM NEWS, V64, P634; SHOICHET BK, 1995, P NATL ACAD SCI USA, V92, P452, DOI 10.1073/pnas.92.2.452; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; TANGE T, 1994, APPL MICROBIOL BIOT, V41, P239, DOI 10.1007/s002530050137; WELLS JA, 1988, TRENDS BIOCHEM SCI, V13, P291, DOI 10.1016/0968-0004(88)90121-1; [No title captured]; [No title captured]	33	164	256	0	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					893	896		10.1038/12884	http://dx.doi.org/10.1038/12884			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471932				2022-12-27	WOS:000082365800032
J	Gulcher, J; Stefansson, K				Gulcher, J; Stefansson, K			An Icelandic saga on a centralized healthcare database and democratic decision making	NATURE BIOTECHNOLOGY			English	Editorial Material									DeCode Genet, IS-110 Reykjavik, Iceland		Gulcher, J (corresponding author), DeCode Genet, Lynghals 1, IS-110 Reykjavik, Iceland.		Stefansson, Kari/AAE-7187-2019						0	20	20	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					620	620		10.1038/10796	http://dx.doi.org/10.1038/10796			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10409337				2022-12-27	WOS:000081296900005
J	Craig, TA; Benson, LM; Tomlinson, AJ; Veenstra, TD; Naylor, S; Kumar, R				Craig, TA; Benson, LM; Tomlinson, AJ; Veenstra, TD; Naylor, S; Kumar, R			Analysis of transcription complexes and effects of ligands by microelectrospray ionization mass spectrometry	NATURE BIOTECHNOLOGY			English	Article						mass spectrometry; vitamin D receptors; retinoic acid receptors; transcription; DNA response elements	RETINOID-X RECEPTOR; DNA-BINDING DOMAIN; ELECTROSPRAY-IONIZATION; VITAMIN-D; NUCLEAR RECEPTOR; D-3 RECEPTOR; RESPONSE ELEMENTS; MOLECULAR ACTIONS; ACID RECEPTORS; PROTEIN	The human vitamin D receptor (VDR) and retinoid X receptor-alpha (RXR alpha) modulate gene activity by forming homodimeric or heterodimeric complexes with specific DNA sequences and interaction with other elements of the transcriptional apparatus in the presence of their known endogenous ligands 1 alpha,25-dihydroxyvitamin D-3 (1,25-[OH](2)D-3) and 9-cis-retinoic acid (9-c-RA). We used rapid buffer exchange gel filtration in conjunction with microelectrospray ionization mass spectrometry (mu ESI-MS) to study the binding of these receptors to the osteopontin vitamin D response element (OP VDRE). In the absence of DNA, both VDR and RXR alpha existed primarily as monomers, but in the presence of OP VDRE, homodimeric RXR alpha and heterodimeric RXR alpha-VDR complexes were shown to bind OP VDRE. Addition of 9-c-RA increased RXR alpha homodimer-OP VDRE complexes, and addition of 1,25-(OH)2D3 resulted in formation of 1,25-(OH)(2)D-3-VDR-RXR alpha-OP VDRE complexes. Addition of low-affinity binding ligands had no detectable effect on the VDR-RXR alpha-OP VDRE transcription complex. These results demonstrate the utility of mu ESI-MS in analyzing multimeric, high-molecular-weight protein-protein and protein-DNA complexes, and the effects of ligands on these transcriptional complexes.	Mayo Clin, Nephrol Res Unit, Rochester, MN 55905 USA; Mayo Clin, Biomed Mass Spectrometry Facil, Rochester, MN 55905 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Dept Med, Rochester, MN 55905 USA; Mayo Clin, Dept Pharmacol, Rochester, MN 55905 USA; Mayo Clin, Clin Pharmacol Unit, Rochester, MN 55905 USA; Pacific NW Natl Lab, Environm & Mol Sci Lab, Richland, WA 99352 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Naylor, S (corresponding author), Mayo Clin, Nephrol Res Unit, Rochester, MN 55905 USA.	naylor.stephen@mayo.edu; rkumar@mayo.edu		Kumar, Rajiv/0000-0003-3497-3057	NIDDK NIH HHS [R01 DK025409, DK 25409] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025409] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Bagchi Milan K., 1998, P159; Benjamin DR, 1998, P NATL ACAD SCI USA, V95, P7391, DOI 10.1073/pnas.95.13.7391; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Carlberg C, 1996, ENDOCRINE, V4, P91, DOI 10.1007/BF02782754; Cheng XH, 1996, P NATL ACAD SCI USA, V93, P7022, DOI 10.1073/pnas.93.14.7022; Cheng XH, 1996, ANAL BIOCHEM, V239, P35, DOI 10.1006/abio.1996.0287; Cheskis B, 1996, BIOCHEMISTRY-US, V35, P3309, DOI 10.1021/bi952283r; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; Cheskis Boris, 1998, P133; Craig TA, 1997, BIOCHEMISTRY-US, V36, P10482, DOI 10.1021/bi970561b; Craig TA, 1996, BIOCHEM BIOPH RES CO, V218, P902, DOI 10.1006/bbrc.1996.0160; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; Fitzgerald MC, 1996, P NATL ACAD SCI USA, V93, P6851, DOI 10.1073/pnas.93.14.6851; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GOODLETT DR, 1993, BIOL MASS SPECTROM, V22, P181, DOI 10.1002/bms.1200220307; Haussler MR, 1997, J ENDOCRINOL, V154, pS57; Johnson KL, 1997, RAPID COMMUN MASS SP, V11, P939, DOI 10.1002/(SICI)1097-0231(199705)11:8<939::AID-RCM936>3.0.CO;2-3; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Kahlen JP, 1996, BIOCHEM BIOPH RES CO, V218, P882, DOI 10.1006/bbrc.1996.0157; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; Lemon BD, 1997, MOL CELL BIOL, V17, P1923, DOI 10.1128/MCB.17.4.1923; Loo JA, 1997, MASS SPECTROM REV, V16, P1; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Nemirovskiy OV, 1997, J AM SOC MASS SPECTR, V8, P809, DOI 10.1016/S1044-0305(97)00086-X; *PHARM BIOT, 1994, GST FUS SYST MAN; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; Potier N, 1998, PROTEIN SCI, V7, P1388; REVELLE L, 1984, BIOCHEMISTRY-US, V23, P1983, DOI 10.1021/bi00304a016; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; Schwartz B L, 1996, Methods Mol Biol, V61, P115; SHETERLINE P, 1995, PROTEIN PROFILE TRAN, V2, P1209; Siuzdak G., 1996, MASS SPECTROMETRY BI; Smith RD, 1997, CHEM SOC REV, V26, P191, DOI 10.1039/cs9972600191; SONE T, 1991, J BIOL CHEM, V266, P23296; Veenstra TD, 1997, BIOCHEMISTRY-US, V36, P3535, DOI 10.1021/bi9628329; Veenstra TD, 1998, NAT BIOTECHNOL, V16, P262, DOI 10.1038/nbt0398-262; Veenstra TD, 1998, J AM SOC MASS SPECTR, V9, P8, DOI 10.1016/S1044-0305(97)00229-8; YANG Q, 1998, ADV CHROMATOGRAPHIC, P95	42	37	37	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1214	1218		10.1038/70767	http://dx.doi.org/10.1038/70767			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585721				2022-12-27	WOS:000084170700031
J	Hukuhara, T; Hayakawa, T; Wijonarko, A				Hukuhara, T; Hayakawa, T; Wijonarko, A			Increased baculovirus susceptibility of armyworm larvae feeding on transgenic rice plants expressing an entomopoxvirus gene	NATURE BIOTECHNOLOGY			English	Article						transgenic rice plants; baculovirus; entomopoxvirus; armyworm	VIRUS ENHANCING FACTOR; NUCLEAR POLYHEDROSIS-VIRUS; PSEUDALETIA-SEPARATA; STRIPE VIRUS; PROTOPLASTS; LEPIDOPTERA; RESISTANT; SEQUENCE; CULTURE	We have introduced an entomopoxvirus gene encoding a virus enhancing factor (EF) into rice, which resulted in high-level accumulation of the EF in the transgenic plants. The introduced gene was stably inherited in the progeny of the primary transformants, as shown by analysis of their genomic DNA. Bioassays for insect susceptibility to baculovirus infection showed that armyworm larvae feeding on the transgenic rice had increased susceptibility to a Nucleopolyhedrovirus. Thus, introduction of the EF gene into plants can be used as a strategy to increase the effectiveness of baculoviruses in insect pest management.	Nihon Univ, Coll Bioresource Sci, Fujisawa, Kanagawa 2528510, Japan; Plantech Res Inst, Yokohama, Kanagawa 2270033, Japan; Tokyo Univ Agr & Technol, Fac Agr, Fuchu, Tokyo 1838509, Japan	Nihon University; Tokyo University of Agriculture & Technology	Hukuhara, T (corresponding author), Nihon Univ, Coll Bioresource Sci, Fujisawa, Kanagawa 2528510, Japan.							BABA A, 1986, PLANT CELL PHYSIOL, V27, P463; BERKSON J, 1955, J AM STAT ASSOC, V50, P529, DOI 10.2307/2280974; BLAK BC, 1997, BACULOVIRUSES, P341; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Dougherty EM, 1996, BIOL CONTROL, V7, P71, DOI 10.1006/bcon.1996.0067; FUJIMOTO H, 1993, BIO-TECHNOL, V11, P1151, DOI 10.1038/nbt1093-1151; HAYAKAWA T, 1992, P NATL ACAD SCI USA, V89, P9865, DOI 10.1073/pnas.89.20.9865; Hayakawa T., 1997, Recent Research Developments in Agricultural & Biological Chemistry, V1, P51; Hayakawa T, 1996, GENE, V177, P269, DOI 10.1016/0378-1119(96)00297-1; HUKUHARA T, 1995, J INVERTEBR PATHOL, V65, P315, DOI 10.1006/jipa.1995.1050; Hunter-Fujita FR, 1998, INSECT VIRUSES PEST; Jaques R.P., 1985, P285; Kalmakoff J., 1982, P435; KYOZUKA J, 1987, MOL GEN GENET, V206, P408, DOI 10.1007/BF00428879; Miller LK, 1997, BACULOVIRUSES, P217, DOI DOI 10.1007/978; Mitsuhashi W, 1998, J INVERTEBR PATHOL, V71, P186, DOI 10.1006/jipa.1997.4732; MURPHY FA, 1995, VIRUS TAXONOMY, P104; OHIRA K, 1973, PLANT CELL PHYSIOL, V14, P1113; OHTA S, 1990, PLANT CELL PHYSIOL, V31, P805; PFADT RE, 1985, FUNDAMENTALS APPL EN, P247; RICHARDS E, 1973, CURRENT PROTOCOLS MO; SHAPIRO M, 1994, J ECON ENTOMOL, V87, P356, DOI 10.1093/jee/87.2.356; SHIMAMOTO K, 1989, NATURE, V338, P274, DOI 10.1038/338274a0; TANADA Y, 1985, J INVERTEBR PATHOL, V45, P125, DOI 10.1016/0022-2011(85)90001-1; TANADA Y, 1969, J INVERTEBR PATHOL, V13, P394, DOI 10.1016/0022-2011(69)90192-X; Tomita M, 1998, APPL ENTOMOL ZOOL, V33, P277, DOI 10.1303/aez.33.277; Wijonarko A, 1998, J INVERTEBR PATHOL, V72, P82, DOI 10.1006/jipa.1998.4756; XU JH, 1992, J INVERTEBR PATHOL, V60, P259, DOI 10.1016/0022-2011(92)90007-Q; XU JH, 1994, J INVERTEBR PATHOL, V63, P14, DOI 10.1006/jipa.1994.1003; YAMAMOTO T, 1978, J INVERTEBR PATHOL, V31, P48, DOI 10.1016/0022-2011(78)90108-8; ZHU YF, 1991, J GEN VIROL, V72, P763, DOI 10.1099/0022-1317-72-4-763	32	20	24	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1122	1124		10.1038/15110	http://dx.doi.org/10.1038/15110			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545922				2022-12-27	WOS:000083428000033
J	Hunkeler, D; Sun, AM; Korbutt, GS; Rajotte, RV; Gill, RG; Calafiore, R; Morel, P				Hunkeler, D; Sun, AM; Korbutt, GS; Rajotte, RV; Gill, RG; Calafiore, R; Morel, P			Bioartificial organs and acceptable risk	NATURE BIOTECHNOLOGY			English	Editorial Material							EX-VIVO CONNECTION; PIG KIDNEYS; NO EVIDENCE; XENOGRAFTS; INFECTION; HUMANS		Swiss Fed Inst Technol, Lab Polymers & Biomat, CH-1015 Lausanne, Switzerland; Univ Toronto, Dept Physiol, Toronto, ON, Canada; Univ Alberta, Surg Med Res Inst, Edmonton, AB, Canada; Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA; Univ Perugia, Lab Study & Transplant Pancreat Islets, I-06100 Perugia, Italy; Univ Hosp Geneva, Clin & Polyclin Digest Surg, Transplantat Unit, Geneva, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Toronto; University of Alberta; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Perugia; University of Geneva	Hunkeler, D (corresponding author), Swiss Fed Inst Technol, Lab Polymers & Biomat, CH-1015 Lausanne, Switzerland.		Gill, Ronald/GWM-5338-2022					AEBISCHER P, 1996, MRS BULL, V21, P59; Bach FH, 1998, NATURE, V391, P326, DOI 10.1038/34766; BRADIS K, 1999, SCIENCE, V285, P1236; Breimer ME, 1996, XENOTRANSPLANTATION, V3, P328, DOI 10.1111/j.1399-3089.1996.tb00155.x; CALAFIORE R, 1998, ANN NY ACD SCI, V830, P313; DEMETRIOU AA, 1999, ANN NY ACAD SCI, V875, P350; GROTH CG, 1994, LANCET, V344, P1402, DOI 10.1016/S0140-6736(94)90570-3; Heneine W, 1998, LANCET, V352, P695, DOI 10.1016/S0140-6736(98)07145-1; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Lanza RP, 1996, NAT BIOTECHNOL, V14, P1107, DOI 10.1038/nbt0996-1107; Lohr M, 1999, J MOL MED, V77, P393, DOI 10.1007/s001090050366; Masood E, 1998, NATURE, V394, P513, DOI 10.1038/28920; Patience C, 1998, LANCET, V352, P699, DOI 10.1016/S0140-6736(98)04369-4; Rydberg L, 1996, XENOTRANSPLANTATION, V3, P340, DOI 10.1111/j.1399-3089.1996.tb00156.x; Sun YL, 1996, J CLIN INVEST, V98, P1417, DOI 10.1172/JCI118929	15	20	21	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1045	1045		10.1038/14989	http://dx.doi.org/10.1038/14989			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545868	Bronze			2022-12-27	WOS:000083428000005
J	Huynh, T; Abraham, G; Murray, J; Brockbank, K; Hagen, PO; Sullivan, S				Huynh, T; Abraham, G; Murray, J; Brockbank, K; Hagen, PO; Sullivan, S			Remodeling of an acellular collagen graft into a physiologically responsive neovessel	NATURE BIOTECHNOLOGY			English	Article						collagen; biomaterials; tissue engineering; vascular prostheses	INTESTINAL SUBMUCOSA; BLOOD-VESSEL; CELLS; MODEL; EQUIVALENT; CULTURE; WALL	Surgical treatment of vascular disease has become common, creating the need for a readily available, small-diameter vascular graft. However, the use of synthetic materials is limited to grafts larger than 5-6 mm because of the frequency of occlusion observed with smaller-diameter prosthetics. An alternative to synthetic materials would be a biomaterial that could be used in the design of a tissue-engineered graft. We demonstrate that a small-diameter (4 mm) graft constructed from a collagen biomaterial derived from the submucosa of the small intestine and type I bovine collagen has the potential to integrate into the host tissue and provide a scaffold for remodeling into a functional blood vessel. The results obtained using a rabbit arterial bypass model have shown excellent hemostasis and patency. Furthermore, within three months after implantation, the collagen grafts were remodeled into cellularized vessels that exhibited physiological activity in response to vasoactive agents.	Organogenesis Inc, Canton, MA 02021 USA; Duke Univ, Med Ctr, Durham, NC 27710 USA; KGB Associates Inc, Charleston, SC 29401 USA	Duke University	Sullivan, S (corresponding author), Organogenesis Inc, Canton, MA 02021 USA.	ssullivan@organo.com	Brockbank, Kelvin/GWV-4265-2022					ABRAHAM GA, 1998, Patent No. 49969; *AM HEART ASS, 1995, HEART STROK FACTS S; BADYLAK SF, 1989, J SURG RES, V47, P74, DOI 10.1016/0022-4804(89)90050-4; Bowlin GL, 1997, CELL TRANSPLANT, V6, P623, DOI 10.1016/S0963-6897(97)00096-1; BREWSTER DC, 1995, VASCULAR SURG, P492; CALLOW AD, 1986, BIOL SYNTHETIC VASCU, P11; CRAMER R, 1973, RADIOLOGY, V109, P585, DOI 10.1148/109.3.585; DAVIDS L, 1999, TISSUE ENG PROSTHETI, P3; DAVIES MG, 1994, J CLIN INVEST, V94, P1680, DOI 10.1172/JCI117513; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; EDWARDS WS, 1966, SURG GYNECOL OBSTETR, V122, P37; EGUSA S, 1968, ACTA MED OKAYAMA, V22, P153; Falanga V, 1998, ARCH DERMATOL, V134, P293, DOI 10.1001/archderm.134.3.293; GUNDRY SR, 1987, J SURG RES, V43, P75, DOI 10.1016/0022-4804(87)90049-7; HardinYoung J, 1996, BIOTECHNOL BIOENG, V49, P675, DOI 10.1002/(SICI)1097-0290(19960320)49:6<675::AID-BIT9>3.0.CO;2-L; HERRING M, 1978, SURGERY, V84, P498; KEMP PD, 1993, Patent No. 5256418; Kim KM, 1999, AM J PATHOL, V154, P843, DOI 10.1016/S0002-9440(10)65331-X; KOTTKEMARCHANT K, 1989, BIOMATERIALS, V10, P147, DOI 10.1016/0142-9612(89)90017-3; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; Lantz G C, 1990, J Invest Surg, V3, P217, DOI 10.3109/08941939009140351; LAWLER MR, 1971, AM J SURG, V122, P517, DOI 10.1016/0002-9610(71)90478-8; LEVESQUE MJ, 1989, BIORHEOLOGY, V26, P345; MATSUDA T, 1995, J THORAC CARDIOV SUR, V110, P988, DOI 10.1016/S0022-5223(05)80166-7; MATSUMOTO T, 1966, SURGERY, V60, P739; MILLS I, 1999, TISSUE ENG PROSTHETI, P425; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; ODONNELL TF, 1984, J VASC SURG, V1, P136; OMALLEY MK, 1986, SURGERY, V99, P36; PARK KD, 1988, J BIOMED MATER RES, V22, P977, DOI 10.1002/jbm.820221103; PASIC M, 1994, ANN THORAC SURG, V58, P677, DOI 10.1016/0003-4975(94)90726-9; SOWTON E, 1991, BRIT HEART J, V66, P325; STEPHEN M, 1977, SURGERY, V81, P314; TERMIN PL, 1993, AAMI CARD SCI TECHN; Tranquillo RT, 1996, BIOMATERIALS, V17, P349, DOI 10.1016/0142-9612(96)85573-6; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; Williams S K, 1994, J Invest Surg, V7, P503, DOI 10.3109/08941939409015367; Zarge JI, 1997, PRINCIPLES TISSUE EN, P349; ZIEGLER T, 1995, CELL MATER, V5, P115	39	236	275	4	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1083	1086		10.1038/15062	http://dx.doi.org/10.1038/15062			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545913				2022-12-27	WOS:000083428000024
J	Culver, KW; Hsieh, WT; Huyen, Y; Chen, V; Liu, JL; Khripine, Y; Khorlin, A				Culver, KW; Hsieh, WT; Huyen, Y; Chen, V; Liu, JL; Khripine, Y; Khorlin, A			Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides	NATURE BIOTECHNOLOGY			English	Article						gene repair; triplexing oligonucleotides; gene therapy; adenosine deaminase	TRIPLE-HELIX FORMATION; GENE-THERAPY; FORMING OLIGONUCLEOTIDES; STRAND BREAKS; BASE-PAIRS; IN-VITRO; DNA; INHIBITION; SEQUENCE; TRANSCRIPTION	A sequence-specific genomic delivery system for the correction of chromosomal mutations was designed by incorporating two different binding domains into a single-stranded oligonucleotide. A repair domain (RD) contained the native sequence of the target region, A third strand-forming domain (TFD) was designed to form a tripler by Hoogsteen interactions. The design was based upon the premise that the RD will rapidly form a heteroduplex that is anchored synergistically by the TFD, Deoxyoligonucleotides were designed to form triplexes in the human adenosine deaminase (ADA) and p53 genes adjacent to known point mutations, Transfection of ADA-deficient human lymphocytes corrected the mutant sequence in 1-2% of cells. Neither the RD or TFD individually corrected the mutation, Transfection of p53 mutant human glioblastoma cells corrected the mutation and induced apoptosis in 7.5% of cells.	Codon Pharmaceut Inc, Gaithersburg, MD 20877 USA		Culver, KW (corresponding author), Novartis Pharmaceut, E Hanover, NJ 07936 USA.	ken.culver@pharma.novartis.com						Agrawal S, 1997, P NATL ACAD SCI USA, V94, P2620, DOI 10.1073/pnas.94.6.2620; BLAESE RM, 1990, HUM GENE THER, V1, P327; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; Chan PP, 1999, J BIOL CHEM, V274, P11541, DOI 10.1074/jbc.274.17.11541; Chan PP, 1997, J MOL MED, V75, P267, DOI 10.1007/s001090050112; ColeStrauss A, 1996, SCIENCE, V273, P1386, DOI 10.1126/science.273.5280.1386; CULVER K, 1991, P NATL ACAD SCI USA, V88, P3155, DOI 10.1073/pnas.88.8.3155; Escude C, 1998, P NATL ACAD SCI USA, V95, P3591, DOI 10.1073/pnas.95.7.3591; FOSSELLA JA, 1993, NUCLEIC ACIDS RES, V21, P4511, DOI 10.1093/nar/21.19.4511; FUJIWARA T, 1994, INT J CANCER, V56, P834, DOI 10.1002/ijc.2910560614; Gamper HB, 1998, J AM CHEM SOC, V120, P2182, DOI 10.1021/ja971397i; Goncz KK, 1998, HUM MOL GENET, V7, P1913, DOI 10.1093/hmg/7.12.1913; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; Hanvey J C, 1991, Antisense Res Dev, V1, P307; HIRSCHHORN R, 1995, CLIN IMMUNOL IMMUNOP, V76, pS219, DOI 10.1016/S0090-1229(95)90288-0; HIRSCHHORN R, 1978, CLIN IMMUNOL IMMUNOP, V9, P287, DOI 10.1016/0090-1229(78)90100-9; HSIEH P, 1992, P NATL ACAD SCI USA, V89, P6492, DOI 10.1073/pnas.89.14.6492; Hussain SP, 1998, CANCER RES, V58, P4023; Kren BT, 1997, HEPATOLOGY, V25, P1462, DOI 10.1002/hep.510250626; Kunzelmann K, 1996, GENE THER, V3, P859; LI X, 1995, BIOTECH HISTOCHEM, V70, P234, DOI 10.3109/10520299509108200; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; Majumdar A, 1998, NAT GENET, V20, P212, DOI 10.1038/2530; MARKERT ML, 1989, AM J HUM GENET, V45, P354; PANYUTIN IG, 1994, NUCLEIC ACIDS RES, V22, P4979, DOI 10.1093/nar/22.23.4979; RAO BJ, 1994, P NATL ACAD SCI USA, V91, P6161, DOI 10.1073/pnas.91.13.6161; Russell DW, 1998, NAT GENET, V18, P325, DOI 10.1038/ng0498-325; SETO S, 1986, J IMMUNOL, V136, P2839; Strauss M, 1998, NAT MED, V4, P274, DOI 10.1038/nm0398-274; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sun JS, 1996, CURR OPIN STRUC BIOL, V6, P327, DOI 10.1016/S0959-440X(96)80051-0; Svinarchuk F, 1997, NUCLEIC ACIDS RES, V25, P3459, DOI 10.1093/nar/25.17.3459; Tang MX, 1996, BIOCONJUGATE CHEM, V7, P703, DOI 10.1021/bc9600630; Vlieghe D, 1996, SCIENCE, V273, P1702, DOI 10.1126/science.273.5282.1702; VOLKMANN S, 1995, NUCLEIC ACIDS RES, V23, P1204, DOI 10.1093/nar/23.7.1204; WANG G, 1995, MOL CELL BIOL, V15, P1759; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; Yanez RJ, 1998, GENE THER, V5, P149, DOI 10.1038/sj.gt.3300601	39	62	69	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					989	993		10.1038/13684	http://dx.doi.org/10.1038/13684			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504700				2022-12-27	WOS:000083015700025
J	Slater, S; Mitsky, TA; Houmiel, KL; Hao, M; Reiser, SE; Taylor, NB; Tran, M; Valentin, HE; Rodriguez, DJ; Stone, DA; Padgette, SR; Kishore, G; Gruys, KJ				Slater, S; Mitsky, TA; Houmiel, KL; Hao, M; Reiser, SE; Taylor, NB; Tran, M; Valentin, HE; Rodriguez, DJ; Stone, DA; Padgette, SR; Kishore, G; Gruys, KJ			Metabolic engineering of Arabidopsis and Brassica for poly(3-hydroxybutyrate-co-3-hydroxyvalerate) copolymer production	NATURE BIOTECHNOLOGY			English	Article						poly(hydroxyalkanoate); biodegradable polymer; green chemistry; PHA copolymer	BIOSYNTHETIC THREONINE DEAMINASE; ESCHERICHIA-COLI; PLANTS; POLYHYDROXYBUTYRATE; SEQUENCES; PLASTIDS; NAPUS	Poly(hydroxyalkanoates) are natural polymers with thermoplastic properties. One polymer of this class with commercial applicability, poly(3-hydroxybutyrate-co-3-hydroxyvale) (PHBV) can be produced by bacterial fermentation, but the process is not economically competitive with polymer production from petrochemicals, Poly(hydroxyalkanoate) production in green plants promises much lower costs, but producing copolymer with the appropriate monomer composition is problematic. In this study, we have engineered Arabidopsis and Brassica to produce PHBV in leaves and seeds, respectively, by redirecting the metabolic flow of intermediates from fatty acid and amino acid biosynthesis. We present a pathway for the biosynthesis of PHBV in plant plastids, and also report copolymer production, metabolic intermediate analyses, and pathway dynamics.	Monsanto Co, St Louis, MO 63198 USA	Monsanto	Gruys, KJ (corresponding author), Monsanto Co, 700 Chesterfield Pkwy N, St Louis, MO 63198 USA.	kenneth.j.gruys@monsanto.com						ANDERSON AJ, 1990, MICROBIOL REV, V54, P450, DOI 10.1128/MMBR.54.4.450-472.1990; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broun P, 1998, PLANT J, V13, P201, DOI 10.1046/j.1365-313X.1998.00023.x; BURNS RO, 1979, J BIOL CHEM, V254, P1074; BYRUM D, 1992, FEMS MICROBIOL REV, V102, P247; CASHMORE AR, 1983, GENETIC ENG PLANTS A, P29; CORUZZI G, 1984, EMBO J, V3, P1671, DOI 10.1002/j.1460-2075.1984.tb02031.x; EISENSTEIN E, 1995, BIOCHEMISTRY-US, V34, P9403, DOI 10.1021/bi00029a016; Eschenlauer AC, 1996, INT J BIOL MACROMOL, V19, P121, DOI 10.1016/0141-8130(96)01114-2; FRY J, 1987, PLANT CELL REP, V6, P321, DOI 10.1007/BF00269550; GRUYS KJ, 1998, Patent No. 9800557; Hagelstein P, 1997, J PLANT PHYSIOL, V150, P23, DOI 10.1016/S0176-1617(97)80176-9; Holmes P.A., 1984, Patent US, Patent No. 4477654; HOLMES PA, 1985, PHYS TECHNOL, V16, P32, DOI 10.1088/0305-4624/16/1/305; KANG F, 1994, PLANT J, V6, P795, DOI 10.1046/j.1365-313X.1994.6060795.x; KOIZUMI F, 1995, J MACROMOL SCI PURE, VA32, P759, DOI 10.1080/10601329508010287; LAWTHER RP, 1987, NUCLEIC ACIDS RES, V15, P2137, DOI 10.1093/nar/15.5.2137; Lydon J, 1999, BOOK SOIL P, P445; Matthews BF, 1999, BOOK SOIL P, P205; NAWRATH C, 1994, P NATL ACAD SCI USA, V91, P12760, DOI 10.1073/pnas.91.26.12760; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; PLEDGER WJ, 1973, J BACTERIOL, V114, P183, DOI 10.1128/JB.114.1.183-194.1973; PLEDGER WJ, 1973, J BACTERIOL, V114, P195, DOI 10.1128/JB.114.1.195-207.1973; POIRIER Y, 1992, SCIENCE, V256, P520, DOI 10.1126/science.256.5056.520; POIRIER Y, 1995, BIO-TECHNOL, V13, P142, DOI 10.1038/nbt0295-142; QURESHI AA, 1982, J CHROMATOGR, V249, P333, DOI 10.1016/S0021-9673(00)86343-8; Slater S, 1998, J BACTERIOL, V180, P1979, DOI 10.1128/JB.180.8.1979-1987.1998; STEINBUCHEL A, 1991, BIOMATERIALS NOVEL M, P27; TAILLON BE, 1988, GENE, V63, P245, DOI 10.1016/0378-1119(88)90528-8; Umbarger H. E., 1996, ESCHERICHIA COLI SAL, P442; VANDERLEIJ FR, 1995, CAN J MICROBIOL, V41, P222, DOI 10.1139/m95-191; WILLIS DE, 1987, J CHROMATOGR, V408, P217, DOI 10.1016/S0021-9673(01)81804-5; Ye GN, 1999, PLANT J, V19, P249, DOI 10.1046/j.1365-313X.1999.00520.x	34	141	169	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1011	1016		10.1038/13711	http://dx.doi.org/10.1038/13711			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504704				2022-12-27	WOS:000083015700029
J	Murphy, JC; Wibbenmeyer, JA; Fox, GE; Willson, RC				Murphy, JC; Wibbenmeyer, JA; Fox, GE; Willson, RC			Purification of plasmid DNA using selective precipitation by compaction agents - A scaleable method for the liquid-phase separation of plasmid DNA from RNA.	NATURE BIOTECHNOLOGY			English	Editorial Material							GENE-THERAPY; DELIVERY; SHAPE	A scaleable method for the liquid-phase separation of plasmid DNA from RNA.	Univ Houston, Dept Chem Engn, Houston, TX 77204 USA; Baylor Coll Med, Houston, TX 77030 USA	University of Houston System; University of Houston; Baylor College of Medicine	Murphy, JC (corresponding author), Univ Houston, Dept Chem Engn, Houston, TX 77204 USA.	willson@uh.edu	Willson, richard/AAD-4832-2019					Anderson WF, 1998, NATURE, V392, P25; ARSCOTT PG, 1990, BIOPOLYMERS, V30, P619, DOI 10.1002/bip.360300514; BEDNAR J, 1994, J MOL BIOL, V235, P825, DOI 10.1006/jmbi.1994.1042; GOSULE LC, 1976, NATURE, V259, P333, DOI 10.1038/259333a0; HOOPES BC, 1981, NUCLEIC ACIDS RES, V9, P5493, DOI 10.1093/nar/9.20.5493; Horn N, 1996, U.S. patent, Patent No. [5,576,196, 5576196]; HORN NA, 1995, HUM GENE THER, V6, P565, DOI 10.1089/hum.1995.6.5-565; LEZ Z, 1987, ANAL BIOCHEM, V160, P332; Marquet M, 1996, U.S. patent, Patent No. [5,561,064, 5561064]; Parasrampuria DA, 1998, BIOPHARM-APPL T BIO, V11, P38; Rolland AP, 1998, CRIT REV THER DRUG, V15, P143, DOI 10.1615/CritRevTherDrugCarrierSyst.v15.i2.20; Sambrock J, 1989, MOL CLONING LAB MANU, V1; WILSON RW, 1979, BIOCHEMISTRY-US, V18, P2192, DOI 10.1021/bi00578a009	13	84	94	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					822	823		10.1038/11777	http://dx.doi.org/10.1038/11777			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429254				2022-12-27	WOS:000081751400036
J	Gerngross, TU				Gerngross, TU			Can biotechnology move us toward a sustainable society?	NATURE BIOTECHNOLOGY			English	Article							POLYSTYRENE; PAPER		Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA	Dartmouth College	Gerngross, TU (corresponding author), Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.	tillman@dartmouth.edu						Alper J, 1999, SCIENCE, V283, P1625, DOI 10.1126/science.283.5408.1625; Atkinson B, 1991, BIOCH ENG BIOTECHNOL; BYROM D, 1993, Patent No. 5364778; CHARLES M, 1994, BIOPROCESS ENG; Hocking M.B., 1993, HDB CHEM TECHNOLOGY; HOCKING MB, 1991, ENVIRON MANAGE, V15, P731, DOI 10.1007/BF02394812; HOCKING MB, 1991, SCIENCE, V251, P504, DOI 10.1126/science.251.4993.504; Lee SY, 1998, POLYM DEGRAD STABIL, V59, P387, DOI 10.1016/S0141-3910(97)00176-6; Lee SY, 1997, NAT BIOTECHNOL, V15, P17, DOI 10.1038/nbt0197-17b; Lee SY, 1996, TRENDS BIOTECHNOL, V14, P431, DOI 10.1016/0167-7799(96)10061-5; PIMENTEL D, 1986, NEW DIRECTIONS AGR A; POOL R, 1989, SCIENCE, V245, P1187, DOI 10.1126/science.245.4923.1187; REESE KM, 1989, CHEM ENG NEWS, V67, P60; SHAPOURI H, 1995, 721 USDA; Ulrich G.D., 1984, GUIDE CHEM ENG PROCE; *US DEP EN, 1991, MAN CONS EN 1991; Van Wegen RJ, 1998, CHEM ENG RES DES, V76, P417, DOI 10.1205/026387698524848; Williams SF, 1996, CHEMTECH, V26, P38; [No title captured]	19	101	102	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					541	544		10.1038/9843	http://dx.doi.org/10.1038/9843			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385316				2022-12-27	WOS:000080716500023
J	Baguisi, A; Behboodi, E; Melican, DT; Pollock, JS; Destrempes, MM; Cammuso, C; Williams, JL; Nims, SD; Porter, CA; Midura, P; Palacios, MJ; Ayres, SL; Denniston, RS; Hayes, ML; Ziomek, CA; Meade, HM; Godke, RA; Gavin, WG; Overstrom, EW; Echelard, Y				Baguisi, A; Behboodi, E; Melican, DT; Pollock, JS; Destrempes, MM; Cammuso, C; Williams, JL; Nims, SD; Porter, CA; Midura, P; Palacios, MJ; Ayres, SL; Denniston, RS; Hayes, ML; Ziomek, CA; Meade, HM; Godke, RA; Gavin, WG; Overstrom, EW; Echelard, Y			Production of goats by somatic cell nuclear transfer	NATURE BIOTECHNOLOGY			English	Article						nuclear transfer; oocyte; transgenic; antithrombin III; goat	FETAL FIBROBLASTS; SHEEP; AMPLIFICATION; EMBRYOS; GENES; ADULT; LINE; MICE; DNA	In this study, we demonstrate the production of transgenic goats by nuclear transfer of fetal somatic cells. Donor karyoplasts were obtained from a primary fetal somatic cell line derived from a 40-day transgenic female fetus produced by artificial insemination of a nontransgenic adult female with semen from a transgenic male. Live offspring were produced with two nuclear transfer procedures. In one protocol, oocytes at the arrested metaphase II stage were enucleated, electrofused with donor somatic cells, and simultaneously activated. In the second protocol, activated in vivo oocytes were enucleated at the telophase II stage, electrofused with donor somatic cells, and simultaneously activated a second time to induce genome reactivation. Three healthy identical female offspring were born. Genotypic analyses confirmed that all cloned offspring were derived from the donor cell line. Analysis of the milk of one of the transgenic cloned animals showed high-level production of human antithrombin III, similar to the parental transgenic line.	Genzyme Transgen Corp, Framingham, MA 01701 USA; Tufts Univ, Sch Vet Med, Nucl Transfer Lab, North Grafton, MA 01356 USA; Tufts Univ, Sch Vet Med, Dept Biomed Sci, North Grafton, MA 01356 USA; Genzyme Corp, Cell & Prot Therapeut Dept, Framingham, MA 01701 USA; Louisiana State Univ, Dept Anim Sci, Baton Rouge, LA 70803 USA	Sanofi-Aventis; Tufts University; Tufts University; Sanofi-Aventis; Genzyme Corporation; Louisiana State University System; Louisiana State University	Overstrom, EW (corresponding author), Genzyme Transgen Corp, Framingham, MA 01701 USA.	eoverstrom@infonet.tufts.edu; yechelard@genzyme.com	Jeong, Wonjun/AAM-5937-2020		NICHD NIH HHS [R43 HD35395-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R43HD035395] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AASEN E, 1990, BIO-TECHNOL, V8, P1279, DOI 10.1038/nbt1290-1279; AMILLS M, 1995, VET IMMUNOL IMMUNOP, V48, P313, DOI 10.1016/0165-2427(95)05442-9; BURDON TG, 1992, MOL REPROD DEV, V33, P436, DOI 10.1002/mrd.1080330410; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Clark AJ, 1998, J MAMMARY GLAND BIOL, V3, P337, DOI 10.1023/A:1018723712996; DELEON FAP, 1992, J HERED, V83, P36, DOI 10.1093/oxfordjournals.jhered.a111154; DIBERARDINO D, 1987, J HERED, V78, P225, DOI 10.1093/oxfordjournals.jhered.a110371; EBERT KM, 1993, THERIOGENOLOGY, V39, P121, DOI 10.1016/0093-691X(93)90028-4; Edmunds T, 1998, BLOOD, V91, P4561, DOI 10.1182/blood.V91.12.4561; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; KLINGER K, 1992, AM J HUM GENET, V51, P55; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Meade HM, 1999, GENE EXPRESSION SYSTEMS, P399, DOI 10.1016/B978-012253840-7/50015-8; Ryot K. D., 1989, Indian Journal of Animal Reproduction, V10, P49; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; van de Corput MPC, 1998, HISTOCHEM CELL BIOL, V110, P431, DOI 10.1007/s004180050304; Vignon X, 1998, CR ACAD SCI III-VIE, V321, P735, DOI 10.1016/S0764-4469(98)80014-0; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wells DN, 1997, BIOL REPROD, V57, P385, DOI 10.1095/biolreprod57.2.385; WHITELAW CBA, 1993, TRANSGENIC RES, V2, P29, DOI 10.1007/BF01977678; WILKIE TM, 1986, DEV BIOL, V118, P9, DOI 10.1016/0012-1606(86)90068-0; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wineland NE, 1998, J AM VET MED ASSOC, V212, P713; Zhang Y, 1998, BIOL REPROD, V58, P266, DOI 10.1095/biolreprod58.1.266	26	753	962	3	96	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					456	461		10.1038/8632	http://dx.doi.org/10.1038/8632			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331804				2022-12-27	WOS:000080074500029
J	Brink, JA; Prior, B; DaSilva, EJ				Brink, JA; Prior, B; DaSilva, EJ			Developing biotechnology around the world	NATURE BIOTECHNOLOGY			English	Article									UNESCO, BAC BETCEN, Agr Res Council, Vegetable & Ornamental Plant Inst, ZA-0001 Pretoria, South Africa; Univ Stellenbosch, Dept Microbiol, ZA-7062 Matieland, South Africa; UNESCO, Div Life Sci, F-75732 Paris, France	Agricultural Research Council of South Africa; Stellenbosch University	Brink, JA (corresponding author), UNESCO, BAC BETCEN, Agr Res Council, Vegetable & Ornamental Plant Inst, Private Bag X293, ZA-0001 Pretoria, South Africa.							VASIL IK, 1995, PLANT MOL BIOL REP, V13, P227, DOI 10.1007/BF02670901; Vasil IK, 1998, NAT BIOTECHNOL, V16, P399, DOI 10.1038/nbt0598-399	2	4	5	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					434	436		10.1038/8602	http://dx.doi.org/10.1038/8602			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331796				2022-12-27	WOS:000080074500021
J	Douglas, JT; Miller, CR; Kim, M; Dmitriev, I; Mikheeva, G; Krasnykh, V; Curiel, DT				Douglas, JT; Miller, CR; Kim, M; Dmitriev, I; Mikheeva, G; Krasnykh, V; Curiel, DT			A system for the propagation of adenoviral vectors with genetically modified receptor specificities	NATURE BIOTECHNOLOGY			English	Article						adenoviral vector; artificial receptor; gene therapy; targeting	GROWTH-FACTOR RECEPTOR; TARGETED GENE DELIVERY; ESCHERICHIA-COLI; MODIFIED FIBERS; PENTON BASE; CELL LINE; TROPISM; VIRUS; PROTEIN; TYPE-5	The development of genetically modified adenovirus (Ad) vectors with specificity for a single cell type will require both the introduction of novel tropism determinants and the ablation of endogenous tropism. Consequently, it will not be possible to exploit the native cellular entry pathway in the propagation of these targeted Ad vectors. Based on the concept that Ad enters cells by a two-step process in which a primary receptor serves as a high affinity binding site for the Ad fiber knob, with subsequent internalization mediated by av integrins, we designed two artificial primary receptors. The extracellular domain of one of these synthetic receptors was derived from a single-chain antibody (sFv) with specificity for Ad5 knob, while the second receptor consisted of an icosapeptide identified by biopanning a phage display library against Ad5 knob. Expression of either of these artificial virus-binding receptors in fiber receptor-negative cells possessing cry integrins conferred susceptibility to Ad infection. We then created a novel mechanism for cell binding by genetically modifying both the vector and the target cell. In this approach, six histidine (His) residues were incorporated at the C-terminal of the Ad fiber protein. The resultant Ad vector was able to infect nonpermissive cells displaying the cognate artificial receptor, containing an anti-His sFv. This strategy, comprising a genetically engineered Ad virion and a modified cell line, should be useful in the propagation of targeted Ad vectors that lack the ability to bind the native fiber receptor.	Univ Alabama, Gene Therapy Ctr, Dept Med, Div Pulm & Crit Care Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Radiat Oncol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Curiel, DT (corresponding author), Univ Alabama, Gene Therapy Ctr, Dept Med, Div Pulm & Crit Care Med, Birmingham, AL 35294 USA.		Miller, Ryan/B-9365-2008	Miller, Ryan/0000-0002-0096-8762	NATIONAL CANCER INSTITUTE [R01CA074242] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050255] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 74242] Funding Source: Medline; NHLBI NIH HHS [R01 HL 50255] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAI M, 1993, J VIROL, V67, P5198, DOI 10.1128/JVI.67.9.5198-5205.1993; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CROMPTON J, 1994, J GEN VIROL, V75, P133, DOI 10.1099/0022-1317-75-1-133; CURIEL DT, 1992, HUM GENE THER, V3, P147, DOI 10.1089/hum.1992.3.2-147; Dmitriev I, 1998, J VIROL, V72, P9706, DOI 10.1128/JVI.72.12.9706-9713.1998; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Goldman CK, 1997, CANCER RES, V57, P1447; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hong SS, 1997, EMBO J, V16, P2294, DOI 10.1093/emboj/16.9.2294; KIPRIYANOV SM, 1994, MOL IMMUNOL, V31, P1047, DOI 10.1016/0161-5890(94)90100-7; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; Krasnykh V, 1998, J VIROL, V72, P1844, DOI 10.1128/JVI.72.3.1844-1852.1998; Krasnykh VN, 1996, J VIROL, V70, P6839, DOI 10.1128/JVI.70.10.6839-6846.1996; Leon RP, 1998, P NATL ACAD SCI USA, V95, P13159, DOI 10.1073/pnas.95.22.13159; Lindner P, 1997, BIOTECHNIQUES, V22, P140, DOI 10.2144/97221rr01; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; MICHAEL SI, 1995, GENE THER, V2, P660; Miller CR, 1998, CANCER RES, V58, P5738; Pickles RJ, 1998, J VIROL, V72, P6014, DOI 10.1128/JVI.72.7.6014-6023.1998; Rancourt C, 1998, CLIN CANCER RES, V4, P2455; REYNOLDS PN, 1998, TUMOR TARGET, V3, P156; Rieder E, 1996, P NATL ACAD SCI USA, V93, P10428, DOI 10.1073/pnas.93.19.10428; Rogers BE, 1997, GENE THER, V4, P1387, DOI 10.1038/sj.gt.3300541; ROGERS BE, 1998, TUMOR TARGET, V3, P25; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Wang XH, 1999, J VIROL, V73, P2559, DOI 10.1128/JVI.73.3.2559-2562.1999; Watkins SJ, 1997, GENE THER, V4, P1004, DOI 10.1038/sj.gt.3300511; Wickham TJ, 1996, J VIROL, V70, P6831, DOI 10.1128/JVI.70.10.6831-6838.1996; Wickham TJ, 1997, J VIROL, V71, P7663, DOI 10.1128/JVI.71.10.7663-7669.1997; Wickham TJ, 1996, NAT BIOTECHNOL, V14, P1570, DOI 10.1038/nbt1196-1570; Wickham TJ, 1995, GENE THER, V2, P750; Wickham TJ, 1997, J VIROL, V71, P8221, DOI 10.1128/JVI.71.11.8221-8229.1997; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Zabner J, 1997, J CLIN INVEST, V100, P1144, DOI 10.1172/JCI119625	41	112	128	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					470	475		10.1038/8647	http://dx.doi.org/10.1038/8647			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331807				2022-12-27	WOS:000080074500032
J	Roy, S; Zhang, K; Roth, T; Vinogradov, S; Kao, RS; Kabanov, A				Roy, S; Zhang, K; Roth, T; Vinogradov, S; Kao, RS; Kabanov, A			Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides	NATURE BIOTECHNOLOGY			English	Article						gene therapy; antisense oligonucleotides; basement membrane; block copolymer	HIGH-GLUCOSE; ENDOTHELIAL-CELLS; OVEREXPRESSION; RETINOPATHY; RAT; COLLAGEN; LAMININ	We have investigated whether antisense oligonucleotides delivered intravitreally could reduce gene expression specifically in the retina. In this study, phosphorothioate antisense oligonucleotides targeted to fibronectin transcripts were coupled to a novel carrier and used to specifically reduce fibronectin (FN) expression in retinal vascular cells. Using confocal microscopy, fluorescence from fluorescein isothio-cyanate-labeled FN-oligonucleotides was detected in retinal vascular cells at 24 h postinjection and persisted until day 6 (the end point of this study). The fibronectin mRNA level was consistently decreased to 86.7% +/- 7.9% of control (p<0.05) at day 2, and 46.7% +/- 4.9% of control (p<0.01) at day 6. In contrast, the p-actin mRNA level, an internal control, was unaltered in rat retinas that received FN-oligonucleotides. Fibronectin protein level at day 6 was also significantly reduced to 61.4% +/- 16% of control (p<0.01). No toxic effect resulting from the carrier was detected histologically. Thus, intravitreal delivery of antisense oligonucleotides to modulate abnormal gene expression in retinal diseases may he an effective approach for ocular gene therapy.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; Univ Massachusetts, Sch Med, Worcester, MA 01655 USA; Univ Nebraska, Med Ctr, Omaha, NE 68198 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Nebraska System; University of Nebraska Medical Center	Roy, S (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA.		Kabanov, Alexander V/N-3356-2013; Kabanov, Alexander/AAY-5751-2020	Kabanov, Alexander V/0000-0002-3665-946X; Kabanov, Alexander/0000-0002-3665-946X	NATIONAL EYE INSTITUTE [R29EY011990] Funding Source: NIH RePORTER; NEI NIH HHS [EY11990-01A1] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		CAGLIERO E, 1991, DIABETES, V40, P102, DOI 10.2337/diabetes.40.1.102; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLVIN RB, 1989, FIBRONECTIN, P213; ESSNER E, 1988, EXP EYE RES, V47, P317, DOI 10.1016/0014-4835(88)90014-0; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; FITZGERALD MEC, 1990, MICROVASC RES, V39, P15, DOI 10.1016/0026-2862(90)90056-W; Hangai M, 1996, INVEST OPHTH VIS SCI, V37, P2678; KABANOV AV, 1995, BIOCONJUGATE CHEM, V6, P7, DOI 10.1021/bc00031a002; KABANOV AV, 1995, BIOCONJUGATE CHEM, V6, P2; MAGNUSON VL, 1991, J BIOL CHEM, V266, P14654; MANDARINO LJ, 1993, EXP EYE RES, V57, P609, DOI 10.1006/exer.1993.1166; Mundigl O, 1998, J NEUROSCI, V18, P93; OSTERBY R, 1990, DIABETES MELLITUS TH, P220; Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851; ROTH T, 1993, P NATL ACAD SCI USA, V90, P9640, DOI 10.1073/pnas.90.20.9640; Roy S, 1997, DIABETOLOGIA, V40, P1011, DOI 10.1007/s001250050782; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; Roy S, 1996, DIABETOLOGIA, V39, P735; ROY S, 1994, J CLIN INVEST, V93, P438, DOI 10.1172/JCI116979; Roy S, 1996, INVEST OPHTH VIS SCI, V37, P258; SANNA PP, 1992, BIOTECH HISTOCHEM, V67, P346, DOI 10.3109/10520299209110047; SCWARZBAUER JE, 1987, EMBO J, V6, P2573; Vinogradov SV, 1998, BIOCONJUGATE CHEM, V9, P805, DOI 10.1021/bc980048q	23	55	58	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					476	479		10.1038/8654	http://dx.doi.org/10.1038/8654			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331808				2022-12-27	WOS:000080074500033
J	Strauss, S; Boerjan, W; Cairney, J; Campbell, M; Dean, J; Ellis, D; Jouanin, L; Sundberg, B				Strauss, S; Boerjan, W; Cairney, J; Campbell, M; Dean, J; Ellis, D; Jouanin, L; Sundberg, B			Forest biotechnology makes its position known	NATURE BIOTECHNOLOGY			English	Editorial Material									Oregon State Univ, Corvallis, OR 97331 USA; Flanders Interuniv, Ghent, Belgium; Inst Paper Sci & Technol, Atlanta, GA 30318 USA; Univ Oxford, Oxford, England; Univ Georgia, Athens, GA 30602 USA; BC Res, Vancouver, BC, Canada; INRA, F-78026 Versailles, France; Swedish Univ Agr Sci, S-90183 Umea, Sweden	Oregon State University; University of Oxford; University System of Georgia; University of Georgia; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Swedish University of Agricultural Sciences	Strauss, S (corresponding author), Oregon State Univ, Corvallis, OR 97331 USA.		Boerjan, Wout/Y-4158-2019; Dean, Jeffrey F.D./G-2184-2010; Dean, Jeffrey F.D./N-7304-2019	Boerjan, Wout/0000-0003-1495-510X; Dean, Jeffrey F.D./0000-0003-1208-1023; Dean, Jeffrey F.D./0000-0003-1208-1023; Campbell, Malcolm/0000-0002-1396-6651					0	12	12	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1145	1145		10.1038/70652	http://dx.doi.org/10.1038/70652			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585674	Bronze			2022-12-27	WOS:000084170700004
J	Tibbe, AGJ; de Grooth, BG; Greve, J; Liberti, PA; Dolan, GJ; Terstappen, LWMM				Tibbe, AGJ; de Grooth, BG; Greve, J; Liberti, PA; Dolan, GJ; Terstappen, LWMM			Optical tracking and detection of immunomagnetically selected and aligned cells	NATURE BIOTECHNOLOGY			English	Article						cytometry; cell analysis; compact disk player; ferrofluids; ferromagnetic nanoparticles	FLOW-CYTOMETRY	We have developed a platform for cell analysis based on immunomagnetic selection and magnetic alignment of cells in combination with an epi-illumination tracking and detection system. Whole blood was labeled with ferromagnetic nanoparticles and fluorescent probes, and placed in a magnetic field in a chamber. Cells labeled with ferromagnetic nanoparticles moved upward and aligned along ferromagnetic lines deposited by lithographic techniques on an optically transparent surface of the chamber. An epi-illumination system using a 635 nm laser diode as a light source scanned the lines and measured signals obtained from the aligned cells. The cell counts per unit of blood volume obtained with the system correlated well with those obtained from the counts from a standard hematology analyzer and flow cytometer, The cell analysis platform is significantly less complex and more sensitive than current cell analysis equipment and provides additional functionality through its ability to subject the cells to repeated and varied analyses while they remain in a natural environment (i.e., whole blood).	Immunicon Corp, Huntingdon Valley, PA USA; Univ Twente, NL-7500 AE Enschede, Netherlands	University of Twente	Terstappen, LWMM (corresponding author), Immunicon Corp, Huntingdon Valley, PA USA.		terstappen, leon/O-4923-2018	terstappen, leon/0000-0001-5944-3787				Coulter W. H., 1956, P NATIONAL ELECTRONI, V12, P1034, DOI [10.1038/366591a0, DOI 10.1038/366591A0]; DEGROOTH BG, 1985, CYTOMETRY, V6, P226; Dietz LJ, 1996, CYTOMETRY, V23, P177; Jackson J., 1975, CLASSICAL ELECTRODYN; KAMENTSKY LA, 1991, CYTOMETRY, V12, P381, DOI 10.1002/cyto.990120502; KOSENOW W, 1952, ACTA HAEMATOL-BASEL, V7, P217, DOI 10.1159/000204055; MANSBERG HP, 1974, J HISTOCHEM CYTOCHEM, V22, P711, DOI 10.1177/22.7.711; SEWELL WA, 1997, LEUCOCYTE TYPING, V6; SHAPIRO HM, 1986, CYTOMETRY, V7, P107, DOI 10.1002/cyto.990070118; 1997, Patent No. 5698271	10	98	130	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1210	1213		10.1038/70761	http://dx.doi.org/10.1038/70761			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585720				2022-12-27	WOS:000084170700030
J	Bailey, JE				Bailey, JE			Lessons from metabolic engineering for functional genomics and drug discovery	NATURE BIOTECHNOLOGY			English	Editorial Material							CELL-CYCLE REGULATION; ESCHERICHIA-COLI; GROWTH; FLUX		Swiss Fed Inst Technol, Inst Biotechnol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Bailey, JE (corresponding author), Swiss Fed Inst Technol, Inst Biotechnol, CH-8093 Zurich, Switzerland.	bailey@ebiotech.biol.ethz.ch						AIBA S, 1979, BIOTECHNOL BIOENG, V21, P1373, DOI 10.1002/bit.260210806; BIMBAUM S, 1991, J BIOTECHNOL BIOENG, V37, P309; DOMACH MM, 1984, BIOTECHNOL BIOENG, V26, P203, DOI 10.1002/bit.260260303; *ELS SCI LTD, 1998, TRENDS GUID BIOINF; Fell D., 1997, UNDERSTANDING CONTRO; Fell DA, 1998, BIOTECHNOL BIOENG, V58, P121, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<121::AID-BIT2>3.3.CO;2-F; Follstad BD, 1999, BIOTECHNOL BIOENG, V63, P675, DOI 10.1002/(SICI)1097-0290(19990620)63:6<675::AID-BIT5>3.0.CO;2-R; GALAZZO JL, 1990, ENZYME MICROB TECH, V12, P162, DOI 10.1016/0141-0229(90)90033-M; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; KOSINSKI MJ, 1992, APPL MICROBIOL BIOT, V36, P782; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; Lee KH, 1996, BIOTECHNOL BIOENG, V50, P273, DOI 10.1002/(SICI)1097-0290(19960505)50:3<273::AID-BIT6>3.0.CO;2-D; Lee KH, 1996, BIOTECHNOL BIOENG, V50, P336, DOI 10.1002/(SICI)1097-0290(19960505)50:3<336::AID-BIT12>3.0.CO;2-L; PAPOUTSAKIS ET, 1984, BIOTECHNOL BIOENG, V26, P174, DOI 10.1002/bit.260260210; SCHAAFF I, 1989, YEAST, V5, P285, DOI 10.1002/yea.320050408; Tyson JJ, 1996, TRENDS BIOCHEM SCI, V21, P89; Varner J, 1999, METAB ENG, V1, P88, DOI 10.1006/mben.1998.0104	18	109	119	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					616	618		10.1038/10794	http://dx.doi.org/10.1038/10794			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10409335				2022-12-27	WOS:000081296900003
J	Dove, A				Dove, A			The long arm of DNA	NATURE BIOTECHNOLOGY			English	Article																		Lyons LA, 1997, NAT GENET, V15, P47, DOI 10.1038/ng0197-47; 1998, LLOYDS LIST     1119; 1999, NAT GENET, V21, P243; 1999, NY TIMES        0309, pB1	4	2	2	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					649	651		10.1038/10859	http://dx.doi.org/10.1038/10859			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404156				2022-12-27	WOS:000081296900023
J	Kieber-Emmons, T; Luo, P; Qiu, JP; Chang, TY; O, IS; Blaszczyk-Thurin, M; Steplewski, Z				Kieber-Emmons, T; Luo, P; Qiu, JP; Chang, TY; O, IS; Blaszczyk-Thurin, M; Steplewski, Z			Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses	NATURE BIOTECHNOLOGY			English	Article						vaccine; cancer; mimotype; mimic; carbohydrate; Lewis Y; Meth A	MELANOMA-CELL VACCINE; METH-A SARCOMA; ANTICARBOHYDRATE ANTIBODIES; CAPSULAR POLYSACCHARIDE; CONJUGATE VACCINE; INDUCE ANTIBODIES; BINDING PEPTIDES; SIALYL LEWIS(X); BREAST-CANCER; IMMUNOGENICITY	Tumor-associated carbohydrate (TAC) antigens are important targets in cancer vaccine efforts. Carbohydrates are, however, frequently poor immunogens, in that they are T-cell-independent antigens. Molecular mimicry of TAC by peptides is an alternative approach to generating anti-carbohydrate immune responses. Here we demonstrate that peptide mimotopes can elicit antibody responses that cross-react with representative human TAC antigens. Primary immunization with such a multiple antigenic peptide, along with QS-21 as adjuvant, elicits cytotoxic antibodies reactive with naturally occurring forms of TAC expressed on tumor cells, and vaccination of mice with peptide mimotopes reduced tumor growth and prolonged host survival in a murine tumor model.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19104 USA	University of Pennsylvania; The Wistar Institute; Jefferson University	Kieber-Emmons, T (corresponding author), Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.	tom@xray.med.upenn.edu		O-Sullivan, InSug/0000-0003-0161-2028	NIAID NIH HHS [AI 45133] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045133] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AbdelMotal UM, 1996, EUR J IMMUNOL, V26, P544, DOI 10.1002/eji.1830260307; ADLURI S, 1995, CANCER IMMUNOL IMMUN, V41, P185, DOI 10.1007/BF01521345; Agadjanyan M, 1997, NAT BIOTECHNOL, V15, P547, DOI 10.1038/nbt0697-547; Bohm CM, 1997, SCAND J IMMUNOL, V46, P27, DOI 10.1046/j.1365-3083.1996.d01-91.x; Chapman PB, 1995, SEMIN CANCER BIOL, V6, P367, DOI 10.1016/1044-579X(95)90006-3; Dabelsteen E, 1996, J PATHOL, V179, P358; Fehr T, 1997, J EXP MED, V185, P1785, DOI 10.1084/jem.185.10.1785; FRASSANITO MA, 1995, CANCER RES, V55, P124; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Harris SL, 1997, P NATL ACAD SCI USA, V94, P2454, DOI 10.1073/pnas.94.6.2454; HELLING F, 1995, CANCER RES, V55, P2783; HOESS R, 1993, GENE, V128, P43, DOI 10.1016/0378-1119(93)90151-R; Houghton AN, 1998, NAT MED, V4, P270, DOI 10.1038/nm0398-270; IMBERTY A, 1995, GLYCOCONJUGATE J, V12, P331, DOI 10.1007/BF00731336; Ishikawa D, 1998, FEBS LETT, V441, P20, DOI 10.1016/S0014-5793(98)01511-7; Jiao Y, 1998, JPN J CANCER RES, V89, P657, DOI 10.1111/j.1349-7006.1998.tb03268.x; Jones RC, 1996, ANN SURG ONCOL, V3, P437, DOI 10.1007/BF02305761; KITAMURA K, 1994, P NATL ACAD SCI USA, V91, P12957, DOI 10.1073/pnas.91.26.12957; KITAMURA K, 1995, P NATL ACAD SCI USA, V92, P2805, DOI 10.1073/pnas.92.7.2805; Kudryashov V, 1998, CANCER IMMUNOL IMMUN, V45, P281, DOI 10.1007/s002620050444; Kundu N, 1996, JNCI-J NATL CANCER I, V88, P536, DOI 10.1093/jnci/88.8.536; LIVINGSTON PO, 1995, IMMUNOL REV, V145, P147, DOI 10.1111/j.1600-065X.1995.tb00080.x; Livingston PO, 1997, CANCER IMMUNOL IMMUN, V45, P1, DOI 10.1007/s002620050394; Livingston PO, 1997, CANCER IMMUNOL IMMUN, V45, P10, DOI 10.1007/s002620050395; LONGENECKER BM, 1994, ADV EXP MED BIOL, V353, P105; Luo P, 1998, MOL IMMUNOL, V35, P865, DOI 10.1016/S0161-5890(98)00067-4; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; MURAI H, 1985, J BIOCHEM-TOKYO, V97, P1129, DOI 10.1093/oxfordjournals.jbchem.a135157; NOGUCHI Y, 1995, P NATL ACAD SCI USA, V92, P2219, DOI 10.1073/pnas.92.6.2219; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; Pantel K, 1996, LANCET, V347, P649, DOI 10.1016/S0140-6736(96)91203-9; Phalipon A, 1997, EUR J IMMUNOL, V27, P2620, DOI 10.1002/eji.1830271022; Pincus SH, 1998, J IMMUNOL, V160, P293; Putterman C, 1998, J EXP MED, V188, P29, DOI 10.1084/jem.188.1.29; Qiu JP, 1999, HYBRIDOMA, V18, P103, DOI 10.1089/hyb.1999.18.103; Ravindranath MH, 1997, CANCER, V79, P1686, DOI 10.1002/(SICI)1097-0142(19970501)79:9<1686::AID-CNCR8>3.0.CO;2-A; Ravindranath MH, 1998, INT J CANCER, V75, P117, DOI 10.1002/(SICI)1097-0215(19980105)75:1<117::AID-IJC18>3.0.CO;2-D; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; STEPLEWSKI Z, 1991, In Vivo (Attiki), V5, P79; Taki T, 1997, FEBS LETT, V418, P219, DOI 10.1016/S0014-5793(97)01386-0; Tsuyuoka K, 1996, J IMMUNOL, V157, P661; Valadon P, 1996, J MOL BIOL, V261, P11, DOI 10.1006/jmbi.1996.0438; WESTERINK MAJ, 1995, P NATL ACAD SCI USA, V92, P4021, DOI 10.1073/pnas.92.9.4021; Zhang HL, 1997, INFECT IMMUN, V65, P1158, DOI 10.1128/IAI.65.4.1158-1164.1997; ZHANG SL, 1995, CANCER RES, V55, P3364; Zhang SL, 1997, INT J CANCER, V73, P50, DOI 10.1002/(SICI)1097-0215(19970926)73:1<50::AID-IJC9>3.3.CO;2-O	46	100	106	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					660	665		10.1038/10870	http://dx.doi.org/10.1038/10870			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404158				2022-12-27	WOS:000081296900025
J	Gouka, RJ; Gerk, C; Hooykaas, PJJ; Bundock, P; Musters, W; Verrips, CT; de Groot, MJA				Gouka, RJ; Gerk, C; Hooykaas, PJJ; Bundock, P; Musters, W; Verrips, CT; de Groot, MJA			Transformation of Aspergillus awamori by Agrobacterium tumefaciens-mediated homologous recombination	NATURE BIOTECHNOLOGY			English	Article						targeting; integration; cutinase; titration	HETEROLOGOUS PROTEIN-PRODUCTION; FUSARIUM-SOLANI-PISI; INTACT YEAST-CELLS; FILAMENTOUS FUNGI; EXPRESSION SYSTEM; ESCHERICHIA-COLI; MULTIPLE COPIES; GENE; STRAINS; NIGER	Agrobacterium tumefaciens is known to transfer part of its tumor-inducing (Ti) plasmid to the filamentous fungus Aspergillus awamori by illegitimate recombination with the fungal genome. Here, we show that when this Ti DNA shares homology with the A. awamori genome, integration can also occur by homologous recombination, On the basis of this finding, we have developed an efficient method for constructing recombinant mold strains free from bacterial DNA by A. tumefaciens-mediated transformation. Multiple copies of a gene can be integrated rapidly at a predetermined locus in the genome, yielding transformants free of bacterial antibiotic resistance genes or other foreign DNA. Recombinant A. awamori strains were constructed containing up to nine copies of a Fusarium solani pisi cutinase expression cassette integrated in tandem at the pyrG locus. This allowed us to study how mRNA and protein levels are affected by gene copy number, without the influence of chromosomal environmental effects. Cutinase mRNA and protein were maximal with four gene copies, indicating a limitation at the transcriptional level. This transformation system will potentially stimulate market acceptance of derived products by avoiding introduction of bacterial and other foreign DNA into the fungi.	Unilever Res Labs Vlaardingen, NL-3133 AT Vlaardingen, Netherlands; Leiden Univ, Inst Mol Plant Sci, Glusius Lab, NL-2333 AL Leiden, Netherlands	Unilever; Leiden University; Leiden University - Excl LUMC	Gouka, RJ (corresponding author), Unilever Res Labs Vlaardingen, Olivier van Noortlaan 120, NL-3133 AT Vlaardingen, Netherlands.	robin.gouka@unilever.com	Hooykaas, Paul JJ/S-4256-2017	Hooykaas, Paul JJ/0000-0002-9736-6927; Musters, C.J.M./0000-0003-1321-6786				Archer DB, 1997, CRIT REV BIOTECHNOL, V17, P273, DOI 10.3109/07388559709146616; ARCHER DB, 1994, ANTON LEEUW INT J G, V65, P245, DOI 10.1007/BF00871952; BEIJERSBERGEN A, 1992, SCIENCE, V256, P1324, DOI 10.1126/science.256.5061.1324; Bennett J. W., 1991, MORE GENE MANIPULATI, P441; BUNDOCK P, 1995, EMBO J, V14, P3206, DOI 10.1002/j.1460-2075.1995.tb07323.x; de Groot MJA, 1998, NAT BIOTECHNOL, V16, P839, DOI 10.1038/nbt0998-839; DEBLOCK M, 1993, EUPHYTICA, V71, P1, DOI 10.1007/BF00023461; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gouka RJ, 1996, APPL MICROBIOL BIOT, V46, P28, DOI 10.1007/s002530050779; GOUKA RJ, 1995, CURR GENET, V27, P536, DOI 10.1007/BF00314444; Gouka RJ, 1997, APPL MICROBIOL BIOT, V47, P1, DOI 10.1007/s002530050880; Gouka RJ, 1996, APPL ENVIRON MICROB, V62, P1951, DOI 10.1128/AEM.62.6.1951-1957.1996; GWYNNE DI, 1989, BIOCHEM SOC T, V17, P338, DOI 10.1042/bst0170338; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOOYKAAS PJJ, 1979, J GEN MICROBIOL, V110, P99, DOI 10.1099/00221287-110-1-99; KOLAR M, 1988, GENE, V62, P127, DOI 10.1016/0378-1119(88)90586-0; KUBICEKPRANZ EM, 1991, J BIOTECHNOL, V20, P83, DOI 10.1016/0168-1656(91)90037-V; LOWE DA, 1992, HDB APPL MYCOLOGY FU, P681; MEILHOC E, 1990, BIO-TECHNOL, V8, P223, DOI 10.1038/nbt0390-223; MOZO T, 1991, PLANT MOL BIOL, V16, P917, DOI 10.1007/BF00015085; OFFRINGA R, 1992, THESIS LEIDEN U LEID; Sambrock J, 1989, MOL CLONING LAB MANU, V1; Timberlake WE., 1991, MORE GENE MANIPULATI, P51; VANDENHONDEL CAM, 1991, APPLIED MOL GENETICS, P1; VANDENHONDEL CAMJJ, 1992, ANTON LEEUW INT J G, V61, P153, DOI 10.1007/BF00580623; VANGEMEREN IA, 1995, J BIOTECHNOL, V40, P155, DOI 10.1016/0168-1656(95)00041-N; vanGemeren IA, 1996, APPL MICROBIOL BIOT, V45, P755, DOI 10.1007/s002530050759; VERDOES JC, 1994, GENE, V145, P179, DOI 10.1016/0378-1119(94)90003-5; VERDOES JC, 1993, TRANSGENIC RES, V2, P84, DOI 10.1007/BF01969381; VERDOES JC, 1995, APPL MICROBIOL BIOT, V43, P195, DOI 10.1007/s002530050390; WARD M, 1989, EXP MYCOL, V13, P289, DOI 10.1016/0147-5975(89)90050-9	31	116	148	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					598	601		10.1038/9915	http://dx.doi.org/10.1038/9915			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385327				2022-12-27	WOS:000080716500034
J	Miller, HI				Miller, HI			Biosafety protocol - Cynicism and politics dominate UN biotechnology deliberations	NATURE BIOTECHNOLOGY			English	Editorial Material									Stanford Univ, Hoover Inst, Stanford, CA 94305 USA	Stanford University	Miller, HI (corresponding author), Stanford Univ, Hoover Inst, Stanford, CA 94305 USA.								0	2	2	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					515	515		10.1038/9775	http://dx.doi.org/10.1038/9775			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385299				2022-12-27	WOS:000080716500005
J	Baggot, B				Baggot, B			Taxing biotechnology	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					501	501		10.1038/8683	http://dx.doi.org/10.1038/8683			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331813				2022-12-27	WOS:000080074500038
J	Lyamichev, V; Mast, AL; Hall, JG; Prudent, JR; Kaiser, MW; Takova, T; Kwiatkowski, RW; Sander, TJ; de Arruda, M; Arco, DA; Neri, BP; Brow, MAD				Lyamichev, V; Mast, AL; Hall, JG; Prudent, JR; Kaiser, MW; Takova, T; Kwiatkowski, RW; Sander, TJ; de Arruda, M; Arco, DA; Neri, BP; Brow, MAD			Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes	NATURE BIOTECHNOLOGY			English	Article						polymorphism; single nucleotide polymorphism; invasive cleavage	NUCLEOTIDE EXCISION-REPAIR; SINGLE-STRANDED-DNA; CYSTIC-FIBROSIS; ENDONUCLEASE; 5'-EXONUCLEASE; FAMILY; ASSAY; FEN-1	Flap endonucleases (FENs) isolated from archaea are shown to recognize and cleave a structure formed when two overlapping oligonucleotides hybridize to a target DNA strand. The downstream oligonucleotide probe is cleaved, and the precise site of cleavage is dependent on the amount of overlap with the upstream oligonucleotide. We have demonstrated that use of thermostable archaeal FENs allows the reaction to be performed at temperatures that promote probe turnover without the need for temperature cycling. The resulting amplification of the cleavage signal enables the detection of specific DNA targets at sub-attomole levels within complex mixtures. Moreover, we provide evidence that this cleavage is sufficiently specific to enable discrimination of single-base differences and can differentiate homozygotes from heterozygotes in single-copy genes in genomic DNA.	Third Wave Technol, Madison, WI 53719 USA		Brow, MAD (corresponding author), Third Wave Technol, 502 S Rosa Rd, Madison, WI 53719 USA.			Prudent, James/0000-0002-8948-1781				Bertina RM, 1997, CLIN CHEM, V43, P1678; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; COPLEY CG, 1992, BIOTECHNIQUES, V13, P888; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DUCK P, 1990, BIOTECHNIQUES, V9, P142; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LISHANSKI A, 1994, P NATL ACAD SCI USA, V91, P2674, DOI 10.1073/pnas.91.7.2674; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; OKANO K, 1995, ANAL BIOCHEM, V228, P101, DOI 10.1006/abio.1995.1320; Sambrook J., 2002, MOL CLONING LAB MANU; SFERRA TJ, 1993, ANNU REV MED, V44, P133, DOI 10.1146/annurev.med.44.1.133	15	366	599	4	47	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					292	296		10.1038/7044	http://dx.doi.org/10.1038/7044			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096299				2022-12-27	WOS:000078977500033
J	[Anonymous]				[Anonymous]			Who pulls the strings in biotechnology?	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					1	1						1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625341				2022-12-27	WOS:000084699900001
J	[Anonymous]				[Anonymous]			Recent patents in angiogenesis research	NATURE BIOTECHNOLOGY			English	Article																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1231	1231						1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585726				2022-12-27	WOS:000084170700036
J	Baggot, BX				Baggot, BX			Patent office decisions strengthened by Supreme Court - Because of the Supreme Court's decision in Dickinson v. Zurko, inventors may find it harder to overturn the decisions of patent examiners.	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1131	1133		10.1038/15121	http://dx.doi.org/10.1038/15121			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545924				2022-12-27	WOS:000083428000035
J	Utomo, ARH; Nikitin, AY; Lee, WH				Utomo, ARH; Nikitin, AY; Lee, WH			Temporal, spatial, and cell type-specific control of Cre-mediated DNA recombination in transgenic mice	NATURE BIOTECHNOLOGY			English	Article						conditional gene regulation; Cre recombinase; mammary gland; tetracycline-controlled transactivator; whey acidic protein	SITE-SPECIFIC RECOMBINATION; TETRACYCLINE-RESPONSIVE PROMOTER; GENE-EXPRESSION; MAMMALIAN-CELLS; RETINOBLASTOMA GENE; IN-VIVO; SOMATIC MUTAGENESIS; MAMMARY-GLAND; PROTEIN GENE; MOUSE	We have developed a universal system for temporal, spatial, and cell type-specific control of gene expression in mice that (1) integrates the advantages of tetracycline-controlled gene expression and Cre-recombinase-loxP site-mediated gene inactivation, and (2) simplifies schemes of animal crosses by combination of two control elements in a single transgene. Two transgenic strains were generated in which the cell type-specific control was provided by either the retinoblastoma gene promoter or the whey acidic protein promoter. Both promoters drive the expression of the reverse tetracycline-controlled transactivator (rtTA). Placed in cis configuration to the rtTA transcription unit, the rtTA-inducible promoter directs expression of ore recombinase. In both strains crossed with cActXstopXLacZ reporter mice, which have a loxP-stop of transcription/translation-loxP-LacZ cassette driven by chicken beta-actin promoter, Cre-loxP-mediated DNA recombination leading to LacZ expression was accurately regulated in a temporal, spatial, and cell type-specific manner. This approach can be applied to establishment of analogous mouse strains with virtually any promoter as systems to control gene regulation in a variety of cell types.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Lee, WH (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	leew@uthscsa.edu	Utomo, Ahmad Rusdan H/GPW-8717-2022; Utomo, Ahmad/AAO-5605-2020; utomo, ahmad/CAF-9546-2022; Utomo, Ahmad Rusdan Handoyo/CAJ-0570-2022	Utomo, Ahmad Rusdan H/0000-0003-3092-3714; 	NCI NIH HHS [CA58318] Funding Source: Medline; NEI NIH HHS [EY05758] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		A-Mohammadi S, 1998, GENE THER, V5, P76, DOI 10.1038/sj.gt.3300557; Akagi K, 1997, NUCLEIC ACIDS RES, V25, P1766, DOI 10.1093/nar/25.9.1766; ALALI W, 1989, J PERIODONTOL, V60, P582, DOI 10.1902/jop.1989.60.10.582; Anderson WF, 1998, NATURE, V392, P25; Baron U, 1999, P NATL ACAD SCI USA, V96, P1013, DOI 10.1073/pnas.96.3.1013; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; BAYNA EM, 1990, NUCLEIC ACIDS RES, V18, P2977, DOI 10.1093/nar/18.10.2977; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; Blau HM, 1999, P NATL ACAD SCI USA, V96, P797, DOI 10.1073/pnas.96.3.797; BOCKER R, 1984, ARZNEIMITTEL-FORSCH, V34-1, P446; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; Brocard J, 1997, P NATL ACAD SCI USA, V94, P14559, DOI 10.1073/pnas.94.26.14559; Buchholz F, 1996, NUCLEIC ACIDS RES, V24, P4256, DOI 10.1093/nar/24.21.4256; Buchholz F, 1998, NAT BIOTECHNOL, V16, P657, DOI 10.1038/nbt0798-657; Burcin MM, 1999, P NATL ACAD SCI USA, V96, P355, DOI 10.1073/pnas.96.2.355; CHANG CY, 1993, CELL GROWTH DIFFER, V4, P1057; ChrastBalz J, 1996, NUCLEIC ACIDS RES, V24, P2900, DOI 10.1093/nar/24.15.2900; CORDONCARDO C, 1994, AM J PATHOL, V144, P500; Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960-9822(07)00562-3; DRYNECKI SM, 1996, P NATL ACAD SCI USA, V93, P6191; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOLUB LM, 1990, J PERIODONTAL RES, V25, P321, DOI 10.1111/j.1600-0765.1990.tb00923.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Harding TC, 1998, NAT BIOTECHNOL, V16, P553, DOI 10.1038/nbt0698-553; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; Kafri T, 1998, P NATL ACAD SCI USA, V95, P11377, DOI 10.1073/pnas.95.19.11377; Kellendonk C, 1996, NUCLEIC ACIDS RES, V24, P1404, DOI 10.1093/nar/24.8.1404; Kellendonk C, 1999, J MOL BIOL, V285, P175, DOI 10.1006/jmbi.1998.2307; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; LARSEN T, 1990, J PERIODONTOL, V61, P30, DOI 10.1902/jop.1990.61.1.30; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; Morsy MA, 1998, P NATL ACAD SCI USA, V95, P7866, DOI 10.1073/pnas.95.14.7866; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; NIKITIN AY, 1993, VIRCHOWS ARCH B, V64, P151, DOI 10.1007/BF02915108; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; PASSMAN RS, 1994, J CLIN INVEST, V94, P2421, DOI 10.1172/JCI117609; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; Porter A, 1998, TRENDS GENET, V14, P73, DOI 10.1016/S0168-9525(97)01326-7; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schultze N, 1996, NAT BIOTECHNOL, V14, P499, DOI 10.1038/nbt0496-499; Schwenk F, 1998, NUCLEIC ACIDS RES, V26, P1427, DOI 10.1093/nar/26.6.1427; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; SORLANO P, 1999, NAT GENET, V21, P70; StOnge L, 1996, NUCLEIC ACIDS RES, V24, P3875, DOI 10.1093/nar/24.19.3875; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wakita T, 1998, J BIOL CHEM, V273, P9001, DOI 10.1074/jbc.273.15.9001; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; WEBSTER GF, 1994, ARCH DERMATOL, V130, P748, DOI 10.1001/archderm.130.6.748; WIVAGG RT, 1976, J PHARM SCI, V65, P916, DOI 10.1002/jps.2600650630; Zhang Y, 1996, NUCLEIC ACIDS RES, V24, P543, DOI 10.1093/nar/24.4.543; Zinyk DL, 1998, CURR BIOL, V8, P665, DOI 10.1016/S0960-9822(98)70255-6	64	165	180	1	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1091	1096		10.1038/15073	http://dx.doi.org/10.1038/15073			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545915				2022-12-27	WOS:000083428000026
J	Brower, V				Brower, V			Tumor angiogenesis - new drugs on the block	NATURE BIOTECHNOLOGY			English	Article								Angiogenesis inhibitors could represent a powerful adjunct to traditional cancer treatments, but the most effective routes for therapeutic intervention remain unclear.										Augustin HG, 1998, TRENDS PHARMACOL SCI, V19, P216, DOI 10.1016/S0165-6147(98)01211-5; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Mauceri HJ, 1998, NATURE, V394, P287, DOI 10.1038/28412; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Moses MA, 1999, P NATL ACAD SCI USA, V96, P2645, DOI 10.1073/pnas.96.6.2645	6	127	159	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					963	968		10.1038/13654	http://dx.doi.org/10.1038/13654			10	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504695				2022-12-27	WOS:000083015700019
J	Fray, RG; Throup, JP; Daykin, M; Wallace, A; Williams, P; Stewart, GSAB; Grierson, D				Fray, RG; Throup, JP; Daykin, M; Wallace, A; Williams, P; Stewart, GSAB; Grierson, D			Plants genetically modified to produce N-acylhomoserine lactones communicate with bacteria	NATURE BIOTECHNOLOGY			English	Article						N-acylhomoserine lactones; plant/microbe interactions; biocontrol; rhizosphere	CARBAPENEM ANTIBIOTIC PRODUCTION; ERWINIA-CAROTOVORA; HOMOSERINE LACTONE; PSEUDOMONAS-AERUGINOSA; SIGNAL MOLECULES; GENE-EXPRESSION; LUXI FAMILY; QUORUM; AUTOINDUCER; TRANSFORMATION	N-acylhomoserine lactones (AHLs) play a critical role in plant/microbe interactions, The AHL, N-(3-oxohexanoyl)-1-homoserine lactone (OHHL), induces exoenzymes that degrade the plant cell wall by the pathogenic bacterium Erwinia carotovora. Conversely, the antifungal activity of the biocontrol bacterium Pseudomonas aureofaciens 30-84 is due (at least in part) to phenazine antibiotics whose synthesis is regulated by N-hexanoylhomoserine lactone (HHL). Targeting the product of an AHL synthase gene (yen1) from Yersinia enterocolitica to the chloroplasts of transgenic tobacco plants caused the synthesis in plants of the cognate AHL signaling molecules (OHHL and HHL). The AHLs produced by the transgenic plants were sufficient to induce target gene expression in several recombinant bacterial AHL biosensors and to restore biocontrol activity to an HHL-deficient P. aureofaciens strain. In addition, pathogenicity was restored to an E. carotovora strain rendered avirulent as a consequence of a mutation in the OHHL synthase gene, carl. The ability to generate bacterial quorum-sensing signaling molecules in the plant offers novel opportunities for disease control and for manipulating plant/microbe interactions.	Univ Nottingham, Sch Biol Sci, Loughborough LE12 5RD, Leics, England; Univ Nottingham, Sch Pharmaceut Sci, Nottingham NG7 2RD, England	University of Nottingham; University of Nottingham	Fray, RG (corresponding author), Univ Nottingham, Sch Biol Sci, Loughborough LE12 5RD, Leics, England.		Williams, Paul/P-5224-2019; Fray, Rupert G/A-9059-2016; Williams, Paul/A-5629-2011	Williams, Paul/0000-0002-1920-5036; Fray, Rupert G/0000-0002-3935-8945; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAINTON NJ, 1992, BIOCHEM J, V288, P997, DOI 10.1042/bj2880997; BECKER JO, 1993, PESTIC SCI, V37, P355, DOI 10.1002/ps.2780370408; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Camara M, 1998, METHOD MICROBIOL, V27, P319; Chernin LS, 1998, J BACTERIOL, V180, P4435, DOI 10.1128/JB.180.17.4435-4441.1998; DATLA RSS, 1993, PLANT SCI, V94, P139, DOI 10.1016/0168-9452(93)90015-R; DEAN C, 1987, MOL GEN GENET, V206, P465, DOI 10.1007/BF00428887; Draper J., 1988, PLANT GENETIC TRANSF, P69; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; Gray KM, 1996, J BACTERIOL, V178, P372, DOI 10.1128/jb.178.2.372-376.1996; Jiang Y, 1998, MOL MICROBIOL, V28, P193, DOI 10.1046/j.1365-2958.1998.00789.x; JONES S, 1993, EMBO J, V12, P2477, DOI 10.1002/j.1460-2075.1993.tb05902.x; McClean KH, 1997, MICROBIOL-UK, V143, P3703, DOI 10.1099/00221287-143-12-3703; McGowan SJ, 1996, MOL MICROBIOL, V22, P415, DOI 10.1046/j.1365-2958.1996.00125.x; More MI, 1996, SCIENCE, V272, P1655, DOI 10.1126/science.272.5268.1655; PALVA TK, 1994, MOL PLANT MICROBE IN, V7, P356, DOI 10.1094/MPMI-7-0356; PEROMBELON MCM, 1980, ANNU REV PHYTOPATHOL, V18, P361, DOI 10.1146/annurev.py.18.090180.002045; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; PIRHONEN M, 1993, EMBO J, V12, P2467, DOI 10.1002/j.1460-2075.1993.tb05901.x; SALMOND GPC, 1995, MOL MICROBIOL, V16, P615, DOI 10.1111/j.1365-2958.1995.tb02424.x; Schripsema J, 1996, J BACTERIOL, V178, P366, DOI 10.1128/jb.178.2.366-371.1996; Shaw PD, 1997, P NATL ACAD SCI USA, V94, P6036, DOI 10.1073/pnas.94.12.6036; SWIFT S, 1993, MOL MICROBIOL, V10, P511, DOI 10.1111/j.1365-2958.1993.tb00923.x; Swift S, 1996, TRENDS BIOCHEM SCI, V21, P214; THROUP JP, 1995, MOL MICROBIOL, V17, P345, DOI 10.1111/j.1365-2958.1995.mmi_17020345.x; Toyota K, 1997, BIOL FERT SOILS, V25, P416, DOI 10.1007/s003740050334; Val DL, 1998, J BACTERIOL, V180, P2644, DOI 10.1128/JB.180.10.2644-2651.1998; Winson MK, 1998, FEMS MICROBIOL LETT, V163, P185, DOI 10.1111/j.1574-6968.1998.tb13044.x; Wood DW, 1996, GENE, V168, P49, DOI 10.1016/0378-1119(95)00754-7; Wood DW, 1997, J BACTERIOL, V179, P7663, DOI 10.1128/jb.179.24.7663-7670.1997	30	93	108	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1017	1020		10.1038/13717	http://dx.doi.org/10.1038/13717			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504705				2022-12-27	WOS:000083015700030
J	Gygi, SP; Rist, B; Gerber, SA; Turecek, F; Gelb, MH; Aebersold, R				Gygi, SP; Rist, B; Gerber, SA; Turecek, F; Gelb, MH; Aebersold, R			Quantitative analysis of complex protein mixtures using isotope-coded affinity tags	NATURE BIOTECHNOLOGY			English	Article						gene expression; functional genomics; proteomics; protein profiling; mass spectrometry	MASS-SPECTROMETRY; SACCHAROMYCES-CEREVISIAE; IDENTIFICATION; DATABASE; SEQUENCES; PEPTIDES; GENOME; SCALE	We describe an approach for the accurate quantification and concurrent sequence identification of the individual proteins within complex mixtures. The method is based on a class of new chemical reagents termed isotope-coded affinity tags (ICATs) and tandem mass spectrometry. Using this strategy, we compared protein expression in the yeast Saccharomyces cerevisiae, using either ethanol or galactose as a carbon source. The measured differences in protein expression correlated with known yeast metabolic function under glucose-repressed conditions. The method is redundant if multiple cysteinyl residues are present, and the relative quantification is highly accurate because it is based on stable isotope dilution techniques. The ICAT approach should provide a widely applicable means to compare quantitatively global protein expression in cells and tissues.	Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Aebersold, R (corresponding author), Univ Washington, Dept Mol Biotechnol, Box 357730, Seattle, WA 98195 USA.	ruedi@u.washington.edu		Gerber, Scott/0000-0002-2964-5051; gelb, michael/0000-0001-7000-5219	NCRR NIH HHS [RR11823] Funding Source: Medline; NHGRI NIH HHS [T32HG00035] Funding Source: Medline; NICHD NIH HHS [HD-02274] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD002274] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000035] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BLEASBY AJ, 1994, NUCLEIC ACIDS RES, V22, P3574; Boucherie H, 1996, ELECTROPHORESIS, V17, P1683, DOI 10.1002/elps.1150171106; CLAUSER KR, 1995, P NATL ACAD SCI USA, V92, P5072, DOI 10.1073/pnas.92.11.5072; DELEENHEER AP, 1992, MASS SPECTROM REV, V11, P249, DOI 10.1002/mas.1280110402; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Figeys D, 1998, ELECTROPHORESIS, V19, P1811, DOI 10.1002/elps.1150191045; Garrels JI, 1997, ELECTROPHORESIS, V18, P1347, DOI 10.1002/elps.1150180810; Gerber SA, 1999, J AM CHEM SOC, V121, P1102, DOI 10.1021/ja982878k; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Gygi SP, 1999, ELECTROPHORESIS, V20, P310, DOI 10.1002/(SICI)1522-2683(19990201)20:2<310::AID-ELPS310>3.0.CO;2-M; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; Johnston M., 1992, MOL CELLULAR BIOL YE, P193; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Link AJ, 1997, ELECTROPHORESIS, V18, P1314, DOI 10.1002/elps.1150180808; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; Opiteck GJ, 1997, ANAL CHEM, V69, P1518, DOI 10.1021/ac961155l; Qin J, 1997, ANAL CHEM, V69, P3995, DOI 10.1021/ac970488v; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; Sechi S, 1998, ANAL CHEM, V70, P5150, DOI 10.1021/ac9806005; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0	24	3911	4305	10	614	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					994	999		10.1038/13690	http://dx.doi.org/10.1038/13690			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504701				2022-12-27	WOS:000083015700026
J	Huang, Q; Shan, SQ; Braun, RD; Lanzen, J; Anyrhambatla, G; Kong, GH; Borelli, M; Corry, P; Dewhirst, MW; Li, CY				Huang, Q; Shan, SQ; Braun, RD; Lanzen, J; Anyrhambatla, G; Kong, GH; Borelli, M; Corry, P; Dewhirst, MW; Li, CY			Noninvasive visualization of tumors in rodent dorsal skin window chambers - A novel model for evaluating anti-cancer therapies.	NATURE BIOTECHNOLOGY			English	Editorial Material							MICROVASCULAR PERMEABILITY; STEALTH LIPOSOMES; GROWTH; ANGIOGENESIS; VASCULARIZATION; MICROVESSELS; EXPRESSION; INHIBITION; PROTEIN; INVITRO		Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; William Beaumont Hosp, Dept Radiat Oncol, Royal Oak, MI 48073 USA	Duke University; Beaumont Health	Li, CY (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA.		Dewhirst, Mark/Q-1302-2019; Li, Chuan-Yuan/H-4148-2013	Dewhirst, Mark/0000-0003-3459-6546; 	NATIONAL CANCER INSTITUTE [P01CA042745, R01CA040355] Funding Source: NIH RePORTER; NCI NIH HHS [CA40355, CA42745] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGIRE GH, 1949, J NATL CANCER I, V10, P225; ANDRADE SP, 1987, BRIT J EXP PATHOL, V68, P755; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DEWHIRST M, 1984, BIORHEOLOGY, V21, P539; DEWHIRST M, 1995, STEALTH LIPOSOMES; Fong TAT, 1999, CANCER RES, V59, P99; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; GABBIANI G, 1984, J CELL SCI, V66, P39; GREVER M, 1997, CANC PRINCIPLES PRAC, V1, P385; GROSS J, 1981, P NATL ACAD SCI-BIOL, V78, P1176, DOI 10.1073/pnas.78.2.1176; HUANG SK, 1994, CANCER RES, V54, P2186; LEUNIG M, 1992, CANCER RES, V52, P6553; Lin PN, 1998, CELL GROWTH DIFFER, V9, P49; MERWIN R, 1950, J NATL CANCER I, V11, P593; MESTRIL R, 1994, BIOCHEM J, V298, P561, DOI 10.1042/bj2980561; NICOSIA RF, 1990, LAB INVEST, V63, P115; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PAPENFUSS HD, 1979, MICROVASC RES, V18, P311, DOI 10.1016/0026-2862(79)90039-6; SHUBIK P, 1976, J NATL CANCER I, V57, P769, DOI 10.1093/jnci/57.4.769; WU NZ, 1993, MICROVASC RES, V46, P231, DOI 10.1006/mvre.1993.1049; WU NZ, 1993, CANCER RES, V53, P3765; WU NZ, 1992, CANCER RES, V52, P4265; YUAN F, 1994, CANCER RES, V54, P3352	24	77	80	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1033	1035		10.1038/13736	http://dx.doi.org/10.1038/13736			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504711				2022-12-27	WOS:000083015700034
J	Waibel, R; Alberto, R; Willuda, J; Finnern, R; Schibli, R; Stichelberger, A; Egli, A; Abram, U; Mach, JP; Pluckthun, A; Schubiger, PA				Waibel, R; Alberto, R; Willuda, J; Finnern, R; Schibli, R; Stichelberger, A; Egli, A; Abram, U; Mach, JP; Pluckthun, A; Schubiger, PA			Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex	NATURE BIOTECHNOLOGY			English	Article						organometallic technetium; recombinant proteins; radiolabeling; targeting; imaging	SINGLE-CHAIN FV; ANTIBODY; BINDING; TC-99M; FRAGMENTS; PEPTIDES; RECEPTOR; LIBRARY	We have developed a technetium labeling technology based on a new organometallic chemistry, which involves simple mixing of the novel reagent, a Tc-99m(I)-carbonyl compound, with a His-tagged recombinant protein. This method obviates the labeling of unpaired engineered cysteines, which frequently create problems in large-scale expression and storage of disulfide-containing proteins. In this study, we labeled antibody single-chain Fv fragments to high specific activities (90 mCi/mg), and the label was very stable to serum and all other challenges tested. The pharmacokinetic characteristics were indistinguishable from iodinated scFv fragments, and thus scFV fragments labeled by the new method will be suitable for biodistribution studies. This novel labeling method should be applicable not only to diagnostic imaging with Tc-99m, but also to radioimmunotherapy approaches with Re-186/188, and its use can be easily extended to almost any recombinant protein or synthetic peptide.	Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland; Paul Scherrer Inst, Ctr Radiopharmaceut Sci, CH-5232 Villigen, Switzerland; Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland; Forschungszentrum Rossendorf EV, Inst Radiochem, D-01062 Dresden, Germany	University of Zurich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; University of Lausanne; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR)	Pluckthun, A (corresponding author), Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland.	plueckthun@biocfebs.unizh.ch	Alberto, Roger/S-6405-2019; Plückthun, Andreas/C-2746-2009	Alberto, Roger/0000-0001-5978-3394; Plückthun, Andreas/0000-0003-4191-5306; Schibli, Roger/0000-0002-1537-3833				ABRAMS MJ, 1983, INORG CHEM, V22, P2798, DOI 10.1021/ic00162a007; Adams GP, 1998, CANCER RES, V58, P485; Alberto R, 1996, POLYHEDRON, V15, P1079, DOI 10.1016/0277-5387(95)00361-4; Alberto R, 1998, J AM CHEM SOC, V120, P7987, DOI 10.1021/ja980745t; Begent RHJ, 1996, NAT MED, V2, P979, DOI 10.1038/nm0996-979; Behr TM, 1998, EUR J NUCL MED, V25, P201, DOI 10.1007/s002590050216; Bogdanov A, 1998, BBA-GENE STRUCT EXPR, V1397, P56, DOI 10.1016/S0167-4781(97)00221-2; CHIZZONITE R, 1992, J IMMUNOL, V148, P3117; FRITZBERG AR, 1987, NUKLEARMED, V26, P7; GEORGE AJT, 1995, P NATL ACAD SCI USA, V92, P8358, DOI 10.1073/pnas.92.18.8358; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KNAPPIK A, 1995, PROTEIN ENG, V8, P81, DOI 10.1093/protein/8.1.81; Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6; LIBERATORE M, 1995, EUR J NUCL MED, V22, P1326, DOI 10.1007/BF00801622; LINDMO T, 1984, J IMMUNOL METHODS, V72, P77, DOI 10.1016/0022-1759(84)90435-6; Lindner P, 1997, BIOTECHNIQUES, V22, P140, DOI 10.2144/97221rr01; MARTELL AE, 1995, CRITICAL SELECTED ST; NEDELMAN MA, 1993, J NUCL MED, V34, P234; Pietersz GA, 1998, J NUCL MED, V39, P47; Pluckthun A, 1996, ANTIBODY ENG PRACTIC, P203; SATTELBERGER AP, 1995, MANGANESE GROUP, P151; SCHOTT ME, 1992, CANCER RES, V55, P5323; SKERRA A, 1991, BIO-TECHNOL, V9, P273, DOI 10.1038/nbt0391-273; Snider H, 1998, AM J SURG, V176, P305, DOI 10.1016/S0002-9610(98)00207-4; Spradau TW, 1999, NUCL MED BIOL, V26, P1, DOI 10.1016/S0969-8051(98)00060-2; Stalteri MA, 1999, BIOCONJUGATE CHEM, V10, P130, DOI 10.1021/bc9800466; TAILLEFER R, 1988, EUR J NUCL MED, V13, P515; Tiling R, 1998, J NUCL MED, V39, P849; Vallabhajosula S, 1996, J NUCL MED, V37, P1016; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; Verhaar MJ, 1996, J NUCL MED, V37, P868; Worn A, 1998, FEBS LETT, V427, P357, DOI 10.1016/S0014-5793(98)00463-3	32	262	300	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					897	901		10.1038/12890	http://dx.doi.org/10.1038/12890			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471933				2022-12-27	WOS:000082365800033
J	Chapman, AP; Antoniw, P; Spitali, M; West, S; Stephens, S; King, DJ				Chapman, AP; Antoniw, P; Spitali, M; West, S; Stephens, S; King, DJ			Therapeutic antibody fragments with prolonged in vivo half-lives	NATURE BIOTECHNOLOGY			English	Article						therapeutic antibodies; antibody engineering; polyethylene glycol; pharmacokinetics	ESCHERICHIA-COLI; RECOMBINANT ANTIBODY; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; TUMOR-LOCALIZATION; EXPRESSION	Antibody fragments can be isolated rapidly using techniques such as phage display and can be expressed to high levels in microbial systems. However, to date such antibody fragments have been of limited use for many therapeutic applications because they are rapidly cleared from the body. We present a strategy for the site-specific chemical modification of antibody fragments with polyethylene glycol, which results in the production of antibody fragments with long in vivo half-lives and full retention of antigen-binding properties. This technology should allow more rapid and economical production of therapeutic antibodies for chronic disease therapy.	Celltech Therapeut, Slough SL1 4EN, Berks, England	Celltech Group Ltd	Chapman, AP (corresponding author), Celltech Therapeut, 216 Bath Rd, Slough SL1 4EN, Berks, England.							BEBBINGTON CR, 1992, BIO-TECHNOL, V10, P169, DOI 10.1038/nbt0292-169; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; Dickman S, 1998, SCIENCE, V280, P1196, DOI 10.1126/science.280.5367.1196; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Horn U, 1996, APPL MICROBIOL BIOT, V46, P524, DOI 10.1007/s002530050855; Humphreys DP, 1998, J IMMUNOL METHODS, V217, P1, DOI 10.1016/S0022-1759(98)00061-1; KING DJ, 1994, CANCER RES, V54, P6176; KING DJ, 1992, ANTIBODY IMMUNOCONJ, V5, P159; KITAMURA K, 1991, CANCER RES, V51, P4310; Monfardini C, 1998, BIOCONJUGATE CHEM, V9, P418, DOI 10.1021/bc970184f; PEDLEY RB, 1994, BRIT J CANCER, V70, P1126, DOI 10.1038/bjc.1994.459; Pen J., 1996, Transgenic plants: a production system for industrial and pharmaceutical proteins., P149; RANKIN ECC, 1995, BRIT J RHEUMATOL, V34, P334; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; Vaughan TJ, 1998, NAT BIOTECHNOL, V16, P535, DOI 10.1038/nbt0698-535; Zeitlin L, 1998, NAT BIOTECHNOL, V16, P1361, DOI 10.1038/4344	16	272	381	0	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					780	783		10.1038/11717	http://dx.doi.org/10.1038/11717			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429243				2022-12-27	WOS:000081751400027
J	Shea, LD; Smiley, E; Bonadio, J; Mooney, DJ				Shea, LD; Smiley, E; Bonadio, J; Mooney, DJ			DNA delivery from polymer matrices for tissue engineering	NATURE BIOTECHNOLOGY			English	Article						gene therapy; PDGF; plasmid DNA; poly(lactide-co-glycolide); tissue engineering	CONTROLLED-RELEASE; GROWTH	We have proposed engineering tissues by the incorporation and sustained release of plasmids encoding tissue-inductive proteins from polymer matrices. Matrices of poly(lactide-co-glycolide) (PLG) were loaded with plasmid, which was subsequently released over a period ranging from days to a month in vitro. Sustained delivery of plasmid DNA from matrices led to the transfection of large numbers of cells. Furthermore, in vivo delivery of a plasmid encoding platelet-derived growth factor enhanced matrix deposition and blood vessel formation in the developing tissue. This contrasts with direct injection of the plasmid, which did not significantly affect tissue formation. This method of DNA delivery may find utility in tissue engineering and gene therapy applications.	Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Mooney, DJ (corresponding author), Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.		Shea, Lonnie D/B-7615-2009	Mooney, David/0000-0001-6299-1194	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013004] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE07057, 1RO1DE13004] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Deuel T.F., 1997, PRINCIPLES TISSUE EN, P133; Fang JM, 1996, P NATL ACAD SCI USA, V93, P5753, DOI 10.1073/pnas.93.12.5753; Giannobile WV, 1996, BONE, V19, pS23, DOI 10.1016/S8756-3282(96)00127-5; Harris LD, 1998, J BIOMED MATER RES, V42, P396, DOI 10.1002/(SICI)1097-4636(19981205)42:3<396::AID-JBM7>3.3.CO;2-P; Hedley ML, 1998, NAT MED, V4, P365, DOI 10.1038/nm0398-365; Jong YS, 1997, J CONTROL RELEASE, V47, P123, DOI 10.1016/S0168-3659(97)01637-4; Kim BS, 1998, TRENDS BIOTECHNOL, V16, P224, DOI 10.1016/S0167-7799(98)01191-3; Labhasetwar V, 1998, J PHARM SCI, V87, P1347, DOI 10.1021/js980077+; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Langer R, 1998, NATURE, V392, P5; Ledley FD, 1996, PHARM RES-DORDR, V13, P1595, DOI 10.1023/A:1016420102549; Mooney DJ, 1997, J BIOMED MATER RES, V37, P413, DOI 10.1002/(SICI)1097-4636(19971205)37:3<413::AID-JBM12>3.0.CO;2-C; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; PETERS MC, 1998, TISSUE ENG THERAPEUT, V2, P55; RAINES EW, 1993, BIOL PLATELET DERIVE, P74; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; Wong Wai Hung, 1997, P51	18	557	596	0	67	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					551	554		10.1038/9853	http://dx.doi.org/10.1038/9853			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385318				2022-12-27	WOS:000080716500025
J	Hofstetter, O; Hofstetter, H; Wilchek, M; Schurig, V; Green, BS				Hofstetter, O; Hofstetter, H; Wilchek, M; Schurig, V; Green, BS			Chiral discrimination using an immunosensor	NATURE BIOTECHNOLOGY			English	Article						applied immunology; chiral sensor; amino acid	SURFACE-PLASMON RESONANCE; D-AMINO ACIDS; MURCHISON METEORITE; D-SERINE; SENSORS; DISEASE; PROTEIN	Based on the stereoselectivity of immunoglobulins, we have developed a new chiral sensor for the detection of low-molecular-weight analytes. Using surface plasmon resonance detection, enantiomers of free, underivatized alpha-amino acids can be monitored in a competitive assay by their interaction with antibodies specific for the chiral center of this class of substances. The sensitivity to the minor enantiomer in nonracemic mixtures exceeds currently available methods; therefore, such immunosensors can readily detect traces of enantiomeric impurities and are attractive for a range of applications in science and industry.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany; Hebrew Univ Jerusalem, Dept Pharmaceut Chem, IL-91120 Jerusalem, Israel	Weizmann Institute of Science; Eberhard Karls University of Tubingen; Hebrew University of Jerusalem	Green, BS (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	csgreen@md2.huji.ac.il	Hofstetter, Heike/GXH-9439-2022	Hofstetter, Heike/0000-0003-4501-4206				Ansell RJ, 1996, CURR OPIN BIOTECH, V7, P89, DOI 10.1016/S0958-1669(96)80101-7; Bodenhofer K, 1997, NATURE, V387, P577, DOI 10.1038/42426; CALDWELL J, 1995, J CHROMATOGR A, V694, P39, DOI 10.1016/0021-9673(94)00812-N; Coppola GM., 1987, ASYMMETRIC SYNTHESIS; Cronin JR, 1997, SCIENCE, V275, P951, DOI 10.1126/science.275.5302.951; EICHELBAUM M, 1996, ADV DRUG RES, V28, P1; Engel MH, 1997, NATURE, V389, P265, DOI 10.1038/38460; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FISHER GH, 1994, MOL CHEM NEUROPATHOL, V23, P115, DOI 10.1007/BF02815405; HASHIMOTO A, 1993, J NEUROCHEM, V61, P348, DOI 10.1111/j.1471-4159.1993.tb03575.x; Hofstetter O, 1998, J AM CHEM SOC, V120, P3251, DOI 10.1021/ja973680n; Imai K, 1996, BIOMED CHROMATOGR, V10, P303, DOI 10.1002/(SICI)1099-0801(199611)10:6<303::AID-BMC624>3.0.CO;2-B; KARLSSON R, 1994, ANAL BIOCHEM, V221, P142, DOI 10.1006/abio.1994.1390; KRETSCHM.E, 1968, Z NATURFORSCH PT A, VA 23, P2135, DOI 10.1515/zna-1968-1247; LIEDBERG B, 1983, SENSOR ACTUATOR, V4, P299, DOI 10.1016/0250-6874(83)85036-7; LUTHRA M, 1994, J BIOL CHEM, V269, P22678; MAN EH, 1983, SCIENCE, V220, P1407, DOI 10.1126/science.6857259; Moore DE, 1996, J AM CHEM SOC, V118, P12997, DOI 10.1021/ja9630405; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; Parker D, 1997, CHEM COMMUN, P141, DOI 10.1039/a603564g; Pizzarello S, 1998, NATURE, V394, P236, DOI 10.1038/28306; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; SCHURIG V, 1995, METHODS ORGANIC CH A, V21, P147; SHAPIRA R, 1988, J NEUROCHEM, V50, P69, DOI 10.1111/j.1471-4159.1988.tb13231.x; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; Stinson SC, 1997, CHEM ENG NEWS, V75, P38; WILCHEK M, 1988, ANAL BIOCHEM, V171, P1, DOI 10.1016/0003-2697(88)90120-0	27	96	100	0	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					371	374		10.1038/7927	http://dx.doi.org/10.1038/7927			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207886				2022-12-27	WOS:000079574400026
J	Freitag, R				Freitag, R			Displacement chromatography for biopolymer separation - The demand for better separation techniques fuels chromatography research.	NATURE BIOTECHNOLOGY			English	Article							HYDROXYAPATITE; EXCHANGE; PROTEINS		ETH, Ctr Biotechnol, Dept Chem, Lausanne, Switzerland		Freitag, R (corresponding author), ETH, Ctr Biotechnol, Dept Chem, Lausanne, Switzerland.			Freitag, Ruth/0000-0002-6569-9137				DeVault D, 1943, J AM CHEM SOC, V65, P532, DOI 10.1021/ja01244a011; FREITAG R, 1995, J CHROMATOGR A, V691, P101, DOI 10.1016/0021-9673(94)01000-5; FREITAG R, 1998, BIOSEPARATION BIOPRO, V1, P89; FREITAG R, 1999, IN PRESS CYTOTECHNOL; FRENZ J, 1990, J CHROMATOGR, V512, P299, DOI 10.1016/S0021-9673(01)89497-8; Gerstner JA, 1996, BIOPHARM-TECHNOL BUS, V9, P30; JAYARAMAN G, 1995, J CHROMATOGR A, V702, P143, DOI 10.1016/0021-9673(94)01007-2; Kasper C, 1996, BIOSEPARATION, V6, P247; Vogt S, 1997, J CHROMATOGR A, V760, P125, DOI 10.1016/S0021-9673(96)00797-2; VOGT S, 1999, IN PRESS BIOTECH PRO	10	14	16	1	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					300	302		10.1038/7054	http://dx.doi.org/10.1038/7054			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096301				2022-12-27	WOS:000078977500035
J	Brower, V				Brower, V			Human ES cells: Can you build a business around them?	NATURE BIOTECHNOLOGY			English	Article																			0	16	17	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					139	142		10.1038/6140	http://dx.doi.org/10.1038/6140			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052348				2022-12-27	WOS:000078508300020
J	Hurwitz, EM				Hurwitz, EM			Biotech finance: A family affair	NATURE BIOTECHNOLOGY			English	Article									Affymetrix, Santa Clara, CA 95051 USA	Affymetrix	Hurwitz, EM (corresponding author), Affymetrix, 3380 Cent Expressway, Santa Clara, CA 95051 USA.								0	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17			S			BE35	BE37		10.1038/4643	http://dx.doi.org/10.1038/4643			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165PD	10052326	Bronze			2022-12-27	WOS:000078529400017
J	Munch, G; Schicktanz, D; Behme, A; Gerlach, M; Riederer, P; Palm, D; Schinzel, R				Munch, G; Schicktanz, D; Behme, A; Gerlach, M; Riederer, P; Palm, D; Schinzel, R			Amino acid specificity of glycation and protein-AGE crosslinking reactivities determined with a dipeptide SPOT library	NATURE BIOTECHNOLOGY			English	Article						advanced glycation end products; protein crosslinking; peptide library	PICTET-SPENGLER REACTION; END-PRODUCTS; MAILLARD REACTION; CHEMICAL SYNTHESIS; METHYLGLYOXAL; PENTOSIDINE; AMYLOIDOSIS; SUPPORT; DISEASE; LYSINE	Advanced glycation end products (AGEs) contribute to changes in protein conformation, loss of function, and irreversible crosslinking. Using a library of dipeptides on cellulose membranes (SPOT library), we have developed an approach to systematically assay the relative reactivities of amino acid side chains and the N-terminal amino group to sugars and protein-AGEs. The sugars react preferentially with cysteine or tryptophan when both the alpha-amino group and the side chains are free. In peptides with blocked N-terminus and free side chains, cysteine, lysine, and histidine were preferred. Crosslinking of protein-AGEs to dipeptides with free side chains and blocked N termini occurred preferentially to arginine and tryptophan. Dipeptide SPOT libraries are excellent tools for comparing individual reactivities of amino acids for nonenzymatic modifications, and could be extended to other chemically reactive molecules.	Univ Wurzburg, Dept Physiol Chem 1, Wurzburg, Germany; Univ Wurzburg, Hosp Psychiat, Dept Clin Neurochem, D-97070 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Munch, G (corresponding author), Univ Wurzburg, Dept Physiol Chem 1, Wurzburg, Germany.							ALABED Y, 1995, BIOORG MED CHEM LETT, V5, P2929, DOI 10.1016/0960-894X(95)00513-S; De Rosa MC, 1998, BIOPHYS CHEM, V72, P323, DOI 10.1016/S0301-4622(98)00117-3; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FRANK R, 1995, J BIOTECHNOL, V41, P259, DOI 10.1016/0168-1656(95)00062-U; Friedman EA, 1997, AM J KIDNEY DIS, V30, P253, DOI 10.1016/S0272-6386(97)90060-3; Hilmes C, 1997, MEAT SCI, V46, P199, DOI 10.1016/S0309-1740(97)00019-3; HIPKISS AR, 1995, FEBS LETT, V371, P81, DOI 10.1016/0014-5793(95)00849-5; Horie K, 1997, BIOCHEM BIOPH RES CO, V236, P327, DOI 10.1006/bbrc.1997.6944; LO TWC, 1994, J BIOL CHEM, V269, P32299; Mayer JP, 1996, TETRAHEDRON LETT, V37, P5633, DOI 10.1016/0040-4039(96)01219-1; Miyata T, 1998, BIOCHEM BIOPH RES CO, V244, P45, DOI 10.1006/bbrc.1998.8203; MIYATA T, 1994, BIOCHEMISTRY-US, V33, P12215, DOI 10.1021/bi00206a026; MIYAZAKI S, 1995, AM J NEPHROL, V15, P535, DOI 10.1159/000168903; Mohan R, 1996, TETRAHEDRON LETT, V37, P3963, DOI 10.1016/0040-4039(96)00773-3; Molina F, 1996, PEPTIDE RES, V9, P151; Moreaux V, 1997, J AGR FOOD CHEM, V45, P1905, DOI 10.1021/jf9605005; Nakamura K, 1997, BIOCHEM BIOPH RES CO, V232, P227, DOI 10.1006/bbrc.1997.6262; Obayashi H, 1996, BIOCHEM BIOPH RES CO, V226, P37, DOI 10.1006/bbrc.1996.1308; Odani H, 1998, FEBS LETT, V427, P381, DOI 10.1016/S0014-5793(98)00416-5; Reineke U, 1998, PROTEIN SCI, V7, P951; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; VLASSARA H, 1994, P NATL ACAD SCI USA, V91, P11704, DOI 10.1073/pnas.91.24.11704; Vlassara H, 1996, ANN MED, V28, P419, DOI 10.3109/07853899608999102; Wang MF, 1999, J AGR FOOD CHEM, V47, P48, DOI 10.1021/jf980804m; WellsKnecht KJ, 1996, NEPHROL DIAL TRANSPL, V11, P41	27	96	103	1	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1006	1010		10.1038/13704	http://dx.doi.org/10.1038/13704			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504703				2022-12-27	WOS:000083015700028
J	Stenman, J; Finne, P; Stahls, A; Grenman, R; Stenman, UH; Palotie, A; Orpana, A				Stenman, J; Finne, P; Stahls, A; Grenman, R; Stenman, UH; Palotie, A; Orpana, A			Accurate determination of relative messenger RNA levels by RT-PCR	NATURE BIOTECHNOLOGY			English	Editorial Material							POLYMERASE CHAIN-REACTION; DNA; QUANTITATION; ASSAY; CELLS; HYBRIDIZATION; AMPLIFICATION; TITRATION; PRODUCT; GENES		Univ Helsinki, Dept Clin Chem, SF-00100 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Lab, Helsinki, Finland; Univ Helsinki, Haartman Inst, Helsinki, Finland; Univ Turku, Cent Hosp, FIN-20520 Turku, Finland; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Turku; University of California System; University of California Los Angeles	Stenman, J (corresponding author), Univ Helsinki, Dept Clin Chem, SF-00100 Helsinki, Finland.			Palotie, Aarno/0000-0002-2527-5874; Finne, Patrik/0000-0002-3742-1576; Stenman, Jakob/0000-0001-9543-3957; Stenman, Ulf-Hakan/0000-0002-2695-3454				ALARD P, 1993, BIOTECHNIQUES, V15, P730; BECKERANDRE M, 1989, NUCLEIC ACIDS RES, V17, P9437, DOI 10.1093/nar/17.22.9437; Chen XN, 1997, P NATL ACAD SCI USA, V94, P10756, DOI 10.1073/pnas.94.20.10756; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; IHALAINEN J, 1994, BIOTECHNIQUES, V16, P938; Ikonen E, 1992, PCR Methods Appl, V1, P234; Karttunen L, 1996, GENOME RES, V6, P392, DOI 10.1101/gr.6.5.392; KATO H, 1984, JPN J CANCER RES, V75, P433; KUBO Y, 1995, CANCER RES, V55, P989; LIVAK KJ, 1995, PCR METH APPL, V4, P357; PANNETIER C, 1993, NUCLEIC ACIDS RES, V21, P577, DOI 10.1093/nar/21.3.577; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; Schutze K, 1998, NAT BIOTECHNOL, V16, P737, DOI 10.1038/nbt0898-737; Suomalainen A, 1998, METH MOL B, V86, P121; SYVANEN AC, 1990, GENOMICS, V8, P684, DOI 10.1016/0888-7543(90)90255-S; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01	20	21	27	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					720	722		10.1038/10942	http://dx.doi.org/10.1038/10942			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10409357				2022-12-27	WOS:000081296900036
J	Hansen, MST; Smith, GJ; Kafri, T; Molteni, V; Siegel, JS; Bushman, FD				Hansen, MST; Smith, GJ; Kafri, T; Molteni, V; Siegel, JS; Bushman, FD			Integration complexes derived from HIV vectors for rapid assays in vitro	NATURE BIOTECHNOLOGY			English	Article						HIV; integrase; AIDS; retroviral vector; quantitative PCR; TaqMan	IMMUNODEFICIENCY-VIRUS TYPE-1; PREINTEGRATION COMPLEXES; DNA INVITRO; REVERSE-TRANSCRIPTASE; PROTEIN INVITRO; NUCLEIC-ACIDS; IN-VITRO; INHIBITION; MOLECULES; CELLS	Of three enzymes encoded by HIV-reverse transcriptase, protease, and integrase-only the first two have been exploited clinically as inhibitor targets. Efforts to develop inhibitors of purified integrase protein have yielded many compounds, but none with clinical utility. A different source of integration activity for studies in vitro is provided by replication intermediates isolated from HIV-infected cells. These preintegration complexes (PICs) can direct integration of the endogenously synthesized viral cDNA into an added target DNA in vitro. Despite their authentic activities, assays of PICs have not been widely used due to technical obstacles, particularly the requirement for handling large amounts of infectious HIV. Here, we describe greatly improved methods for producing PICs using HIV-based vectors that are capable of establishing an integrated provirus but not a spreading infection. We also report the development of a PIC integration assay using DNA-coated microtiter plates, which speeds assays of PIC integration in vitro. We used this method to screen a library of chemicals related to known integrase inhibitors and found a new compound, quinalizarin sulfate, that displayed enhanced activity against PICs.	Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA; Althea Technol, San Diego, CA 92121 USA; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Chem, La Jolla, CA USA	Salk Institute; Salk Institute; University of California System; University of California San Diego	Bushman, FD (corresponding author), Salk Inst Biol Studies, Infect Dis Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	bushman@salk.edu	Siegel, Jay/E-6415-2011	Siegel, Jay/0000-0002-3226-3521	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056553] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34786] Funding Source: Medline; NIGMS NIH HHS [GM56553] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartz SR, 1997, METHODS, V12, P337, DOI 10.1006/meth.1997.0487; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; Bushman F, 1998, P NATL ACAD SCI USA, V95, P11041, DOI 10.1073/pnas.95.19.11041; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHU BCF, 1983, NUCLEIC ACIDS RES, V11, P6513, DOI 10.1093/nar/11.18.6513; Coffin J, 1997, RETROVIRUSES; CUSHMAN M, 1992, BIOCHEM BIOPH RES CO, V185, P85, DOI 10.1016/S0006-291X(05)80958-1; Ellis R J, 1990, Semin Cell Biol, V1, P1; Farnet C, 1997, CELL, V88, P1; FARNET CM, 1991, J VIROL, V65, P1910, DOI 10.1128/JVI.65.4.1910-1915.1991; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; Farnet CM, 1996, P NATL ACAD SCI USA, V93, P9742, DOI 10.1073/pnas.93.18.9742; Farnet CM, 1998, ANTIMICROB AGENTS CH, V42, P2245, DOI 10.1128/AAC.42.9.2245; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; GHOSH SS, 1987, NUCLEIC ACIDS RES, V15, P5353, DOI 10.1093/nar/15.13.5353; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hansen MST, 1998, GENET ENG P, V20, P41; Hansen MST, 1997, J VIROL, V71, P3351, DOI 10.1128/JVI.71.4.3351-3356.1997; Hazuda DJ, 1997, J VIROL, V71, P7005, DOI 10.1128/JVI.71.9.7005-7011.1997; HAZUDA DJ, 1994, NUCLEIC ACIDS RES, V22, P1121, DOI 10.1093/nar/22.6.1121; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hindmarsh P, 1999, J VIROL, V73, P2994, DOI 10.1128/JVI.73.4.2994-3003.1999; Kafri T, 1999, J VIROL, V73, P576, DOI 10.1128/JVI.73.1.576-584.1999; King PJ, 1998, J VIROL, V72, P8420, DOI 10.1128/JVI.72.10.8420-8424.1998; LEE YMH, 1990, J VIROL, V64, P5958, DOI 10.1128/JVI.64.12.5958-5965.1990; LEE YMH, 1991, MOL CELL BIOL, V11, P1419, DOI 10.1128/MCB.11.3.1419; LUND V, 1988, NUCLEIC ACIDS RES, V16, P10861, DOI 10.1093/nar/16.22.10861; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; MILLER MD, 1995, J VIROL, V69, P3938, DOI 10.1128/JVI.69.6.3938-3944.1995; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; Pommier Y, 1997, ANTIVIR CHEM CHEMOTH, V8, P463, DOI 10.1177/095632029700800601; RASMUSSEN SR, 1991, ANAL BIOCHEM, V198, P138, DOI 10.1016/0003-2697(91)90518-X; Robinson WE, 1996, P NATL ACAD SCI USA, V93, P6326, DOI 10.1073/pnas.93.13.6326; Wei SQ, 1998, P NATL ACAD SCI USA, V95, P10535, DOI 10.1073/pnas.95.18.10535	38	42	48	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					578	582		10.1038/9886	http://dx.doi.org/10.1038/9886			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385323				2022-12-27	WOS:000080716500030
J	Cairns, MJ; Hopkins, TM; Witherington, C; Wang, L; Sun, LQ				Cairns, MJ; Hopkins, TM; Witherington, C; Wang, L; Sun, LQ			Target site selection for an RNA-cleaving catalytic DNA	NATURE BIOTECHNOLOGY			English	Article						deoxyribozyme; oligonucleotide; DNAzyme; secondary structure; RNA accessibility	ACCESSIBLE SITES; ANTISENSE OLIGONUCLEOTIDES; MESSENGER-RNA; HYBRIDIZATION; DUPLEXES; RIBOZYMES; LIBRARIES; PROBES	A small catalytic DNA, known as the 10-23 DNA enzyme or deoxyribozyme, has been shown to efficiently hydrolyze RNA at purine-pyrimidine (R-Y) junctions in vitro. Although these potentially cleavable junctions are ubiquitous, they are often protected from deoxyribozyme activity by RNA secondary structure. We have developed a multiplex cleavage assay for screening the entire length of a target RNA molecule for deoxyribozyme cleavage sites that are efficient, both in terms of kinetics and accessibility. This strategy allowed us to simultaneously compare the RNA cleaving activity of 80 deoxyribozymes for a model target gene (HPV16 E6), and an additional 60 deoxyribozymes against the rat c-myc target. The human papilloma virus (HPV) target was used primarily to characterize the multiplex system and determine its validity. The c-myc target, coupled with a smooth muscle cell proliferation assay, allowed us to assess the relationship between in vitro cleavage efficiency and c-myc gene suppression in cell culture. The multiplex reaction approach streamlines the process of revealing effective deoxyribozymes in a functional assay and provides accessibility data that may also be applicable to site selection for other hybridization-based agents.	Johnson & Johnson Res Labs, Sydney, NSW 2001, Australia	Johnson & Johnson	Sun, LQ (corresponding author), Johnson & Johnson Res Labs, GPO Box 3331, Sydney, NSW 2001, Australia.			Cairns, Murray/0000-0003-2490-2538				Bielinska A, 1996, NUCLEIC ACIDS RES, V24, P2176, DOI 10.1093/nar/24.11.2176; Birikh KR, 1997, RNA, V3, P429; CAMPBELL TB, 1995, RNA, V1, P598; Gyi JI, 1998, BIOCHEMISTRY-US, V37, P73, DOI 10.1021/bi9719713; HENDRY P, 1992, NUCLEIC ACIDS RES, V20, P5737, DOI 10.1093/nar/20.21.5737; Ho SP, 1996, NUCLEIC ACIDS RES, V24, P1901, DOI 10.1093/nar/24.10.1901; Ho SP, 1998, NAT BIOTECHNOL, V16, P59, DOI 10.1038/nbt0198-59; INOUE H, 1987, NUCLEIC ACIDS RES, V15, P6131, DOI 10.1093/nar/15.15.6131; Le Tinevez R, 1998, NUCLEIC ACIDS RES, V26, P2273, DOI 10.1093/nar/26.10.2273; LIEBER A, 1995, MOL CELL BIOL, V15, P540, DOI 10.1128/MCB.15.1.540; Lima WF, 1997, J BIOL CHEM, V272, P626; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; Majlessi M, 1998, NUCLEIC ACIDS RES, V26, P2224, DOI 10.1093/nar/26.9.2224; Matveeva O, 1997, NUCLEIC ACIDS RES, V25, P5010, DOI 10.1093/nar/25.24.5010; Milner N, 1997, NAT BIOTECHNOL, V15, P537, DOI 10.1038/nbt0697-537; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; RATMEYER L, 1994, BIOCHEMISTRY-US, V33, P5298, DOI 10.1021/bi00183a037; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SIMONS M, 1994, J CLIN INVEST, V93, P2351, DOI 10.1172/JCI117240; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029	20	127	145	5	66	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					480	486		10.1038/8658	http://dx.doi.org/10.1038/8658			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331809				2022-12-27	WOS:000080074500034
J	Sime, J				Sime, J			Sustaining the growth of UK biotechnology	NATURE BIOTECHNOLOGY			English	Article									BioInd Assoc, London SW1X 8PS, England		Sime, J (corresponding author), BioInd Assoc, 14-15 Belgrave Sq, London SW1X 8PS, England.							*BIOIND ASS, 1999, IND MARK UK BIOT TRE	1	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					442	443		10.1038/8611	http://dx.doi.org/10.1038/8611			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331799				2022-12-27	WOS:000080074500024
J	Thomson, J				Thomson, J			Funding of human embryo research in the US	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Wisconsin, Madison, WI 53715 USA	University of Wisconsin System; University of Wisconsin Madison	Thomson, J (corresponding author), Univ Wisconsin, 1223 Capitol Court, Madison, WI 53715 USA.	thomson@primate.wisc.edu						*ADV COMM DIR AD H, 1994, REP HUM EMBR RES PAN; Keller G, 1999, NAT MED, V5, P151, DOI 10.1038/5512; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145	3	0	1	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					312	312		10.1038/7826	http://dx.doi.org/10.1038/7826			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207858				2022-12-27	WOS:000079574400002
J	Stein, CA				Stein, CA			Keeping the biotechnology of antisense in context	NATURE BIOTECHNOLOGY			English	Editorial Material							MESSENGER-RNA; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; GROWTH-FACTOR; OLIGONUCLEOTIDES; INHIBITION; EXPRESSION; RECEPTORS; CELLS		Columbia Univ, New York, NY 10027 USA	Columbia University	Stein, CA (corresponding author), Columbia Univ, New York, NY 10027 USA.							Benimetskaya L, 1998, NUCLEIC ACIDS RES, V26, P5310, DOI 10.1093/nar/26.23.5310; Benimetskaya L, 1997, NUCLEIC ACIDS RES, V25, P2648, DOI 10.1093/nar/25.13.2648; DEAN NM, 1994, J BIOL CHEM, V269, P16416; GILES RV, 1995, NUCLEIC ACIDS RES, V23, P954, DOI 10.1093/nar/23.6.954; GILES RV, 1995, BLOOD, V86, P744, DOI 10.1182/blood.V86.2.744.bloodjournal862744; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; Monia BP, 1999, NAT MED, V5, P127, DOI 10.1038/5476; MONIA BP, 1992, J BIOL CHEM, V267, P19954; Neckers LM, 1998, APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY, P147; Rockwell P, 1997, P NATL ACAD SCI USA, V94, P6523, DOI 10.1073/pnas.94.12.6523; Smetsers TFCM, 1996, ANTISENSE NUCLEIC A, V6, P63, DOI 10.1089/oli.1.1996.6.63; Tu GC, 1998, J BIOL CHEM, V273, P25125, DOI 10.1074/jbc.273.39.25125	12	60	80	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					209	209		10.1038/6909	http://dx.doi.org/10.1038/6909			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096271	Bronze			2022-12-27	WOS:000078977500004
J	Drake, PF				Drake, PF			The biotechnology industry's Y2K problem	NATURE BIOTECHNOLOGY			English	Article									Vector Securities Int, Deerfield, IL 60015 USA		Drake, PF (corresponding author), Vector Securities Int, 1751 Lake Cook Rd,Suite 350, Deerfield, IL 60015 USA.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17			S			BE38	BE39		10.1038/4644	http://dx.doi.org/10.1038/4644			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165PD	10052327				2022-12-27	WOS:000078529400018
J	[Anonymous]				[Anonymous]			The board game	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					729	729						1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429261				2022-12-27	WOS:000081751400003
J	Bulyk, ML; Gentalen, E; Lockhart, DJ; Church, GM				Bulyk, ML; Gentalen, E; Lockhart, DJ; Church, GM			Quantifying DNA-protein interactions by double-stranded DNA arrays	NATURE BIOTECHNOLOGY			English	Article						dsDNA arrays; restriction enzymes; DNA-protein interactions	DENSITY OLIGONUCLEOTIDE ARRAYS; ECORI RESTRICTION ENDONUCLEASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; COGNATE DNA; BAM-HI; RECOGNITION; BINDING; GENOME; SEQUENCE	We have created double-stranded oligonucleotide arrays to perform highly parallel investigations of DNA-protein interactions. Arrays of single-stranded DNA oligonucleotides, synthesized by a combination of photolithography and solid-state chemistry, have been used for a variety of applications, including large-scale mRNA expression monitoring, genotyping, and sequence-variation analysis. We converted a single-stranded to a double-stranded array by synthesizing a constant sequence at every position on an array and then annealing and enzymatically extending a complementary primer. The efficiency of second-strand synthesis was demonstrated by incorporation of fluorescently labeled dNTPs (2'-deoxyribonucleoside 5'-triphosphates) and by terminal transferase addition of a fluorescently labeled ddNTP. The accuracy of second-strand synthesis was demonstrated by digestion of the arrayed double-stranded DNA (dsDNA) on the array with sequence-specific restriction enzymes. We showed dam methylation of dsDNA arrays by digestion with Dpnl, which cleaves when its recognition site is methylated. This digestion demonstrated that the dsDNA arrays can be further biochemically modified and that the DNA is accessible for interaction with DNA-binding proteins. This dsDNA array approach could be extended to explore the spectrum of sequence-specific protein binding sites in genomes.	Harvard Univ, Grad Biophys Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Affymetrix, Santa Clara, CA 95051 USA	Harvard University; Harvard University; Harvard Medical School; Affymetrix	Church, GM (corresponding author), Harvard Univ, Grad Biophys Program, Boston, MA 02115 USA.	church@salt2.med.harvard.edu		Gentalen, Erik/0000-0002-7982-2431; church, george/0000-0001-6232-9969				BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; Cho RJ, 1998, P NATL ACAD SCI USA, V95, P3752, DOI 10.1073/pnas.95.7.3752; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DESJARLAIS JR, 1994, P NATL ACAD SCI USA, V91, P11099, DOI 10.1073/pnas.91.23.11099; Engler LE, 1997, J MOL BIOL, V269, P82, DOI 10.1006/jmbi.1997.1027; GEORGE J, 1980, J BIOL CHEM, V255, P6521; Gunderson KL, 1998, GENOME RES, V8, P1142, DOI 10.1101/gr.8.11.1142; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; JANSEN C, 1987, BIOCHEM J, V246, P227, DOI 10.1042/bj2460227; Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156; KUZMIN NP, 1984, MOL BIOL+, V18, P166; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LOCKHART DJ, 1996, Patent No. 5556752; Margulies C, 1996, J BIOL CHEM, V271, P17035, DOI 10.1074/jbc.271.29.17035; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; McGall GH, 1997, J AM CHEM SOC, V119, P5081, DOI 10.1021/ja964427a; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; NASRI M, 1987, NUCLEIC ACIDS RES, V15, P7677, DOI 10.1093/nar/15.19.7677; NEIDHARDT FC, 1996, CELLULAR MOL BIOL, V1; Newman M, 1998, EMBO J, V17, P5466, DOI 10.1093/emboj/17.18.5466; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PANAYOTATOS N, 1989, J BIOL CHEM, V264, P15070; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; POLISKY B, 1975, P NATL ACAD SCI USA, V72, P3310, DOI 10.1073/pnas.72.9.3310; Robison K, 1998, J MOL BIOL, V284, P241, DOI 10.1006/jmbi.1998.2160; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SUZUKI M, 1995, PROTEIN ENG, V8, P329, DOI 10.1093/protein/8.4.329; Swartz DR, 1996, SCANNING MICROSCOPY SUPPLEMENT 10, 1996, P273; Tavazoie S, 1998, NAT BIOTECHNOL, V16, P566, DOI 10.1038/nbt0698-566; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; THIELKING V, 1990, BIOCHEMISTRY-US, V29, P4682, DOI 10.1021/bi00471a024; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; WOODBURY CP, 1983, BIOCHEMISTRY-US, V22, P4730, DOI 10.1021/bi00289a018	47	194	229	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					573	577		10.1038/9878	http://dx.doi.org/10.1038/9878			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385322				2022-12-27	WOS:000080716500029
J	Biragyn, A; Tani, K; Grimm, MC; Weeks, S; Kwak, LW				Biragyn, A; Tani, K; Grimm, MC; Weeks, S; Kwak, LW			Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity	NATURE BIOTECHNOLOGY			English	Article						interferon inducible protein 10; monocyte chemotactic protein 3; chemokine fusion; antigen presenting cell targeting; idiotypic vaccine	MONOCYTE CHEMOTACTIC PROTEIN-3; DNA IMMUNIZATION; LEUKOCYTE MIGRATION; LYMPHOMA; ANTIBODY; RECEPTOR; VACCINATION; ENDOCYTOSIS; VACCINES; BINDING	We converted a model, syngeneic, nonimmunogenic tumor antigen into a vaccine by fusing it with a proinflammatory chemokine. Two chemokines, interferon inducible protein 10 and monocyte chemotactic protein 3, were fused to lymphoma Ig variable regions (sFv). The sFv-chemokine fusion proteins elicited chemotactic responses in vitro and induced inflammatory responses in vivo. Furthermore, in two independent models, vaccination with DNA constructs encoding the corresponding fusions generated superior protection against a large tumor challenge (20 times the minimum lethal dose), as compared with the best available protein vaccines. Immunity was not elicited by controls, including fusions with irrelevant sFv; fusions with a truncated chemokine that lacked receptor binding and chemotactic activity; mixtures of free chemokine and sFv proteins; or naked DNA plasmid vaccines encoding unlinked sFv and chemokine. The requirement for linkage of conformationally intact sFv and functionally active chemokine strongly suggested that the mechanism underlying these effects was the novel targeting of antigen presenting cells (APC) for chemokine receptor-mediated uptake of antigen, rather than the simple recruitment of APC to tumor by the chemokine. Finally, in addition to superior potency, these fusions were distinguished from lymphoma Ig fusions with granulocyte-macrophage colony-stimulating factor or other cytokines by their induction of critical effector T cells.	NCI, Dept Expt Transplantat & Immunol, Med Branch, Div Clin Sci, Bethesda, MD 20892 USA; NCI, Sci Applicat Int Corp, Frederick, MD 21702 USA; NCI, Mol Immunoregulat Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kwak, LW (corresponding author), NCI, Dept Expt Transplantat & Immunol, Med Branch, Div Clin Sci, Bethesda, MD 20892 USA.	kwak@mail.ncifcrf.gov		Kwak, Larry/0000-0002-1884-5349; Grimm, Michael/0000-0001-9426-3917	OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGMAN Y, 1977, EUR J IMMUNOL, V7, P413, DOI 10.1002/eji.1830070702; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; Boyle JS, 1998, NATURE, V392, P408, DOI 10.1038/32932; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; CHENG L, 1993, P NATL ACAD SCI USA, V90, P4455, DOI 10.1073/pnas.90.10.4455; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; Feltquate DM, 1997, J IMMUNOL, V158, P2278; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; Haelens A, 1996, IMMUNOBIOLOGY, V195, P499, DOI 10.1016/S0171-2985(96)80019-2; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; HUSTON JS, 1991, METHOD ENZYMOL, V203, P46; Irvine KR, 1996, J IMMUNOL, V156, P238; KAMINSKI MS, 1987, J IMMUNOL, V138, P1289; KIM KJ, 1979, J IMMUNOL, V122, P549; King CA, 1998, NAT MED, V4, P1281, DOI 10.1038/3266; KRUISBEEK AM, 1994, CURRENT PROTOCOLS IM; Kwak LW, 1996, P NATL ACAD SCI USA, V93, P10972, DOI 10.1073/pnas.93.20.10972; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; KWAK LW, 1995, LANCET, V345, P1016, DOI 10.1016/S0140-6736(95)90757-2; Liu MA, 1997, P NATL ACAD SCI USA, V94, P10496, DOI 10.1073/pnas.94.20.10496; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; *NIH, 1985, PUBL NIH, V8623; OHMORI Y, 1990, BIOCHEM BIOPH RES CO, V168, P1261, DOI 10.1016/0006-291X(90)91164-N; Prado GN, 1996, J BIOL CHEM, V271, P19186, DOI 10.1074/jbc.271.32.19186; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Solari R, 1997, J BIOL CHEM, V272, P9617; STEVENSON FK, 1995, IMMUNOL REV, V145, P211, DOI 10.1111/j.1600-065X.1995.tb00083.x; STEVENSON GT, 1975, NATURE, V254, P714, DOI 10.1038/254714a0; Streiter RM, 1995, J BIOL CHEM, V270, P27348; Syrengelas AD, 1996, NAT MED, V2, P1038, DOI 10.1038/nm0996-1038; TAO MH, 1993, NATURE, V362, P755, DOI 10.1038/362755a0; THIRION S, 1994, BIOCHEM BIOPH RES CO, V201, P493, DOI 10.1006/bbrc.1994.1729; Wu YQ, 1997, J IMMUNOL, V159, P6037; XU LL, 1995, EUR J IMMUNOL, V25, P2612, DOI 10.1002/eji.1830250931	36	232	269	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					253	258		10.1038/6995	http://dx.doi.org/10.1038/6995			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096292	Bronze			2022-12-27	WOS:000078977500026
J	Altamirano, MM; Garcia, C; Possani, LD; Fersht, AR				Altamirano, MM; Garcia, C; Possani, LD; Fersht, AR			Oxidative refolding chromatography: folding of the scorpion toxin Cn5	NATURE BIOTECHNOLOGY			English	Article						minichaperone; DsbA; GroEL; peptidyl-prolyl isomerase; disulfide; renaturation	PROTEIN DISULFIDE-ISOMERASE; FORMATION IN-VIVO; ANDROCTONUS-AUSTRALIS HECTOR; SITE CYSTEINE RESIDUES; BOND FORMATION INVIVO; ESCHERICHIA-COLI; GLUCOSAMINE-6-PHOSPHATE DEAMINASE; MOLECULAR CHAPERONES; FUNCTIONAL-ROLE; VICINAL THIOLS	We have made an immobilized and reusable molecular chaperone system for oxidative refolding chromatography. Its three components-GroEL minichaperone (191-345), which can prevent protein aggregation; DsbA, which catalyzes the shuffling and oxidative formation of disulfide bonds; and peptidyl-prolyl isomerase-were immobilized on an agarose gel. The gel was applied to the refolding of denatured and reduced scorpion toxin Cn5. The 66-residue toxin, which has four disulfide bridges and a cis peptidyl-proline bond, had not previously been refolded in reasonable yield. We recovered an 87% yield of protein with 100% biological activity.	Cambridge Ctr Prot Engn, Cambridge CB2 2QH, England; Univ Cambridge, Chem Lab, MRC Ctr, Cambridge CB2 2QH, England; Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Mexico City 04510, DF, Mexico; Univ Nacl Autonoma Mexico, Inst Biotechnol, Dept Mol Recognit & Struct Biol, Cuernavaca 62210, Morelos, Mexico	University of Cambridge; MRC Laboratory Molecular Biology; University of Cambridge; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Fersht, AR (corresponding author), Cambridge Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.	arf10@cam.ac.uk	Possani, Lourival D/J-2397-2013; Fersht, Alan R/B-2189-2008					AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; ALTAMIRANO MM, 1989, ARCH BIOCHEM BIOPHYS, V269, P555, DOI 10.1016/0003-9861(89)90140-9; Altamirano MM, 1997, P NATL ACAD SCI USA, V94, P3576, DOI 10.1073/pnas.94.8.3576; ALTAMIRANO MM, 1992, BIOCHEMISTRY-US, V31, P1153, DOI 10.1021/bi00119a026; Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BUCHNER J, 1992, BIO-TECHNOL, V10, P682, DOI 10.1038/nbt0692-682; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; BULEID NJ, 1993, ACCESSORY PROTEINS, P125; Chatellier J, 1998, P NATL ACAD SCI USA, V95, P9861, DOI 10.1073/pnas.95.17.9861; Clark EDB, 1998, CURR OPIN BIOTECH, V9, P157; CREIGHTON T. E., 1985, UCLA S MOL CELLULAR, V39, P249; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; ELLIS JR, 1996, CHAPERONINS, P1; FLORENCE TM, 1980, BIOCHEM J, V189, P507, DOI 10.1042/bj1890507; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1991, CONFORMATIONS FORCES, P204; Freedman Robert B., 1992, P455; Garcia C, 1997, COMP BIOCHEM PHYS B, V116, P315, DOI 10.1016/S0305-0491(96)00246-5; Golbik R, 1998, J MOL BIOL, V276, P505, DOI 10.1006/jmbi.1997.1538; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hennecke J, 1997, BIOCHEMISTRY-US, V36, P6391, DOI 10.1021/bi963017w; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P6350, DOI 10.1021/bi00186a039; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; LORET EP, 1991, BIOCHEMISTRY-US, V30, P633, DOI 10.1021/bi00217a007; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MATOUSCHEK A, 1995, P NATL ACAD SCI USA, V92, P6319, DOI 10.1073/pnas.92.14.6319; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MORJANA NA, 1994, PROTEIN EXPRES PURIF, V5, P144, DOI 10.1006/prep.1994.1022; Muronetz VI, 1998, FEBS LETT, V426, P107, DOI 10.1016/S0014-5793(98)00319-6; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; SABATIER JM, 1987, INT J PEPT PROT RES, V30, P125; SCHMID FX, 1993, ADV PROTEIN CHEM, V44, P25, DOI 10.1016/S0065-3233(08)60563-X; Stempfer G, 1996, NAT BIOTECHNOL, V14, P329, DOI 10.1038/nbt0396-329; Thomas JG, 1997, APPL BIOCHEM BIOTECH, V66, P197, DOI 10.1007/BF02785589; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, BIOCHEMISTRY-US, V32, P12251, DOI 10.1021/bi00096a039; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P1907, DOI 10.1021/bi00173a038; Zilberberg N, 1996, BIOCHEMISTRY-US, V35, P10215, DOI 10.1021/bi9528309	48	110	134	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					187	191		10.1038/6192	http://dx.doi.org/10.1038/6192			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052357				2022-12-27	WOS:000078508300029
J	Breithaupt, H				Breithaupt, H			The new antibiotics	NATURE BIOTECHNOLOGY			English	Article							GENES											Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Hancock REW, 1998, CURR OPIN MICROBIOL, V1, P493, DOI 10.1016/S1369-5274(98)80079-9; HARVEY J, 1998, USE MISUSE ANTIBIO 1; STROHL WR, 1997, BIOTECHNOLOGY ANTIBI; Valdivia RH, 1997, SCIENCE, V277, P2007, DOI 10.1126/science.277.5334.2007; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833	8	86	106	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1165	1169		10.1038/70705	http://dx.doi.org/10.1038/70705			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585711				2022-12-27	WOS:000084170700020
J	Khan, MS; Maliga, P				Khan, MS; Maliga, P			Fluorescent antibiotic resistance marker for tracking plastid transformation in higher plants	NATURE BIOTECHNOLOGY			English	Article						aminoglycoside 3 ''-adenylyl transferase; green fluorescent protein; plastid transformation; rice; spectinomycin and streptomycin resistance; tobacco	CHLOROPLAST GENOME; NICOTIANA-TABACUM; VITAL MARKER; PROTEIN; TOBACCO; GENE; EXPRESSION; GFP; PROTOPLASTS; CELLS	Plastid transformation in higher plants is accomplished through a gradual process, during which all the 300-10,000 plastid genome copies are uniformly altered. Antibiotic resistance genes incorporated in the plastid genome facilitate maintenance of transplastomes during this process. Given the high number of plastid genome copies in a cell, transformation unavoidably yields chimeric tissues, which requires the identification of transplastomic cells in order to regenerate plants. In the chimeric tissue, however, antibiotic resistance is not cell autonomous: transplastomic and wild-type sectors both have a resistant phenotype because of phenotypic masking by the transgenic cells. We report a system of marker genes for plastid transformation, termed FLARE-S, which is obtained by translationally fusing aminoglycoside 3"-adenyltransferase with the Aequorea victoria green fluorescent protein. 3"-adenyltransferase (FLARE-S) confers resistance to both spectinomycin and streptomycin. The utility of FLARE-S is shown by tracking segregation of individual transformed and wild-type plastids in tobacco and rice plants after bombardment with FLARE-S vector DNA and selection for spectinomycin and streptomycin resistance, respectively. This method facilitates the extension of plastid transformation to nongreen plastids in embryogenic cells of cereal crops.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Maliga, P (corresponding author), Rutgers State Univ, Waksman Inst, 190 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	maliga@waksman.rutgers.edu	khan, Muhammad Sarwar/F-4370-2015; Khan, Muhammad Sarwar/Q-8307-2019	Khan, Muhammad Sarwar/0000-0001-7194-8622				BAULCOMBE DC, 1995, PLANT J, V7, P1045, DOI 10.1046/j.1365-313X.1995.07061045.x; BENDICH AJ, 1987, BIOESSAYS, V6, P279, DOI 10.1002/bies.950060608; CARRER H, 1993, MOL GEN GENET, V241, P49, DOI 10.1007/BF00280200; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHINAULT AC, 1986, PLASMID, V15, P119, DOI 10.1016/0147-619X(86)90048-X; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Daniell H, 1998, NAT BIOTECHNOL, V16, P345, DOI 10.1038/nbt0498-345; Davis SJ, 1998, PLANT MOL BIOL, V36, P521, DOI 10.1023/A:1005991617182; Epel BL, 1996, GENE, V173, P75, DOI 10.1016/0378-1119(95)00678-8; FROMM H, 1987, EMBO J, V6, P3233, DOI 10.1002/j.1460-2075.1987.tb02640.x; GOLDS T, 1993, BIO-TECHNOL, V11, P95, DOI 10.1038/nbt0193-95; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Hibberd JM, 1998, PLANT J, V16, P627, DOI 10.1046/j.1365-313x.1998.00328.x; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; Kohler RH, 1997, SCIENCE, V276, P2039, DOI 10.1126/science.276.5321.2039; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Koop HU, 1996, PLANTA, V199, P193, DOI 10.1007/BF00196559; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maliga P, 1998, TRENDS PLANT SCI, V3, P4, DOI 10.1016/S1360-1385(97)87981-2; MALIGA P, 1993, TRENDS BIOTECHNOL, V11, P101, DOI 10.1016/0167-7799(93)90059-I; Misteli T, 1997, NAT BIOTECHNOL, V15, P961, DOI 10.1038/nbt1097-961; MOLL B, 1990, MOL GEN GENET, V221, P245, DOI 10.1007/BF00261727; MULLER AJ, 1978, MOL GEN GENET, V161, P67, DOI 10.1007/BF00266616; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; ONEILL C, 1993, PLANT J, V3, P729, DOI 10.1111/j.1365-313X.1993.00729.x; Pang SZ, 1996, PLANT PHYSIOL, V112, P893, DOI 10.1104/pp.112.3.893; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; PRASHER DC, 1995, TRENDS GENET, V11, P320, DOI 10.1016/S0168-9525(00)89090-3; Reichel C, 1996, P NATL ACAD SCI USA, V93, P5888, DOI 10.1073/pnas.93.12.5888; Rouwendal GJA, 1997, PLANT MOL BIOL, V33, P989, DOI 10.1023/A:1005740823703; SHEEN J, 1995, PLANT J, V8, P777, DOI 10.1046/j.1365-313X.1995.08050777.x; Sikdar SR, 1998, PLANT CELL REP, V18, P20, DOI 10.1007/s002990050525; STAUB JM, 1993, EMBO J, V12, P601, DOI 10.1002/j.1460-2075.1993.tb05692.x; SVAB Z, 1993, P NATL ACAD SCI USA, V90, P913, DOI 10.1073/pnas.90.3.913; SVAB Z, 1990, P NATL ACAD SCI USA, V87, P8526, DOI 10.1073/pnas.87.21.8526; THOMPSON JA, 1986, PLANT SCI, V47, P123, DOI 10.1016/0168-9452(86)90059-2; ZHANG W, 1988, THEOR APPL GENET, V76, P835, DOI 10.1007/BF00273668; ZOUBENKO OV, 1994, NUCLEIC ACIDS RES, V22, P3819, DOI 10.1093/nar/22.19.3819; [No title captured]	42	175	231	0	23	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					910	915		10.1038/12907	http://dx.doi.org/10.1038/12907			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471936				2022-12-27	WOS:000082365800036
J	Dibner, MD				Dibner, MD			Career alternatives for scientists - More than ever, young PhDs are looking to the biotechnology industry as their first option.	NATURE BIOTECHNOLOGY			English	Editorial Material									LLC & Strateg Outcomes Serv Inc, Inst Biotechnol Informat, Res Triangle Pk, NC 27709 USA		Dibner, MD (corresponding author), LLC & Strateg Outcomes Serv Inc, Inst Biotechnol Informat, POB 14569, Res Triangle Pk, NC 27709 USA.								0	0	0	2	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					825	825		10.1038/11783	http://dx.doi.org/10.1038/11783			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429256	Bronze			2022-12-27	WOS:000081751400037
J	Coulter, D				Coulter, D			Continuing education and networking in the workplace	NATURE BIOTECHNOLOGY			English	Editorial Material									LG Biomed Inst, La Jolla, CA 92037 USA		Coulter, D (corresponding author), LG Biomed Inst, 3252 Holiday Court,Suite 101, La Jolla, CA 92037 USA.								0	0	0	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					503	503		10.1038/8686	http://dx.doi.org/10.1038/8686			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331814				2022-12-27	WOS:000080074500039
J	Persidis, A; Copen, RM				Persidis, A; Copen, RM			Mental disorder drug discovery	NATURE BIOTECHNOLOGY			English	Article									Argonex Inc, Business Dev, Charlottesville, VA 22901 USA		Persidis, A (corresponding author), Argonex Inc, Business Dev, 2044 India Rd, Charlottesville, VA 22901 USA.							Engstrom F, 1997, POSTGRAD MED, V101, P198, DOI 10.3810/pgm.1997.03.174; Farber NB, 1998, PROG BRAIN RES, V116, P421, DOI 10.1016/S0079-6123(08)60453-7; Fleischhacker WW, 1997, DRUGS, V53, P915, DOI 10.2165/00003495-199753060-00002; Ito H, 1999, J NUCL MED, V40, P102; *NAT I MENT HLTH G, 1998, GEN MENT DIS REP NAT; Nemeroff CB, 1998, BIOL PSYCHIAT, V44, P517; Peroutka SJ, 1998, ANN NY ACAD SCI, V861, P16, DOI 10.1111/j.1749-6632.1998.tb10168.x; Persidis A, 1998, NAT BIOTECHNOL, V16, P209, DOI 10.1038/nbt0298-209; Schou M, 1997, ARCH GEN PSYCHIAT, V54, P9; Schwarz MJ, 1998, EUR ARCH PSY CLIN N, V248, P282, DOI 10.1007/s004060050051	10	2	2	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					307	309		10.1038/7073	http://dx.doi.org/10.1038/7073			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096303				2022-12-27	WOS:000078977500036
J	Ostermeier, M; Shim, JH; Benkovic, SJ				Ostermeier, M; Shim, JH; Benkovic, SJ			A combinatorial approach to hybrid enzymes independent of DNA homology	NATURE BIOTECHNOLOGY			English	Article						incremental truncation; DNA shuffling; hybrid enzymes; in vitro evolution; glycinade ribonucleotide transformylase	GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; IN-VITRO RECOMBINATION; MOLECULAR EVOLUTION; DIRECTED EVOLUTION; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; KINETIC MECHANISM; RANDOM INSERTION; PROTEIN; MUTAGENESIS	We present a methodology, termed incremental truncation for the creation of hybrid enzymes (ITCHY), that creates combinatorial fusion libraries between genes in a manner that is independent of DNA homology. We compared the ability of ITCHY and DNA shuffling to create interspecies fusion libraries between fragments of the Escherichia coli and human glycinamide ribonucleotide transformylase genes, which have only 50% identity on the DNA level. Sequencing of several randomly selected positives from each library illustrated that ITCHY identified a more diverse set of active fusion points including those in regions of nonhomology and those with crossover points that diverged from the sequence alignment. Furthermore, some of the hybrids found by ITCHY that were fused at nonhomologous locations had activities that were greater than or equal to the activity of the hybrids found by DNA shuffling.	Penn State Univ, Dept Chem, Wartik Lab 414, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Benkovic, SJ (corresponding author), Penn State Univ, Dept Chem, Wartik Lab 414, University Pk, PA 16802 USA.	sjb1@psu.edu	Ostermeier, Marc/A-2697-2010	Ostermeier, Marc/0000-0003-0900-3665	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024129, R01GM024129] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24129, GM18560] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIMI J, 1990, NUCLEIC ACIDS RES, V18, P6665, DOI 10.1093/nar/18.22.6665; ALMASSY RJ, 1992, P NATL ACAD SCI USA, V89, P6114, DOI 10.1073/pnas.89.13.6114; Arnold F H, 1997, Adv Biochem Eng Biotechnol, V58, P1; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Betton JM, 1997, NAT BIOTECHNOL, V15, P1276, DOI 10.1038/nbt1197-1276; Biondi RM, 1998, NUCLEIC ACIDS RES, V26, P4946, DOI 10.1093/nar/26.21.4946; Bogarad LD, 1999, P NATL ACAD SCI USA, V96, P2591, DOI 10.1073/pnas.96.6.2591; Buchholz F, 1998, NAT BIOTECHNOL, V16, P657, DOI 10.1038/nbt0798-657; Caperelli CA, 1997, ARCH BIOCHEM BIOPHYS, V341, P98, DOI 10.1006/abbi.1997.9947; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; Hallet B, 1997, NUCLEIC ACIDS RES, V25, P1866, DOI 10.1093/nar/25.9.1866; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hopfner KP, 1998, P NATL ACAD SCI USA, V95, P9813, DOI 10.1073/pnas.95.17.9813; Joo H, 1999, NATURE, V399, P670, DOI 10.1038/21395; KAN CC, 1992, J PROTEIN CHEM, V11, P467, DOI 10.1007/BF01025023; Nixon AE, 1997, P NATL ACAD SCI USA, V94, P1069, DOI 10.1073/pnas.94.4.1069; Nixon AE, 1998, TRENDS BIOTECHNOL, V16, P258, DOI 10.1016/S0167-7799(98)01204-9; Ostermeier M, 1999, BIOORGAN MED CHEM, V7, P2139, DOI 10.1016/S0968-0896(99)00143-1; Ostermeier M, 1999, P NATL ACAD SCI USA, V96, P3562, DOI 10.1073/pnas.96.7.3562; Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457; Shao ZX, 1998, NUCLEIC ACIDS RES, V26, P681, DOI 10.1093/nar/26.2.681; Shim JH, 1998, BIOCHEMISTRY-US, V37, P8776, DOI 10.1021/bi980244k; SMITH JM, 1987, J BIOL CHEM, V262, P10565; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; TOMB JF, 1989, BIOTECHNIQUES, V7, P932; Varney MD, 1997, J MED CHEM, V40, P2502, DOI 10.1021/jm9607459; Warren MS, 1996, BIOCHEMISTRY-US, V35, P8855, DOI 10.1021/bi9528715; WU R, 1976, BIOCHEMISTRY-US, V15, P734, DOI 10.1021/bi00649a003; ZEBALA J, 1991, GENE, V100, P51, DOI 10.1016/0378-1119(91)90349-G; Zhang JH, 1997, P NATL ACAD SCI USA, V94, P4504, DOI 10.1073/pnas.94.9.4504; Zhao HM, 1997, NUCLEIC ACIDS RES, V25, P1307, DOI 10.1093/nar/25.6.1307; Zhao HM, 1999, PROTEIN ENG, V12, P47, DOI 10.1093/protein/12.1.47; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	36	184	307	0	44	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1205	1209		10.1038/70754	http://dx.doi.org/10.1038/70754			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585719				2022-12-27	WOS:000084170700029
J	Wildt, S; Deuschle, U				Wildt, S; Deuschle, U			cobA, a red fluorescent transcriptional reporter for Escherichia coli, yeast, and mammalian cells	NATURE BIOTECHNOLOGY			English	Article						reporter gene; red fluorescence; cobA; uroporphyrinogen III methyltransferase	UROPORPHYRINOGEN-III METHYLTRANSFERASE; GENE-EXPRESSION; FISSION YEAST; ARABIDOPSIS; PROTEIN; BIOSYNTHESIS; LUCIFERASE; METHYLASE; SELECTION; SIROHEME	We demonstrate the use of Propionibacterium freudenreichii uroporphyrinogen III methyltransferase (cobA) as a reporter of gene expression in Escherichia coli, fission yeast, and mammalian cells. Overexpression of cobA in cells resulted in bright red fluorescence that was visualized with standard fluorescence microscopy and fluorescence-activated cell sorting analysis at the single-cell level. As with green fluorescent protein (GFP), no addition of exogenous substrate was required. When expressed in Chinese hamster ovary cells from a bicistronic transcript cobA and GFP gave rise to fluorescence signals of similar intensity. The bright red fluorescence generated by the cobA reporter promises a better signal-to-noise ratio than blue and green fluorescent reporter systems, as autofluorescence and light scattering of cells, media, and materials are reduced in the red wavelengths.	Hoffmann La Roche Ag, Div Pharma, Preclin CNS Res & GeneTechnol, CH-4002 Basel, Switzerland	Roche Holding	Deuschle, U (corresponding author), Hoffmann La Roche Ag, Div Pharma, Preclin CNS Res & GeneTechnol, CH-4002 Basel, Switzerland.	ulrich.deuschle@roche.com						AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHOU PL, 1995, BIOSCI BIOTECH BIOCH, V59, P1817, DOI 10.1271/bbb.59.1817; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DIRKS W, 1993, GENE, V128, P247, DOI 10.1016/0378-1119(93)90569-O; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOULD SJ, 1988, ANAL BIOCHEM, V175, P5, DOI 10.1016/0003-2697(88)90353-3; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Leustek T, 1997, J BIOL CHEM, V272, P2744, DOI 10.1074/jbc.272.5.2744; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; MORENO S, 1991, METHOD ENZYMOL, V194, P795; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Plautz JD, 1996, GENE, V173, P83, DOI 10.1016/0378-1119(95)00700-8; Raux E, 1999, BIOCHEM J, V338, P701, DOI 10.1042/0264-6021:3380701; ROESSNER CA, 1995, BIOTECHNIQUES, V19, P760; Sakakibara H, 1996, PLANT J, V10, P883, DOI 10.1046/j.1365-313X.1996.10050883.x; SATTLER I, 1995, J BACTERIOL, V177, P1564, DOI 10.1128/jb.177.6.1564-1569.1995; SCOTT AI, 1994, CIBA F SYMP, V180, P285; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; Tsien RY, 1999, NAT BIOTECHNOL, V17, P956, DOI 10.1038/13648; WARREN MJ, 1990, BIOCHEM J, V265, P725, DOI 10.1042/bj2650725; YOON K, 1988, GENE, V66, P11, DOI 10.1016/0378-1119(88)90220-X; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	27	35	46	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1175	1178		10.1038/70713	http://dx.doi.org/10.1038/70713			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585713				2022-12-27	WOS:000084170700023
J	Singh-Gasson, S; Green, RD; Yue, YJ; Nelson, C; Blattner, F; Sussman, MR; Cerrina, F				Singh-Gasson, S; Green, RD; Yue, YJ; Nelson, C; Blattner, F; Sussman, MR; Cerrina, F			Maskless fabrication of light-directed oligonucleotide microarrays using a digital micromirror array	NATURE BIOTECHNOLOGY			English	Article						oligonucleotide microarrays; digital micromirror device; DNA chips; maskless lithography; I-line; ultraviolet; optical lithography		Oligonucleotide microarrays, also called "DNA chips," are currently made by a light-directed chemistry that requires a large number of photolithographic masks for each chip. Here we describe a maskless array synthesizer (MAS) that replaces the chrome masks with virtual masks generated on a computer, which are relayed to a digital micromirror array. A 1:1 reflective imaging system forms an ultraviolet image of the virtual mask on the active surface of the glass substrate, which is mounted in a flow cell reaction chamber connected to a DNA synthesizer. Programmed chemical coupling cycles follow light exposure, and these steps are repeated with different virtual masks to grow desired oligonucleotides in a selected pattern. This instrument has been used to synthesize oligonucleotide microarrays containing more than 76,000 features measuring 16 mu m(2). The oligonucleotides were synthesized at high repetitive yield and, after hybridization, could readily discriminate single-base pair mismatches. The MAS is adaptable to the fabrication of DNA chips containing probes for thousands of genes, as well as any other solid-phase combinatorial chemistry to be performed in high-density microarrays.	Univ Wisconsin, Ctr Biotechnol, Madison, WI 53706 USA; Univ Wisconsin, Dept Elect & Comp Engn, Ctr Nanotechnol, Madison, WI 53706 USA; Univ Wisconsin, Ctr Environm Toxicol, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Biol Program, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Sussman, MR (corresponding author), Univ Wisconsin, Ctr Biotechnol, Madison, WI 53706 USA.			Nelson, Clark/0000-0002-8796-8326				Cadet J., 1990, BIOORGANIC PHOTOCHEM, V1, P1; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GOVE RJ, 1997, TEXAS INSTRUMENTS WH; McGall GH, 1997, J AM CHEM SOC, V119, P5081, DOI 10.1021/ja964427a; OFFNER A, 1975, OPT ENG, V14, P130, DOI 10.1117/12.7978742; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; SAMPSELL JB, 1994, J VAC SCI TECHNOL B, V12, P3242, DOI 10.1116/1.587506; SMITH WJ, 1990, MODERN OPTICAL ENG, P345; WELFORD WT, 1991, USEFUL OPTICS	9	523	656	6	104	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					974	978		10.1038/13664	http://dx.doi.org/10.1038/13664			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504697				2022-12-27	WOS:000083015700022
J	Anthony, RG; Reichelt, S; Hussey, PJ				Anthony, RG; Reichelt, S; Hussey, PJ			Dinitroaniline herbicide-resistant transgenic tobacco plants generated by co-overexpression of a mutant alpha-tubulin and a beta-tubulin	NATURE BIOTECHNOLOGY			English	Article						dinitroaniline herbicide resistance; alpha- and beta-tubulin; microtubules; transgenic tobacco	ELEUSINE-INDICA; GENES	Dinitroaniline herbicides are used for the selective control of weeds in arable crops. Dinitroaniline herbicide resistance in the invasive weed goosegrass was previously shown to stem from a spontaneous mutation in an alpha-tubulin gene. We transformed and regenerated tobacco plants with an alpha/beta-tubulin double gene construct containing the mutant a-tubulin gene and showed that expression of this construct confers a stably inherited dinitroaniline-resistant phenotype in tobacco. In all transformed lines, the transgene alpha- and beta-tubulins increased the cytoplasmic pool of tubulin approximately 1.5-fold while repressing endogenous alpha- and beta-tubulin synthesis by up to 45% in some tissues. Transgene alpha- and beta-tubulin were overexpressed in every plant tissue analyzed and comprised approximately 66% of the total tubulin in these tissues. Immunolocalization studies revealed that transgene alpha- and beta-tubulins were incorporated into all four microtubule arrays, indicating that they are functional. The majority of the alpha/beta-tubulin pools are encoded by the transgenes, which implies that the mutant alpha-tubulin and the beta-tubulin can perform the majority, if not all, of the roles of microtubules in both juvenile and adult tobacco plants.	Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England	University of London; Royal Holloway University London	Hussey, PJ (corresponding author), Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England.			Hussey, Patrick/0000-0002-7349-8722; Reichelt, Stefanie/0000-0003-4151-0712				Anthony RG, 1998, PLANT J, V16, P297, DOI 10.1046/j.1365-313x.1998.00296.x; Anthony RG, 1999, TRENDS PLANT SCI, V4, P112, DOI 10.1016/S1360-1385(99)01378-3; Anthony RG, 1998, NATURE, V393, P260, DOI 10.1038/30484; APPLEBY AP, 1989, WEED TECHNOL, V3, P198, DOI 10.1017/S0890037X00031626; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Cleveland Don W., 1994, V13, P47; CRONIN KE, 1993, Patent No. 24637; Doyle JJ, 1987, PHYTOCHEM B, V19, P11, DOI 10.1016/j.bse.2009.07.003; ELLIS JR, 1994, PLANT PHYSIOL, V105, P15, DOI 10.1104/pp.105.1.15; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GonzalezGaray ML, 1996, J CELL BIOL, V135, P1525, DOI 10.1083/jcb.135.6.1525; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HUSSEY PJ, 1990, PLANT MOL BIOL, V15, P957, DOI 10.1007/BF00039438; HUSSEY PJ, 1985, FEBS LETT, V181, P131; MOREJOHN LC, 1987, PLANTA, V172, P252, DOI 10.1007/BF00394595; MUDGE LC, 1984, WEED SCI, V32, P591, DOI 10.1017/S0043174500059610; Raff Elizabeth C., 1994, V13, P85; Smertenko A, 1997, PLANTA, V201, P349, DOI 10.1007/s004250050077; SUMIDA S, 1976, PLANT CELL PHYSIOL, V17, P1351; VAUGHN KC, 1987, PLANT PHYSIOL, V83, P956, DOI 10.1104/pp.83.4.956; WALDIN TR, 1992, PLANTA, V188, P258, DOI 10.1007/BF00216822; Yamamoto E, 1998, PLANT CELL, V10, P297, DOI 10.1105/tpc.10.2.297	22	34	37	5	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					712	716		10.1038/10931	http://dx.doi.org/10.1038/10931			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404167				2022-12-27	WOS:000081296900034
J	Scott, SE; Wilkinson, MJ				Scott, SE; Wilkinson, MJ			Low probability of chloroplast movement from oilseed rape (Brassica napus) into wild Brassica rapa	NATURE BIOTECHNOLOGY			English	Article						transplastomic crops; genetic modification; risk assessment; Brassica napus; chloroplast transformation	TRANSGENIC PLANTS; INHERITANCE; CONTAINMENT; RESISTANCE; PANACEA; DNA	Pollen-mediated movement of transgenes from transplastomic oilseed rape (Brassica napus) into wild relatives will be avoided if chloroplasts are maternally transmitted. We assess the probability of chloroplast exchange between conventional oilseed rape and wild Brassica rapa to model the future behavior of transplastomic cultivars. Primers specific to cpDNA were used to demonstrate maternal inheritance of chloroplasts in 47 natural hybrids between cultivated B. napus and wild B. rapa. We conclude that there will be no or negligible pollen-mediated chloroplast dispersal from oilseed rape. Transgene introgression could still occur in mixed populations, however, if B. napus acted as the recurrent female parent. Rate of transfer would then depend on the abundance of mixed populations, their persistence as mixtures, and hybridization frequency within stands. A low incidence of sympatry (0.6-0.7%) between wild B. rapa and cultivated B. napus along the river Thames, UK, in 1997 and 1998, suggests mixed stands will form only rarely. Eighteen feral populations of B. napus also showed a strong tendency toward rapid decline in plant number, seed return, and ultimately, extinction within 3 years, Conversely, hybrid production is significant in mixed stands, and the absence of control practices means that oilseed rape will have slightly greater persistence. We infer that some introgression from transplastomic B. napus into B. rapa is inevitable in mixed populations even though such populations will occur infrequently and will tend to lose B. napus plants relatively quickly. Chloroplast exchange will be extremely rare and scattered.	Univ Reading, Sch Plant Sci, Dept Agr Bot, Reading RG6 6AS, Berks, England	University of Reading	Wilkinson, MJ (corresponding author), Univ Reading, Sch Plant Sci, Dept Agr Bot, POB 221, Reading RG6 6AS, Berks, England.	M.J.Wilkinson@reading.ac.uk		Wilkinson, Michael/0000-0002-9881-6993				CORRIVEAU JL, 1988, AM J BOT, V75, P1443, DOI 10.2307/2444695; CRAWLEY MJ, 1995, P R SOC LOND B, V259, P45; Cummins JE, 1998, NAT BIOTECHNOL, V16, P401, DOI 10.1038/nbt0598-401b; Daniell H, 1998, NAT BIOTECHNOL, V16, P345, DOI 10.1038/nbt0498-345; Daniell H, 1998, NAT BIOTECHNOL, V16, P602, DOI 10.1038/nbt0798-602; ERICKSON L, 1990, MOL GEN GENET, V222, P135, DOI 10.1007/BF00283034; Gray AJ, 1998, NATURE, V392, P653, DOI 10.1038/33537; JURGENSEN RB, 1998, ACTA HORTIC, V407, P193; Robert S, 1998, NATURE, V395, P25, DOI 10.1038/25628; SCHEFFLER JA, 1994, TRANSGENIC RES, V3, P263, DOI 10.1007/BF01973586; Scott SE, 1998, NATURE, V393, P320, DOI 10.1038/30642; Stewart CN, 1998, NAT BIOTECHNOL, V16, P401, DOI 10.1038/nbt0598-401a; TABERLET P, 1991, PLANT MOL BIOL, V17, P1105, DOI 10.1007/BF00037152; Wilkinson MJ, 1995, PROC BRIGHTON CROP, P1035	14	92	116	0	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					390	392		10.1038/7952	http://dx.doi.org/10.1038/7952			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207890				2022-12-27	WOS:000079574400030
J	Purcell, DJ				Purcell, DJ			Financing biotechnology in an inefficient market	NATURE BIOTECHNOLOGY			English	Article									Hambrecht & Quist LLC, New York, NY 10169 USA		Purcell, DJ (corresponding author), Hambrecht & Quist LLC, 230 Pk Ave, New York, NY 10169 USA.								0	2	2	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17			S			BE31	BE32		10.1038/4640	http://dx.doi.org/10.1038/4640			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165PD	10052324				2022-12-27	WOS:000078529400015
J	Redfern, CH; Coward, P; Degtyarev, MY; Lee, EK; Kwa, AT; Hennighausen, L; Bujard, H; Fishman, GI; Conklin, BR				Redfern, CH; Coward, P; Degtyarev, MY; Lee, EK; Kwa, AT; Hennighausen, L; Bujard, H; Fishman, GI; Conklin, BR			Conditional expression and signaling of a specifically designed G(i)-coupled receptor in transgenic mice	NATURE BIOTECHNOLOGY			English	Article						G protein signaling; engineered opioid receptor; synthetic ligand	PROTEIN-COUPLED RECEPTORS; GENE-EXPRESSION; DILATED CARDIOMYOPATHY; MAMMALIAN-CELLS; GI-ALPHA; HEART; TRANSDUCTION; ACTIVATION; LIGANDS	To control G protein signaling in vivo, we have modified G protein-coupled receptors to respond exclusively to synthetic small molecule agonists and not to their natural agonist(s), These engineered receptors are designated RASSLs (receptor activated solely by a synthetic ligand), A prototype RASSL (Ro1) based on the G(j)-coupled kappa opioid receptor was expressed in transgenic mice under the control of the tetracycline transactivator (tet) system, Activation of Ro1 expressed in the heart decreased heart rate by up to 80%, an expected effect of increased G(j) signaling. Maximal heart rate changes occurred in less than 1 min, demonstrating the speed of this inducible signaling system. This Ro1-mediated slowing of heart rate was also subject to desensitization, which lasted more than 24 h. Both the initial effect on heart rate and the desensitization occurred, even though Ro1 is derived from a human opioid receptor not normally involved in heart rate control. In addition, the tet system was used to induce Ro1 expression in hepatocytes and salivary gland, where G(j) signaling is known to control physiologic events such as proliferation and secretion, These studies demonstrate that a RASSL can be inducibly expressed in several mouse tissues and used in vivo to activate G protein signaling in a controllable fashion.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; NIDDKD, NIH, Bethesda, MD 20982 USA; Univ Heidelberg, Zentrum Mol Biol, D-6900 Heidelberg, Germany; Mt Sinai Sch Med, New York, NY 10029 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Ruprecht Karls University Heidelberg; Icahn School of Medicine at Mount Sinai	Conklin, BR (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Gladstone Inst Neurol Dis, POB 419100, San Francisco, CA 94141 USA.		Conklin, Bruce/E-4738-2019	Hennighausen, Lothar/0000-0001-8319-9841; Conklin, Bruce/0000-0003-1463-6061; Fishman, Glenn/0000-0002-2366-8527	NATIONAL CANCER INSTITUTE [K08CA071779] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK061000, Z01DK061000] Funding Source: NIH RePORTER; NCI NIH HHS [CA71779] Funding Source: Medline; NHLBI NIH HHS [HL60664-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Appleyard SM, 1997, J NEUROCHEM, V69, P2405; BOHM M, 1994, J MOL CELL CARDIOL, V26, P133, DOI 10.1006/jmcc.1994.1017; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FU LX, 1992, CARDIOVASC RES, V26, P950, DOI 10.1093/cvr/26.10.950; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; HOLMER SR, 1991, CIRCULATION, V84, P1891, DOI 10.1161/01.CIR.84.5.1891; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; LEFKOWITZ R L, 1990, P84; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Newton GE, 1996, J CLIN INVEST, V98, P2756, DOI 10.1172/JCI119101; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Schnabel P, 1996, CELL SIGNAL, V8, P413, DOI 10.1016/S0898-6568(96)00087-3; Schwenk F, 1998, NUCLEIC ACIDS RES, V26, P1427, DOI 10.1093/nar/26.6.1427; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Spencer DM, 1996, TRENDS GENET, V12, P181, DOI 10.1016/0168-9525(96)10013-5; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Yu ZH, 1996, CIRC RES, V79, P691, DOI 10.1161/01.RES.79.4.691	24	146	147	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					165	169		10.1038/6165	http://dx.doi.org/10.1038/6165			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052353				2022-12-27	WOS:000078508300025
J	Lu, ZR; Kopeckova, P; Kopecek, J				Lu, ZR; Kopeckova, P; Kopecek, J			Polymerizable Fab ' antibody fragments for targeting of anticancer drugs	NATURE BIOTECHNOLOGY			English	Article						polymerizable Fab '; HPMA copolymer; drug targeting; chlorin e(6); anticancer drug	CELLS IN-VITRO; MONOCLONAL-ANTIBODIES; THERAPY; ANTIGENS; AFFINITY; INVIVO; SYSTEM; MICE	We have designed a new pathway for the synthesis of targeted polymeric drug delivery systems, using polymerizable antibody Fab' fragments (MA-Fab'). The targeted systems can be directly prepared by copolymerization of the MA-Fab', N-(2-hydroxypropyl)methacrylamide (HPMA) and drug-containing monomers. Both MA-Fab' and the Fab'-targeted copolymers can effectively bind to target cells. An MA-Fab' (from OV-TL 16 Ab) targeted HPMA copolymer containing mesochlorin e(6) (Mce(6)) was synthesized by copolymerization of MA-Fab', HPMA, and MA-GFLG-Mce(6). The targeted copolymer exhibited a higher cytotoxicity toward OVCAR-3 human ovarian carcinoma cells than the nontargeted Mce(6)-containing copolymer or free Mce(6). The targeted copolymer was internalized more efficiently by OVCAR-3 cells than the nontargeted copolymer.	Univ Utah, Dept Pharmaceut & Pharmaceut Chem CCCD, Salt Lake City, UT 84112 USA; Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Kopecek, J (corresponding author), Univ Utah, Dept Pharmaceut & Pharmaceut Chem CCCD, Salt Lake City, UT 84112 USA.				NATIONAL CANCER INSTITUTE [R01CA051578] Funding Source: NIH RePORTER; NCI NIH HHS [CA51578] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUDITOREHARGREAVES K, 1987, CLIN CHEM, V33, P1509; BOERMAN O, 1989, ANTICANCER RES, V9, P551; BOERMAN O, 1990, ANTICANCER RES, V10, P1289; CALOFFA VR, 1999, 9 INT S REC ADV DRUG, P46; Delgado C, 1996, BRIT J CANCER, V73, P175, DOI 10.1038/bjc.1996.32; DROBNIK J, 1976, MAKROMOL CHEM, V177, P2833; Fritzberg AR, 1996, J MOL RECOGNIT, V9, P309, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<309::AID-JMR275>3.0.CO;2-#; FRITZBERG AR, 1994, J CONTROL RELEASE, V28, P167, DOI 10.1016/0168-3659(94)90163-5; KOPECEK J, 1973, EUR POLYM J, V9, P7, DOI 10.1016/0014-3057(73)90063-3; KOPECEK J, 1991, Patent No. 5037883; LU ZR, 1998, P INT S CONTR REL BI, V25, P788; MAEDA H, 1992, BIOCONJUGATE CHEM, V3, P351, DOI 10.1021/bc00017a001; MONJI N, 1987, APPL BIOCHEM BIOTECH, V14, P107, DOI 10.1007/BF02798429; Omelyanenko V, 1996, J DRUG TARGET, V3, P357, DOI 10.3109/10611869608996827; Omelyanenko V, 1998, INT J CANCER, V75, P600, DOI 10.1002/(SICI)1097-0215(19980209)75:4<600::AID-IJC18>3.0.CO;2-C; PARHAM P, 1983, J IMMUNOL, V131, P2895; PARHAM P, 1982, J IMMUNOL METHODS, V53, P133, DOI 10.1016/0022-1759(82)90137-5; Peterson CM, 1996, CANCER RES, V56, P3980; Putnam D, 1995, ADV POLYM SCI, V122, P55, DOI 10.1007/3540587888_14; REJMANOVA P, 1983, MAKROMOL CHEM, V184, P2009; RIHOVA B, 1988, CLIN IMMUNOL IMMUNOP, V46, P100; Vasey PA, 1999, CLIN CANCER RES, V5, P83	22	118	135	3	28	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1101	1104		10.1038/15085	http://dx.doi.org/10.1038/15085			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545917				2022-12-27	WOS:000083428000028
J	Chang, CCJ; Chen, TT; Cox, BW; Dawes, GN; Stemmer, WPC; Punnonen, J; Patten, PA				Chang, CCJ; Chen, TT; Cox, BW; Dawes, GN; Stemmer, WPC; Punnonen, J; Patten, PA			Evolution of a cytokine using DNA family shuffling	NATURE BIOTECHNOLOGY			English	Article						DNA shuffling; cytokines; interferon; molecular breeding; pharmaceutical proteins	HUMAN GROWTH-HORMONE; INTERFERON-ALPHA; RECEPTOR; INTERLEUKIN-2; RECOMBINATION; MECHANISMS; PROTEINS; DOMAINS; CELLS; IL-2	DNA shuffling of a family of over 20 human interferon-alpha (Hu-IFN-alpha) genes was used to derive variants with increased antiviral and antiproliferation activities in murine cells, A clone with 135,000-fold improved specific activity over Hu-IFN-alpha 2a was obtained in the first cycle of shuffling, After a second cycle of selective shuffling, the most active clone was improved 285,000-fold relative to Hu-IFN-alpha 2a and 185-fold relative to Hu-IFN-alpha 1, Remarkably, the three most active clones were more active than the native murine IFN-alpha s. These chimeras are derived from up to five parental genes but contained no random point mutations. These results demonstrate that diverse cytokine gene families can be used as starting material to rapidly evolve cytokines that are more active, or have superior selectivity profiles, than native cytokine genes.	Maxygen Inc, Santa Clara, CA 95051 USA		Patten, PA (corresponding author), Maxygen Inc, 3410 Cent Expressway, Santa Clara, CA 95051 USA.							ALLEGRETTA M, 1986, J CLIN IMMUNOL, V6, P481, DOI 10.1007/BF00915254; Blatt LM, 1996, J INTERF CYTOK RES, V16, P489, DOI 10.1089/jir.1996.16.489; BURBANK L, 1914, L BURBANK HIS METHOD, V1, P176; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Dusheiko G, 1997, HEPATOLOGY, V26, pS112, DOI 10.1002/hep.510260720; FISH EN, 1992, J INTERFERON RES, V12, P257, DOI 10.1089/jir.1992.12.257; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUNKE I, 1994, ANN HEMATOL, V68, P49; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HAIDANE JBS, 1924, CAMBRIDGE PHIL SOC T, V23, P19; HENCO K, 1985, J MOL BIOL, V185, P227, DOI 10.1016/0022-2836(85)90401-2; HORISBERGER MA, 1995, PHARMACOL THERAPEUT, V66, P507, DOI 10.1016/0163-7258(95)00008-5; Klaus W, 1997, J MOL BIOL, V274, P661, DOI 10.1006/jmbi.1997.1396; KONRAD M, 1989, TRENDS BIOTECHNOL, V7, P175, DOI 10.1016/0167-7799(89)90095-4; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; Lynch M., 1998, GENETICS ANAL QUANTI; Moore JC, 1997, J MOL BIOL, V272, P336, DOI 10.1006/jmbi.1997.1252; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; Patten PA, 1997, CURR OPIN BIOTECH, V8, P724, DOI 10.1016/S0958-1669(97)80127-9; Sambrook J., 2002, MOL CLONING LAB MANU; SCAROZZA AM, 1992, J INTERFERON RES, V12, P35, DOI 10.1089/jir.1992.12.35; SCHOMBURG A, 1993, J CANCER RES CLIN, V119, P745, DOI 10.1007/BF01195347; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STEMMER WPC, 1995, BIO-TECHNOL, V13, P549, DOI 10.1038/nbt0695-549; THOMAS JW, 1995, P NATL ACAD SCI USA, V92, P3779, DOI 10.1073/pnas.92.9.3779; TYMMS MJ, 1990, GENET ANAL-BIOMOL E, V7, P53, DOI 10.1016/0735-0651(90)90041-D; UZE G, 1994, J MOL BIOL, V243, P245, DOI 10.1006/jmbi.1994.1651; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3; vanderMeide PH, 1997, BIOTHERAPY, V10, P39, DOI 10.1007/BF02678216; VIAL T, 1994, DRUG SAFETY, V10, P115, DOI 10.2165/00002018-199410020-00003; WEBER H, 1987, EMBO J, V6, P591, DOI 10.1002/j.1460-2075.1987.tb04795.x; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001	32	110	214	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					793	797		10.1038/11737	http://dx.doi.org/10.1038/11737			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429246				2022-12-27	WOS:000081751400030
J	Miller, HI				Miller, HI			Nasty taste from G-8 GM food policy	NATURE BIOTECHNOLOGY			English	Editorial Material									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)									0	1	1	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					730	730		10.1038/11613	http://dx.doi.org/10.1038/11613			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429217	Bronze			2022-12-27	WOS:000081751400004
J	Gaertig, J; Gao, Y; Tishgarten, T; Clark, TG; Dickerson, HW				Gaertig, J; Gao, Y; Tishgarten, T; Clark, TG; Dickerson, HW			Surface display of a parasite antigen in the ciliate Tetrahymena thermophila	NATURE BIOTECHNOLOGY			English	Article						Tetrahymena; parasite antigen; beta-tubulin; paclitaxel; vaccine	ICHTHYOPHTHIRIUS-MULTIFILIIS; IMMOBILIZATION ANTIGENS; PROTOZOAN TETRAHYMENA; LYSOSOMAL-ENZYMES; BETA-TUBULIN; GENE; TRANSFORMATION; EXPRESSION; VECTOR; MACRONUCLEUS	The ciliated protozoan, Tetrahymena thermophila, offers an attractive medium for the expression of heterologous proteins and could prove particularly useful for the display of foreign proteins on the cell surface. Although progress has been made in transformation of Tetrahymena with heterologous DMA, methods that permit reliable expression of foreign genes have been lacking. Using a mutant strain of T: thermophila carrying a negatively selectable allele of a beta-tubulin gene, we have been able to direct foreign genes to this locus by homologous recombination. Transformed cell lines producing foreign proteins were readily identified and, in at least one case, targeting of proteins to the plasma membrane was accomplished.	Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA; Univ Georgia, Dept Med Microbiol & Parasitol, Athens, GA 30602 USA; Cornell Univ, Dept Microbiol & Immunol, Ithaca, NY 14853 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Cornell University	Gaertig, J (corresponding author), Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA.		Gaertig, Jacek/F-1553-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054017] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1988, CURRENT PROTOCOLS MO; CALZONE FJ, 1983, J BIOL CHEM, V258, P6887; CALZONE FJ, 1982, THESIS U ROCHESTER R; CassidyHanley D, 1997, GENETICS, V146, P135; CLARK TG, 1992, P NATL ACAD SCI USA, V89, P6363, DOI 10.1073/pnas.89.14.6363; Clark TG, 1996, P NATL ACAD SCI USA, V93, P6825, DOI 10.1073/pnas.93.13.6825; CLARK TG, 1996, ANN REV FISH DEV, V5, P113; GAERTIG J, 1994, P NATL ACAD SCI USA, V91, P4549, DOI 10.1073/pnas.91.10.4549; GAERTIG J, 1994, NUCLEIC ACIDS RES, V22, P5391, DOI 10.1093/nar/22.24.5391; GAERTIG J, 1993, CELL MOTIL CYTOSKEL, V25, P243, DOI 10.1002/cm.970250305; Geisse S, 1996, PROTEIN EXPRES PURIF, V8, P271, DOI 10.1006/prep.1996.0101; GILLEY D, 1995, GENE DEV, V9, P2214, DOI 10.1101/gad.9.18.2214; GOROVSKY MA, 1973, J PROTOZOOL, V20, P19, DOI 10.1111/j.1550-7408.1973.tb05995.x; GOROVSKY MA, 1980, ANNU REV GENET, V14, P203, DOI 10.1146/annurev.ge.14.120180.001223; HOROWITZ S, 1985, P NATL ACAD SCI USA, V82, P2452, DOI 10.1073/pnas.82.8.2452; HUNSELER P, 1992, DEV GENET, V13, P167, DOI 10.1002/dvg.1020130211; James DJ, 1996, BIO-TECHNOL, V14, P56, DOI 10.1038/nbt0196-56; KAHN RW, 1993, P NATL ACAD SCI USA, V90, P9295, DOI 10.1073/pnas.90.20.9295; KIY T, 1993, EXP CELL RES, V205, P286, DOI 10.1006/excr.1993.1088; KIY T, 1991, APPL MICROBIOL BIOT, V35, P14; KIY T, 1993, FEMS MICROBIOL LETT, V106, P117, DOI 10.1111/j.1574-6968.1993.tb05944.x; KIY T, 1992, APPL MICROBIOL BIOT, V38, P141; KIY T, 1992, APPL MICROBIOL BIOT, V37, P576; Lin TL, 1996, INFECT IMMUN, V64, P4085, DOI 10.1128/IAI.64.10.4085-4090.1996; LIN TL, 1992, J PROTOZOOL, V39, P457, DOI 10.1111/j.1550-7408.1992.tb04832.x; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; NIGRELLI RF, 1976, T AM MICROSC SOC, V95, P607, DOI 10.2307/3225383; PAN WJ, 1995, MOL CELL BIOL, V15, P3372; PAN WJ, 1995, NUCLEIC ACIDS RES, V23, P1561, DOI 10.1093/nar/23.9.1561; Preer J.R. Jr, 1986, P301; Rees S, 1996, BIOTECHNIQUES, V20, P102; TIEDTKE A, 1988, J CELL PHYSIOL, V136, P554, DOI 10.1002/jcp.1041360324; XU CH, 1995, J EUKARYOT MICROBIOL, V42, P558, DOI 10.1111/j.1550-7408.1995.tb05905.x; YAO MC, 1989, MOL CELL BIOL, V9, P1092, DOI 10.1128/MCB.9.3.1092; YU GL, 1989, P NATL ACAD SCI USA, V86, P8487, DOI 10.1073/pnas.86.21.8487	35	64	77	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					462	465		10.1038/8638	http://dx.doi.org/10.1038/8638			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331805				2022-12-27	WOS:000080074500030
J	Weissleder, R; Tung, CH; Mahmood, U; Bogdanov, A				Weissleder, R; Tung, CH; Mahmood, U; Bogdanov, A			In vivo imaging of tumors with protease-activated near-infrared fluorescent probes	NATURE BIOTECHNOLOGY			English	Article						optical imaging; tumor targeting; proteases	MATRIX METALLOPROTEINASE INHIBITORS; CATHEPSIN-B; SERINE PROTEASES; BREAST-CANCER; EXPRESSION; PROGRESSION; DELIVERY; MMP-9; DERIVATIVES; MEDICINE	We have developed a method to image tumor-associated lysosomal protease activity in a xenograft mouse model in vivo using autoquenched near-infrared fluorescence (NIRF) probes. NIRF probes were bound to a long circulating graft copolymer consisting of poly-L-lysine and methoxypolyethylene glycol succinate. Following intravenous injection, the NIRF probe carrier accumulated in solid tumors due to its long circulation time and leakage through tumor neovasculature. Intratumoral NIRF signal was generated by lysosomal proteases in tumor cells that cleave the macromolecule, thereby releasing previously quenched fluorochrome. In vivo imaging showed a 12-fold increase in NIRF signal, allowing the detection of tumors with submillimeter-sized diameters. This strategy can be used to detect such early stage tumors in vivo and to probe for specific enzyme activity.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Weissleder, R (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Boston, MA 02114 USA.	weissleder@helix.mgh.harvard.edu	Bogdanov, Alexei A/K-4946-2017; Tung, Ching-Hsuan/AIE-6009-2022; Tung, Ching-Hsuan/AHC-5070-2022	Bogdanov, Alexei A/0000-0003-4806-5869; Tung, Ching-Hsuan/0000-0001-6648-6195; Tung, Ching-Hsuan/0000-0001-6648-6195; Mahmood, Umar/0000-0001-7414-6123; /0000-0003-0828-4143	NATIONAL CANCER INSTITUTE [R01CA074424] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA74424-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alfano RR, 1997, ANN NY ACAD SCI, V820, P248, DOI 10.1111/j.1749-6632.1997.tb46200.x; Alfano RR, 1998, ANN NY ACAD SCI, V838, P14, DOI 10.1111/j.1749-6632.1998.tb08184.x; Anderson RT, 1997, EPIDEMIOLOGY, V8, P42, DOI 10.1097/00001648-199701000-00007; BARRETT AJ, 1981, ACTA BIOL MED GER, V40, P1513; Baum RP, 1998, Q J NUCL MED, V42, P33; Benaron DA, 1997, SCIENCE, V276, P2002, DOI 10.1126/science.276.5321.2002; Benaron DA, 1997, PHILOS T ROY SOC B, V352, P755, DOI 10.1098/rstb.1997.0059; Berquin IM, 1996, ADV EXP MED BIOL, V389, P281; BOGDANOV A, 1995, ADV DRUG DELIVER REV, V16, P335, DOI 10.1016/0169-409X(95)00034-5; Bogdanov AA, 1996, BIOCONJUGATE CHEM, V7, P144, DOI 10.1021/bc950089b; Buchsbaum DJ, 1997, CANCER, V80, P2371, DOI 10.1002/(SICI)1097-0142(19971215)80:12+<2371::AID-CNCR6>3.3.CO;2-A; Callahan RJ, 1998, AM J ROENTGENOL, V171, P137, DOI 10.2214/ajr.171.1.9648777; Denis LJ, 1997, INVEST NEW DRUG, V15, P175, DOI 10.1023/A:1005855905442; Dessureault S, 1997, BREAST CANCER RES TR, V45, P29, DOI 10.1023/A:1005878113826; DeVita VT, 1997, CANC PRINCIPLES PRAC; ELSHIRBINY AM, 1994, ADV CLIN CHEM, V31, P99, DOI 10.1016/S0065-2423(08)60334-0; Garcia M, 1996, STEM CELLS, V14, P642, DOI 10.1002/stem.140642; Giavazzi R, 1998, CLIN CANCER RES, V4, P985; Goodwin DA, 1997, CANCER-AM CANCER SOC, V80, P2675; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; HASHIDA S, 1980, J BIOCHEM-TOKYO, V88, P1805, DOI 10.1093/oxfordjournals.jbchem.a133155; Hebden JC, 1997, BRIT J RADIOL, V70, pS206, DOI 10.1259/bjr.1997.0026; Hebden JC, 1997, PHYS MED BIOL, V42, P825, DOI 10.1088/0031-9155/42/5/007; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; HUDIG D, 1989, MOL IMMUNOL, V26, P793, DOI 10.1016/0161-5890(89)90040-0; Jain RK, 1996, SCIENCE, V271, P1079, DOI 10.1126/science.271.5252.1079; KENNEDY AR, 1993, PREV MED, V22, P796, DOI 10.1006/pmed.1993.1073; Keppler D, 1996, BIOCHEM CELL BIOL, V74, P799, DOI 10.1139/o96-086; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Kopans D B, 1997, Surg Oncol Clin N Am, V6, P233; LETO G, 1992, ANTICANCER RES, V12, P235; LIAUDET E, 1995, CELL GROWTH DIFFER, V6, P1045; Manoharan R, 1998, PHOTOCHEM PHOTOBIOL, V67, P15, DOI 10.1562/0031-8655(1998)067<0015:RSAFPM>2.3.CO;2; Marecos E, 1998, BIOCONJUGATE CHEM, V9, P184, DOI 10.1021/bc970146w; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; MULDOON LL, 1995, AM J PATHOL, V147, P1840; Neri D, 1997, NAT BIOTECHNOL, V15, P1271, DOI 10.1038/nbt1197-1271; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; POWERS JC, 1989, J CELL BIOCHEM, V39, P33, DOI 10.1002/jcb.240390105; QUINTART J, 1979, J CELL BIOL, V82, P644, DOI 10.1083/jcb.82.3.644; Rha SY, 1998, ONCOL REP, V5, P875; Roselli M, 1996, J CLIN ONCOL, V14, P2031, DOI 10.1200/JCO.1996.14.7.2031; Rusckowski M, 1997, J PEPT RES, V50, P393; SHAU H, 1985, IMMUNOLOGY, V55, P647; Stocchi L, 1998, DIS COLON RECTUM, V41, P232, DOI 10.1007/BF02238254; Tamura Y, 1998, J MED CHEM, V41, P640, DOI 10.1021/jm9707582; Tearney GJ, 1997, SCIENCE, V276, P2037, DOI 10.1126/science.276.5321.2037; Teates C D, 1993, Curr Probl Diagn Radiol, V22, P229; TSURUGI K, 1980, EUR J BIOCHEM, V109, P9, DOI 10.1111/j.1432-1033.1980.tb04761.x; Villringer A, 1997, ADV EXP MED BIOL, V413, P1; Weissleder R, 1998, EUR J CANCER, V34, P1448, DOI 10.1016/S0959-8049(98)00195-6; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132; Wu J, 1997, P NATL ACAD SCI USA, V94, P8783, DOI 10.1073/pnas.94.16.8783; YAVELOW J, 1983, CANCER RES, V43, P2454; Yu AE, 1997, DRUG AGING, V11, P229, DOI 10.2165/00002512-199711030-00006	55	1339	1462	16	522	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					375	378		10.1038/7933	http://dx.doi.org/10.1038/7933			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207887				2022-12-27	WOS:000079574400027
J	Goto, F; Yoshihara, T; Shigemoto, N; Toki, S; Takaiwa, F				Goto, F; Yoshihara, T; Shigemoto, N; Toki, S; Takaiwa, F			Iron fortification of rice seed by the soybean ferritin gene	NATURE BIOTECHNOLOGY			English	Article						nutrition; iron content; genetic improvement; glutelin promoter; Oryza sativa	TRANSGENIC TOBACCO; NODULE DEVELOPMENT; PROTEIN BODIES; PISUM-SATIVUM; MESSENGER-RNA; N-TERMINUS; IN-VITRO; ACCUMULATION; EXPRESSION; LEAVES	To improve the iron content of rice, we have transferred the entire coding sequence of the soybean ferritin gene into Oryza sativa (L. cv. Kita-ake) by Agrobacterium-mediated transformation. The rice seed-storage protein glutelin promoter, GluB-1, was used to drive expression of the soybean gene specifically in developing, self-pollinated seeds (T1 seeds) of transgenic plants, as confirmed by reverse transcription PCR analysis. Stable accumulation of the ferritin subunit in the rice seed was demonstrated by western blot analysis, and its specific accumulation in the endosperm by immunologic tissue printing. The iron content of T1 seeds was as much as threefold greater than that of their untransformed counterparts.	Cent Res Inst Elect Power Ind, Dept Biosci, Chiba 2701194, Japan; Natl Inst Agrobiol Resources, Dept Biotechnol, Ibaraki, Osaka 3058602, Japan; Hiroshima Pref Agr Res Ctr, Inst Biotechnol, Hiroshima 7390151, Japan	Central Research Institute of Electric Power Industry - Japan; National Institute of Agrobiological Sciences - Japan	Yoshihara, T (corresponding author), Cent Res Inst Elect Power Ind, Dept Biosci, 1646 Abiko, Chiba 2701194, Japan.							ANDREWS SC, 1992, J INORG BIOCHEM, V47, P161, DOI 10.1016/0162-0134(92)84062-R; [Anonymous], 1992, STANDARD METHODS EXA; Beard JL, 1996, J NUTR, V126, P154, DOI 10.1093/jn/126.1.154; Becker F, 1995, PHYS CHEM EARTH/DELT, V20, P1, DOI 10.1016/0079-1946(95)00002-R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHU CC, 1975, SCI SINICA, V18, P659; CRAIG WJ, 1994, AM J CLIN NUTR, V59, p1233S, DOI 10.1093/ajcn/59.5.1233S; Delhaize E, 1996, PLANT PHYSIOL, V111, P849, DOI 10.1104/pp.111.3.849; ENGERBLUM G, 1993, ANAL BIOCHEM, V210, P235; GILLOOLY M, 1983, BRIT J NUTR, V49, P331, DOI 10.1079/BJN19830042; Goto F, 1998, TRANSGENIC RES, V7, P173, DOI 10.1023/A:1008836812714; Inoue K., 1995, Japanese Journal of Soil Science and Plant Nutrition, V66, P527; KAMACHI K, 1992, PLANT PHYSIOL, V99, P1481, DOI 10.1104/pp.99.4.1481; KIMATA Y, 1994, PLANT PHYSIOL, V104, P263, DOI 10.1104/pp.104.1.263; LESCURE AM, 1991, P NATL ACAD SCI USA, V88, P8222, DOI 10.1073/pnas.88.18.8222; LOBREAUX S, 1991, BIOCHEM J, V274, P601, DOI 10.1042/bj2740601; LOBREAUX S, 1992, PLANT MOL BIOL, V19, P563, DOI 10.1007/BF00026783; LOBREAUX S, 1992, BIOCHEM J, V288, P931, DOI 10.1042/bj2880931; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; OHTANI T, 1990, PLANT MOL BIOL, V16, P117; PROUDHON D, 1989, PLANT PHYSIOL, V90, P586, DOI 10.1104/pp.90.2.586; RAGLAND M, 1990, J BIOL CHEM, V265, P18339; RAGLAND M, 1993, PLANT MOL BIOL, V21, P555, DOI 10.1007/BF00028813; Sambrook J., 1989, MOL CLONING; SHIRSAT AH, 1989, PLANT SCI, V61, P75, DOI 10.1016/0168-9452(89)90121-0; SHURE M, 1983, CELL, V35, P225, DOI 10.1016/0092-8674(83)90225-8; SPENCE MJ, 1991, PLANT MOL BIOL, V17, P499, DOI 10.1007/BF00040644; STURM A, 1988, PLANTA, V175, P170, DOI 10.1007/BF00392425; TAKAIWA F, 1991, PLANT MOL BIOL, V17, P875, DOI 10.1007/BF00037068; TAKAIWA F, 1995, PLANT SCI, V111, P39, DOI 10.1016/0168-9452(95)04215-G; Takaiwa F, 1996, PLANT MOL BIOL, V30, P1207, DOI 10.1007/BF00019553; THEIL EC, 1990, J BIOL CHEM, V265, P4771; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; Theil EC, 1997, EUR J CLIN NUTR, V51, pS28; UTSUMI S, 1993, PLANT SCI, V92, P191, DOI 10.1016/0168-9452(93)90206-F; VANDERMARK F, 1983, BIOCHEM BIOPH RES CO, V115, P463, DOI 10.1016/S0006-291X(83)80167-3; VANWUYTSWINKEL O, 1995, BIOCHEM J, V305, P253, DOI 10.1042/bj3050253; VANWUYTSWINKEL O, 1995, BIOCHEM J, V305, P959, DOI 10.1042/bj3050959; *WHO, 1992, A453 WHO; Wu CY, 1998, PLANT J, V14, P673, DOI 10.1046/j.1365-313x.1998.00167.x; YIP R, 1994, J NUTR, V124, pS1479, DOI 10.1093/jn/124.suppl_8.1479S; 1992, STANDARD TABLES FOOD	42	498	619	5	101	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					282	286		10.1038/7029	http://dx.doi.org/10.1038/7029			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096297				2022-12-27	WOS:000078977500031
J	Anseth, KS; Shastri, VR; Langer, R				Anseth, KS; Shastri, VR; Langer, R			Photopolymerizable degradable polyanhydrides with osteocompatibility	NATURE BIOTECHNOLOGY			English	Article						degradable networks; bone substitutes; drug delivery	INTRAPERITONEAL BARRIER; PREVENTION; REFORMATION; COMPOSITES; BONE	We have developed a new family of photopolymerizable, methacrylated anhydride monomers and oligomers that combine high strength, controlled degradation, and photoprocessibility in a singular system. Networks with degradation times ranging from 1 week to nearly 1 year and that retain up to 90% of their tensile modulus at 40% mass loss are attainable. In vivo studies in rats have shown that these networks possess excellent osteocompatibility. These combined properties could offer many advantages in medical applications ranging from dentistry to orthopedics.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; Univ Colorado, Dept Chem Engn, Boulder, CO 80309 USA	Massachusetts Institute of Technology (MIT); University of Colorado System; University of Colorado Boulder	Langer, R (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.				NIAMS NIH HHS [AR4197] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anseth KS, 1995, ADV POLYM SCI, V122, P177; ANSETH KS, 1995, MACROMOLECULES, V28, P4040, DOI 10.1021/ma00115a045; CONSTANTZ BR, 1995, SCIENCE, V267, P1796, DOI 10.1126/science.7892603; DANIELS AU, 1990, J APPL BIOMATER, V1, P57, DOI 10.1002/jab.770010109; Hill J. W., 1932, J AM CHEM SOC, V54, P1569; HILLWEST JL, 1994, OBSTET GYNECOL, V83, P59; KOHN DH, 1992, MAT SCI TECHNOLOGY, V14, P29; MUGGLL S, 1998, IN PRESS J BIOMED MA; STEINLEITNER A, 1991, OBSTET GYNECOL, V77, P48; STEINLEITNER A, 1992, FERTIL STERIL, V57, P305; SVALDI DC, 1998, WILEY POLYM NETWORKS, V1, P161; TORMALA P, 1988, Patent No. 4743257	12	160	184	0	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					156	159		10.1038/6152	http://dx.doi.org/10.1038/6152			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052351				2022-12-27	WOS:000078508300023
J	Weikert, S; Papac, D; Briggs, J; Cowfer, D; Tom, S; Gawlitzek, M; Lofgren, J; Mehta, S; Chisholm, V; Modi, N; Eppler, S; Carroll, K; Chamow, S; Peers, D; Berman, P; Krummen, L				Weikert, S; Papac, D; Briggs, J; Cowfer, D; Tom, S; Gawlitzek, M; Lofgren, J; Mehta, S; Chisholm, V; Modi, N; Eppler, S; Carroll, K; Chamow, S; Peers, D; Berman, P; Krummen, L			Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins	NATURE BIOTECHNOLOGY			English	Article						glycosylation; glycosyltransferase overexpression; recombinant protein expression; Chinese hamster ovary cells	TISSUE-PLASMINOGEN ACTIVATOR; LINKED OLIGOSACCHARIDES; INTERFERON-GAMMA; CHO CELLS; EXPRESSION; ALPHA-2,6-SIALYLTRANSFERASE; CULTURE; ERYTHROPOIETIN	We have engineered two Chinese hamster ovary cell lines secreting different recombinant glycoproteins to express high levels of human beta 1,4-galactosyltransferase (GT, E.C. 2.4.1.38) and/or alpha 2,3-sialyltransferase (ST, E.C. 2.4.99.6). N-linked oligosaccharide structures synthesized by cells overexpressing the glycosyltransferases showed greater homogeneity compared with control cell lines. When GT was overexpressed, oligosaccharides terminating with GlcNAc were significantly reduced compared with controls, whereas overexpression of ST resulted in sialylation of greater than or equal to 90% of available branches. As expected, GT overexpression resulted in reduction of oligosaccharides terminating with GlcNAc, whereas overexpression of ST resulted in sialylation of greater than or equal to 90% of available branches. The more highly sialylated glycoproteins had a significantly longer mean residence time in a rabbit model of pharmacokinetics. These experiments demonstrate the feasibility of genetically engineering cell lines to produce therapeutics with desired glycosylation patterns.	Genentech Inc, Dept Cell Culture & Fermentat Res & Dev, S San Francisco, CA 94080 USA; Genentech Inc, Dept Analyt Chem, S San Francisco, CA 94080 USA; Genentech Inc, Dept Recovery Sci, S San Francisco, CA 94080 USA; Genentech Inc, Dept Biol Mol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Metab & Pharmacokinet, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mfg Sci, S San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Krummen, L (corresponding author), Genentech Inc, Dept Cell Culture & Fermentat Res & Dev, S San Francisco, CA 94080 USA.			Modi, Nishit/0000-0002-5111-867X; Briggs, John/0000-0001-6165-097X				Andersen Dana C., 1994, Current Opinion in Biotechnology, V5, P546, DOI 10.1016/0958-1669(94)90072-8; ANUMULA KR, 1995, ANAL BIOCHEM, V230, P24, DOI 10.1006/abio.1995.1432; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; CURLING EMA, 1990, BIOCHEM J, V272, P333, DOI 10.1042/bj2720333; FUKUDA MN, 1989, BLOOD, V73, P84; GOOCHEE CF, 1992, FRONTIERS BIOPROCESS, V2, P198; GRABENHORST E, 1995, EUR J BIOCHEM, V232, P718, DOI 10.1111/j.1432-1033.1995.718zz.x; GRAMER MJ, 1993, BIOTECHNOL PROGR, V9, P366, DOI 10.1021/bp00022a003; HILBERG F, 1987, P NATL ACAD SCI USA, V84, P5232, DOI 10.1073/pnas.84.15.5232; JEFFRIES R, 1996, ANTIBODY ENG CHEM IM, V65, P111; JENKINS N, 1994, ENZYME MICROB TECH, V16, P354, DOI 10.1016/0141-0229(94)90149-X; KEYT BA, 1994, P NATL ACAD SCI USA, V91, P3670, DOI 10.1073/pnas.91.9.3670; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; LEE UE, 1989, J BIOL CHEM, V164, P13848; LEE YC, 1983, J BIOL CHEM, V258, P199; LIU DTY, 1992, TRENDS BIOTECHNOL, V10, P114, DOI 10.1016/0167-7799(92)90192-X; Lucas BK, 1996, NUCLEIC ACIDS RES, V24, P1774, DOI 10.1093/nar/24.9.1774; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MINCH SL, 1995, BIOTECHNOL PROGR, V11, P348, DOI 10.1021/bp00033a015; Monaco L, 1996, CYTOTECHNOLOGY, V22, P197, DOI 10.1007/BF00353939; Papac DI, 1998, GLYCOBIOLOGY, V8, P445, DOI 10.1093/glycob/8.5.445; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; *STAT CONS INC, 1986, AM STAT, V40, P52; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WASLEY LC, 1991, BLOOD, V77, P2624; WEN DX, 1992, J BIOL CHEM, V267, P2512	27	161	218	1	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1116	1121		10.1038/15104	http://dx.doi.org/10.1038/15104			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545921				2022-12-27	WOS:000083428000032
J	Ducor, P				Ducor, P			Research tool patents and the experimental use exemption - a no-win situation? Because their very purpose is experimentation, applying the experimental use exemption to research tool patents requires a close analysis.	NATURE BIOTECHNOLOGY			English	Editorial Material									BMG Avocats, CH-1211 Geneva 12, Switzerland		Ducor, P (corresponding author), BMG Avocats, Ave Champel 8C,Case Postale 385, CH-1211 Geneva 12, Switzerland.							BARTON J, 1995, INT REV IND PROP COP, V26, P614; BARTON JH, 1995, IIC-INT REV IND PROP, V26, P605; Lehrman S, 1999, NATURE, V397, P460, DOI 10.1038/17169; LEHRMAN S, 1995, NATURE, V375, P348, DOI 10.1038/375348a0	4	5	5	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1027	1028		10.1038/13729	http://dx.doi.org/10.1038/13729			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biotechnology & Applied Microbiology	243UM	10504708				2022-12-27	WOS:000083015700032
J	Persidis, A				Persidis, A			Bioinformatics	NATURE BIOTECHNOLOGY			English	Editorial Material							DATA-BANK; PROTEIN		Argonex Inc, Charlottesville, VA 22901 USA		Persidis, A (corresponding author), Argonex Inc, 2044 India Rd, Charlottesville, VA 22901 USA.	apersidis@argonex.com						Adleman LM, 1999, J COMPUT BIOL, V6, P53, DOI 10.1089/cmb.1999.6.53; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; APPEL RD, 1993, ELECTROPHORESIS, V14, P1232, DOI 10.1002/elps.11501401185; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2247, DOI 10.1093/nar/19.suppl.2247; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BAIROCH A, 1991, COMPUT APPL BIOSCI, V7, P268; Baker PG, 1999, BIOINFORMATICS, V15, P510, DOI 10.1093/bioinformatics/15.6.510; Brenner S, 1998, CIBA F SYMP, V213, P106; Brenner S, 1998, NOVART FDN SYMP, V213, P111; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Ellsworth DL, 1999, ANN EPIDEMIOL, V9, P207, DOI 10.1016/S1047-2797(99)00007-1; Gelbart WM, 1998, SCIENCE, V282, P659, DOI 10.1126/science.282.5389.659; HOLLISTER C, 1986, NUCLEIC ACIDS RES, V14, P21; Kolatkar PR, 1998, STUD HEALTH TECHNOL, V52, P356; Malakoff D, 1999, SCIENCE, V284, P1742, DOI 10.1126/science.284.5421.1742; MOORE J, 1988, BIOTECHNIQUES, V6, P566; Reichhardt T, 1999, NATURE, V399, P517; Wendl MC, 1998, GENOME RES, V8, P975, DOI 10.1101/gr.8.9.975	18	18	18	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					828	830		10.1038/11793	http://dx.doi.org/10.1038/11793			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429259				2022-12-27	WOS:000081751400038
J	Wagner, J; Akerud, P; Castro, DS; Holm, PC; Canals, JM; Snyder, EY; Perlmann, T; Arenas, E				Wagner, J; Akerud, P; Castro, DS; Holm, PC; Canals, JM; Snyder, EY; Perlmann, T; Arenas, E			Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes	NATURE BIOTECHNOLOGY			English	Article						cell therapy; differentiation; Parkinson's disease; progenitor cells; tyrosine hydroxylase	CENTRAL-NERVOUS-SYSTEM; NEUROTROPHIC FACTOR; NGFI-B; NEURONS; NURR1; RECEPTOR; PROGENITOR; BRAIN; GENE; GDNF	The implementation of neural stem cell lines as a source material for brain tissue transplants is currently limited by the ability to induce specific neurochemical phenotypes in these cells. Here, we show that coordinated induction of a ventral mesencephalic dopaminergic phenotype in an immortalized multipotent neural stem cell line can be achieved in vitro. This process requires both the overexpression of the nuclear receptor Nurr1 and factors derived from local type 1 astrocytes. Over 80% of cells obtained by this method demonstrate a phenotype indistinguishable from that of endogenous dopaminergic neurons. Moreover, this procedure yields an unlimited number of cells that can engraft in vivo and that may constitute a useful source material for neuronal replacement in Parkinson's disease.	Karolinska Inst, Dept Med Biochem & Biophys, Mol Neurobiol Lab, S-17177 Stockholm, Sweden; Karolinska Inst, Stockholm Branch, Ludwig Inst Canc Res, S-17177 Stockholm, Sweden; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Childrens Hosp, Div Neurosci, Boston, MA 02115 USA	Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Arenas, E (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Mol Neurobiol Lab, S-17177 Stockholm, Sweden.	ernest@cajal.mbb.ki.se	Holm, Pontus/G-2747-2010; Arenas, Ernest/AAO-5231-2020; Castro, Diogo S/I-6217-2016; Canals, Josep M/M-3846-2014	Arenas, Ernest/0000-0003-0197-6577; Castro, Diogo S/0000-0001-8178-9565; Canals, Josep M/0000-0001-6829-7670				ALTMAN J, 1995, RAT NERVOUS SYSTEM, P1054; Castillo SO, 1998, MOL CELL NEUROSCI, V11, P36, DOI 10.1006/mcne.1998.0673; DENISDONINI S, 1984, NATURE, V307, P641, DOI 10.1038/307641a0; Eichele G, 1997, TRENDS GENET, V13, P343, DOI 10.1016/S0168-9525(97)01218-3; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; HYMAN C, 1994, J NEUROSCI, V14, P335; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; KITCHENS DL, 1994, J NEUROBIOL, V25, P797, DOI 10.1002/neu.480250705; Krezel W, 1998, SCIENCE, V279, P863, DOI 10.1126/science.279.5352.863; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7772, DOI 10.1073/pnas.91.16.7772; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Naveilhan P, 1998, P NATL ACAD SCI USA, V95, P1295, DOI 10.1073/pnas.95.3.1295; OMALLEY EK, 1992, BRAIN RES, V582, P65, DOI 10.1016/0006-8993(92)90317-3; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Rosenthal A, 1998, NEURON, V20, P169, DOI 10.1016/S0896-6273(00)80445-6; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Snyder EY, 1996, CLIN NEUROSCI, V3, P310; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; Zetterstrom RH, 1996, MOL BRAIN RES, V41, P111, DOI 10.1016/0169-328X(96)00074-5; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	34	302	373	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					653	659		10.1038/10862	http://dx.doi.org/10.1038/10862			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404157				2022-12-27	WOS:000081296900024
J	Drews, J				Drews, J			Basic science and pharmaceutical innovation	NATURE BIOTECHNOLOGY			English	Editorial Material									Int Biomed Management Partners, Basel, Switzerland		Drews, J (corresponding author), Int Biomed Management Partners, Basel, Switzerland.							BOHME G, 1978, STARNBERGER STUDIEN, P339; BOHME G, 1978, STARNBERGER STUDIEN; DREWS J, 1999, QUEST TOMORROWS MED, pCH2; DREWS J, 1989, FORSCHUNG ROCHE	4	8	9	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					406	406		10.1038/8531	http://dx.doi.org/10.1038/8531			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331778				2022-12-27	WOS:000080074500003
J	Farace, C				Farace, C			Promoting life science in Lyon	NATURE BIOTECHNOLOGY			English	Article									Grand Lyon DGDEI, Lyon Life Sci Network, F-69399 Lyon, France		Farace, C (corresponding author), Grand Lyon DGDEI, Lyon Life Sci Network, BP 3103,20 Rue Lac, F-69399 Lyon, France.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					447	448		10.1038/8620	http://dx.doi.org/10.1038/8620			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331801				2022-12-27	WOS:000080074500026
J	Persidis, A				Persidis, A			Tissue engineering	NATURE BIOTECHNOLOGY			English	Editorial Material							ARTIFICIAL SKIN; IN-VIVO; IMPLANT		Argonex Inc, Charlottesville, VA 22901 USA		Persidis, A (corresponding author), Argonex Inc, 2044 India Rd, Charlottesville, VA 22901 USA.	apersidis@argonex.com						BISCHOFF F, 1972, CLIN CHEM, V18, P869; BURKE JF, 1981, ANN SURG, V194, P413, DOI 10.1097/00000658-198110000-00005; de Groot K, 1998, TISSUE ENG, V4, P337; HALL CW, 1966, T AM SOC ART INT ORG, V12, P340; Heath CA, 1998, TRENDS BIOTECHNOL, V16, P163, DOI 10.1016/S0167-7799(97)01165-7; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; LEININGER RI, 1972, T AM SOC ART INT ORG, V18, P312; LEVIN MP, 1979, J PERIODONTOL, V50, P250, DOI 10.1902/jop.1979.50.5.250; Lysaght MJ, 1998, TISSUE ENG, V4, P231, DOI 10.1089/ten.1998.4.231; Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415; Mansbridge J, 1998, TISSUE ENG, V4, P403, DOI 10.1089/ten.1998.4.403; Mayhew TA, 1998, TISSUE ENG, V4, P325, DOI 10.1089/ten.1998.4.325; Omstead DR, 1998, TISSUE ENG, V4, P239, DOI 10.1089/ten.1998.4.239; Osborne CS, 1999, BIOMATERIALS, V20, P283, DOI 10.1016/S0142-9612(98)00179-3; SCHMOLKA IR, 1972, J BIOMED MATER RES, V6, P571, DOI 10.1002/jbm.820060609; Spain TL, 1998, TISSUE ENG, V4, P343, DOI 10.1089/ten.1998.4.343; SPIRA M, 1969, Journal of Biomedical Materials Research, V3, P213, DOI 10.1002/jbm.820030203; Su CH, 1999, BIOMATERIALS, V20, P61, DOI 10.1016/S0142-9612(98)00139-2	19	84	99	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					508	510		10.1038/8700	http://dx.doi.org/10.1038/8700			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331816				2022-12-27	WOS:000080074500041
J	Christians, FC; Scapozza, L; Crameri, A; Folkers, G; Stemmer, WPC				Christians, FC; Scapozza, L; Crameri, A; Folkers, G; Stemmer, WPC			Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling	NATURE BIOTECHNOLOGY			English	Article						random mutagenesis; sexual PCR/DNA shuffling; suicide gene; gene transfer; zidovudine	RANDOM SEQUENCE SELECTION; FAVORABLE BINDING-SITES; SIMPLEX VIRUS TYPE-1; IN-VITRO; MOLECULAR EVOLUTION; MUTANTS; ACTIVATION; COMPLEX; PROTEIN	The thymidine kinase (TK) genes from herpes simplex virus (HSV) types 1 and 2 were recombined in vitro with a technique called DNA family shuffling. A high throughput robotic screen identified chimeras with an enhanced ability to phosphoryl;ate zidovudine (AZT). Improved clones were combined, reshuffled, and screened on increasingly lower concentrations of AZT. After four rounds of shuffling and screening, two clones were isolated that sensitize Escherichia coli to 32-fold less AZT compared with HSV-1 TK and 16,000-fold less than HSV-2 TK. Both clones are hybrids derived from several crossover events between the two parental genes and carry several additional amino acid substitutions not found in either parent, including active site mutations. Kinetic measurements show that the chimeric enzymes had acquired reduced Kw for AZT as well as decreased specificity for thymidine. In agreement with the kinetic data, molecular modeling suggests that the active sites of both evolved enzymes better accommodate the azido group of AZT at the expense of thymidine. Despite the overall similarity of the two chimeric enzymes, each contains key contributions from different parents in positions influencing substrate affinity. Such mutants could be useful for anti-HIV gene therapy, and similar directed-evolution approaches could improve other enzyme-prodrug combinations.	Maxygen Inc, Santa Clara, CA 95051 USA; Swiss Fed Inst Technol, Dept Pharm, ETH Zurich, CH-8057 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Stemmer, WPC (corresponding author), Maxygen Inc, 3410 Cent Expressway, Santa Clara, CA 95051 USA.	pim_stemmer@maxygen.com		Scapozza, Leonardo/0000-0003-1079-648X; Folkers, Gerd/0000-0002-3620-705X				Balzarini J, 1998, NAT MED, V4, P132, DOI 10.1038/nm0298-132a; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; BLACK ME, 1993, BIOCHEMISTRY-US, V32, P11618, DOI 10.1021/bi00094a019; Bouayadi K, 1997, CANCER RES, V57, P110; BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; Buchholz F, 1998, NAT BIOTECHNOL, V16, P657, DOI 10.1038/nbt0798-657; CHAMPNESS JN, 1998, STRUCT FUNCT GENET, V32, P350; Cleland W W, 1979, Methods Enzymol, V63, P103; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Drake RR, 1997, ANTIVIR RES, V35, P177, DOI 10.1016/S0166-3542(97)00027-2; GENTRY GA, 1992, PHARMACOL THERAPEUT, V54, P319, DOI 10.1016/0163-7258(92)90006-L; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Guettari N, 1997, VIROLOGY, V235, P398, DOI 10.1006/viro.1997.8706; HIRSCH MS, 1996, FIELDS VIROLOGY, P431; IGARASHI K, 1967, GENETICS, V57, P643; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kumamaru T, 1998, NAT BIOTECHNOL, V16, P663, DOI 10.1038/nbt0798-663; Kussmann-Gerber S, 1998, EUR J BIOCHEM, V255, P472, DOI 10.1046/j.1432-1327.1998.2550472.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lavie A, 1997, NAT STRUCT BIOL, V4, P601, DOI 10.1038/nsb0897-601; Lavie A, 1997, NAT MED, V3, P922, DOI 10.1038/nm0897-922; Martin LA, 1996, CANCER METAST REV, V15, P301, DOI 10.1007/BF00046344; Moore JC, 1997, J MOL BIOL, V272, P336, DOI 10.1006/jmbi.1997.1252; MUNIR KM, 1993, P NATL ACAD SCI USA, V90, P4012, DOI 10.1073/pnas.90.9.4012; Patten PA, 1997, CURR OPIN BIOTECH, V8, P724, DOI 10.1016/S0958-1669(97)80127-9; PERLMAN DA, 1995, COMP PHYS COMMUN, V91, P1; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; WADE RC, 1993, J MED CHEM, V36, P140, DOI 10.1021/jm00053a018; Wild K, 1997, PROTEIN SCI, V6, P2097; Xu YW, 1997, P NATL ACAD SCI USA, V94, P7162, DOI 10.1073/pnas.94.14.7162; Zhang JH, 1997, P NATL ACAD SCI USA, V94, P4504, DOI 10.1073/pnas.94.9.4504	33	103	233	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					259	264		10.1038/7003	http://dx.doi.org/10.1038/7003			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096293				2022-12-27	WOS:000078977500027
J	Jost, B; Vilotte, JL; Duluc, I; Rodeau, JL; Freund, JN				Jost, B; Vilotte, JL; Duluc, I; Rodeau, JL; Freund, JN			Production of low-lactose milk by ectopic expression of intestinal lactase in the mouse mammary gland	NATURE BIOTECHNOLOGY			English	Article						lactose maldigestion; transgenic mice; fat globules	ALPHA-LACTALBUMIN; PHLORIZIN HYDROLASE; TRANSGENIC MICE; EPITHELIAL-CELLS; PROTEIN-C; MEMBRANE; INTOLERANCE; RAT; MATURATION; TISSUE	We have investigated, in mice, an in vivo method for producing low-lactose milk, based on the creation of transgenic animals carrying a hybrid gene in which the intestinal lactase-phlorizin hydrolase cDNA was placed under the control of the mammary-specific alpha-lactalbumin promoter. Transgenic females expressed lactase protein and activity during lactation at the apical side of mammary alveolar cells. Active lactase was also secreted into milk, anchored in the outer membrane of fat globules. Lactase synthesis in the mammary gland caused a significant decrease in milk lactose (50-85%) without obvious changes in fat and protein concentrations. Sucklings nourished with low-lactose milk developed normally. Hence, these data validate the use of transgenic animals expressing lactase in the mammary gland to produce low-lactose milk in vivo, and they demonstrate that the secretion of an intestinal digestive enzyme into milk can selectively modify its composition.	INSERM U381, Strasbourg, France; Inst Natl Rech Agron, CIJ, Jouy En Josas, France; CNRS, UPR 9009, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Freund, JN (corresponding author), INSERM U381, Strasbourg, France.	jean-noel.freund@inserm.u-strasbg.fr	DULUC, Isabelle/AAA-7062-2022; Freund, Jean-Noel/R-4383-2016; Vilotte, Jean-Luc/AAF-4688-2019; Duluc, Isabelle/O-1972-2017	DULUC, Isabelle/0000-0001-8396-6385; Freund, Jean-Noel/0000-0002-0971-3774; Duluc, Isabelle/0000-0001-8396-6385				BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRAND JC, 1991, AM J CLIN NUTR, V54, P148, DOI 10.1093/ajcn/54.1.148; BULLER HA, 1987, J BIOL CHEM, V262, P17206; Cooper B T, 1986, Dig Dis, V4, P72, DOI 10.1159/000171139; DITULLIO P, 1992, BIO-TECHNOL, V10, P74, DOI 10.1038/nbt0192-74; DREWS R, 1995, P NATL ACAD SCI USA, V92, P10462, DOI 10.1073/pnas.92.23.10462; DROHAN WN, 1994, TRANSGENIC RES, V3, P355, DOI 10.1007/BF01976767; DULUC I, 1994, J CELL BIOL, V126, P211, DOI 10.1083/jcb.126.1.211; DULUC I, 1993, J CELL BIOL, V123, P1577, DOI 10.1083/jcb.123.6.1577; DULUC I, 1991, GENE, V103, P275, DOI 10.1016/0378-1119(91)90286-K; FAERMAN A, 1995, J HISTOCHEM CYTOCHEM, V43, P461, DOI 10.1177/43.5.7730585; HANSEN SA, 1975, J CHROMATOGR, V105, P388, DOI 10.1016/S0021-9673(01)82270-6; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; Jost B, 1997, BIOCHEM J, V327, P95, DOI 10.1042/bj3270095; KOLDOVSKY O, 1969, ANAL BIOCHEM, V27, P409, DOI 10.1016/0003-2697(69)90054-2; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LUCAS A, 1978, BRIT MED J, V1, P1018, DOI 10.1136/bmj.1.6119.1018; MEPHAM TB, 1987, PHYSL LACTATION, P30; Mercier J. C., 1986, Exploiting new technologies in animal breeding. Genetic developments., P122; MOLENAAR AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P611, DOI 10.1177/40.5.1374090; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1991, J BIOL CHEM, V266, P12313; *NAT DAIR COUNC, 1985, DAIRY COUNCIL DIG, V56, P25; NEELE AM, 1995, GASTROENTEROLOGY, V109, P1234, DOI 10.1016/0016-5085(95)90583-9; NSIEMVO E, 1986, GEN PHYSIOL BIOPHYS, V5, P53; Panzer P, 1998, J BIOL CHEM, V273, P13861, DOI 10.1074/jbc.273.22.13861; PATTON S, 1975, BIOCHIM BIOPHYS ACTA, V415, P273, DOI 10.1016/0304-4157(75)90011-8; RODEAU JL, 1987, DEV BIOL, V120, P481, DOI 10.1016/0012-1606(87)90251-X; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; SAHI T, 1994, SCAND J GASTROENTERO, V29, P7, DOI 10.3109/00365529409091740; SASAKI M, 1978, P NATL ACAD SCI USA, V75, P5020, DOI 10.1073/pnas.75.10.5020; SAVILAHTI E, 1983, ARCH DIS CHILD, V58, P246, DOI 10.1136/adc.58.4.246; SCHMITZ J, 1973, BIOCHIM BIOPHYS ACTA, V323, P98, DOI 10.1016/0005-2736(73)90434-3; SIMONS JP, 1987, NATURE, V328, P530, DOI 10.1038/328530a0; STINNAKRE MG, 1994, P NATL ACAD SCI USA, V91, P6544, DOI 10.1073/pnas.91.14.6544; Suarez FL, 1995, ALIMENT PHARM THER, V9, P589, DOI 10.1111/j.1365-2036.1995.tb00427.x; TAMM A, 1994, SCAND J GASTROENTERO, V29, P55, DOI 10.3109/00365529409091744; VILLAKO K, 1994, SCAND J GASTROENTERO, V29, P36, DOI 10.3109/00365529409091743; VILOTTE JL, 1989, EUR J BIOCHEM, V186, P43, DOI 10.1111/j.1432-1033.1989.tb15175.x; VILOTTE JL, 1992, GENE, V119, P287, DOI 10.1016/0378-1119(92)90285-W; VILOTTE JL, 1996, ANIMAL GENET, V27, pA99	41	49	56	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					160	164		10.1038/6158	http://dx.doi.org/10.1038/6158			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052352				2022-12-27	WOS:000078508300024
J	Lytton, M				Lytton, M			Confronting consolidation issues: Is this the right move for you?	NATURE BIOTECHNOLOGY			English	Article									Palmer & Dodge, Technol Grp, Boston, MA 02108 USA		Lytton, M (corresponding author), Palmer & Dodge, Technol Grp, 1 Beacon St, Boston, MA 02108 USA.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17			S			BE27	BE28		10.1038/4637	http://dx.doi.org/10.1038/4637			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165PD	10052322	Bronze			2022-12-27	WOS:000078529400013
J	Birchler, M; Viti, F; Zardi, L; Spiess, B; Neri, D				Birchler, M; Viti, F; Zardi, L; Spiess, B; Neri, D			Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment	NATURE BIOTECHNOLOGY			English	Article						recombinant antibody; angiogenesis; photo dynamic therapy; fibronectin isoform; ED-B domain	PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION; FIBRONECTIN ISOFORM; DISPLAY LIBRARY; MARKER; CARCINOMA; DELIVERY; CANCER; DOMAIN	Molecules that selectively target and occlude new blood vessels would be useful for diagnosis and treatment of pathologies associated with angiogenesis. We show that a phage-derived human antibody fragment (L19) with high affinity for the ED-B domain of fibronectin, a marker of angiogenesis, selectively localizes to newly formed blood vessels in a rabbit model of ocular angiogenesis. The L19 antibody, chemically coupled to a photosensitizer and irradiated with red light, mediates complete and selective occlusion of ocular neovasculature and promotes apoptosis of the corresponding endothelial cells. These results demonstrate that new ocular blood vessels can be distinguished immunochemically from preexisting ones and suggest that the targeted delivery of photosensitizers may be effective in treating angiogenesis-related pathologies.	ETH Honggerberg, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland; Ist Nazl Ric Canc, I-16132 Genoa, Italy; Univ Zurich, Vet Chirurg Klin, ETH Zurich, Dept Appl Life Sci, CH-8057 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Genoa; IRCCS AOU San Martino IST; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Neri, D (corresponding author), ETH Honggerberg, Inst Mol Biol & Biophys, Einsteinstr, CH-8093 Zurich, Switzerland.		Neri, Dario/P-4368-2016; Spiess, Bernhard/G-6277-2011	Neri, Dario/0000-0001-5234-7370; 				Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Carnemolla B, 1996, INT J CANCER, V68, P397, DOI 10.1002/(SICI)1097-0215(19961104)68:3<397::AID-IJC20>3.3.CO;2-D; CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Fattorusso R, 1999, STRUCTURE, V7, P381, DOI 10.1016/S0969-2126(99)80051-3; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLLI S, 1994, CANCER RES, V54, P2643; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Haimovici R, 1997, CURR EYE RES, V16, P83, DOI 10.1076/ceyr.16.2.83.5088; HUANG H, 1997, SCIENCE, V275, P547; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6; LEVY JG, 1995, TRENDS BIOTECHNOL, V13, P14, DOI 10.1016/S0167-7799(00)88895-2; LU XM, 1992, J IMMUNOL METHODS, V156, P85; MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480; Murdter TE, 1997, CANCER RES, V57, P2440; Neri D, 1997, NAT BIOTECHNOL, V15, P1271, DOI 10.1038/nbt1197-1271; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; Pini A, 1998, J BIOL CHEM, V273, P21769, DOI 10.1074/jbc.273.34.21769; REGILLO CD, 1994, OPHTHALMOLOGY, V101, P280; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rowe PM, 1998, LANCET, V351, P1496, DOI 10.1016/S0140-6736(05)78884-X; Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092; Tarli L, 1999, BLOOD, V94, P192, DOI 10.1182/blood.V94.1.192.413k22_192_198; van den Bergh H, 1998, ENDOSCOPY, V30, P392, DOI 10.1055/s-2007-1001289; Viti F, 1999, CANCER RES, V59, P347; WAN S, 1981, PHOTOCHEM PHOTOBIOL, V34, P679, DOI 10.1111/j.1751-1097.1981.tb09424.x; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; YARMUSH ML, 1993, CRIT REV THER DRUG, V10, P197; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x; Zetter BR, 1997, NAT BIOTECHNOL, V15, P1243, DOI 10.1038/nbt1197-1243	32	111	136	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					984	988		10.1038/13679	http://dx.doi.org/10.1038/13679			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504699				2022-12-27	WOS:000083015700024
J	Matz, MV; Fradkov, AF; Labas, YA; Savitsky, AP; Zaraisky, AG; Markelov, ML; Lukyanov, SA				Matz, MV; Fradkov, AF; Labas, YA; Savitsky, AP; Zaraisky, AG; Markelov, ML; Lukyanov, SA			Fluorescent proteins from nonbioluminescent Anthozoa species	NATURE BIOTECHNOLOGY			English	Article						green fluorescent protein; fluorophore; Anthozoa	EXTINCTION COEFFICIENTS; BIOLUMINESCENCE; EXCITATION	We have cloned six fluorescent proteins homologous to the green fluorescent protein (GFP) from Aequorea victoria, Two of these have spectral characteristics dramatically different from GFP, emitting at yellow and red wavelengths. All the proteins were isolated from nonbioluminescent reef corals, demonstrating that GFP-like proteins are not always functionally linked to bioluminescence. The new proteins share the same beta-can fold first observed in GFP, and this provided a basis for the comparative analysis of structural features important for fluorescence. The usefulness of the new proteins for in vivo labeling was demonstrated by expressing them in mammalian cell culture and in mRNA microinjection assays in Xenopus embryos.	Russian Acad Sci, Inst Bioorgan Chem, Moscow 117871, Russia; Russian Acad Sci, Inst Ecol & Evolut, Moscow 17071, Russia; Russian Acad Sci, Inst Biochem, Moscow 17071, Russia	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Sciences; Research Center of Biotechnology RAS; Russian Academy of Sciences	Lukyanov, SA (corresponding author), Russian Acad Sci, Inst Bioorgan Chem, Moscow 117871, Russia.		Zaraisky, Andrey G/Q-2323-2016; Savitsky, Alexander P/O-9799-2015; Lukyanov, Sergey/F-9140-2014; Matz, Mikhail V/K-4392-2017	Zaraisky, Andrey G/0000-0003-4681-8169; Savitsky, Alexander P/0000-0002-6820-2341; Matz, Mikhail V/0000-0001-5453-9819				Brejc K, 1997, P NATL ACAD SCI USA, V94, P2306, DOI 10.1073/pnas.94.6.2306; CATALASTUCKI R, 1959, NATURE, V183, P949, DOI 10.1038/183949a0; Chattoraj M, 1996, P NATL ACAD SCI USA, V93, P8362, DOI 10.1073/pnas.93.16.8362; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; DELBEEK JC, 1994, REEF AQUARIUM COMPRE, V2; DELGRAVE S, 1995, BIOTECHNOLOGY, V13, P151; EHRIG T, 1995, FEBS LETT, V367, P163, DOI 10.1016/0014-5793(95)00557-P; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hastings JW, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P17; HELM R, 1995, NATURE, V373, P663; JOHNSON FH, 1962, J CELL COMPAR PHYSL, V60, P85, DOI 10.1002/jcp.1030600111; Kawaguti S., 1944, Palao Tropical Biological Station Studies Tokyo, V2, P617; Kendall JM, 1998, TRENDS BIOTECHNOL, V16, P216, DOI 10.1016/S0167-7799(98)01184-6; LABAS YA, 1973, BIOPHYSICS LIVING CE, V4, P83; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Matz M, 1999, NUCLEIC ACIDS RES, V27, P1558, DOI 10.1093/nar/27.6.1558; MAZEL CH, 1995, MAR ECOL PROG SER, V120, P185, DOI 10.3354/meps120185; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Morin J.G., 1974, pUnpaginated; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PRASHER DC, 1995, TRENDS GENET, V11, P320, DOI 10.1016/S0168-9525(00)89090-3; Rees JF, 1998, J EXP BIOL, V201, P1211; SCHLICHTER D, 1994, OECOLOGIA, V99, P124, DOI 10.1007/BF00317092; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Ward W.W., 1979, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V4, P1; WARD WW, 1979, J BIOL CHEM, V254, P781; Ward WW, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P45; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; ZARAISKY AG, 1995, DEVELOPMENT, V121, P3839	32	1372	1635	5	230	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					969	973		10.1038/13657	http://dx.doi.org/10.1038/13657			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504696				2022-12-27	WOS:000083015700021
J	Link, AJ; Eng, J; Schieltz, DM; Carmack, E; Mize, GJ; Morris, DR; Garvik, BM; Yates, JR				Link, AJ; Eng, J; Schieltz, DM; Carmack, E; Mize, GJ; Morris, DR; Garvik, BM; Yates, JR			Direct analysis of protein complexes using mass spectrometry	NATURE BIOTECHNOLOGY			English	Article						protein identification; mass spectrometry; multidimensional chromatography; ribosome; yeast genome	YEAST RIBOSOMAL-PROTEINS; AMINO-ACID-SEQUENCES; LOW-FEMTOMOLE LEVEL; SACCHAROMYCES-CEREVISIAE; LIQUID-CHROMATOGRAPHY; IDENTIFICATION; PEPTIDES; DATABASE; NOMENCLATURE; SEPARATION	We describe a rapid, sensitive process for comprehensively identifying proteins in macromolecular complexes that uses multidimensional liquid chromatography (LC) and tandem mass spectrometry (MS/MS) to separate and fragment peptides. The SEQUEST algorithm, relying upon translated genomic sequences, infers amino acid sequences from the fragment ions. The method was applied to the Saccharomyces cerevisiae ribosome leading to the identification of a novel protein component of the yeast and human 40S subunit. By offering the ability to identify >100 proteins in a single run, this process enables components in even the largest macromolecular complexes to be analyzed comprehensively.	Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Inst, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Yates, JR (corresponding author), Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA.	jyates@u.washington.edu	Abrams, William R/A-5782-2008; Eng, Jimmy K/I-4202-2012; Morris, David/G-4503-2011	Eng, Jimmy K/0000-0001-6352-6737; 	NATIONAL CANCER INSTITUTE [R01CA039053] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NCI NIH HHS [CA39053] Funding Source: Medline; NCRR NIH HHS [RR11823] Funding Source: Medline; NIGMS NIH HHS [GM52095] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Battaner E, 1971, METHOD ENZYMOL, V20, P446; Chantrel Y, 1998, GENETICS, V148, P559; Cherry JM, 1997, NATURE, V387, P67, DOI 10.1038/387s067; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; GIDDINGS JC, 1987, J HIGH RES CHROMATOG, V10, P319, DOI 10.1002/jhrc.1240100517; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Link AJ, 1997, INT J MASS SPECTROM, V160, P303, DOI 10.1016/S0168-1176(96)04489-8; Link AJ, 1997, ELECTROPHORESIS, V18, P1314, DOI 10.1002/elps.1150180808; LUNDELL N, 1992, CHROMATOGRAPHIA, V34, P369, DOI 10.1007/BF02268370; MAGER WH, 1991, MOL CELL BIOCHEM, V104, P181; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; Neubauer G, 1997, P NATL ACAD SCI USA, V94, P385, DOI 10.1073/pnas.94.2.385; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Opiteck GJ, 1997, ANAL CHEM, V69, P1518, DOI 10.1021/ac961155l; OTAKA E, 1981, MOL GEN GENET, V181, P176, DOI 10.1007/BF00268424; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; RAUE HA, 1991, METHOD ENZYMOL, V194, P453; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Ruan H, 1997, MRNA FORMATION FUNCT, P305, DOI 10.1016/B978-012587545-5/50017-; TAKAHASHI N, 1985, J CHROMATOGR, V326, P407, DOI 10.1016/S0021-9673(01)87466-5; Warner J R, 1978, Methods Cell Biol, V20, P45, DOI 10.1016/S0091-679X(08)62008-7; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020	30	1890	2029	2	322	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					676	682		10.1038/10890	http://dx.doi.org/10.1038/10890			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404161				2022-12-27	WOS:000081296900028
J	Scott, RM; Love, P				Scott, RM; Love, P			Biotechnology is booming in Washington State	NATURE BIOTECHNOLOGY			English	Article									Washington Biotechnol & Biomed Assoc, Seattle, WA 98101 USA		Scott, RM (corresponding author), Washington Biotechnol & Biomed Assoc, 1100 Olive Way,Suite 300, Seattle, WA 98101 USA.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					449	450		10.1038/8623	http://dx.doi.org/10.1038/8623			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331802				2022-12-27	WOS:000080074500027
J	Crompton, T				Crompton, T			Feeding the world, harmoniously	NATURE BIOTECHNOLOGY			English	Editorial Material									UN, Int Dev Org, Int Ctr Genet Engn & Biotechnol, Liaison Off, Vienna, Austria		Crompton, T (corresponding author), UN, Int Dev Org, Int Ctr Genet Engn & Biotechnol, Liaison Off, Vienna, Austria.							CROMPTN T, 1998, J BIOLAW BUS, V2, P60; VONSCHOMBERG R, 1998, 90220EEC STOA	2	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					208	208		10.1038/6908	http://dx.doi.org/10.1038/6908			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096270	Bronze			2022-12-27	WOS:000078977500003
J	Niiler, E				Niiler, E			Demise of the life science company begins	NATURE BIOTECHNOLOGY			English	News Item																			0	3	3	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					14	14		10.1038/71841	http://dx.doi.org/10.1038/71841			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625374				2022-12-27	WOS:000084699900008
J	Lunde, E; Munthe, LA; Vabo, A; Sandlie, I; Bogen, B				Lunde, E; Munthe, LA; Vabo, A; Sandlie, I; Bogen, B			Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells	NATURE BIOTECHNOLOGY			English	Article						recombinant immunoglobulin; MHC class II; antigen processing; vaccination; immunization	COMPLEX CLASS-II; MONOCLONAL-ANTIBODY; IMMUNOGLOBULIN-D; TH2 CLONES; HLA-DR; RECEPTOR; PEPTIDES; MOLECULES; RESPONSES; REGION	We have developed a strategy for improving the stimulation of T cells during immune responses by constructing recombinant antibodies that enhance the delivery of antigen to antigen-presenting cells, such as B cells. These antibodies have variable regions specific for surface molecules on B cells, and a constant region with an inserted antigen. In vitro, such antibodies make B cells approximately 1000-fold more efficient at presenting antigen and stimulating specific T cells. In vivo, the antibodies turn B cells of the spleen into potent stimulators of T cells. This approach may be useful for the generation of new vaccines.	Univ Oslo, Inst Immunol & Rheumatol, N-0172 Oslo, Norway; Univ Oslo, Dept Biol, Oslo, Norway	University of Oslo; University of Oslo	Lunde, E (corresponding author), Univ Oslo, Inst Immunol & Rheumatol, Fr Qvamsgt 1, N-0172 Oslo, Norway.		Munthe, Ludvig/GRJ-3355-2022	Munthe, Ludvig A/0000-0002-0344-3654				ASHWELL JD, 1984, J EXP MED, V159, P881, DOI 10.1084/jem.159.3.881; BAIER G, 1995, J VIROL, V69, P2357, DOI 10.1128/JVI.69.4.2357-2365.1995; BIKOFF EK, 1988, EUR J IMMUNOL, V18, P341, DOI 10.1002/eji.1830180304; BOGEN B, 1989, EMBO J, V8, P1947, DOI 10.1002/j.1460-2075.1989.tb03599.x; BOGEN B, 1990, EUR J IMMUNOL, V20, P2359, DOI 10.1002/eji.1830201030; BOGEN B, 1992, EUR J IMMUNOL, V22, P703, DOI 10.1002/eji.1830220313; Bogen B, 1996, EUR J IMMUNOL, V26, P2671, DOI 10.1002/eji.1830261119; BOGEN B, 1986, EUR J IMMUNOL, V16, P1373, DOI 10.1002/eji.1830161110; BOGEN B, 1986, EUR J IMMUNOL, V16, P1379, DOI 10.1002/eji.1830161111; BONA C, 1994, CELL MOL BIOL, V40, P21; CASTEN LA, 1988, J IMMUNOL, V140, P404; CHANG TL, 1990, J IMMUNOL, V145, P2803; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; DENNERT G, 1980, CELL IMMUNOL, V53, P350, DOI 10.1016/0008-8749(80)90335-4; ESPOSITOFARESE ME, 1995, J IMMUNOL, V155, P1725; GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750; Gerloni M, 1997, NAT BIOTECHNOL, V15, P876, DOI 10.1038/nbt0997-876; HUCK S, 1986, NUCLEIC ACIDS RES, V14, P1779, DOI 10.1093/nar/14.4.1779; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KAWAMURA H, 1986, J IMMUNOL, V136, P58; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAURITZSEN GF, 1991, SCAND J IMMUNOL, V33, P647, DOI 10.1111/j.1365-3083.1991.tb02537.x; LEES A, 1990, J IMMUNOL, V145, P3594; LESK A, 1992, ANTIBODY ENG PRACTIC; LIEBERMAN R, 1978, SPRINGER SEMIN IMMUN, V1, P7, DOI 10.1007/BF00198644; LUCAS B, 1995, J EXP MED, V181, P1623, DOI 10.1084/jem.181.5.1623; Lunde E, 1997, MOL IMMUNOL, V34, P1167, DOI 10.1016/S0161-5890(97)00143-0; Munthe LA, 1996, CELL IMMUNOL, V170, P283, DOI 10.1006/cimm.1996.0162; Norderhaug L, 1997, J IMMUNOL METHODS, V204, P77, DOI 10.1016/S0022-1759(97)00034-3; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; Rudensky A, 1993, Chem Immunol, V57, P134; SAOUDI A, 1995, J EXP MED, V182, P335, DOI 10.1084/jem.182.2.335; SNIDER DP, 1987, J IMMUNOL, V139, P1609; SNIDER DP, 1989, J IMMUNOL, V143, P59; SNODGRASS HR, 1992, EUR J IMMUNOL, V22, P2169, DOI 10.1002/eji.1830220832; SQUIRE CM, 1994, J IMMUNOL, V152, P4388; TISCH R, 1987, P NATL ACAD SCI USA, V84, P3831, DOI 10.1073/pnas.84.11.3831; Xiong SD, 1997, NAT BIOTECHNOL, V15, P882, DOI 10.1038/nbt0997-882; ZAGHOUANI H, 1993, SCIENCE, V259, P224, DOI 10.1126/science.7678469	41	51	57	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					670	675		10.1038/10883	http://dx.doi.org/10.1038/10883			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404160				2022-12-27	WOS:000081296900027
J	Pinto, YM; Kok, RA; Baulcombe, DC				Pinto, YM; Kok, RA; Baulcombe, DC			Resistance to rice yellow mottle virus (RYMV) in cultivated African rice varieties containing RYMV transgenes	NATURE BIOTECHNOLOGY			English	Article						cultivated African rice; virus resistance; RYMV; posttranscriptional gene silencing	DISCHARGE PARTICLE-ACCELERATION; PLANTS; GENE; EXPRESSION; BOMBARDMENT; SEQUENCE; GENOME; DNA	The disease caused by rice yellow mottle virus (RYMV) is a serious problem for African rice growers in large-scale irrigated programs. As there are very few suitable natural sources of RYMV resistance, we have investigated a transgenic approach using widely grown, RYMV-susceptible cultivars of rice and a transgene encoding the RNA-dependent RNA polymerase of RYMV. Transformed lines were resistant to RYMV strains from different African locations. In the most extreme examples there was complete suppression of virus multiplication. Resistance was stable over at least three generations. Subject to satisfactory field testing, these transgenic lines may be suitable for introduction into RYMV-affected rice-growing areas. In the most resistant line, transcription analysis indicated that the resistance derives from an RNA-based mechanism associated with posttranscriptional gene silencing.	John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Baulcombe, DC (corresponding author), John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.			Baulcombe, David/0000-0003-0780-6878				ALBAR A, 1995, ETUDE RICE YELLOW MO, P10; Arencibia A, 1998, MOL BREEDING, V4, P99, DOI 10.1023/A:1009627409668; AWODERU VA, 1991, TROP PEST MANAGE, V37, P356, DOI 10.1080/09670879109371614; BAKKER W, 1974, 829 CTR AGR PUBL DOC, P152; Bendahmane A, 1997, THEOR APPL GENET, V95, P153, DOI 10.1007/s001220050543; CHRISTOU P, 1991, BIO-TECHNOL, V9, P957, DOI 10.1038/nbt1091-957; COOLEY J, 1995, THEOR APPL GENET, V90, P97, DOI 10.1007/BF00221001; Covey SN, 1997, NATURE, V385, P781, DOI 10.1038/385781a0; FAUQUET C, 1977, PLANT DIS REP, V61, P443; FOMBA SN, 1988, PLANT DIS, V72, P641, DOI 10.1094/PD-72-0641; HAYAKAWA T, 1992, P NATL ACAD SCI USA, V89, P9865, DOI 10.1073/pnas.89.20.9865; *IITA, 1985, IITA ANN REP INT I T; Ingelbrecht IL, 1999, PLANT PHYSIOL, V119, P1187, DOI 10.1104/pp.119.4.1187; Itoh K, 1997, MOL GEN GENET, V255, P351, DOI 10.1007/s004380050506; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; Kohli A, 1998, P NATL ACAD SCI USA, V95, P7203, DOI 10.1073/pnas.95.12.7203; Kumpatla SP, 1997, PLANT PHYSIOL, V115, P361, DOI 10.1104/pp.115.2.361; LINDBO JA, 1992, MOL PLANT MICROBE IN, V5, P144, DOI 10.1094/MPMI-5-144; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; MAKINEN K, 1995, J GEN VIROL, V76, P2817, DOI 10.1099/0022-1317-76-11-2817; Morino K, 1999, PLANT J, V17, P275, DOI 10.1046/j.1365-313X.1999.00373.x; MUELLER E, 1995, PLANT J, V7, P1001, DOI 10.1046/j.1365-313X.1995.07061001.x; NGON A, 1994, VIROLOGY, V206, P287; Oard JH, 1996, MOL BREEDING, V2, P359, DOI 10.1007/BF00437914; Rubio T, 1999, MOL PLANT MICROBE IN, V12, P87, DOI 10.1094/MPMI.1999.12.2.87; Sambrook J., 2002, MOL CLONING LAB MANU; SANFORD JC, 1985, J THEOR BIOL, V113, P395, DOI 10.1016/S0022-5193(85)80234-4; SMITH HA, 1994, PLANT CELL, V6, P1441, DOI 10.1105/tpc.6.10.1441; STARN M, 1997, PLANT J, V12, P63; Takano M, 1997, PLANT J, V11, P353, DOI 10.1046/j.1365-313X.1997.11030353.x; Vain P, 1998, THEOR APPL GENET, V96, P266, DOI 10.1007/s001220050735; VAIN P, 1993, PLANT CELL REP, V12, P84, DOI 10.1007/BF00241940; *WARDA, 1994, WARDA ANN REP W AFR; Zheng HH, 1997, THEOR APPL GENET, V94, P522, DOI 10.1007/s001220050446	34	62	93	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					702	707		10.1038/10917	http://dx.doi.org/10.1038/10917			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404165				2022-12-27	WOS:000081296900032
J	Ward, E; Bernasconi, P				Ward, E; Bernasconi, P			Target-based discovery of crop protection chemicals	NATURE BIOTECHNOLOGY			English	Editorial Material									Novartis Agribusiness Biotechnol Res, Res Triangle Pk, NC USA		Ward, E (corresponding author), Novartis Agribusiness Biotechnol Res, Res Triangle Pk, NC USA.								0	14	15	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					618	619		10.1038/10795	http://dx.doi.org/10.1038/10795			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10409336				2022-12-27	WOS:000081296900004
J	Endersby, JM				Endersby, JM			Kick-starting biotechnology in Ontario	NATURE BIOTECHNOLOGY			English	Article																		*GOV CAN, 1999 BUDG SPEECH; *GOV ONT, 1998, FUT RIGHT HER SUMM R; *KPMG, 1999, COMP ALT; *NAT BIOT ADV COMM, 1998, LEAD NEXT MILL 6 REP; *OECD, 1997, MAIN SCI TECHN IND 1; ONTARIO MINISTRY FIN; 1998, CONSENSUS FORECA SEP	7	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					444	446		10.1038/8614	http://dx.doi.org/10.1038/8614			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331800				2022-12-27	WOS:000080074500025
J	Brune, W; Menard, C; Hobom, U; Odenbreit, S; Messerle, M; Koszinowski, UH				Brune, W; Menard, C; Hobom, U; Odenbreit, S; Messerle, M; Koszinowski, UH			Rapid identification of essential and nonessential herpesvirus genes by direct transposon mutagenesis	NATURE BIOTECHNOLOGY			English	Article						BAC; transposon mutagenesis; cytomegalovirus; functional genomics	SIMPLEX VIRUS TYPE-1; MURINE CYTOMEGALOVIRUS; SHUTTLE MUTAGENESIS; MINI-TRANSPOSON; REPLICATION; SEQUENCE; GENOME; DNA; DELETION; CLONING	Herpesviruses are important pathogens in animals and humans. The large DNA genomes of several herpesviruses have been sequenced, but the function of the majority of putative genes is elusive. Determining which genes are essential for their replication is important for identifying potential chemotherapy targets, designing herpesvirus vectors, and generating attenuated vaccines. For this purpose, we recently reported that herpesvirus genomes can be maintained as infectious bacterial artificial chromosomes (BAC) in Escherichia coli. Here we describe a one-step procedure for random-insertion mutagenesis of a herpesvirus BAC using a Tn1721-based transposon system. Transposon insertion sites were determined by direct sequencing, and infectious virus was recovered by transfecting cultured cells with the mutant genomes. Lethal mutations were rescued by cotransfecting cells containing noninfectious genomes with the corresponding wild-type subgenomic fragments. We also constructed revertant genomes by allelic exchange in bacteria. These methods, which are generally applicable to any cloned herpesvirus genome, will facilitate analysis of gene function for this virus family.	Univ Munich, Max Von Pettenkofer Inst, Dept Virol, D-80336 Munich, Germany; Univ Munich, Max Von Pettenkofer Inst, Dept Bacteriol, D-80336 Munich, Germany	University of Munich; University of Munich	Koszinowski, UH (corresponding author), Univ Munich, Max Von Pettenkofer Inst, Dept Virol, Pettenkoferstr 9A, D-80336 Munich, Germany.	koszinowski@m3401.mpk.med.uni-muenchen.de	Brune, Wolfram/H-5058-2019	Brune, Wolfram/0000-0002-6078-5255; Messerle, Martin/0000-0002-1227-3933				BERG CM, 1989, MOBILE DNA, P879; BLOMFIELD IC, 1991, MOL MICROBIOL, V5, P1447, DOI 10.1111/j.1365-2958.1991.tb00791.x; CHANG YE, 1993, J VIROL, V67, P6348, DOI 10.1128/JVI.67.11.6348-6356.1993; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; EBELING A, 1983, J VIROL, V47, P421, DOI 10.1128/JVI.47.3.421-433.1983; GLORIOSO JC, 1995, ANNU REV MICROBIOL, V49, P675, DOI 10.1146/annurev.mi.49.100195.003331; HAAS R, 1993, GENE, V130, P23, DOI 10.1016/0378-1119(93)90342-Z; Hengel H, 1998, TRENDS MICROBIOL, V6, P190, DOI 10.1016/S0966-842X(98)01255-4; JENKINS FJ, 1986, J VIROL, V59, P494, DOI 10.1128/JVI.59.2.494-499.1986; JENKINS FJ, 1985, P NATL ACAD SCI USA, V82, P4773, DOI 10.1073/pnas.82.14.4773; Kahrs AF, 1995, GENE, V167, P53, DOI 10.1016/0378-1119(95)00671-0; Martinez R, 1996, J VIROL, V70, P2075, DOI 10.1128/JVI.70.4.2075-2085.1996; Messerle M, 1997, P NATL ACAD SCI USA, V94, P14759, DOI 10.1073/pnas.94.26.14759; Mocarski E, 1996, FIELDS VIROLOGY, P2447; Mocarski ES, 1996, INTERVIROLOGY, V39, P320, DOI 10.1159/000150503; Posfai G, 1997, J BACTERIOL, V179, P4426, DOI 10.1128/jb.179.13.4426-4428.1997; Rawlinson WD, 1996, J VIROL, V70, P8833, DOI 10.1128/JVI.70.12.8833-8849.1996; Roizman B, 1996, FIELDS VIROLOGY, P2231; SACKS WR, 1987, J VIROL, V61, P829, DOI 10.1128/JVI.61.3.829-839.1987; Simon MI, 1997, NAT BIOTECHNOL, V15, P839, DOI 10.1038/nbt0997-839; SPAETE RR, 1994, J GEN VIROL, V75, P3287, DOI 10.1099/0022-1317-75-12-3287; Stavropoulos TA, 1998, J VIROL, V72, P7137, DOI 10.1128/JVI.72.9.7137-7143.1998; WEBER PC, 1987, SCIENCE, V236, P576, DOI 10.1126/science.3033824	24	90	95	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					360	364		10.1038/7914	http://dx.doi.org/10.1038/7914			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207884				2022-12-27	WOS:000079574400024
J	Cherry, JR; Lamsa, MH; Schneider, P; Vind, J; Svendsen, A; Jones, A; Pedersen, AH				Cherry, JR; Lamsa, MH; Schneider, P; Vind, J; Svendsen, A; Jones, A; Pedersen, AH			Directed evolution of a fungal peroxidase	NATURE BIOTECHNOLOGY			English	Article						peroxidase; directed evolution; thermostability; DNA shuffling; protein engineering	COPRINUS-CINEREUS PEROXIDASE; SACCHAROMYCES-CEREVISIAE; PROTEIN; ACID; THERMOSTABILITY; RECOMBINATION; GENES	The Coprinus cinereus (CIP) heme peroxidase was subjected to multiple rounds of directed evolution in an effort to produce a mutant suitable for use as a dye-transfer inhibitor in laundry detergent. The wild-type peroxidase is rapidly inactivated under laundry conditions due to the high pH (10.5), high temperature (50 degrees C), and high peroxide concentration (5-10 mM). Peroxidase mutants were initially generated using two parallel approaches: site-directed mutagenesis based on structure-function considerations, and error-prone PCR to create random mutations. Mutants were expressed in Saccharomyces cerevisiae and screened for improved stability by measuring residual activity after incubation under conditions mimicking those in a washing machine. Manually combining mutations from the site-directed and random approaches led to a mutant with 110 times the thermal stability and 2.8 times the oxidative stability of wild-type CiP. In the final two rounds, mutants were randomly recombined by using the efficient yeast homologous recombination system to shuffle point mutations among a large number of parents, This in vivo shuffling led to the most dramatic improvements in oxidative stability, yielding a mutant with 174 times the thermal stability and 100 times the oxidative stability of wild-type CiP.	Novo Nordisk Biotech Inc, Davis, CA 95616 USA; Novo Nordisk AS, Enzyme Design, DK-2880 Bagsvaerd, Denmark	Novo Nordisk; Novo Nordisk	Cherry, JR (corresponding author), Novo Nordisk Biotech Inc, 1445 Drew Ave, Davis, CA 95616 USA.	cherry@nnbt.com						Abelskov AK, 1997, BIOCHEMISTRY-US, V36, P9453, DOI 10.1021/bi970387r; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Kuchner O, 1997, TRENDS BIOTECHNOL, V15, P523, DOI 10.1016/S0167-7799(97)01138-4; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Leung DW, 1989, TECHNIQUE, V1, P11; LopezCamacho C, 1996, BIOCHEM J, V314, P833, DOI 10.1042/bj3140833; MANIVASAKAM P, 1993, NUCLEIC ACIDS RES, V21, P4414, DOI 10.1093/nar/21.18.4414; MANIVASAKAM P, 1995, NUCLEIC ACIDS RES, V23, P2799, DOI 10.1093/nar/23.14.2799; MATSUMURA M, 1986, NATURE, V323, P356, DOI 10.1038/323356a0; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; Nedwin GE, 1997, ENVIR SCI R, V54, P13; PETERSEN JFW, 1993, J MOL BIOL, V232, P989, DOI 10.1006/jmbi.1993.1445; POMPON D, 1989, GENE, V83, P15, DOI 10.1016/0378-1119(89)90399-5; POULOS TL, 1980, J BIOL CHEM, V255, P8199; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Zhao HM, 1997, NUCLEIC ACIDS RES, V25, P1307, DOI 10.1093/nar/25.6.1307	19	248	278	2	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					379	384		10.1038/7939	http://dx.doi.org/10.1038/7939			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207888				2022-12-27	WOS:000079574400028
J	Huls, GA; Heijnen, IAFM; Cuomo, ME; Koningsberger, JC; Wiegman, L; Boel, E; de Vries, ARV; Loyson, SAJ; Helfrich, W; Henegouwen, GPV; van Meijer, M; de Kruif, J; Logtenberg, T				Huls, GA; Heijnen, IAFM; Cuomo, ME; Koningsberger, JC; Wiegman, L; Boel, E; de Vries, ARV; Loyson, SAJ; Helfrich, W; Henegouwen, GPV; van Meijer, M; de Kruif, J; Logtenberg, T			A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments	NATURE BIOTECHNOLOGY			English	Article						phage display; Ep-CAM; single-chain Fv; immunotherapy; recombinant antibodies	IMMUNE-RESPONSE; HUMAN IGG1; MOUSE; THERAPY; ANTIGEN; PHARMACOKINETICS; IMMUNOTHERAPY; GLYCOPROTEIN; RECOGNITION; SELECTION	A single-chain Fv antibody fragment specific for the tumor-associated Ep-CAM molecule was isolated from a semisynthetic phage display library and converted into an intact, fully human IgG1 monoclonal antibody (huMab), The purified huMab had an affinity of 5 nM and effectively mediated tumor cell killing in: in vitro and in vivo assays. These experiments show that nonimmunized phage antibody display libraries can be used to obtain high-affinity, functional, and clinically applicable huMabs directed against a tumor-associated antigen.	Univ Utrecht Hosp, Dept Immunol, Utrecht, Netherlands; Univ Utrecht Hosp, Dept Gastroenterol, Utrecht, Netherlands; Univ Utrecht Hosp, Dept Pathol, Utrecht, Netherlands; Univ Utrecht Hosp, Dept Microbiol, Utrecht, Netherlands; Univ Utrecht Hosp, Utrecht Biotechnol Syst, Utrecht, Netherlands; Univ Groningen Hosp, Dept Clin Immunol, NL-9713 EZ Groningen, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Groningen	Logtenberg, T (corresponding author), Univ Utrecht Hosp, Dept Immunol, Utrecht, Netherlands.	t.logtenberg@lab.azu.nl	Huls, G.A./L-4398-2015	Helfrich, Wijnand/0000-0001-7004-3995				Balzar M, 1998, MOL CELL BIOL, V18, P4833, DOI 10.1128/MCB.18.8.4833; Bruggemann M, 1996, IMMUNOL TODAY, V17, P391, DOI 10.1016/0167-5699(96)10025-6; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; DEKRUIF J, 1995, J MOL BIOL, V248, P97, DOI 10.1006/jmbi.1995.0204; DEKRUIF J, 1995, P NATL ACAD SCI USA, V92, P3938, DOI 10.1073/pnas.92.9.3938; deKruif J, 1996, FEBS LETT, V399, P232, DOI 10.1016/S0014-5793(96)01335-X; DELEIJ L, 1994, INT J CANCER, P60; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; GOTTLINGER HG, 1986, INT J CANCER, V38, P47; HAKIMI J, 1991, J IMMUNOL, V147, P1352; HALE JE, 1995, ANAL BIOCHEM, V231, P46, DOI 10.1006/abio.1995.1501; Heijnen I A, 1997, Int Rev Immunol, V16, P29, DOI 10.3109/08830189709045702; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; JUNGHANS RP, 1990, CANCER RES, V50, P1495; KARLSSON R, 1991, J IMMUNOL METHODS, V198, P129; KHAZAELI MB, 1989, CANCER RES, V51, P5461; LANKHOF H, 1996, THESIS U UTRECHT NET; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; LIU AY, 1987, P NATL ACAD SCI USA, V84, P3439, DOI 10.1073/pnas.84.10.3439; LOBUGLIO AF, 1989, P NATL ACAD SCI USA, V86, P4220, DOI 10.1073/pnas.86.11.4220; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; MEERMAN HJ, 1994, BIO-TECHNOL, V12, P1107, DOI 10.1038/nbt1194-1107; Mendez MJ, 1997, NAT GENET, V15, P146, DOI 10.1038/ng0297-146; MILLER RA, 1983, BLOOD, V62, P988; MOMBURG F, 1987, CANCER RES, V47, P2883; NARAMURA M, 1993, CANCER IMMUNOL IMMUN, V37, P343, DOI 10.1007/BF01518458; NISHIMURA Y, 1987, CANCER RES, V47, P999; PAK KY, 1991, NUCL MED BIOL, V18, P483; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; RIETHMULLER G, 1994, LANCET, V343, P1177, DOI 10.1016/S0140-6736(94)92398-1; SHAWLER DL, 1985, J IMMUNOL, V135, P1530; SIMON B, 1990, P NATL ACAD SCI USA, V87, P2755, DOI 10.1073/pnas.87.7.2755; STEPHENS S, 1995, IMMUNOLOGY, V85, P668; STEPLEWSKI Z, 1988, P NATL ACAD SCI USA, V85, P4852, DOI 10.1073/pnas.85.13.4852; TAKAHASHI H, 1995, GASTROENTEROLOGY, V108, P172, DOI 10.1016/0016-5085(95)90022-5; THAMPOE IJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P342, DOI 10.1016/0003-9861(88)90040-9; VALERIUS T, 1993, BLOOD, V82, P931; VANSTRIJP JAG, 1989, J CLIN INVEST, V84, P107, DOI 10.1172/JCI114129; Vaughan TJ, 1998, NAT BIOTECHNOL, V16, P535, DOI 10.1038/nbt0698-535; Velders MP, 1996, J IMMUNOTHER, V19, P245, DOI 10.1097/00002371-199607000-00001; Vincenti F, 1998, NEW ENGL J MED, V338, P161, DOI 10.1056/NEJM199801153380304; WALKER MR, 1989, BIOCHEM J, V259, P347, DOI 10.1042/bj2590347; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	45	79	102	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					276	281		10.1038/7023	http://dx.doi.org/10.1038/7023			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096296				2022-12-27	WOS:000078977500030
J	Li, XY; Eastman, EM; Schwartz, RJ; Draghia-Akli, R				Li, XY; Eastman, EM; Schwartz, RJ; Draghia-Akli, R			Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences	NATURE BIOTECHNOLOGY			English	Article						gene therapy; myogenic regulatory elements; human growth hormone releasing hormone	ALPHA-ACTIN GENE; M-CAT ELEMENTS; PLASMID DNA; EXPRESSION; TRANSCRIPTION; MYOGENESIS; VECTOR; INJECTION; MODULATE; INVIVO	Relatively low levels of expression from naturally occurring promoters have limited the use of muscle as a gene therapy target. Myogenic restricted gene promoters display complex organization usually involving combinations of several myogenic regulatory elements. By random assembly of E-box, MEF-2, TEF-1, and SRE sites into synthetic promoter recombinant libraries, and screening of hundreds of individual clones for transcriptional activity in vitro and in vivo, several artificial promoters were isolated whose transcriptional potencies greatly exceed those of natural myogenic and viral gene promoters.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; GeneMed, The Woodlands, TX 77318 USA	Baylor College of Medicine	Schwartz, RJ (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	schwartz@bcm.tmc.edu		Draghia-Akli, Ruxandra/0000-0001-6372-4039				ACSADI G, 1991, NEW BIOL, V3, P71; Barnhart KM, 1998, HUM GENE THER, V9, P2545; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; CHOW KL, 1991, P NATL ACAD SCI USA, V88, P1301, DOI 10.1073/pnas.88.4.1301; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; Draghia-Akli R, 1997, NAT BIOTECHNOL, V15, P1285, DOI 10.1038/nbt1197-1285; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Haase G, 1997, NAT MED, V3, P429, DOI 10.1038/nm0497-429; Hartikka J, 1996, HUM GENE THER, V7, P1205, DOI 10.1089/hum.1996.7.10-1205; HAYWARD LJ, 1986, J CELL BIOL, V102, P1485, DOI 10.1083/jcb.102.4.1485; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1994, ONCOGENE, V9, P1047; Machon O, 1998, GENE, V208, P73, DOI 10.1016/S0378-1119(97)00659-8; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; Montgomery DL, 1997, PHARMACOL THERAPEUT, V74, P195, DOI 10.1016/S0163-7258(97)82003-7; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; SCHWARTZ RJ, 1981, BIOCHEMISTRY-US, V20, P4122, DOI 10.1021/bi00517a027; Skarli M, 1998, GENE THER, V5, P514, DOI 10.1038/sj.gt.3300618; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363	24	182	225	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					241	245		10.1038/6981	http://dx.doi.org/10.1038/6981			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096290				2022-12-27	WOS:000078977500024
J	Walsh, G				Walsh, G			Drug approval in Europe - The EMEA gets good grades, but has room for improvement	NATURE BIOTECHNOLOGY			English	Article									Univ Limerick, Limerick, Ireland	University of Limerick	Walsh, G (corresponding author), Univ Limerick, Limerick, Ireland.		Walsh, Gary/X-1951-2019	Walsh, Gary/0000-0002-1300-8314					0	3	3	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					237	240		10.1038/6977	http://dx.doi.org/10.1038/6977			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096289				2022-12-27	WOS:000078977500023
J	Umana, P; Jean-Mairet, J; Moudry, R; Amstutz, H; Bailey, JE				Umana, P; Jean-Mairet, J; Moudry, R; Amstutz, H; Bailey, JE			Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity	NATURE BIOTECHNOLOGY			English	Article						glycosylation; effector function; antitumor antibody; tetracycline	TIME-OF-FLIGHT; MONOCLONAL-ANTIBODY; MASS-SPECTROMETRY; IN-VIVO; OLIGOSACCHARIDES; CELLS; GLYCOSYLATION; NEUROBLASTOMA; EXPRESSION; MODULATE	The glycosylation pattern of chCE7, an antineuroblastoma chimeric IgG1, was engineered in Chinese hamster ovary cells with tetracycline-regulated expression of beta(1,4)-N-acetylglucosaminyltransferase III (GnTIII), a glycosyltransferase catalyzing formation of bisected oligosaccharides that have been implicated in antibody-dependent cellular cytotoxicity (ADCC). Measurement of the ADCC activity of chCE7 produced at different tetracycline levels showed an optimal range of GnTIII expression for maximal chCE7 in vitro ADCC activity, and this activity correlated with the level of constant region-associated, bisected complex oligosaccharides determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The new optimized variants of chCE7 exhibit substantial ADCC activity and, hence, may be useful for treatment of neuroblastoma. The strategy presented here should be applicable to optimize the ADCC activity of other therapeutic IgGs.	ETH Zurich, Inst Biotechnol, CH-8093 Zurich, Switzerland; Swiss Red Cross, Blood Transfus Serv, Cent Lab, ZLB, CH-3000 Bern 22, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Bailey, JE (corresponding author), ETH Zurich, Inst Biotechnol, CH-8093 Zurich, Switzerland.							AMSTUTZ H, 1993, INT J CANCER, V53, P147, DOI 10.1002/ijc.2910530127; BERGWERFF AA, 1995, GLYCOCONJUGATE J, V12, P318, DOI 10.1007/BF00731335; BIBILA TA, 1995, BIOTECHNOL PROGR, V11, P1, DOI 10.1021/bp00031a001; CLACKSON T, 1991, PCR PRACTICAL APPROA, P187; Deo YM, 1997, IMMUNOL TODAY, V18, P127, DOI 10.1016/S0167-5699(97)01007-4; Dillman RO, 1997, CANCER BIOTHER RADIO, V12, P223, DOI 10.1089/cbr.1997.12.223; DURR U, 1993, EUR J NUCL MED, V20, P858; Field M, 1996, ANAL BIOCHEM, V239, P92, DOI 10.1006/abio.1996.0295; Frost JD, 1997, CANCER, V80, P317, DOI 10.1002/(SICI)1097-0142(19970715)80:2<317::AID-CNCR21>3.0.CO;2-W; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARVEY DJ, 1993, RAPID COMMUN MASS SP, V7, P614, DOI 10.1002/rcm.1290070712; KNSTER B, 1997, ANAL BIOCHEM, V250, P82; KOLBER MA, 1988, J IMMUNOL METHODS, V108, P255, DOI 10.1016/0022-1759(88)90427-9; Lifely MR, 1995, GLYCOBIOLOGY, V5, P813, DOI 10.1093/glycob/5.8.813; Lund J, 1996, J IMMUNOL, V157, P4963; Naven TJP, 1996, RAPID COMMUN MASS SP, V10, P1361, DOI 10.1002/(SICI)1097-0231(199608)10:11<1361::AID-RCM642>3.0.CO;2-A; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; REFF ME, 1994, BLOOD, V83, P435; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; STANLEY P, 1984, J BIOL CHEM, V261, P13370; Surfus JE, 1996, J IMMUNOTHER, V19, P184, DOI 10.1097/00002371-199605000-00003; TRILL JJ, 1995, CURR OPIN BIOTECH, V6, P553, DOI 10.1016/0958-1669(95)80092-1; Wormald MR, 1997, BIOCHEMISTRY-US, V36, P1370, DOI 10.1021/bi9621472; Wright A, 1997, TRENDS BIOTECHNOL, V15, P26, DOI 10.1016/S0167-7799(96)10062-7; YU IP, 1994, ARCH BIOCHEM BIOPHYS, V308, P387	26	573	1043	1	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					176	180		10.1038/6179	http://dx.doi.org/10.1038/6179			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052355				2022-12-27	WOS:000078508300027
J	Ballinger, MD; Shyamala, V; Forrest, LD; Deuter-Reinhard, M; Doyle, LV; Wang, JX; Panganiban-Lustan, L; Stratton, JR; Apell, G; Winter, JA; Doyle, MV; Rosenberg, S; Kavanaugh, WM				Ballinger, MD; Shyamala, V; Forrest, LD; Deuter-Reinhard, M; Doyle, LV; Wang, JX; Panganiban-Lustan, L; Stratton, JR; Apell, G; Winter, JA; Doyle, MV; Rosenberg, S; Kavanaugh, WM			Semirational design of a potent, artificial agonist of fibroblast growth factor receptors	NATURE BIOTECHNOLOGY			English	Article						fibroblast growth factor; protein design; receptors; ligands; cytokines; mimetics; angiogenesis	RABBIT MODEL; BINDING; DIMERIZATION; ACTIVATION; ISCHEMIA; OLIGOMERIZATION; ANGIOGENESIS; SPECIFICITY; PEPTIDES; DOMAINS	Fibroblast growth factors (FGFs) are being investigated in human clinical trials as treatments for angina, claudication, and stroke. We designed a molecule structurally unrelated to all FGFs, which potently mimicked basic FGF activity, by combining domains that (1) bind FGF receptors (2) bind heparin, and (3) mediate dimerization. A 26-residue peptide identified by phage display specifically bound FGF receptor (FGFR) Ic extracellular domain but had no homology with FGFs. When fused with the c-jun leucine zipper domain, which binds heparin and forms homodimers, the polypeptide specifically reproduced the mitogenic and morphogenic activities of basic FGF with similar potency (EC50= 240 pM). The polypeptide required interaction with heparin for activity, demonstrating the importance of heparin for FGFR activation even with designed ligands structurally unrelated to FGF. Our results demonstrate the feasibility of engineering potent artificial agonists for the receptor tyrosine kinases, and have important implications for the design of nonpeptidic ligands for FGF receptors. Furthermore, artificial FGFR agonists may be useful alternatives to FGF in the treatment of ischemic vascular disease.	Chiron Corp, Oakland, CA 94608 USA	Novartis	Kavanaugh, WM (corresponding author), Chiron Corp, 4560 Horton St,Room 4-4144, Oakland, CA 94608 USA.	Mike_Kavanaugh@cc.chiron.com						ASAHARA T, 1995, CIRCULATION, V92, P365, DOI 10.1161/01.CIR.92.9.365; BAFFOUR R, 1992, J VASC SURG, V16, P181, DOI 10.1016/0741-5214(92)90106-I; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; CLAUDE P, 1988, NEURON, V1, P783, DOI 10.1016/0896-6273(88)90126-2; CRAMERI R, 1995, GENE, V160, P139, DOI 10.1016/0378-1119(95)00190-H; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; deKruif J, 1996, J BIOL CHEM, V271, P7630, DOI 10.1074/jbc.271.13.7630; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; DOYLE MV, 1996, COMBINATORIAL LIB SY, P171; GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HARADA K, 1994, J CLIN INVEST, V94, P623, DOI 10.1172/JCI117378; HULME EC, 1993, RECEPTOR LIGAND INTE, P101; Kiefer M C, 1991, Growth Factors, V5, P115, DOI 10.3109/08977199109000276; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LANDAU C, 1995, AM HEART J, V129, P924, DOI 10.1016/0002-8703(95)90113-2; LAZAROUS DF, 1995, CIRCULATION, V91, P145, DOI 10.1161/01.CIR.91.1.145; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PATEL LR, 1994, P NATL ACAD SCI USA, V91, P7360, DOI 10.1073/pnas.91.15.7360; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Ray J, 1997, P NATL ACAD SCI USA, V94, P7047, DOI 10.1073/pnas.94.13.7047; RILEY LG, 1994, EUR J BIOCHEM, V219, P877, DOI 10.1111/j.1432-1033.1994.tb18569.x; Shyamala V, 1999, ANAL BIOCHEM, V266, P140, DOI 10.1006/abio.1998.2922; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Tian SS, 1998, SCIENCE, V281, P257, DOI 10.1126/science.281.5374.257; Waksman G, 1998, NAT STRUCT BIOL, V5, P527, DOI 10.1038/778; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILKIE AOM, 1995, CURR BIOL, V5, P500; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; YANAGISAWAMIWA A, 1992, SCIENCE, V257, P1401, DOI 10.1126/science.1382313; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643; Zhang B, 1999, SCIENCE, V284, P974, DOI 10.1126/science.284.5416.974	38	57	79	2	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1199	1204		10.1038/70746	http://dx.doi.org/10.1038/70746			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585718				2022-12-27	WOS:000084170700028
J	Gutierrez-Campos, R; Torres-Acosta, JA; Saucedo-Arias, LJ; Gomez-Lim, MA				Gutierrez-Campos, R; Torres-Acosta, JA; Saucedo-Arias, LJ; Gomez-Lim, MA			The use of cysteine proteinase inhibitors to engineer resistance against potyviruses in transgenic tobacco plants	NATURE BIOTECHNOLOGY			English	Article						genetic engineering; transgenic plants; potyvirus; tobacco etch virus; tobacco; proteinase inhibitors; virus resistance	EXPRESSION; VIRUS; ORYZACYSTATIN; CYSTATINS; CLONING; RICE; RNA; MULTICYSTATIN; PRODUCTS; SEEDS	As the processing mechanism of all known potyviruses involves the activity of cysteine proteinases, we asked whether constitutive expression of a rice cysteine proteinase inhibitor gene could induce resistance against two important potyviruses, tobacco etch virus (TEV) and potato virus Y (PVY), in transgenic tobacco plants. Tobacco lines expressing the foreign gene at varying levels were examined for resistance against TEV and PVY infection. There was a clear, direct correlation between the level of oryzacystatin message, inhibition of papain (a cysteine proteinase), and resistance to TEV and PVY in all lines tested. The inhibitor was ineffective against tobacco mosaic virus (TMV) infection because processing of this virus does not involve cysteine proteinases. These results show that plant cystatins can be used against different potyviruses and potentially also against other viruses, whose replication involves cysteine proteinase activity.	Ctr Invest & Estudios Avanzados, Dept Ingn Genet, Unidad Irapuato, Irapuato, Mexico; Univ Autonoma Aguascalientes, Ctr Basico, Dept Quim, Aguascalientes 20100, Ags, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Universidad Autonoma de Aguascalientes	Gomez-Lim, MA (corresponding author), Ctr Invest & Estudios Avanzados, Dept Ingn Genet, Unidad Irapuato, Apartado Postal 629, Irapuato, Mexico.			gomez lim, MIGUEL ANGEL/0000-0002-5589-0720				ABE K, 1987, J BIOL CHEM, V262, P16793; AOKI H, 1995, ANTIMICROB AGENTS CH, V39, P846, DOI 10.1128/AAC.39.4.846; AUDY P, 1994, MOL PLANT MICROBE IN, V7, P15, DOI 10.1094/MPMI-7-0015; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DOPICO B, 1993, PLANT MOL BIOL, V21, P437, DOI 10.1007/BF00028802; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; DOUGHERTY WG, 1980, VIROLOGY, V101, P466, DOI 10.1016/0042-6822(80)90460-2; DOUGHERTY WG, 1988, ANNU REV PHYTOPATHOL, V26, P123, DOI 10.1146/annurev.py.26.090188.001011; FERNANDES KVS, 1993, PLANT MOL BIOL, V23, P215, DOI 10.1007/BF00021433; GAN SS, 1995, SCIENCE, V270, P1986, DOI 10.1126/science.270.5244.1986; GERLACH WL, 1979, NUCLEIC ACIDS RES, V7, P1869, DOI 10.1093/nar/7.7.1869; HAMILL JD, 1991, PLANT CELL REP, V10, P221, DOI 10.1007/BF00232562; HEINS ME, 1991, J AGR FOOD CHEM, V39, P1515; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HOSOYAMA H, 1994, BIOSCI BIOTECH BIOCH, V58, P1500, DOI 10.1271/bbb.58.1500; Irie K, 1996, PLANT MOL BIOL, V30, P149, DOI 10.1007/BF00017809; KASSCHAU KD, 1995, VIROLOGY, V209, P268, DOI 10.1006/viro.1995.1254; LINDBO JA, 1992, MOL PLANT MICROBE IN, V5, P144, DOI 10.1094/MPMI-5-144; LING K, 1991, BIO-TECHNOL, V9, P752, DOI 10.1038/nbt0891-752; LOMONOSSOFF GP, 1995, ANNU REV PHYTOPATHOL, V33, P323, DOI 10.1146/annurev.py.33.090195.001543; LOPEZGOMEZ R, 1992, HORTSCIENCE, V27, P440, DOI 10.21273/HORTSCI.27.5.440; MACHLEIDT W, 1993, INNOVATIONS PROTEASE, P349; MAITI IB, 1993, P NATL ACAD SCI USA, V90, P6110, DOI 10.1073/pnas.90.13.6110; MASOUD SA, 1993, PLANT MOL BIOL, V21, P655, DOI 10.1007/BF00014548; ORR GL, 1994, J INSECT PHYSIOL, V40, P893, DOI 10.1016/0022-1910(94)90023-X; REGNER F, 1992, PLANT CELL REP, V11, P30, DOI 10.1007/BF00231835; RIECHMANN JL, 1992, J GEN VIROL, V73, P1, DOI 10.1099/0022-1317-73-1-1; Sambrook J., 2002, MOL CLONING LAB MANU; SHIH DS, 1987, J VIROL, V61, P912, DOI 10.1128/JVI.61.3.912-915.1987; Spall VE, 1997, SEMIN VIROL, V8, P15, DOI 10.1006/smvy.1997.0102; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; URWIN PE, 1995, PLANT J, V8, P1021; WALDRON C, 1993, PLANT MOL BIOL, V23, P801, DOI 10.1007/BF00021535	34	125	139	1	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1223	1226		10.1038/70781	http://dx.doi.org/10.1038/70781			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585723				2022-12-27	WOS:000084170700033
J	Subramanian, A; Ranganathan, P; Diamond, SL				Subramanian, A; Ranganathan, P; Diamond, SL			Nuclear targeting peptide scaffolds for lipofection of nondividing mammalian cells	NATURE BIOTECHNOLOGY			English	Article						gene transfer; endothelium; lipofection; nuclear import	ADENOVIRUS-DEPENDENT RELEASE; PROTEIN IMPORT PATHWAY; GENE-TRANSFER; ENDOTHELIAL-CELLS; CATIONIC LIPOSOMES; PLASMID DNA; ARTERIAL-WALL; ACIDIC PH; DELIVERY; EXPRESSION	Lipofection of nondividing cells is inefficient because much of the transfected DNA is retained in endosomes, and that which escapes to the cytoplasm enters the nucleus at low rates. To improve the final rate-limiting step of nuclear import, we conjugated a nonclassical nuclear localization signal (NLS) containing the M9 sequence of heterogeneous nuclear ribonucleoprotein (hnRNP) A1, to a cationic peptide scaffold derived from a scrambled sequence of the SV40 T-antigen consensus NLS (ScT). The ScT was added to improve DNA binding of the M9 sequence. Lipofection of confluent endothelium with plasmid complexed with the M9-ScT conjugate resulted in 83% transfection and a 63-fold increase in marker gene expression. The M9-ScT conjugate localized fluorescent plasmid into the nucleus of permeabilized cells, and addition of the nuclear pore blocker wheat germ agglutinin prevented nuclear import. This method of gene transfer may lead to viral- and lipid-free transfection of nondividing cells.	Univ Penn, Dept Chem Engn, Inst Med & Engn, Vagelos Res Labs 1010, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Diamond, SL (corresponding author), Univ Penn, Dept Chem Engn, Inst Med & Engn, Vagelos Res Labs 1010, Philadelphia, PA 19104 USA.				PHS HHS [R21-14014] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; CAPECCHI MR, 1980, CELL, V22, P479, DOI 10.1016/0092-8674(80)90358-X; Edgell CJS, 1998, BIOTECHNIQUES, V25, P264, DOI 10.2144/98252gt01; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; FLUGELMAN MY, 1992, CIRCULATION, V85, P1110, DOI 10.1161/01.CIR.85.3.1110; Fritz JD, 1996, HUM GENE THER, V7, P1395, DOI 10.1089/hum.1996.7.12-1395; GAO X, 1993, NUCLEIC ACIDS RES, V21, P2867, DOI 10.1093/nar/21.12.2867; GO YM, 1998, AM J PHYSIOL, V274, pH1; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Greber UF, 1996, EMBO J, V15, P1766, DOI 10.1002/j.1460-2075.1996.tb00525.x; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; Hart SL, 1998, HUM GENE THER, V9, P575, DOI 10.1089/hum.1998.9.4-575; HONG Z, 1995, CHIN MED J, V108, P332; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; LEGENDRE JY, 1992, PHARMACEUT RES, V9, P1235, DOI 10.1023/A:1015836829670; LEMERCHAND P, 1993, CIRC RES, V72, P1132; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928; Nakielny S, 1996, EXP CELL RES, V229, P261, DOI 10.1006/excr.1996.0369; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; SCHACHTNER SK, 1995, CIRC RES, V76, P701, DOI 10.1161/01.RES.76.5.701; Sebestyen MG, 1998, NAT BIOTECHNOL, V16, P80, DOI 10.1038/nbt0198-80; SETH P, 1984, J BIOL CHEM, V259, P4350; SETH P, 1994, J VIROL, V68, P1204, DOI 10.1128/JVI.68.2.1204-1206.1994; SETH P, 1994, J VIROL, V51, P60650; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; STEG PG, 1994, CIRCULATION, V90, P1648, DOI 10.1161/01.CIR.90.4.1648; Subramanian A, 1997, TISSUE ENG, V3, P39, DOI 10.1089/ten.1997.3.39; SUBRAMANIAN A, 1997, ANN BIOMED ENG, V25, P428; SUNG WL, 1993, CIRC RES, V73, P797; Tseng WC, 1997, J BIOL CHEM, V272, P25641, DOI 10.1074/jbc.272.41.25641; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91	36	201	215	1	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					873	877		10.1038/12860	http://dx.doi.org/10.1038/12860			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471928				2022-12-27	WOS:000082365800028
J	Borisjuk, NV; Borisjuk, LG; Logendra, S; Petersen, F; Gleba, Y; Raskin, I				Borisjuk, NV; Borisjuk, LG; Logendra, S; Petersen, F; Gleba, Y; Raskin, I			Production of recombinant proteins in plant root exudates	NATURE BIOTECHNOLOGY			English	Article						agricultural biotechnology; transgenic plants; recombinant proteins; protein secretion; hydroponic	GREEN-FLUORESCENT PROTEIN; CELLS; EXPRESSION; SECRETION; EXTRACTION	The large-scale production of recombinant proteins in plants is limited by relatively low yields and difficulties in extraction and purification. These problems were addressed by engineering tobacco plants to continuously secrete recombinant proteins from their roots into a simple hydroponic medium. Three heterologous proteins of diverse origins (green fluorescent protein of jellyfish, human placental alkaline phosphatase [SEAP], and bacterial xylanase) were produced using the root secretion method (rhizo-secretion). Protein secretion was dependent on the presence of the endoplasmic reticulum signal peptide fused to the recombinant protein sequence. All three secreted proteins retained their biological activity and, as shown for SEAP, accumulated in much higher amounts in the medium than in the root tissue.	Rutgers State Univ, Cook Coll, Biotech Ctr, New Brunswick, NJ 08901 USA; Rutgers State Univ, Cook Coll, Dept Biochem & Microbiol, New Brunswick, NJ 08903 USA; Inst Cell Biol & Genet Engn, UA-252650 Kiev, Ukraine	Rutgers State University New Brunswick; Rutgers State University New Brunswick; National Academy of Sciences Ukraine; Institute of Cell Biology & Genetic Engineering of the National Academy of Sciences of Ukraine	Raskin, I (corresponding author), Rutgers State Univ, Cook Coll, Biotech Ctr, Foran Hall, New Brunswick, NJ 08901 USA.	raskin@aesop.rutgers.edu	Borisjuk, Nikolai/AAI-3809-2020	Borisjuk, Nikolai/0000-0001-5250-9771; Borisjuk, Ljudmilla/0000-0001-6910-0841; Gleba, Yuri/0000-0003-4675-7474				BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BIELY P, 1988, METHOD ENZYMOL, V160, P536; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Conrad U, 1998, PLANT MOL BIOL, V38, P101, DOI 10.1023/A:1006029617949; Davis SJ, 1998, PLANT MOL BIOL, V36, P521, DOI 10.1023/A:1005991617182; DENECKE J, 1990, PLANT CELL, V2, P51, DOI 10.1105/tpc.2.1.51; FIREK S, 1993, PLANT MOL BIOL, V23, P861, DOI 10.1007/BF00021540; Hawes M., 1992, ADV PLANT PATHOL, V8, P119; HERBERS K, 1995, BIO-TECHNOL, V13, P63, DOI 10.1038/nbt0195-63; Hood EE, 1997, MOL BREEDING, V3, P291, DOI 10.1023/A:1009676322162; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Marschner H, 1986, MINERAL NUTR HIGHER; Ni M, 1996, PLANT MOL BIOL, V30, P77, DOI 10.1007/BF00017804; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Reichel C, 1996, P NATL ACAD SCI USA, V93, P5888, DOI 10.1073/pnas.93.12.5888; REISMAN HB, 1993, CRIT REV BIOTECHNOL, V13, P195, DOI 10.1080/0738855031874353; Sambrock J, 1989, MOL CLONING LAB MANU, V1; SHEPHERD T, 1993, ANN BOT-LONDON, V72, P155, DOI 10.1006/anbo.1993.1094; SMITH RA, 1985, SCIENCE, V229, P1219, DOI 10.1126/science.3939723; TERRY ME, 1980, PLANT PHYSIOL, V66, P321, DOI 10.1104/pp.66.2.321; URSIN VM, 1993, PLANT PHYSIOL, V102, P1033, DOI 10.1104/pp.102.3.1033; Wongsamuth R, 1997, BIOTECHNOL BIOENG, V54, P401, DOI 10.1002/(SICI)1097-0290(19970605)54:5&lt;401::AID-BIT1&gt;3.0.CO;2-I	24	146	184	2	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					466	469		10.1038/8643	http://dx.doi.org/10.1038/8643			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331806				2022-12-27	WOS:000080074500031
J	Persidis, A				Persidis, A			Autoimmune disease drug discovery	NATURE BIOTECHNOLOGY			English	Editorial Material									RheoGene, Charlottesville, VA 22903 USA		Persidis, A (corresponding author), RheoGene, 706 Forest St, Charlottesville, VA 22903 USA.							Bastenie P A, 1975, Bull Mem Acad R Med Belg, V130, P517; Benvenga S, 1999, J ENDOCRINOL INVEST, V22, P535, DOI 10.1007/BF03343605; BERTRAM U, 1965, ACTA ALLERGOL, V20, P472, DOI 10.1111/j.1398-9995.1965.tb03082.x; DEALMEIDA M, 1991, HUM REPROD, V6, P405, DOI 10.1093/oxfordjournals.humrep.a137350; Eilat D, 1999, IMMUNOL TODAY, V20, P339, DOI 10.1016/S0167-5699(99)01457-7; Giovannoni G, 1999, J ROY COLL PHYS LOND, V33, P315; Komai K, 1999, J NEUROL SCI, V166, P126, DOI 10.1016/S0022-510X(99)00125-2; MICHALSKI JP, 1975, NEW ENGL J MED, V293, P1228, DOI 10.1056/NEJM197512112932404; MINCHINTON RM, 1982, LANCET, V2, P391; Nikezic-Ardolic M, 1999, LUPUS, V8, P375, DOI 10.1177/096120339900800509; Persidis A, 1999, NAT BIOTECHNOL, V17, P726, DOI 10.1038/10954; Piccirillo CA, 1999, HUM GENE THER, V10, P1915, DOI 10.1089/10430349950017275; Puxeddu A, 1965, Haematologica, V50, P1073; Sundermann A, 1965, Folia Haematol Int Mag Klin Morphol Blutforsch, V84, P387; WACHSMUTH ED, 1972, BMJ-BRIT MED J, V3, P623, DOI 10.1136/bmj.3.5827.623; Willenborg DO, 1996, J IMMUNOL, V157, P1973; Wong FS, 1999, NAT MED, V5, P1026, DOI 10.1038/12465	17	14	14	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1038	1039		10.1038/13748	http://dx.doi.org/10.1038/13748			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504714	Bronze			2022-12-27	WOS:000083015700035
J	Wood, DW; Wu, W; Belfort, G; Derbyshire, V; Belfort, M				Wood, DW; Wu, W; Belfort, G; Derbyshire, V; Belfort, M			A genetic system yields self-cleaving inteins for bioseparations	NATURE BIOTECHNOLOGY			English	Article						mini-intein mutants; pH-sensitive cleavage; function of conserved residues	PROTEIN-SPLICING DOMAIN; ENDONUCLEASE; MODULATION; DEFINITION; MECHANISM; CLEAVAGE; SEQUENCE; SITE	A self-cleaving element for use in bioseparations has been derived from a naturally occurring, 43 kDa protein splicing element (intein) through a combination of protein engineering and random mutagenesis. A mini-intein (18 kDa) previously engineered for reduced size had compromised activity and was therefore subjected to random mutagenesis and genetic selection. In one selection a mini-intein was isolated with restored splicing activity, while in another, a mutant was isolated with enhanced, pH-sensitive C-terminal cleavage activity. The enhanced-cleavage mutant has utility in affinity fusion-based protein purification. These mutants also provide new insights into the structural and functional roles of some conserved residues in protein splicing.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Albany, NY 12201 USA; Rensselaer Polytech Inst, Isermann Dept Chem Engn, Troy, NY 12180 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Rensselaer Polytechnic Institute	Belfort, M (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA.		Wood, David W/B-2992-2012	Belfort, Marlene/0000-0002-1592-5618	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039422, R37GM039422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39422, GM44844] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELFORT M, 1984, J BACTERIOL, V160, P371, DOI 10.1128/JB.160.1.371-378.1984; Chong SR, 1998, NUCLEIC ACIDS RES, V26, P5109, DOI 10.1093/nar/26.22.5109; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; Chong SR, 1997, J BIOL CHEM, V272, P15587, DOI 10.1074/jbc.272.25.15587; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; Dalgaard JZ, 1997, J COMPUT BIOL, V4, P193, DOI 10.1089/cmb.1997.4.193; Dalgaard JZ, 1997, NUCLEIC ACIDS RES, V25, P4626, DOI 10.1093/nar/25.22.4626; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; Derbyshire V, 1997, P NATL ACAD SCI USA, V94, P11466, DOI 10.1073/pnas.94.21.11466; Derbyshire V, 1997, J MOL BIOL, V265, P494, DOI 10.1006/jmbi.1996.0754; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Gimble FS, 1998, CHEM BIOL, V5, pR251, DOI 10.1016/S1074-5521(98)90109-0; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; Shao ZX, 1996, CURR OPIN STRUC BIOL, V6, P513, DOI 10.1016/S0959-440X(96)80117-5; Shingledecker K, 1998, GENE, V207, P187, DOI 10.1016/S0378-1119(97)00624-0; Stoddard BL, 1998, NAT STRUCT BIOL, V5, P3, DOI 10.1038/nsb0198-3; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	21	200	214	1	59	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					889	892		10.1038/12879	http://dx.doi.org/10.1038/12879			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471931				2022-12-27	WOS:000082365800031
J	Whitcombe, D; Theaker, J; Guy, SP; Brown, T; Little, S				Whitcombe, D; Theaker, J; Guy, SP; Brown, T; Little, S			Detection of PCR products using self-probing amplicons and fluorescence	NATURE BIOTECHNOLOGY			English	Article						homogeneous assays; fluorescent probes; diagnostics; PCR; ARMS; single-tube genotyping; multiplexing	POLYMERASE CHAIN-REACTION; MOLECULAR BEACONS; DNA; AMPLIFICATION; ASSAY; POLYMORPHISM; MUTATIONS; PROBES; ARMS	Molecular diagnostics is progressing from low-throughput, heterogeneous, mostly manual technologies to higher throughput, closed-tube, and automated methods. Fluorescence is the favored signaling technology for such assays, and a number of techniques rely on energy transfer between a fluorophore and a proximal quencher molecule, In these methods, dual-labeled probes hybridize to an amplicon and changes in the quenching of the fluorophore are detected. We describe a new technology that is simple to use, gives highly specific information, and avoids the major difficulties of the alternative methods, It uses a primer with an integral tail that is used to probe an extension product of the primer, The probing of a target sequence is thereby converted into a unimolecular event, which has substantial benefits in terms of kinetics, thermodynamics, assay design, and probe reliability.	AstraZeneca Diagnost, Northwich CW9 7RA, Cheshire, England; Univ Southampton, Dept Chem, Southampton SO17 1BJ, Hants, England	AstraZeneca; University of Southampton	Whitcombe, D (corresponding author), AstraZeneca Diagnost, Gadbrook Pk, Northwich CW9 7RA, Cheshire, England.		Brown, Tom/B-8521-2008; Brown, Tom/C-9185-2016	Brown, Tom/0000-0003-4683-1873; Brown, Tom/0000-0002-6538-3036				Brownie J, 1997, NUCLEIC ACIDS RES, V25, P3235, DOI 10.1093/nar/25.16.3235; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; FERRIE RM, 1992, AM J HUM GENET, V51, P251; FERRIE RM, 1998, Patent No. 152242; Gelmini S, 1997, CLIN CHEM, V43, P752; Gibson NJ, 1997, CLIN CHEM, V43, P1336; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Ibrahim MS, 1997, MOL CELL PROBE, V11, P143, DOI 10.1006/mcpr.1996.0093; Ibrahim MS, 1998, ANAL CHEM, V70, P2013, DOI 10.1021/ac971091u; ISHIGURO T, 1995, ANAL BIOCHEM, V229, P207, DOI 10.1006/abio.1995.1404; LIVAK KJ, 1995, NAT GENET, V9, P341, DOI 10.1038/ng0495-341; Nazarenko IA, 1997, NUCLEIC ACIDS RES, V25, P2516, DOI 10.1093/nar/25.12.2516; NEWTON CR, 1993, NUCLEIC ACIDS RES, V21, P1155, DOI 10.1093/nar/21.5.1155; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; Tseng SY, 1997, ANAL BIOCHEM, V245, P207, DOI 10.1006/abio.1996.9970; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; VANDERVELDEN PA, 1993, HUM MOL GENET, V2, P1753; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; Wittwer CT, 1997, BIOTECHNIQUES, V22, P176, DOI 10.2144/97221pf02	21	545	794	3	99	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					804	807		10.1038/11751	http://dx.doi.org/10.1038/11751			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429248				2022-12-27	WOS:000081751400032
J	Dalum, I; Butler, DM; Jensen, MR; Hindersson, P; Steinaa, L; Waterston, AM; Grell, SN; Feldmann, M; Elsner, HI; Mouritsen, S				Dalum, I; Butler, DM; Jensen, MR; Hindersson, P; Steinaa, L; Waterston, AM; Grell, SN; Feldmann, M; Elsner, HI; Mouritsen, S			Therapeutic antibodies elicited by immunization against TNF-alpha	NATURE BIOTECHNOLOGY			English	Article						TNF-alpha; vaccination; active immunization; autoantibodies; anti-TNF-alpha; collagen-induced arthritis (CIA); cachexia; chronic inflammatory disease	TUMOR-NECROSIS-FACTOR; COLLAGEN-INDUCED ARTHRITIS; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODIES; FUSION PROTEIN; SELF PROTEIN; T-CELLS; MICE; DISEASE; DETERMINANTS	Tumor necrosis factor-alpha (TNF-alpha) is critically involved in the pathogenesis of several chronic inflammatory diseases. Monoclonal antibodies against TNF-alpha are currently used for the treatment of rheumatoid arthritis and Crohn's disease. This report describes a simple and effective method for active immunization against self TNF-alpha. This vaccination approach leads to a T-cell-dependent polyclonal and sustainable anti-TNF-alpha autoantibody response that declines upon discontinuation of booster injections. The autoantibodies are elicited by injecting modified recombinant TNF-alpha molecules containing foreign immunodominant T-helper epitopes. In mice immunized with such molecules, the symptoms of experimental cachexia and type II collagen-induced arthritis are ameliorated. These results suggest that vaccination against TNF-alpha may be a useful approach for the treatment of rheumatoid arthritis and other chronic inflammatory diseases.	M&E Biotech AS, DK-2970 Horsholm, Denmark; Kennedy Inst Rheumatol, London, England	University of Oxford	Mouritsen, S (corresponding author), M&E Biotech AS, 6 Kogle Alle, DK-2970 Horsholm, Denmark.			Steinaa, Lucilla/0000-0003-3691-3971				BLOOM JW, 1993, J IMMUNOL, V151, P2707; CERAMI A, 1985, IMMUNOL LETT, V11, P173, DOI 10.1016/0165-2478(85)90165-8; Dalum I, 1997, MOL IMMUNOL, V34, P1113, DOI 10.1016/S0161-5890(97)00147-8; Dalum I, 1996, J IMMUNOL, V157, P4796; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Neurath MF, 1997, EUR J IMMUNOL, V27, P1743, DOI 10.1002/eji.1830270722; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; RUFF MR, 1980, J IMMUNOL, V125, P1671; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SHASTRI N, 1986, J IMMUNOL, V137, P911; STAINES NA, 1994, BRIT J RHEUMATOL, V33, P798; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; THORBECKE GJ, 1992, P NATL ACAD SCI USA, V89, P7375, DOI 10.1073/pnas.89.16.7375; WILLIAMS RO, 1995, IMMUNOLOGY, V84, P433; WILLIAMS RO, 1992, J IMMUNOL METHODS, V147, P93, DOI 10.1016/S0022-1759(12)80033-0; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784	25	121	143	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					666	669		10.1038/10878	http://dx.doi.org/10.1038/10878			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404159				2022-12-27	WOS:000081296900026
J	Korwek, EL; Zannoni, LW				Korwek, EL; Zannoni, LW			Boon or threat to international trade in biotechnology?	NATURE BIOTECHNOLOGY			English	Editorial Material									Hogan & Hartson, Washington, DC 20004 USA		Korwek, EL (corresponding author), Hogan & Hartson, Columbia Sq,555 13th St NW, Washington, DC 20004 USA.								0	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					513	514		10.1038/9774	http://dx.doi.org/10.1038/9774			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385298				2022-12-27	WOS:000080716500004
J	Persidis, A				Persidis, A			Antisense therapeutics	NATURE BIOTECHNOLOGY			English	Editorial Material							MESSENGER-RNA; PNA		Argonex Inc, Business Dev, Charlottesville, VA 22901 USA		Persidis, A (corresponding author), Argonex Inc, Business Dev, 2044 India Rd, Charlottesville, VA 22901 USA.	apersidis@argonex.corn						Crooke ST, 1996, ANNU REV PHARMACOL, V36, P107, DOI 10.1146/annurev.pa.36.040196.000543; Desai RP, 1999, APPL ENVIRON MICROB, V65, P936; Ecker DJ, 1998, NAT BIOTECHNOL, V16, P332, DOI 10.1038/nbt0498-332; Flechsler I, 1998, ADV EXP MED BIOL, V451, P469; Good L, 1998, NAT BIOTECHNOL, V16, P355, DOI 10.1038/nbt0498-355; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; Im SA, 1999, CANCER RES, V59, P895; Li YX, 1999, VIROLOGY, V255, P138, DOI 10.1006/viro.1998.9571; Monteith DK, 1998, TOXICOL SCI, V46, P365, DOI 10.1093/toxsci/46.2.365; Naka K, 1999, BIOCHEM BIOPH RES CO, V255, P753, DOI 10.1006/bbrc.1998.9938; Nielsen PE, 1999, CURR OPIN BIOTECH, V10, P71, DOI 10.1016/S0958-1669(99)80013-5; ORKIN SH, 1977, J BIOL CHEM, V252, P5606; ROSENBERG UB, 1985, NATURE, V313, P703, DOI 10.1038/313703a0; WORTZMAN MS, 1980, BIOCHIM BIOPHYS ACTA, V609, P84, DOI 10.1016/0005-2787(80)90203-8	14	29	32	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					403	404		10.1038/7973	http://dx.doi.org/10.1038/7973			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207893				2022-12-27	WOS:000079574400036
J	Sykes, KF; Johnston, SA				Sykes, KF; Johnston, SA			Linear expression elements: a rapid, in vivo, method to screen for gene functions	NATURE BIOTECHNOLOGY			English	Article						functional genomics; genetic vaccines; gene delivery; gene screening	IMMUNIZATION; DNA; CLONING	The increasing accumulation of genomic sequence information has accentuated the need for new methods to efficiently assess gene function and to prepare reagents to study these functions. Toward solving this general problem in functional genomics, we report a method by which any PCR-amplified open-reading frame (ORF) can be noncovalently linked to a eukaryotic promoter and terminator, and directly injected into animals to produce local gene expression. We also demonstrate that ORFs can be delivered into mice to produce antibodies specific for the encoded foreign protein by simply attaching mammalian promoter and terminator sequences. This technology makes it possible to screen large numbers of genes rapidly for their functions in vivo or to produce immune responses without the necessity of cloning, bacterial propagation, or protein purification.	Univ Texas, SW Med Ctr, Dept Internal Med, Ctr Biomed Invent, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Johnston, SA (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Ctr Biomed Invent, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARRY MA, 1994, BIOTECHNIQUES, V16, P616; BARRY MA, 1995, NATURE, V377, P632, DOI 10.1038/377632a0; BUTTRICK PM, 1992, CIRC RES, V70, P193, DOI 10.1161/01.RES.70.1.193; FISHER R, 1985, J BIOL CHEM, V260, P1223; Harlow E., 1988, ANTIBODIES LAB MANUA; LAQUEYRERIE A, 1995, INFECT IMMUN, V63, P4003, DOI 10.1128/IAI.63.10.4003-4010.1995; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; Nisson P E, 1991, PCR Methods Appl, V1, P120; SANFORD J C, 1991, Technique (Philadelphia), V3, P3; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; WILLIAMS RS, 1991, P NATL ACAD SCI USA, V88, P2726, DOI 10.1073/pnas.88.7.2726; WOLFF JA, 1990, SCIENCE, V246, P1464; XIE TD, 1993, BIOPHYS J, V65, P1684, DOI 10.1016/S0006-3495(93)81208-6	15	45	58	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					355	359		10.1038/7908	http://dx.doi.org/10.1038/7908			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207883				2022-12-27	WOS:000079574400023
J	Hubner, P; Studer, E; Luthy, J				Hubner, P; Studer, E; Luthy, J			Quantitation of genetically modified organisms in food	NATURE BIOTECHNOLOGY			English	Editorial Material									Canton, Zurich, Switzerland; Univ Bern, Bern, Switzerland	University of Bern	Hubner, P (corresponding author), Canton, Zurich, Switzerland.							[Anonymous], 1997, OFFICIAL J EUROPEA L, V43, P1; *BUND GES, SCHWEIZ LEB; *FLUK CHEM AG, CERT GMO STAND RR SO; Hardegger M, 1999, EUR FOOD RES TECHNOL, V209, P83, DOI 10.1007/s002170050462; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; *STRAT DIAGN INC, GMO SOYA TEST KIT; Studer E, 1998, Z LEBENSM UNTERS F A, V207, P207, DOI 10.1007/s002170050320; 1998, OFFICIAL J EUROPEA L, V159, P4; 1999, SCF 1999 OP SCF CS N; 1995, SCHWEIB LET	10	48	53	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1137	1138		10.1038/15129	http://dx.doi.org/10.1038/15129			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545927				2022-12-27	WOS:000083428000037
J	Archer, R				Archer, R			The drug discovery factory: An inevitable evolutionary consequence of high-throughput parallel processing	NATURE BIOTECHNOLOGY			English	Editorial Material									Automat Partnership, Royston SG8 6HB, England		Archer, R (corresponding author), Automat Partnership, Melbourn Sci Pk, Royston SG8 6HB, England.								0	17	17	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					834	834		10.1038/12782	http://dx.doi.org/10.1038/12782			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471905	Bronze			2022-12-27	WOS:000082365800005
J	Shimkets, RA; Lowe, DG; Tai, JTN; Sehl, P; Jin, HK; Yang, RH; Predki, PF; Rothberg, BEG; Murtha, MT; Roth, ME; Shenoy, SG; Windemuth, A; Simpson, JW; Simons, JF; Daley, MP; Gold, SA; McKenna, MP; Hillan, K; Went, GT; Rothberg, JM				Shimkets, RA; Lowe, DG; Tai, JTN; Sehl, P; Jin, HK; Yang, RH; Predki, PF; Rothberg, BEG; Murtha, MT; Roth, ME; Shenoy, SG; Windemuth, A; Simpson, JW; Simons, JF; Daley, MP; Gold, SA; McKenna, MP; Hillan, K; Went, GT; Rothberg, JM			Gene expression analysis by transcript profiling coupled to a gene database query	NATURE BIOTECHNOLOGY			English	Article						cardiac hypertrophy; differential gene expression; transcript profiling; oligonucleotide poisoning	MESSENGER-RNA EXPRESSION; CARDIAC-HYPERTROPHY; PRESSURE-OVERLOAD; RAT-HEART; DNA MICROARRAY; ADULT-RAT; HYBRIDIZATION; CDNA; SEQUENCE; MUSCLE	We describe an mRNA profiling technique for determining differential gene expression that utilizes, but does not require, prior knowledge of gene sequences, This method permits high-throughput reproducible detection of most expressed sequences with a sensitivity of greater than 1 part in 100,000, Gene identification by database query of a restriction endonuclease fingerprint, confirmed by competitive PCR using gene-specific oligonucleotides, facilitates gene discovery by minimizing isolation procedures. This process, called GeneCalling, was validated by analysis of the gene expression profiles of normal and hypertrophic rat hearts following in vivo pressure overload.	CuraGen Corp, New Haven, CT 06511 USA; Genentech Inc, Dept Cardiovasc Res, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Shimkets, RA (corresponding author), CuraGen Corp, 555 Long Wharf Dr, New Haven, CT 06511 USA.	Rshimket@curagen.com	Daley, Michael/HHN-1017-2022	Daley, Michael/0000-0003-4673-8214				ANVERSA P, 1980, J MOL CELL CARDIOL, V12, P781, DOI 10.1016/0022-2828(80)90080-2; Bachem CWB, 1996, PLANT J, V9, P745, DOI 10.1046/j.1365-313X.1996.9050745.x; BATRA S, 1991, J CARDIOVASC PHARM, V17, pS151, DOI 10.1097/00005344-199117002-00037; BHALERAO J, 1995, J BIOL CHEM, V270, P16385, DOI 10.1074/jbc.270.27.16385; BOHELER KR, 1992, TRENDS CARDIOVAS MED, V2, P176, DOI 10.1016/1050-1738(92)90046-U; BOLUYT MO, 1994, CIRC RES, V75, P23, DOI 10.1161/01.RES.75.1.23; CHAPMAN D, 1990, CIRC RES, V67, P787, DOI 10.1161/01.RES.67.4.787; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; DAY ML, 1987, HYPERTENSION, V9, P485, DOI 10.1161/01.HYP.9.5.485; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Drmanac S, 1996, GENOMICS, V37, P29, DOI 10.1006/geno.1996.0517; Engelmann GL, 1996, MOL CELL BIOCHEM, V164, P47, DOI 10.1007/BF00408640; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; IVANOVA NB, 1995, NUCLEIC ACIDS RES, V23, P2954, DOI 10.1093/nar/23.15.2954; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KATO K, 1995, NUCLEIC ACIDS RES, V23, P3685, DOI 10.1093/nar/23.18.3685; KIMURA S, 1989, HEART CIRC PHYSL, V25, pH1006; KORECKY B, 1978, AM J PHYSIOL, V234, pH123, DOI 10.1152/ajpheart.1978.234.2.H123; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Milosavljevic A, 1996, GENOMICS, V37, P77, DOI 10.1006/geno.1996.0523; MILOSAVLJEVIC A, 1995, GENOMICS, V27, P83, DOI 10.1006/geno.1995.1009; Milosavljevic A, 1996, GENOME RES, V6, P132, DOI 10.1101/gr.6.2.132; PARADIS P, 1992, BIOCHEM CELL BIOL, V70, P593, DOI 10.1139/o92-090; Pepe G, 1997, J MOL CELL CARDIOL, V29, P1877, DOI 10.1006/jmcc.1997.0426; Sage EH, 1997, NAT MED, V3, P144; SAMUEL JL, 1991, J CLIN INVEST, V88, P1737, DOI 10.1172/JCI115492; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHIAFFINO S, 1989, CIRC RES, V64, P937, DOI 10.1161/01.RES.64.5.937; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; vandenHeuvel GB, 1996, KIDNEY INT, V49, P752, DOI 10.1038/ki.1996.104; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	40	135	176	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					798	803		10.1038/11743	http://dx.doi.org/10.1038/11743			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429247				2022-12-27	WOS:000081751400031
J	Geyer, C; Hodits, RA; Janus, F; Leiter, JME; Moscho, A; Rosenboom, H				Geyer, C; Hodits, RA; Janus, F; Leiter, JME; Moscho, A; Rosenboom, H			Deal making for growth	NATURE BIOTECHNOLOGY			English	Article									McKinsey New Venture, Munich, Germany		Geyer, C (corresponding author), McKinsey New Venture, Prinzregentenstr 22, Munich, Germany.								0	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					645	648		10.1038/10856	http://dx.doi.org/10.1038/10856			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404155				2022-12-27	WOS:000081296900022
J	Apte, A				Apte, A			Web cloning	NATURE BIOTECHNOLOGY			English	Editorial Material									Biosoft Int, Palo Alto, CA USA		Apte, A (corresponding author), Biosoft Int, Palo Alto, CA USA.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					505	505		10.1038/8690	http://dx.doi.org/10.1038/8690			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331815	Bronze			2022-12-27	WOS:000080074500040
J	Kasuga, M; Liu, Q; Miura, S; Yamaguchi-Shinozaki, K; Shinozaki, K				Kasuga, M; Liu, Q; Miura, S; Yamaguchi-Shinozaki, K; Shinozaki, K			Improving plant drought, salt, and freezing tolerance by gene transfer of a single stress-inducible transcription factor	NATURE BIOTECHNOLOGY			English	Article						drought tolerance; freezing tolerance; transgenic plants; multigene expression; stress-inducible promoter	ARABIDOPSIS-THALIANA L; CIS-ACTING ELEMENT; LOW-TEMPERATURE; WATER-DEFICIT; DEHYDRATION STRESS; TRANSGENIC TOBACCO; SEQUENCE-ANALYSIS; COLD STRESS; EXPRESSION; DNA	Plant productivity is greatly affected by environmental stresses such as drought, salt loading, and freezing. We reported previously that a cis-acting promoter element, the dehydration response element (DRE), plays an important role in regulating gene expression in response to these stresses, The transcription factor DREB1A specifically interacts with the DRE and induces expression of stress tolerance genes. We show here that overexpression of the cDNA encoding DREB1A in transgenic plants activated the expression of many of these stress tolerance genes under normal growing conditions and resulted in improved tolerance to drought, salt loading, and freezing. However, use of the strong constitutive 35S cauliflower mosaic virus (CaMV) promoter to drive expression of DREB1A also resulted in severe growth retardation under normal growing conditions. In contrast, expression of DREB1A from the stress inducible rd29A promoter gave rise to minimal effects on plant growth while providing an even greater tolerance to stress conditions than did expression of the gene from the CaMV promoter.	Minist Agr Forestry & Fisheries, Japan Int Res Ctr Agr Sci, Biol Resources Div, Tsukuba, Ibaraki 3058686, Japan; RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Plant Mol Biol Lab, Tsukuba, Ibaraki 3050074, Japan	Japan International Research Center for Agricultural Sciences; Ministry of Agriculture Forestry & Fisheries - Japan; RIKEN	Yamaguchi-Shinozaki, K (corresponding author), Minist Agr Forestry & Fisheries, Japan Int Res Ctr Agr Sci, Biol Resources Div, 2-1 Ohwashi, Tsukuba, Ibaraki 3058686, Japan.	kazukoys@jircas.affrc.go.jp	Shinozaki, Kazuo/G-4202-2013; Yamaguchi-Shinozaki, Kazuko/K-9004-2015	Shinozaki, Kazuo/0000-0002-6317-9867; Yamaguchi-Shinozaki, Kazuko/0000-0002-0249-8258				Artus NN, 1996, P NATL ACAD SCI USA, V93, P13404, DOI 10.1073/pnas.93.23.13404; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Bray EA, 1997, TRENDS PLANT SCI, V2, P48, DOI 10.1016/S1360-1385(97)82562-9; DURE L, 1989, PLANT MOL BIOL, V12, P475, DOI 10.1007/BF00036962; GILMOUR SJ, 1992, PLANT MOL BIOL, V18, P13, DOI 10.1007/BF00018452; Hayashi H, 1997, PLANT J, V12, P133, DOI 10.1046/j.1365-313X.1997.12010133.x; Holmberg N, 1998, TRENDS PLANT SCI, V3, P61, DOI 10.1016/S1360-1385(97)01163-1; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; IshizakiNishizawa O, 1996, NAT BIOTECHNOL, V14, P1003, DOI 10.1038/nbt0896-1003; Iwasaki T., 1997, PLANT PHYSIOL, V115, P1287; Jaglo-Ottosen KR, 1998, SCIENCE, V280, P104, DOI 10.1126/science.280.5360.104; Jiang C, 1996, PLANT MOL BIOL, V30, P679, DOI 10.1007/BF00049344; KISHOR PBK, 1995, PLANT PHYSIOL, V108, P1387, DOI 10.1104/pp.108.4.1387; KIYOSUE T, 1994, PLANT CELL PHYSIOL, V35, P225; KIYOSUE T, 1993, BIOCHEM BIOPH RES CO, V196, P1214, DOI 10.1006/bbrc.1993.2381; KODAMA H, 1994, PLANT PHYSIOL, V105, P601, DOI 10.1104/pp.105.2.601; KURKELA S, 1992, PLANT MOL BIOL, V19, P689, DOI 10.1007/BF00026794; LIN CT, 1992, PLANT PHYSIOL, V99, P519, DOI 10.1104/pp.99.2.519; Liu Q, 1998, PLANT CELL, V10, P1391, DOI 10.1105/tpc.10.8.1391; McKersie BD, 1996, PLANT PHYSIOL, V111, P1177, DOI 10.1104/pp.111.4.1177; MITUHARA I, 1996, PLANT CELL PHYSL, V37, P49; NORDIN K, 1991, PLANT MOL BIOL, V16, P1061, DOI 10.1007/BF00016077; Ouellet F, 1998, FEBS LETT, V423, P324, DOI 10.1016/S0014-5793(98)00116-1; Shinozaki K, 1997, PLANT PHYSIOL, V115, P327, DOI 10.1104/pp.115.2.327; Shinozaki K, 1996, CURR OPIN BIOTECH, V7, P161, DOI 10.1016/S0958-1669(96)80007-3; Stockinger EJ, 1997, P NATL ACAD SCI USA, V94, P1035, DOI 10.1073/pnas.94.3.1035; TARCZYNSKI MC, 1993, SCIENCE, V259, P508, DOI 10.1126/science.259.5094.508; THOMASHOW MF, 1994, ARABIDOPSIS, P807, DOI DOI 10.1101/0.807-834; WANG H, 1995, PLANT MOL BIOL, V28, P605, DOI 10.1007/BF00021187; Xu DP, 1996, PLANT PHYSIOL, V110, P249, DOI 10.1104/pp.110.1.249; YAMAGUCHISHINOZAKI K, 1993, MOL GEN GENET, V238, P17, DOI 10.1007/BF00279525; YAMAGUCHISHINOZAKI K, 1993, PLANT PHYSIOL, V101, P1119, DOI 10.1104/pp.101.3.1119; YAMAGUCHISHINOZAKI K, 1993, MOL GEN GENET, V236, P331, DOI 10.1007/BF00277130; YAMAGUCHISHINOZAKI K, 1994, PLANT CELL, V6, P251, DOI 10.1105/tpc.6.2.251; YOSHIBA Y, 1995, PLANT J, V7, P751, DOI 10.1046/j.1365-313X.1995.07050751.x	35	1474	1887	12	363	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					287	291		10.1038/7036	http://dx.doi.org/10.1038/7036			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096298				2022-12-27	WOS:000078977500032
J	Agris, CH				Agris, CH			Patents - Intellectual property protection for plants	NATURE BIOTECHNOLOGY			English	Editorial Material																		EVANS DA, 1983, SCIENCE, V221, P949, DOI 10.1126/science.221.4614.949; Moffat AS, 1998, SCIENCE, V282, P2176, DOI 10.1126/science.282.5397.2176; *OJ EPO, 1984, T4983 OJ EPO, P112; *OJ EPO, 1990, T32087 OJ EPO, P71; *OJ EPO, 1995, T35693 OJ EPO, P545; 5840851; 5066830; 10289; 5844118	9	4	4	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					197	198		10.1038/6205	http://dx.doi.org/10.1038/6205			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052359				2022-12-27	WOS:000078508300031
J	Encell, LP; Landis, DM; Loeb, LA				Encell, LP; Landis, DM; Loeb, LA			Improving enzymes for cancer gene therapy	NATURE BIOTECHNOLOGY			English	Review						directed evolution; gene therapy; myelosuppression; protein engineering; tumor ablation	MARROW TRANSPLANT RECIPIENTS; DIHYDROFOLATE-REDUCTASE CDNA; DRUG-RESISTANCE GENES; THYMIDINE KINASE; BONE-MARROW; IN-VITRO; THYMIDYLATE SYNTHASE; ESCHERICHIA-COLI; TRANSGENIC MICE; METHOTREXATE	New techniques now make it feasible to tailor enzymes for cancer gene therapy. Novel enzymes with desired properties can be created and selected from vast libraries of mutants containing random substitutions within catalytic domains. In this review, we first consider genes for the ablation of tumors, namely, genes that have been mutated (or potentially can be mutated) to afford enhanced activation of prodrugs and increased sensitization of tumors to specific chemotherapeutic agents. We then consider genes that have been mutated to provide better protection of normal host tissues, such as bone marrow, against the toxicity of specific chemotherapeutic agents. Expression of the mutant enzyme could render sensitive tissues, such as bone marrow, more resistant to specific cytotoxic agents.	Univ Washington, Sch Med, Dept Pathol, Joseph Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Sch Med, Dept Pathol, Joseph Gottstein Mem Canc Res Lab, Box 357705, Seattle, WA 98195 USA.	laloeb@u.washington.edu			NCI NIH HHS [CA78885] Funding Source: Medline; NIEHS NIH HHS [T32 ES07032] Funding Source: Medline; PHS HHS [5 T32 07266] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007032] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BANERJEE D, 1994, STEM CELLS, V12, P378, DOI 10.1002/stem.5530120404; BARBOUR KW, 1990, MOL PHARMACOL, V37, P515; BI WL, 1993, HUM GENE THER, V4, P725, DOI 10.1089/hum.1993.4.6-725; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; BLACK ME, 1993, BIOCHEMISTRY-US, V32, P11618, DOI 10.1021/bi00094a019; Brenner MK, 1998, CANCER INVEST, V16, P269, DOI 10.3109/07357909809039777; CADWELL RC, 1994, PCR METH APPL, V3, pS136; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; Chinnasamy N, 1998, GENE THER, V5, P842, DOI 10.1038/sj.gt.3300699; Christians FC, 1997, CANCER RES, V57, P2007; Christians FC, 1996, P NATL ACAD SCI USA, V93, P6124, DOI 10.1073/pnas.93.12.6124; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; Dachs GU, 1997, ONCOL RES, V9, P313; Davis BM, 1997, CANCER RES, V57, P5093; Elion G B, 1980, Adv Enzyme Regul, V18, P53, DOI 10.1016/0065-2571(80)90008-4; Encell LP, 1998, CANCER RES, V58, P1013; ErcikanAbali EA, 1996, CANCER RES, V56, P4142; GREM JL, 1990, CANC CHEMOTHERAPY PR, P180; Guengerich F. P., 1995, CYTOCHROME P, P473; GULICK AM, 1995, P NATL ACAD SCI USA, V92, P8140, DOI 10.1073/pnas.92.18.8140; HABER DA, 1981, J BIOL CHEM, V256, P9501; HARRAP KR, 1989, ADV ENZYME REGUL, V29, P161, DOI 10.1016/0065-2571(89)90099-X; HORWITZ MSZ, 1986, P NATL ACAD SCI USA, V83, P7405, DOI 10.1073/pnas.83.19.7405; James RI, 1997, EXP HEMATOL, V25, P1286; Kivisto KT, 1995, BRIT J CLIN PHARMACO, V40, P523, DOI 10.1111/j.1365-2125.1995.tb05796.x; Landis DM, 1998, J BIOL CHEM, V273, P25809, DOI 10.1074/jbc.273.40.25809; LEBLANC GA, 1989, DRUG METAB REV, V20, P395, DOI 10.3109/03602538909103550; LOEB LA, 1991, CANCER RES, V51, P3075; LOKTIONOVA NA, IN PRESS BIOCH PHARM; Maze R, 1996, P NATL ACAD SCI USA, V93, P206, DOI 10.1073/pnas.93.1.206; McIvor RS, 1996, BONE MARROW TRANSPL, V18, pS50; MCIVOR RS, 1990, NUCLEIC ACIDS RES, V18, P7025, DOI 10.1093/nar/18.23.7025; MICKISCH GH, 1991, CANCER RES, V51, P5417; Mineishi S, 1998, CANCER GENE THER, V5, P144; Mineishi S, 1997, GENE THER, V4, P570, DOI 10.1038/sj.gt.3300439; MOOLTEN FL, 1990, HUM GENE THER, V1, P125, DOI 10.1089/hum.1990.1.2-125; MOOLTEN FL, 1994, CANCER GENE THER, V1, P279; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; Pope IM, 1997, EUR J CANCER, V33, P1005, DOI 10.1016/S0959-8049(96)00483-2; Rafferty JA, 1996, CANCER METAST REV, V15, P365, DOI 10.1007/BF00046348; RODE W, 1980, J BIOL CHEM, V255, P1305; ROSENBERG SA, 1993, CANC PRINCIPLES PRAC, P2598; SANTI DV, 1984, FOLATES PTERINS, P345; Skandalis A, 1997, CHEM BIOL, V4, P889, DOI 10.1016/S1074-5521(97)90297-0; Spencer HT, 1996, BLOOD, V87, P2579, DOI 10.1182/blood.V87.6.2579.bloodjournal8762579; SRIMATKANDADA S, 1989, J BIOL CHEM, V264, P3524; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; SWEASY JB, 1993, P NATL ACAD SCI USA, V90, P4626, DOI 10.1073/pnas.90.10.4626; THILLET J, 1988, J BIOL CHEM, V263, P12500; Tong YZ, 1998, J BIOL CHEM, V273, P11611, DOI 10.1074/jbc.273.19.11611; Tong YZ, 1998, J BIOL CHEM, V273, P31209, DOI 10.1074/jbc.273.47.31209; WILLIAMS DA, 1987, J EXP MED, V166, P210, DOI 10.1084/jem.166.1.210; Xu-Welliver M, 1998, CANCER RES, V58, P1936; Zhao HM, 1997, P NATL ACAD SCI USA, V94, P7997, DOI 10.1073/pnas.94.15.7997; ZHAO SC, 1994, CANCER GENE THER, V1, P27; Zhao SC, 1997, HUM GENE THER, V8, P903, DOI 10.1089/hum.1997.8.8-903	56	50	51	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					143	147		10.1038/6142	http://dx.doi.org/10.1038/6142			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052349				2022-12-27	WOS:000078508300021
J	Papadopoulos, S				Papadopoulos, S			Biotechnology's consolidation conundrum	NATURE BIOTECHNOLOGY			English	Article									Paine Webber, New York, NY 10019 USA		Papadopoulos, S (corresponding author), Paine Webber, 1285 Ave Americas, New York, NY 10019 USA.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17			S			BE40	BE41		10.1038/4645	http://dx.doi.org/10.1038/4645			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165PD	10052328				2022-12-27	WOS:000078529400019
J	Mahadevappa, M; Warrington, JA				Mahadevappa, M; Warrington, JA			A high-density probe array sample preparation method using 10-to 100-fold fewer cells	NATURE BIOTECHNOLOGY			English	Editorial Material							GENE-EXPRESSION; MICROARRAY		Affymetrix Inc, High Throughput Screening, Santa Clara, CA 95051 USA	Affymetrix	Mahadevappa, M (corresponding author), Affymetrix Inc, High Throughput Screening, 3380 Cent Expressway, Santa Clara, CA 95051 USA.							*AFF INC, 1998, EUK EXPR AN TARG PRE; Berne RM., 1988, PHYSIOLOGY, VSecond ed.; Choi SY, 1996, J BIOCHEM MOL BIOL, V29, P272; Endege WO, 1999, BIOTECHNIQUES, V26, P542, DOI 10.2144/99263cr04; FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Lander ES, 1999, NAT GENET, V21, P3, DOI 10.1038/4427; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Phillips Jennifer, 1996, Methods (Orlando), V10, P283, DOI 10.1006/meth.1996.0104; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	17	137	143	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1134	1136		10.1038/15124	http://dx.doi.org/10.1038/15124			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545926				2022-12-27	WOS:000083428000036
J	Zhang, LH; Xu, JL; Birch, RG				Zhang, LH; Xu, JL; Birch, RG			Engineered detoxification confers resistance against a pathogenic bacterium	NATURE BIOTECHNOLOGY			English	Article						disease resistance; antipathogenesis; transgenic plants; sugarcane; albicidin detoxification	LEAF SCALD DISEASE; XANTHOMONAS-ALBILINEANS; PANTOEA-DISPERSA; SUGARCANE; EXPRESSION; PLANTS; GENE; PHASEOLICOLA; CHLOROSIS; MARKER	We generated transgenic sugarcane plants that express an albicidin detoxifying gene (albD), which was cloned from a bacterium that provides biocontrol against leaf scald disease. Plants with albicidin detoxification capacity equivalent to 1-10 ng of AlbD enzyme per mg of leaf protein did not develop chlorotic disease symptoms in inoculated leaves, whereas all untransformed control plants developed severe symptoms. Transgenic lines with high AlbD activity in young stems were also protected against systemic multiplication of the pathogen, which is the precursor to economic disease. We have shown that genetic modification to express a toxin-resistance gene can confer resistance to both disease symptoms and multiplication of a toxigenic pathogen in its host.	Univ Queensland, Dept Bot, Brisbane, Qld 4072, Australia	University of Queensland	Birch, RG (corresponding author), Univ Queensland, Dept Bot, Brisbane, Qld 4072, Australia.							ANZAI H, 1989, MOL GEN GENET, V219, P492, DOI 10.1007/BF00259626; BEVAN MW, 1983, NATURE, V304, P184, DOI 10.1038/304184a0; BIRCH RG, 1985, J GEN MICROBIOL, V131, P1069; BIRCH RG, 1987, PHYSIOL MOL PLANT P, V30, P199, DOI 10.1016/0885-5765(87)90033-6; BIRCH RG, 1987, PHYSIOL MOL PLANT P, V30, P207, DOI 10.1016/0885-5765(87)90034-8; BIRCH RG, 1983, PHYTOPATHOLOGY, V73, P1368, DOI 10.1094/Phyto-73-1368; Bower R, 1996, MOL BREEDING, V2, P239, DOI 10.1007/BF00564201; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Christensen AH, 1996, TRANSGENIC RES, V5, P213, DOI 10.1007/BF01969712; DELAFUENTEMARTINEZ JM, 1992, BIO-TECHNOL, V10, P905, DOI 10.1038/nbt0892-905; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; HANSOM S, 1999, IN PRESS P INT SOC S; JOHAL GS, 1992, SCIENCE, V258, P985, DOI 10.1126/science.1359642; LEA P, 1993, PLANT BIOCH MOL BIOL; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; PATIL SS, 1976, NATURE, V259, P486, DOI 10.1038/259486a0; PATIL SS, 1974, PHYTOPATHOLOGY, V64, P590, DOI 10.1094/Phyto-64-590; Ricaud C, 1989, DIS SUGARCANE MAJOR, P39, DOI [10.1016/B978-0-444-42797-7.50007-7, DOI 10.1016/B978-0-444-42797-7.50007-7]; ROTT P, 1994, PLANT DIS, V78, P241, DOI 10.1094/PD-78-0241; Rudolph K., 1976, PHYSL PLANT PATHOLOG, P207; SAMBROOK J, 1979, MOL CLONING LAB MANU; WALTON JD, 1993, ANNU REV PHYTOPATHOL, V31, P275, DOI 10.1146/annurev.py.31.090193.001423; Zhang L, 1996, LETT APPL MICROBIOL, V22, P132, DOI 10.1111/j.1472-765X.1996.tb01126.x; Zhang LH, 1997, P NATL ACAD SCI USA, V94, P9984, DOI 10.1073/pnas.94.18.9984	24	69	86	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1021	1024		10.1038/13721	http://dx.doi.org/10.1038/13721			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504706				2022-12-27	WOS:000083015700031
J	Millecamps, S; Kiefer, H; Navarro, V; Geoffroy, MC; Robert, JJ; Finiels, F; Mallet, J; Barkats, M				Millecamps, S; Kiefer, H; Navarro, V; Geoffroy, MC; Robert, JJ; Finiels, F; Mallet, J; Barkats, M			Neuron-restrictive silencer elements mediate neuron specificity of adenoviral gene expression	NATURE BIOTECHNOLOGY			English	Article						neuron-specific expression; adenoviral vectors; gene transfer; central nervous system gene therapy; motor neuron disease	SODIUM-CHANNEL GENE; RECEPTOR GENE; RAT MODEL; DISEASE; THERAPY; VECTOR; BRAIN; PROTEIN; MUSCLE	Neuron-restrictive silencer elements (NRSEs) were used to target the gene expression of adenoviral vectors specifically to neuron cells in the central nervous system. By generating adenoviral constructs in which NRSE sequences were placed upstream from the ubiquitous phosphoglycerate kinase promoter, the specificity of expression of a luciferase reporter gene was tested in both cell lines and primary cultures. Whereas transgene expression was negligible in nonneuronal cells following infection with an adenovirus containing 12 NRSEs, neuronal cells strongly expressed luciferase when infected with the same adenovirus. The NRSEs restricted expression of the luciferase gene to neuronal cells in vivo when adenoviruses were injected both intramuscularly into mice and intracerebrally into rats. This NRSE strategy may avoid side effects resulting from the ectopic expression of therapeutic genes in the treatment of neurological diseases. In particular, it may allow the direct transfection of motor neurons without promoting transgene expression within inoculated muscles or the secretion of transgene products into the bloodstream.	Hop La Pitie Salpetriere, Lab Genet Mol Neurotransmiss & Proc Neurodegenera, CNRS, UMR C9923, Paris, France; Rhone Poulenc Rorer, Vitry Sur Seine, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Sanofi-Aventis	Mallet, J (corresponding author), Hop La Pitie Salpetriere, Lab Genet Mol Neurotransmiss & Proc Neurodegenera, CNRS, UMR C9923, Paris, France.	mallet@infobiogen.fr	Kiefer, Helene/AAY-9185-2020; Kiefer, Hélène/Q-2752-2018; Millecamps, Stéphanie/W-7184-2018	Kiefer, Hélène/0000-0002-6631-741X; Millecamps, Stéphanie/0000-0002-0745-6735; Navarro, Vincent/0000-0003-0077-8114; Geoffroy, Marie-Claude/0000-0001-8298-467X				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Anderson WF, 1998, NATURE, V392, P25; Barkats M, 1998, PROG NEUROBIOL, V55, P333, DOI 10.1016/S0301-0082(98)00028-8; Barkats M, 1997, NEUROSCIENCE, V78, P703, DOI 10.1016/S0306-4522(96)00526-X; BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; Bessis A, 1997, P NATL ACAD SCI USA, V94, P5906, DOI 10.1073/pnas.94.11.5906; BilangBleuel A, 1997, P NATL ACAD SCI USA, V94, P8818, DOI 10.1073/pnas.94.16.8818; Chen HH, 1997, P NATL ACAD SCI USA, V94, P1645, DOI 10.1073/pnas.94.5.1645; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Corti O, 1999, NAT BIOTECHNOL, V17, P349, DOI 10.1038/7901; Finiels F, 1995, NEUROREPORT, V6, P2473, DOI 10.1097/00001756-199512150-00009; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; GHADGE GD, 1995, GENE THER, V2, P132; Haase G, 1997, NAT MED, V3, P429, DOI 10.1038/nm0497-429; Hawrot E, 1979, Methods Enzymol, V58, P574; HORELLOU P, 1994, NEUROREPORT, V6, P49, DOI 10.1097/00001756-199412300-00014; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; LE GLS, 1993, SCIENCE, V259, P988; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MOULLIER P, 1993, TRANSPLANTATION, V56, P427, DOI 10.1097/00007890-199308000-00034; Peel AL, 1997, GENE THER, V4, P16, DOI 10.1038/sj.gt.3300358; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Sendtner M, 1997, NAT MED, V3, P380, DOI 10.1038/nm0497-380; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Wood IC, 1996, J BIOL CHEM, V271, P14221, DOI 10.1074/jbc.271.24.14221	29	42	48	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					865	869		10.1038/12849	http://dx.doi.org/10.1038/12849			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471926				2022-12-27	WOS:000082365800026
J	Kojima, T; Kitamura, T				Kojima, T; Kitamura, T			A signal sequence trap based on a constitutively active cytokine receptor	NATURE BIOTECHNOLOGY			English	Article						signal sequence trap; retrovirus cDNA library	SECRETED PROTEINS; MOLECULAR-CLONING; MPL; IDENTIFICATION; MEMBER; GROWTH; SUPERFAMILY; EXPRESSION; CDNA	Targeting of secreted and cell-surface proteins to the cell membrane is mediated by a short hydrophobic stretch of amino acids, termed the signal sequence. We have developed a method that detects signal sequences in cDNA fragments based on their ability to redirect a constitutively active mutant of a cytokine receptor to the cell surface, thereby permitting interleukin-3 (IL-3)-independent growth of Ba/F3 cells. Retrovirus-mediated expression of the fusions in IL-3-dependent cells was followed by selection of clones for growth in the absence of IL-3. Infection of cells with 5x10(6) viral particles in a pilot experiment led to the isolation of 150 known and 48 novel cDNA clones, and all the known cDNA clones were found to encode secreted and cell-surface proteins. In addition, we isolated type II membrane proteins, which have not been detected by existing signal sequence trap strategies.	Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, Tokyo 108, Japan	University of Tokyo	Kitamura, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.		Kitamura, Toshio/AAA-2071-2021					KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KAISER CA, 1986, MOL CELL BIOL, V6, P2382, DOI 10.1128/MCB.6.7.2382; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Klein RD, 1996, P NATL ACAD SCI USA, V93, P7108, DOI 10.1073/pnas.93.14.7108; LEE F, 1985, P NATL ACAD SCI USA, V82, P4360, DOI 10.1073/pnas.82.13.4360; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Scherer PE, 1998, NAT BIOTECHNOL, V16, P581, DOI 10.1038/nbt0698-581; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	14	77	92	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					487	490		10.1038/8666	http://dx.doi.org/10.1038/8666			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331810				2022-12-27	WOS:000080074500035
J	Corti, O; Sabate, O; Horellou, P; Colin, P; Dumas, S; Buchet, D; Buc-Caron, MH; Mallet, J				Corti, O; Sabate, O; Horellou, P; Colin, P; Dumas, S; Buchet, D; Buc-Caron, MH; Mallet, J			A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors	NATURE BIOTECHNOLOGY			English	Article						doxycycline; adenovirus; human neural progenitors; tyrosine hydroxylase	CENTRAL-NERVOUS-SYSTEM; LONG-TERM EXPRESSION; PRODUCE L-DOPA; PARKINSONS-DISEASE; GENE-TRANSFER; MAMMALIAN-CELLS; SKIN FIBROBLASTS; TRANSGENIC MICE; MOUSE-BRAIN; RAT MODEL	Ex vivo gene transfer is emerging as a promising therapeutic approach to human neurodegenerative diseases. By combining efficient methodologies for cell amplification and gene delivery, large numbers of cells can be generated with the capacity to synthesize therapeutic molecules. These cells can then be transplanted into the degenerating central nervous system (CNS). Applying this approach to human diseases will require the development of suitable cellular vehicles, as well as safe gene delivery systems capable of tightly controlled transgene expression. For such brain repair technologies, human neural progenitors may be extremely valuable, because of their human CNS origin and developmental potential. We have used these cells to develop a system for the regulated expression of a gene of therapeutic potential. We report the construction of a single adenovirus encoding human tyrosine hydroxylase 1 (hTH-1) under the negative control of the tetracycline-based gene regulatory system. Human neural progenitors infected with this vector produced large amounts of hTH-1. Most importantly, doxycycline allowed a reversible switch of transgene transcription both in vitro and in vivo. This system may be applied to the development of therapies for human neurodegenerative diseases.	Hop La Pitie Salpetriere, CNRS, Lab Genet Mol Neurotransmiss & Proc Neurodegenera, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Mallet, J (corresponding author), Hop La Pitie Salpetriere, CNRS, Lab Genet Mol Neurotransmiss & Proc Neurodegenera, F-75013 Paris, France.		Corti, Olga/I-4981-2016; Horellou, Philippe/B-4290-2019; Corti, Olga/AAC-3160-2019	Corti, Olga/0000-0003-2093-7389; Horellou, Philippe/0000-0003-2467-8177; 				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BRUNDIN P, 1988, EXP BRAIN RES, V70, P192; BUC CM, 1995, NEUROBIOL DIS, V2, P37; Corti O, 1996, NEUROREPORT, V7, P1655, DOI 10.1097/00001756-199607080-00026; DUMAS S, 1992, J CHEM NEUROANAT, V5, P11, DOI 10.1016/0891-0618(92)90030-T; Fisher LJ, 1997, NEUROBIOL DIS, V4, P1, DOI 10.1006/nbdi.1997.0137; FISHER LJ, 1991, NEURON, V6, P371, DOI 10.1016/0896-6273(91)90246-V; Freese A., 1997, Society for Neuroscience Abstracts, V23, P540; GENY C, 1994, J NEUROSCI, V14, P7553; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; Harding TC, 1998, NAT BIOTECHNOL, V16, P553, DOI 10.1038/nbt0698-553; HORELLOU P, 1990, NEURON, V5, P393, DOI 10.1016/0896-6273(90)90078-T; Horellou P, 1997, EXP NEUROL, V144, P131, DOI 10.1006/exnr.1996.6399; KAPLITT MG, 1994, P NATL ACAD SCI USA, V91, P8979, DOI 10.1073/pnas.91.19.8979; KAY MA, 1992, P NATL ACAD SCI USA, V89, P89, DOI 10.1073/pnas.89.1.89; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Kojima H, 1997, BIOCHEM BIOPH RES CO, V238, P569, DOI 10.1006/bbrc.1997.7183; Laniece P, 1996, J NEUROCHEM, V66, P1819; LIM B, 1989, P NATL ACAD SCI USA, V86, P8892, DOI 10.1073/pnas.86.22.8892; Lindvall O, 1997, NEUROREPORT, V8, pR3, DOI 10.1097/00001756-199709290-00036; MARSDEN CD, 1976, LANCET, V1, P292, DOI 10.1016/S0140-6736(76)91416-1; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; Miller N, 1997, HUM GENE THER, V8, P803, DOI 10.1089/hum.1997.8.7-803; Mohammadi SA, 1997, GENE THER, V4, P993, DOI 10.1038/sj.gt.3300491; MOULLIER P, 1993, TRANSPLANTATION, V56, P427, DOI 10.1097/00007890-199308000-00034; OBESO JA, 1994, EUR J NEUROSCI, V6, P889, DOI 10.1111/j.1460-9568.1994.tb00584.x; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; Pedersen EB, 1997, NEUROSCIENCE, V78, P685, DOI 10.1016/S0306-4522(96)00620-3; Raymon HK, 1997, EXP NEUROL, V144, P82, DOI 10.1006/exnr.1996.6392; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; SABATE O, 1995, NAT GENET, V9, P256, DOI 10.1038/ng0395-256; Saez E, 1997, CURR OPIN BIOTECH, V8, P608, DOI 10.1016/S0958-1669(97)80037-7; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; STLOUIS D, 1988, P NATL ACAD SCI USA, V85, P3150; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Uchida K, 1989, Hum Cell, V2, P150; UNGERSTEDT U, 1970, Brain Research, V24, P485, DOI 10.1016/0006-8993(70)90187-3; Whittemore S R, 1997, Adv Neurol, V72, P113; WOLFF JA, 1989, P NATL ACAD SCI USA, V86, P9011, DOI 10.1073/pnas.86.22.9011; Yu JS, 1996, CANCER RES, V56, P5423	45	82	87	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					349	354		10.1038/7901	http://dx.doi.org/10.1038/7901			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207882				2022-12-27	WOS:000079574400022
J	Birndorf, HC				Birndorf, HC			Rational financing	NATURE BIOTECHNOLOGY			English	Article									Nanogen, San Diego, CA 92121 USA		Birndorf, HC (corresponding author), Nanogen, 10398 Pacific Ctr Court, San Diego, CA 92121 USA.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17			S			BE33	BE34		10.1038/4641	http://dx.doi.org/10.1038/4641			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165PD	10052325	Bronze			2022-12-27	WOS:000078529400016
J	Strohman, RC				Strohman, RC			Five stages of the Human Genome Project	NATURE BIOTECHNOLOGY			English	Editorial Material							BIOLOGY		Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Strohman, RC (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.							[Anonymous], 1996, FORM TRANSFORMATION; Duesberg P, 1998, P NATL ACAD SCI USA, V95, P13692, DOI 10.1073/pnas.95.23.13692; FELL D, 1997, CELL BIOCHEM FUNCT, V229, P236; Gilbert SF, 1996, DEV BIOL, V173, P357, DOI 10.1006/dbio.1996.0032; GOODWIN BC, 1993, J THEOR BIOL, V163, P135, DOI 10.1006/jtbi.1993.1112; KAUFFMAN SA, 1969, J THEOR BIOL, V22, P437, DOI 10.1016/0022-5193(69)90015-0; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; SAVAGEAU MA, 1991, NEW BIOL, V3, P190; Sing CF, 1996, CIBA F SYMP, V197, P211; STROHMAN R, 1994, BIO-TECHNOL, V12, P156, DOI 10.1038/nbt0294-156; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; Wahlsten D, 1999, ANNU REV PSYCHOL, V50, P599, DOI 10.1146/annurev.psych.50.1.599; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; 1998, CELL MOL LIFE SCI, V54	14	6	6	1	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					112	112		10.1038/6074	http://dx.doi.org/10.1038/6074			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052331				2022-12-27	WOS:000078508300003
J	Fox, JL				Fox, JL			FDA not yet moved by biotech food critics	NATURE BIOTECHNOLOGY			English	News Item																			0	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					15	15		10.1038/71844	http://dx.doi.org/10.1038/71844			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625375				2022-12-27	WOS:000084699900009
J	Sagar, A; Daemmrich, A; Ashiya, M				Sagar, A; Daemmrich, A; Ashiya, M			The tragedy of the commoners: biotechnology and its publics	NATURE BIOTECHNOLOGY			English	Editorial Material									Harvard Univ, John F Kennedy Sch Govt, Belfer Ctr Sci & Int Affairs, Sci Technol & Publ Policy Program, Cambridge, MA 02138 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Harvard University; Dana-Farber Cancer Institute	Sagar, A (corresponding author), Harvard Univ, John F Kennedy Sch Govt, Belfer Ctr Sci & Int Affairs, Sci Technol & Publ Policy Program, Cambridge, MA 02138 USA.			Daemmrich, Arthur/0000-0001-5798-5494; Sagar, Ambuj/0000-0002-5361-0852				*AGREV, 1998, NOUR 10 BILLION PEOP; BARRE R, 1998, WORLD SCI REPORT 199; Beck Ulrich., 1992, RISK SOC NEW MODERNI; NELKIN D, 1995, HDB SCI TECHNOLOGY S, P445; Persley GJ, 1999, BIOTECHNOLOGY DEV CO; *RUR ADV FDN INT, 1999, TRAIT TECHN TERM WID; Slovic Paul, 1991, ACCEPTABLE EVIDENCE, P48; *UN DEV PROGR, 1999, HUM DEV REP 1999, P36; World Bank, 1999, WORLD DEV REP 1999; *WORLD BANK, 1999, GLOB DEV FIN 1999; 1999, ECONOMIST       0109, P21	11	42	44	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					2	4		10.1038/71861	http://dx.doi.org/10.1038/71861			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625342				2022-12-27	WOS:000084699900003
J	Garrett, SD; Lee, HA; Morgan, MRA				Garrett, SD; Lee, HA; Morgan, MRA			A nonisotopic estrogen receptor-based assay to detect estrogenic compounds	NATURE BIOTECHNOLOGY			English	Article						human estrogen receptor; phytoestrogens; estrogens; rapid screening; flavonoids	SOYBEAN FOODS; BINDING; ISOFLAVONES; GENISTEIN; PHYTOESTROGENS; CHEMICALS; DAIDZEIN; SYSTEM; BETA	We have used the ligand binding domain of the recombinant human estrogen receptor (hER) to develop a nonisotopic assay for detection of estrogenic compounds. The assay is based on competition of the estrogenic ligand with 17 beta-estradiol for binding to the receptor, which leaves 17 beta-estradiol free to bind to an anti-17 beta-estradiol antibody. Unbound anti-17 beta-estradiol antibody then binds to immobilized 17 beta-estradiol-protein conjugate (to which hER is unable to bind for steric reasons), and is detected by an enzyme-labeled anti-rabbit IgG antibody. We used the assay to detect estrogenic compounds (mainly members of the flavonoid group of plant polyphenols) in a variety of commonly consumed plant foods.	Inst Food Res, Norwich NR4 7UA, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Lee, HA (corresponding author), Inst Food Res, Norwich Res Pk, Norwich NR4 7UA, Norfolk, England.	heather.lee@bbsrc.ac.uk						ADLERCREUTZ H, 1995, ENVIRON HEALTH PERSP, V103, P103, DOI 10.2307/3432518; Anthony MS, 1996, J NUTR, V126, P43, DOI 10.1093/jn/126.1.43; Bolger R, 1998, ENVIRON HEALTH PERSP, V106, P551, DOI 10.1289/ehp.98106551; Clarkson TB, 1998, P SOC EXP BIOL MED, V217, P365; COWARD L, 1993, J AGR FOOD CHEM, V41, P1961, DOI 10.1021/jf00035a027; Creeke PI, 1998, FOOD AGR IMMUNOL, V10, P325, DOI 10.1080/09540109809354996; ERLANGER BF, 1957, J BIOL CHEM, V228, P713; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; HAGGBLAD J, 1995, BIOTECHNIQUES, V18, P146; JONES LA, 1995, ENVIRON HEALTH PERSP, V103, P63, DOI 10.2307/3432510; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lapcik O, 1998, J STEROID BIOCHEM, V64, P261, DOI 10.1016/S0960-0760(97)00199-4; LEWIS DFV, 1995, J STEROID BIOCHEM, V52, P55, DOI 10.1016/0960-0760(94)00151-B; Liggins J, 1998, ANAL BIOCHEM, V264, P1, DOI 10.1006/abio.1998.2825; MIKSICEK RJ, 1994, J STEROID BIOCHEM, V49, P153, DOI 10.1016/0960-0760(94)90005-1; MIKSICEK RJ, 1995, P SOC EXP BIOL MED, V208, P44; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Murphy PA, 1997, J AGR FOOD CHEM, V45, P4635, DOI 10.1021/jf970590t; OBOURN JD, 1993, BIOCHEMISTRY-US, V32, P6229, DOI 10.1021/bi00075a016; REDEUILH G, 1985, J BIOL CHEM, V260, P3996; SEIELSTAD DA, 1995, MOL ENDOCRINOL, V9, P647, DOI 10.1210/me.9.6.647; Seifert M, 1999, ANAL CHIM ACTA, V386, P191, DOI 10.1016/S0003-2670(99)00044-6; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.1289/ehp.95103s7113; WANG HJ, 1994, J AGR FOOD CHEM, V42, P1666, DOI 10.1021/jf00044a016; WIESE TE, 1997, CHEM IND, V24, P648	25	37	40	0	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1219	1222		10.1038/70773	http://dx.doi.org/10.1038/70773			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585722				2022-12-27	WOS:000084170700032
J	Ledley, FD				Ledley, FD			Can pharmacogenomics make a difference in drug development?	NATURE BIOTECHNOLOGY			English	Editorial Material									Variagenics, Cambridge, MA 02138 USA		Ledley, FD (corresponding author), Variagenics, Cambridge, MA 02138 USA.								0	19	20	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					731	731		10.1038/11614	http://dx.doi.org/10.1038/11614			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429218	Bronze			2022-12-27	WOS:000081751400005
J	Alayash, AI				Alayash, AI			Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants?	NATURE BIOTECHNOLOGY			English	Review						blood substitutes; blood pressure; oxidants	CROSS-LINKED HEMOGLOBIN; CELL-FREE HEMOGLOBIN; NITRIC-OXIDE; FREE-RADICALS; EFFICACY; POLYMERIZATION; METHEMOGLOBIN; MECHANISMS; FAILURE	Hemoglobin-based blood substitutes are being developed as oxygen-carrying agents for the prevention of ischemic tissue damage and hypovolemic (low blood volume) shock. The ability of cell-free hemoglobin blood substitutes to affect vascular tone through the removal of nitric oxide has also prompted an evaluation of their usefulness for maintaining blood pressure in critically ill patients. Before the clinical potential of these substitutes can be fully realized, however, concerns remain as to the intrinsic toxicity of the hemoglobin molecule, particularly the interference of the heme prosthetic group with the tissue oxidant/antioxidant balance. This review provides some insights into the complex redox chemistry of hemoglobin and places an emphasis on how current knowledge may be exploited both to selectively enhance/suppress specific chemical reaction pathway(s) and to ultimately design safer hemoglobin-based therapeutics.	US FDA, Lab Plasma Derivat, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Alayash, AI (corresponding author), US FDA, Lab Plasma Derivat, Ctr Biol Evaluat & Res, NIH Campus,Bldg 29,Room 112,8800 Rockville Pike, Bethesda, MD 20892 USA.	Alayash@cber.fda.gv						Abassi Z, 1997, J LAB CLIN MED, V129, P603, DOI 10.1016/S0022-2143(97)90194-3; Adamson JG, 1998, TISS ENG, P62; ALAYASH AI, 1995, MOL MED TODAY, V1, P122, DOI 10.1016/S1357-4310(95)80089-1; Alayash AI, 1999, J BIOL CHEM, V274, P2029, DOI 10.1074/jbc.274.4.2029; Alayash AI, 1998, ARCH BIOCHEM BIOPHYS, V349, P65, DOI 10.1006/abbi.1997.0449; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; Bunn HF, 1986, HEMOGLOBIN MOL GENET; Caron A, 1999, J APPL PHYSIOL, V86, P541, DOI 10.1152/jappl.1999.86.2.541; CASHON RE, 1995, ARCH BIOCHEM BIOPHYS, V316, P461, DOI 10.1006/abbi.1995.1061; Chang TMS, 1999, TRENDS BIOTECHNOL, V17, P61, DOI 10.1016/S0167-7799(98)01242-6; CHANG TMS, 1998, BLOOD SUBSTITUTES PR, V1; D'Agnillo F, 1998, NAT BIOTECHNOL, V16, P667, DOI 10.1038/nbt0798-667; DAGNILLO F, IN PRESS ADV DRUG DE; DARLEYUSMAR VW, 1994, BIOCHEMIST, P13; Doherty DH, 1998, NAT BIOTECHNOL, V16, P672, DOI 10.1038/nbt0798-672; Doyle MP, 1999, J BIOL CHEM, V274, P2583, DOI 10.1074/jbc.274.4.2583; Faivre B, 1998, ARTIF CELL BLOOD SUB, V26, P17, DOI 10.3109/10731199809118943; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; Goldman DW, 1998, AM J PHYSIOL-HEART C, V275, pH1046, DOI 10.1152/ajpheart.1998.275.3.H1046; GOULD SA, 1990, ANN SURG, V211, P394, DOI 10.1097/00000658-199004000-00003; GRISHAM MB, 1991, PEROXIDASES CHEM BIO, P335; Gulati A, 1999, J LAB CLIN MED, V133, P112, DOI 10.1016/S0022-2143(99)90003-3; HESS JR, 1993, J APPL PHYSIOL, V74, P1769, DOI 10.1152/jappl.1993.74.4.1769; KING NK, 1963, J BIOL CHEM, V238, P1520; LEE R, 1995, J APPL PHYSIOL, V79, P236, DOI 10.1152/jappl.1995.79.1.236; LEE R, 1989, J SURG RES, V47, P407, DOI 10.1016/0022-4804(89)90092-9; Linberg R, 1998, ARTIF CELL BLOOD SUB, V26, P133, DOI 10.3109/10731199809119772; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; LOOKER D, 1992, NATURE, V356, P258, DOI 10.1038/356258a0; Loscalzo J, 1997, J LAB CLIN MED, V129, P580, DOI 10.1016/S0022-2143(97)90191-8; Marden MC, 1995, TRANSFUS CLIN BIOL, V2, P473, DOI 10.1016/S1246-7820(05)80074-6; MCLEOD L, IN PRESS AM J PHYSL; MONCADA S, 1991, PHARMACOL REV, V43, P109; Moore KP, 1998, J BIOL CHEM, V273, P31731, DOI 10.1074/jbc.273.48.31731; MOTTERLINI R, 1995, AM J PHYSIOL-HEART C, V269, pH648, DOI 10.1152/ajpheart.1995.269.2.H648; Nelson DJ, 1998, TISS ENG, P39; PEAH G, 1997, CRIT CARE MED, V25, P1480; Phillips WT, 1999, J PHARMACOL EXP THER, V288, P665; ROGERS MS, 1995, BBA-PROTEIN STRUCT M, V1248, P135, DOI 10.1016/0167-4838(95)00017-O; ROLFS JR, 1998, J BIOL CHEM, V273, P12123; RUDOLPH AS, 1991, P NATL ACAD SCI USA, V88, P10976, DOI 10.1073/pnas.88.23.10976; Sakai H, 1997, BIOCONJUGATE CHEM, V8, P23, DOI 10.1021/bc960069p; SONG D, 1995, TRANSFUSION, V35, P552, DOI 10.1046/j.1537-2995.1995.35795357876.x; Svistunenko DA, 1997, J BIOL CHEM, V272, P7114, DOI 10.1074/jbc.272.11.7114; SVISTUNENKO DA, 1997, J CHEM SOC P2, V2, P2539; TALARICO T, 1998, BIOCHIM BIOPHYS ACTA, V250, P350; VANDEGRIFF KD, 1991, J BIOL CHEM, V266, P2697; WEIL MH, 1970, CIRCULATION, V41, P989, DOI 10.1161/01.CIR.41.6.989; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; Winslow R.M, 1992, HEMOGLOBIN BASED RED; Winslow RM, 1998, J APPL PHYSIOL, V85, P993, DOI 10.1152/jappl.1998.85.3.993; Winslow Robert M., 1996, P146; 1998, BUSINESS NEWS    SEP, P16	53	178	182	1	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					545	549		10.1038/9849	http://dx.doi.org/10.1038/9849			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385317				2022-12-27	WOS:000080716500024
J	Eisenstein, RI; Resnick, DS				Eisenstein, RI; Resnick, DS			Public access to data may be closer than you think - How to shield your valuable research from the reach of the Shelby Amendment.	NATURE BIOTECHNOLOGY			English	Article									Peabody & Brown, Patent & Interference Practice Grp, Boston, MA 02110 USA		Eisenstein, RI (corresponding author), Peabody & Brown, Patent & Interference Practice Grp, 101 Fed St, Boston, MA 02110 USA.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					604	606		10.1038/9924	http://dx.doi.org/10.1038/9924			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385328				2022-12-27	WOS:000080716500035
J	Hols, P; Kleerebezem, M; Schanck, AN; Ferain, T; Hugenholtz, J; Delcour, J; de Vos, WM				Hols, P; Kleerebezem, M; Schanck, AN; Ferain, T; Hugenholtz, J; Delcour, J; de Vos, WM			Conversion of Lactococcus lactis from homolactic to homoalanine fermentation through metabolic engineering	NATURE BIOTECHNOLOGY			English	Article						alanine; alanine racemase; alanine dehydrogenase; Lactococcus lactis	ALPHA-ACETOLACTATE SYNTHASE; CATABOLIC ALANINE RACEMASE; ESCHERICHIA-COLI; LACTOBACILLUS-PLANTARUM; SUBSP LACTIS; MOLECULAR-CLONING; ZYMOMONAS-MOBILIS; ACID BACTERIA; DEHYDROGENASE; GENE	We report the engineering of Lactococcus lactis to produce the amino acid L-alanine. The primary end product of sugar metabolism in wild-type L. lactis is lactate (homolactic fermentation). The terminal enzymatic reaction (pyruvate + NADH-->L-lactate + NAD(+)) is performed by L-lactate dehydrogenase (L-LDH). We rerouted the carbon flux toward alanine by expressing the Bacillus sphaericus alanine dehydrogenase (L-AlaDH; pyruvate + NADH + NH4+-->L-alanine + NAD(+) + H2O). Expression of L-AlaDH in an L-LDH-deficient strain permitted production of alanine as the sole end product (homoalanine fermentation). Finally, stereospecific production (>99%) of L-alanine was achieved by disrupting the gene encoding alanine racemase, opening the door to the industrial production of this stereoisomer in food products or bioreactors.	NIZO Food Res, Microbial Ingredients Sect, NL-6710 BA Ede, Netherlands; Univ Catholique Louvain, Genet Mol Lab, B-1348 Louvain, Belgium; Univ Catholique Louvain, Chim Phys & Cristallog Lab, B-1348 Louvain, Belgium	NIZO Food Research; Universite Catholique Louvain; Universite Catholique Louvain	Hols, P (corresponding author), NIZO Food Res, Microbial Ingredients Sect, POB 20, NL-6710 BA Ede, Netherlands.		Kleerebezem, Michiel/AAT-2078-2021	Kleerebezem, Michiel/0000-0001-8552-2235				BUIST G, 1995, J BACTERIOL, V177, P1554, DOI 10.1128/jb.177.6.1554-1563.1995; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHEN JD, 1988, GENE, V64, P155, DOI 10.1016/0378-1119(88)90489-1; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; deVos WM, 1996, ANTON LEEUW INT J G, V70, P223, DOI 10.1007/BF00395934; ELMANNS B, 1995, BIOSCOPE, V2, P39; Ferain T, 1996, J BACTERIOL, V178, P7311, DOI 10.1128/jb.178.24.7311-7315.1996; FERAIN T, 1994, J BACTERIOL, V176, P596, DOI 10.1128/jb.176.3.596-601.1994; FERRARI E, 1985, BIO-TECHNOL, V3, P1003, DOI 10.1038/nbt1185-1003; FOUCAUD C, 1995, LETT APPL MICROBIOL, V21, P10, DOI 10.1111/j.1472-765X.1995.tb00994.x; FURUI M, 1983, J FERMENT TECHNOL, V61, P587; Galkin A, 1997, APPL ENVIRON MICROB, V63, P4651, DOI 10.1128/AEM.63.12.4651-4656.1997; HASHIMOTO S, 1993, BIOTECHNOL LETT, V15, P1117, DOI 10.1007/BF00131200; HILLIER AJ, 1982, METHOD ENZYMOL, V89, P362; HIROSE Y, 1979, MICROBIAL TECHNOLOGY, P211; Hols P, 1997, J BACTERIOL, V179, P3804, DOI 10.1128/jb.179.11.3804-3807.1997; KITAI A, 1972, MICROBIAL PRODUCTION, P325; Kuipers OP, 1997, TRENDS BIOTECHNOL, V15, P135, DOI 10.1016/S0167-7799(97)01029-9; KURODA SI, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00456a025; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEENHOUTS KJ, 1989, APPL ENVIRON MICROB, V55, P394, DOI 10.1128/AEM.55.2.394-400.1989; LEUCHTENBERGER W, 1996, PRODUCTS PRIMARY MET, V6, P465; LOBOCKA M, 1994, J BACTERIOL, V176, P1500, DOI 10.1128/jb.176.5.1500-1510.1994; MOU L, 1976, J DAIRY RES, V43, P275, DOI 10.1017/S0022029900015831; OHASHIMA T, 1979, EUR J BIOCHEM, V100, P29, DOI 10.1111/j.1432-1033.1979.tb02030.x; OHTA K, 1991, APPL ENVIRON MICROB, V57, P893, DOI 10.1128/AEM.57.4.893-900.1991; OHTA T, 1994, APPL MICROBIOL BIOT, V42, P246, DOI [10.1007/BF00902724, 10.1007/s002530050245]; Orlygsson J, 1995, ANTON LEEUW INT J G, V68, P273, DOI 10.1007/BF00874136; PLATTEEUW C, 1995, APPL ENVIRON MICROB, V61, P3967, DOI 10.1128/AEM.61.11.3967-3971.1995; Ravot G, 1996, APPL ENVIRON MICROB, V62, P2657, DOI 10.1128/AEM.62.7.2657-2659.1996; Sambrook J., 2002, MOL CLONING LAB MANU; SNOEP JL, 1992, J BACTERIOL, V174, P4838, DOI 10.1128/JB.174.14.4838-4841.1992; STARRENBURG MJC, 1991, APPL ENVIRON MICROB, V57, P3535, DOI 10.1128/AEM.57.12.3535-3540.1991; UHLENBUSCH I, 1991, APPL ENVIRON MICROB, V57, P1360, DOI 10.1128/AEM.57.5.1360-1366.1991; VEGARUD G, 1983, J DAIRY SCI, V66, P2294, DOI 10.3168/jds.S0022-0302(83)82085-2; VOS P, 1989, J BACTERIOL, V171, P2795, DOI 10.1128/jb.171.5.2795-2802.1989; WANG E, 1978, BIOCHEMISTRY-US, V17, P1313, DOI 10.1021/bi00600a028; WASSERMAN SA, 1984, BIOCHEMISTRY-US, V23, P5182, DOI 10.1021/bi00317a015; WELLS JM, 1993, J APPL BACTERIOL, V74, P629, DOI 10.1111/j.1365-2672.1993.tb05195.x; YAMAMOTO T, 1985, PHYSIOL BEHAV, V35, P411, DOI 10.1016/0031-9384(85)90317-8	40	137	153	0	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					588	592		10.1038/9902	http://dx.doi.org/10.1038/9902			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385325				2022-12-27	WOS:000080716500032
J	Humes, HD; Buffington, DA; MacKay, SM; Funke, AJ; Weitzel, WF				Humes, HD; Buffington, DA; MacKay, SM; Funke, AJ; Weitzel, WF			Replacement of renal function in uremic animals with a tissue-engineered kidney	NATURE BIOTECHNOLOGY			English	Article						tissue engineering; cell therapy; kidney tubule cells	CRITICALLY ILL PATIENTS; BIOARTIFICIAL PANCREAS; GROWTH-FACTORS; FAILURE; TUBULE	Current renal substitution therapy with hemodialysis or hemofiltration has been the only successful long-term ex vivo organ substitution therapy to date. Although this approach is life sustaining, it is still unacceptably suboptimal with poor clinical outcomes of patients with either chronic end-stage renal disease or acute renal failure. This current therapy utilizes synthetic membranes to substitute for the small solute clearance function of the renal glomerulus but does not replace the transport, metabolic, and endocrinologic functions of the tubular cells. The addition of tubule cell replacement therapy in a tissue-engineered bioartificial kidney comprising both biologic and synthetic components will likely optimize renal replacement to improve clinical outcomes. This report demonstrates that the combination of a synthetic hemofiltration device and a renal tubule cell therapy device containing porcine renal tubule cells in an extracorporeal perfusion circuit successfully replaces filtration, transport, metabolic, and endocrinologic functions of the kidney in acutely uremic dogs.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Vet Adm Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Humes, HD (corresponding author), Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.	dhumes@umich.edu		Westover, Angela/0000-0002-7556-9838; Humes, David/0000-0002-4309-1614; Buffington, Deborah/0000-0002-1541-2003	NIDDK NIH HHS [DK-48175, DK-39255, DK-50539] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R44DK050539, R43DK050539, R43DK048175, P50DK039255] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRY CA, 1996, KIDNEY, P334; BIDLACK JM, 1976, COMP BIOCHEM PHYS B, V55, P161, DOI 10.1016/0305-0491(76)90223-6; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; CURTHOYS NP, 1983, MINER ELECTROL METAB, V9, P236; Gage FH, 1998, NATURE, V392, P18; Humes HD, 1996, AM J PHYSIOL-RENAL, V271, pF42, DOI 10.1152/ajprenal.1996.271.1.F42; HUMES HD, 1992, EXP CELL RES, V201, P8, DOI 10.1016/0014-4827(92)90342-6; Humes HD, 1997, AM J KIDNEY DIS, V30, pS28, DOI 10.1016/S0272-6386(97)90539-4; HUMES HD, 1995, KIDNEY INT, V48, pS26; Humes HD, 1997, P ASSOC AM PHYSICIAN, V109, P547; HUMES HD, IN PRESS KIDNEY INT; Humes HD, 1995, BIOMEDICAL ENG HDB, P1807; KNOX FG, 1983, CIRC RES, V52, P491, DOI 10.1161/01.RES.52.5.491; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; LEHMANN J, 1983, RENAL ENDOCRINOLOGYE, P114; MacKay SM, 1998, ASAIO J, V44, P179, DOI 10.1097/00002480-199805000-00011; Maki T, 1996, DIABETES, V45, P342, DOI 10.2337/diabetes.45.3.342; MEHTA RL, 1994, SEMIN NEPHROL, V14, P64; NIKOLOVSKI J, IN PRESS CELL TRANSP; ONeil JJ, 1997, TRANSPLANT P, V29, P2116, DOI 10.1016/S0041-1345(97)00255-8; PITTS RF, 1945, SCIENCE, V102, P49, DOI 10.1126/science.102.2638.49; PITTS RF, 1945, SCIENCE, V102, P81, DOI 10.1126/science.102.2639.81; PITTS RF, 1948, FED PROC, V7, P418; SCHOOLWERTH AC, 1991, KIDNEY INT, V40, P961, DOI 10.1038/ki.1991.301; TIMPL R, 1979, J BIOL CHEM, V254, P9933; Watanabe FD, 1997, ANN SURG, V225, P484, DOI 10.1097/00000658-199705000-00005; Yagi N, 1997, SEMIN NEPHROL, V17, P306; ZAROWITZ BJ, 1986, J CLIN PHARMACOL, V26, P686, DOI 10.1002/j.1552-4604.1986.tb02973.x; 1998, AM J KIDNEY DIS S1, V32, P669	29	209	243	0	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					451	455		10.1038/8626	http://dx.doi.org/10.1038/8626			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331803				2022-12-27	WOS:000080074500028
J	Sansom, G				Sansom, G			European biotechnology turns East	NATURE BIOTECHNOLOGY			English	Article																		Abbott A, 1999, NATURE, V397, P4, DOI 10.1038/16096; DICKSON D, 1994, NATURE, V372, P591	2	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					437	439		10.1038/8606	http://dx.doi.org/10.1038/8606			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331797				2022-12-27	WOS:000080074500022
J	Miller, HI				Miller, HI			The real curse of Frankenfood	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	6	6	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					113	113		10.1038/6075	http://dx.doi.org/10.1038/6075			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052332				2022-12-27	WOS:000078508300004
J	Schneider, S; Buchert, M; Georgiev, O; Catimel, B; Halford, M; Stacker, SA; Baechi, T; Moelling, K; Hovens, CM				Schneider, S; Buchert, M; Georgiev, O; Catimel, B; Halford, M; Stacker, SA; Baechi, T; Moelling, K; Hovens, CM			Mutagenesis and selection of PDZ domains that bind new protein targets	NATURE BIOTECHNOLOGY			English	Article						protein engineering; PDZ domains; in vivo screening; intracellular targeting	RECEPTOR; RECOGNITION; LIBRARIES; COMPLEXES; SEQUENCES; SYSTEM; SITES	PDZ domains are a recently characterized protein-recognition module. In most cases, PDZ domains bind to the C-terminal end of target proteins and are thought thereby to link these target proteins into functional signaling networks. We report the isolation of artificial PDZ domains selected via a mutagenesis screen in vivo, each recognizing a different C-terminal peptide. We demonstrate that the PDZ domains isolated can bind selectively to their target peptides in vitro and in vivo. Two of the target peptides chosen are the C-terminal ends of two cellular transmembrane proteins with which no known PDZ domains have been reported to interact. By targeting these artificial PDZ domains to the nucleus, interacting target peptides were efficiently transported to the same subcellular localization. One of the isolated PDZ domains was tested and shown to be efficiently directed to the plasma membrane when cotransfected with the full-length transmembrane protein in mammalian cells. Thus, artificial PDZ domains can be engineered and used to target intracellular proteins to different subcellular compartments.	Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland; Univ Zurich, Elekt Mikroskop Zent Lab, CH-8028 Zurich, Switzerland; Univ Zurich, Inst Mol Biol 2, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich; University of Zurich	Moelling, K (corresponding author), Univ Zurich, Inst Med Virol, Gloriastr 30-32, CH-8028 Zurich, Switzerland.			Stacker, Steven/0000-0003-4096-9273; Hovens, Christopher/0000-0002-0610-1289; Buchert, Michael/0000-0003-2672-0148; CATIMEL, Bruno/0000-0002-4350-6875				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchert M, 1997, BIOTECHNIQUES, V23, P396, DOI 10.2144/97233bm10; CADWELL RC, 1992, PCR METH APPL, V26, P259; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; Catimel B, 1997, J CHROMATOGR A, V776, P15, DOI 10.1016/S0021-9673(97)00087-3; CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Jannot CB, 1997, BIOCHEM BIOPH RES CO, V230, P242, DOI 10.1006/bbrc.1996.5930; Jones TL, 1997, ONCOGENE, V14, P2159, DOI 10.1038/sj.onc.1201082; Kast P, 1997, CURR OPIN STRUC BIOL, V7, P470, DOI 10.1016/S0959-440X(97)80109-1; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUNES S, 1985, J MOL BIOL, V184, P375, DOI 10.1016/0022-2836(85)90288-8; KURIAN J, 1997, ANNU REV BIOPH BIOM, V16, P6141; LOFAS S, 1995, BIOSENS BIOELECTRON, V10, P813, DOI 10.1016/0956-5663(95)99220-F; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; Miller J.H., 1972, EXPT MOL GENETICS; MORTON TA, 1995, ANAL BIOCHEM, V227, P176, DOI 10.1006/abio.1995.1268; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Nord K, 1997, NAT BIOTECHNOL, V15, P772, DOI 10.1038/nbt0897-772; Nygren PA, 1997, CURR OPIN STRUC BIOL, V7, P463, DOI 10.1016/S0959-440X(97)80108-X; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; PRASAD R, 1993, CANCER RES, V53, P5624; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Schneider S, 1997, GENE, V197, P337, DOI 10.1016/S0378-1119(97)00280-1; Shao ZX, 1996, CURR OPIN STRUC BIOL, V6, P513, DOI 10.1016/S0959-440X(96)80117-5; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805	35	73	85	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					170	175		10.1038/6172	http://dx.doi.org/10.1038/6172			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052354				2022-12-27	WOS:000078508300026
J	Hoyle, B				Hoyle, B			Giga-speed bioinformatics to power Genome Canada	NATURE BIOTECHNOLOGY			English	News Item																			0	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					950	950		10.1038/13642	http://dx.doi.org/10.1038/13642			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504688	Bronze			2022-12-27	WOS:000083015700012
J	Rigaut, G; Shevchenko, A; Rutz, B; Wilm, M; Mann, M; Seraphin, B				Rigaut, G; Shevchenko, A; Rutz, B; Wilm, M; Mann, M; Seraphin, B			A generic protein purification method for protein complex characterization and proteome exploration	NATURE BIOTECHNOLOGY			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; MASS-SPECTROMETRY; GENETIC-ANALYSIS; YEAST; IDENTIFICATION; GENOME; GELS; U1	We have developed a generic procedure to purify proteins expressed at their natural level under native conditions using a novel tandem affinity purification (TAP) tag. The TAP tag allows the rapid purification of complexes from a relatively small number of cells without prior knowledge of the complex composition, activity, or function. Combined with mass spectrometry, the TAP strategy allows for the identification of proteins interacting with a given target protein. The TAP method has been tested in yeast but should be applicable to other cells or organisms.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Seraphin, B (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Wilm, Matthias/0000-0002-5461-6834; Seraphin, Bertrand/0000-0002-5168-1921				Caspary F, 1999, EMBO J, V18, P3463, DOI 10.1093/emboj/18.12.3463; DOUGHERTY WG, 1989, VIROLOGY, V171, P356, DOI 10.1016/0042-6822(89)90603-X; Ford C F, 1991, Protein Expr Purif, V2, P95, DOI 10.1016/1046-5928(91)90057-P; FORTES P, 1999, IN PRESS GENES DEV, V3; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gottschalk A, 1998, RNA, V4, P374; Puig O, 1998, YEAST, V14, P1139; RIEDEL N, 1986, P NATL ACAD SCI USA, V83, P8097, DOI 10.1073/pnas.83.21.8097; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; Sheibani N, 1999, PREP BIOCHEM BIOTECH, V29, P77, DOI 10.1080/10826069908544695; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; 1998, Patent No. 115448	16	2136	2268	7	237	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1030	1032		10.1038/13732	http://dx.doi.org/10.1038/13732			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504710				2022-12-27	WOS:000083015700033
J	Shelton, AM; Roush, RT				Shelton, AM; Roush, RT			False reports and the ears of men	NATURE BIOTECHNOLOGY			English	Editorial Material							RESISTANCE MANAGEMENT; THURINGIENSIS		Cornell Univ, New York State Agr Expt Stn, Dept Entomol, Geneva, NY 14456 USA; Univ Adelaide, Waite Agr Res Inst, Dept Appl & Mol Ecol, Glen Osmond, SA 5064, Australia	Cornell University; University of Adelaide	Shelton, AM (corresponding author), Cornell Univ, New York State Agr Expt Stn, Dept Entomol, Geneva, NY 14456 USA.							Beringer JE, 1999, NATURE, V399, P405, DOI 10.1038/20784; FUMENTO M, 1999, WALL STREET J   0625; Gould F, 1997, P NATL ACAD SCI USA, V94, P3519, DOI 10.1073/pnas.94.8.3519; Hodgson J, 1999, NAT BIOTECHNOL, V17, P627, DOI 10.1038/10834; Huang F, 1999, SCIENCE, V284, P965, DOI 10.1126/science.284.5416.965; Liu YB, 1999, NATURE, V400, P519, DOI 10.1038/22919; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; METZ TD, 1995, MOL BREEDING, V1, P309, DOI 10.1007/BF01248408; Roush RT, 1997, PESTIC SCI, V51, P328, DOI 10.1002/(SICI)1096-9063(199711)51:3&lt;328::AID-PS650&gt;3.0.CO;2-B; STEFFEY K, 1999, BT CORN MANAGEMENT E, P72	10	22	24	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					832	832		10.1038/12779	http://dx.doi.org/10.1038/12779			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471903				2022-12-27	WOS:000082365800003
J	Branden, LJ; Mohamed, AJ; Smith, CIE				Branden, LJ; Mohamed, AJ; Smith, CIE			A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA	NATURE BIOTECHNOLOGY			English	Article						nuclear localization signal; peptide nucleic acid; transfection; translocation; plasmid; oligonucleotide	POLYETHYLENIMINE; PROTEIN; LIGANDS; VECTOR; IMPORT; GENE	We have combined a peptide nucleic acid (PNA) with the SV40 core nuclear localization signal (NLS), to create a bifunctional PNA-NLS peptide. The PNA-NLS peptide increased the nuclear uptake of oligonucleotides and enhanced the transfection efficacy of plasmids. Gene expression from an enhanced green fluorescent protein plasmid and a lacZ plasmid was preserved when hybridized to PNA-NLS. In combination with the transfection agent polyethyleneimine, we have improved both the nuclear translocation of fluorescence-marked oligonucleotides, and the efficacy of plasmid transfection, up to eightfold. The technique obviates the use of cumbersome coupling procedures of the vector due to DNA-PNA duplex formation or displacement of the antisense plasmid DNA strand by a PNA molecule.	Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, SE-14157 Huddinge, Sweden; Huddinge Hosp, Dept Clin Immunol Microbiol Pathol & Infect Dis, S-14186 Huddinge, Sweden; Univ Coll S Stockholm, SE-14104 Stockholm, Sweden; Karolinska Inst, Huddinge Hosp, Gene Therapy Res Ctr, Clin Res Ctr, SE-14186 Huddinge, Sweden	Karolinska Institutet; Sodertorn University; Karolinska Institutet	Branden, LJ (corresponding author), Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, SE-14157 Huddinge, Sweden.			SMITH, C. I. Edvard/0000-0003-1907-3392; Branden, Lars/0000-0002-1904-0470				*AUSUBEL FM, 1992, MOBILITY SHIFT ASSAY; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Bukrinsky MI, 1998, MOL MED, V4, P138, DOI 10.1007/BF03401911; Kircheis R, 1997, GENE THER, V4, P409, DOI 10.1038/sj.gt.3300418; Knudsen H, 1996, NUCLEIC ACIDS RES, V24, P494, DOI 10.1093/nar/24.3.494; MICHAUD N, 1993, EXP CELL RES, V208, P128, DOI 10.1006/excr.1993.1230; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; MUJUMDAR RB, 1993, BIOCONJUGATE CHEM, V4, P105, DOI 10.1021/bc00020a001; NIELSEN PE, 1991, BIOCONJUGATE CHEM, V2, P57, DOI 10.1021/bc00007a010; *PERS BIOS INC, PEPT NUCL AC PNA SYN; Sebestyen MG, 1998, NAT BIOTECHNOL, V16, P80, DOI 10.1038/nbt0198-80; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191; YONEDA Y, 1992, EXP CELL RES, V201, P313, DOI 10.1016/0014-4827(92)90279-H; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91	14	323	357	4	48	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					784	787		10.1038/11726	http://dx.doi.org/10.1038/11726			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429244				2022-12-27	WOS:000081751400028
J	Matsumura, I; Wallingford, JB; Surana, NK; Vize, PD; Ellington, AD				Matsumura, I; Wallingford, JB; Surana, NK; Vize, PD; Ellington, AD			Directed evolution of the surface chemistry of the reporter enzyme beta-glucuronidase	NATURE BIOTECHNOLOGY			English	Article						beta-glucuronidase; reporter gene; in vitro evolution; directed evolution; DNA shuffling; Xenopus laevis	ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; MESSENGER-RNAS; GENE; EXPRESSION; XENOPUS; PURIFICATION; ESTERASE; EMBRYOS; MARKER	The use of the Escherichia coli enzyme beta-glucuronidase (GUS) as a reporter in gene expression studies is limited due to loss of activity during tissue fixation by glutaraldehyde or formaldehyde. We have directed the evolution of a GUS variant that is significantly more resistant to both glutaraldehyde and formaldehyde than the wild-type enzyme. A variant with eight amino acid changes was isolated after three rounds of mutation, DNA shuffling, and screening. Surprisingly, although glutaraldehyde is known to modify and cross-link free amines, only one lysine residue was mutated. Instead, amino acid changes generally occurred near conserved lysines, implying that the surface chemistry of the enzyme was selected to either accept or avoid glutaraldehyde modifications that would normally have inhibited function. We have shown that the GUS variant can be used to trace cell lineages in Xenopus embryos under standard fixation conditions, allowing double staining when used in conjunction with other reporters.	Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Texas, Dept Zool, Ctr Dev Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Ellington, AD (corresponding author), Univ Texas, Inst Mol & Cellular Biol, ICMB A4800-MBB 3-424,26th & Speedway, Austin, TX 78712 USA.	andy.ellington@mail.utexas.edu	Matsumura, Ichiro/E-1985-2011					BLANCO C, 1987, BIOCHIMIE, V69, P157, DOI 10.1016/0300-9084(87)90248-3; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Craig S., 1992, GUS protocols: using the GUS gene as a reporter of gene expression., P115; DAMORE MA, 1988, BIOCHEMISTRY-US, V27, P7131, DOI 10.1021/bi00418a070; FARRELL LB, 1990, PLANT MOL BIOL, V15, P821, DOI 10.1007/BF00039422; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; GRIMM E, 1995, NUCLEIC ACIDS RES, V23, P4518, DOI 10.1093/nar/23.21.4518; HABEEB AFS, 1968, ARCH BIOCHEM BIOPHYS, V126, P16, DOI 10.1016/0003-9861(68)90554-7; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; JEFFERSON RA, 1989, NATURE, V342, P837, DOI 10.1038/342837a0; KING PV, 1986, FOCUS, V8, P30; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Krieg Paul A., 1996, P141; Martin T., 1992, GUS protocols: using the GUS gene as a reporter of gene expression., P23; Moore JC, 1996, NAT BIOTECHNOL, V14, P458, DOI 10.1038/nbt0496-458; Naleway JJ, 1992, GUS PROTOCOLS USING, P61; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NISHIMURA Y, 1986, P NATL ACAD SCI USA, V83, P7292, DOI 10.1073/pnas.83.19.7292; OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685; PENG HB, 1991, METHOD CELL BIOL, V36, P657; Ray J, 1998, GENOMICS, V48, P248, DOI 10.1006/geno.1997.5189; Raz E, 1998, DEV BIOL, V203, P290, DOI 10.1006/dbio.1998.8999; SCHLAMAN HRM, 1994, GENE, V138, P259, DOI 10.1016/0378-1119(94)90820-6; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; VANDERLOOS CM, 1993, HISTOCHEM J, V25, P1; VIZE PD, 1991, METHOD CELL BIOL, V36, P367; Wallingford JB, 1998, DEV BIOL, V202, P103, DOI 10.1006/dbio.1998.8989; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; Zhang JH, 1997, P NATL ACAD SCI USA, V94, P4504, DOI 10.1073/pnas.94.9.4504; Zhang XJ, 1995, PROTEIN ENG, V8, P1017, DOI 10.1093/protein/8.10.1017	34	55	63	0	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					696	701		10.1038/10910	http://dx.doi.org/10.1038/10910			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404164				2022-12-27	WOS:000081296900031
J	Mizuta, T; Fujiwara, M; Hatta, T; Abe, T; Miyano-Kurosaki, N; Shigeta, S; Yokota, T; Takaku, H				Mizuta, T; Fujiwara, M; Hatta, T; Abe, T; Miyano-Kurosaki, N; Shigeta, S; Yokota, T; Takaku, H			Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A	NATURE BIOTECHNOLOGY			English	Article						antisense therapeutics; influenza A virus; animal model	HUMAN-IMMUNODEFICIENCY-VIRUS; PHOSPHOROTHIOATE ANALOGS; IN-VITRO; EXPRESSION; INHIBITION; OLIGODEOXYNUCLEOTIDES; CELL; REPLICATION; DNA; NUCLEOPROTEIN	We have investigated the ability of antisense phosphorothioate oligonucleotides to enhance the survival of mice infected with influenza A virus. The oligonucleotides were complementary to sequences surrounding the translation initiation codons of the viral PB2 or PA genes (PB2-as or PA-as, respectively) of the influenza A virus RNA polymerases. Intravenous administration of PB2-as in a complex with a cationic liposome, Tfx-10, significantly prolonged the mean survival time in days and increased overall survival rates of mice infected with the influenza A virus. Liposomally encapsulated PB2-as inhibited viral growth in lung tissues and reduced pulmonary consolidations. Liposomally encapsulated PB2-as could be an effective therapeutic agent against influenza A virus.	Chiba Inst Technol, Dept Ind Chem, Chiba 2750016, Japan; Rat Drug Design Labs, Matsukawa, Fukushima 9601242, Japan; Fukushima Univ, Sch Med, Dept Microbiol, Fukushima 9601295, Japan	Chiba Institute of Technology; Fukushima Medical University; Fukushima University	Takaku, H (corresponding author), Chiba Inst Technol, Dept Ind Chem, 2-17-1 Tsudanuma, Chiba 2750016, Japan.							Abe T, 1998, ANTIVIR CHEM CHEMOTH, V9, P253, DOI 10.1177/095632029800900306; Agatsuma T, 1997, ANTIVIR RES, V34, P121, DOI 10.1016/S0166-3542(97)01032-2; AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; Davis HL, 1998, J IMMUNOL, V160, P870; DETJEN BM, 1987, J VIROL, V61, P16, DOI 10.1128/JVI.61.1.16-22.1987; ERICKSON RP, 1992, GENE REGULATION BIOL; Hatta T, 1996, BIOCHEM BIOPH RES CO, V223, P341, DOI 10.1006/bbrc.1996.0896; Hatta T, 1997, BIOCHEM BIOPH RES CO, V232, P545, DOI 10.1006/bbrc.1997.6185; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; Jambrina E, 1997, VIROLOGY, V235, P209, DOI 10.1006/viro.1997.8682; Keogh MC, 1997, GENE THER, V4, P162, DOI 10.1038/sj.gt.3300374; KIM SG, 1993, BIOORG MED CHEM LETT, V3, P1223, DOI 10.1016/S0960-894X(00)80320-0; KIM SG, 1995, BIOORGAN MED CHEM, V3, P49, DOI 10.1016/0968-0896(94)00142-P; LEITER JME, 1990, P NATL ACAD SCI USA, V87, P3430, DOI 10.1073/pnas.87.9.3430; LEONETTI JP, 1990, P NATL ACAD SCI USA, V87, P2448, DOI 10.1073/pnas.87.7.2448; Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MILHAUD PG, 1991, J INTERFERON RES, V11, P261, DOI 10.1089/jir.1991.11.261; Millan CLB, 1998, P NATL ACAD SCI USA, V95, P15553, DOI 10.1073/pnas.95.26.15553; MILLER PS, 1985, BIOCHIMIE, V67, P769, DOI 10.1016/S0300-9084(85)80166-8; MILLER PS, 1981, BIOCHEMISTRY-US, V20, P1874, DOI 10.1021/bi00510a024; NAKAGAWA Y, 1995, J VIROL, V69, P728, DOI 10.1128/JVI.69.2.728-733.1995; ROTHENBERG M, 1989, J NATL CANCER I, V81, P1538; SANZEZQUERRO JJ, 1995, J VIROL, V69, P2420, DOI 10.1128/JVI.69.4.2420-2426.1995; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SKORSKI T, 1994, P NATL ACAD SCI USA, V91, P4504, DOI 10.1073/pnas.91.10.4504; SMITH CC, 1986, P NATL ACAD SCI USA, V83, P2787, DOI 10.1073/pnas.83.9.2787; STEC WJ, 1984, J AM CHEM SOC, V106, P6077, DOI 10.1021/ja00332a054; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67; STEIN CA, 1991, J ACQ IMMUN DEF SYND, V4, P686; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; STEWART MJ, 1992, HUM GENE THER, V3, P267, DOI 10.1089/hum.1992.3.3-267; THIERRY AR, 1992, NUCLEIC ACIDS RES, V20, P5691, DOI 10.1093/nar/20.21.5691; Tsan MF, 1997, HUM GENE THER, V8, P817, DOI 10.1089/hum.1997.8.7-817; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Whitesell L, 1991, Antisense Res Dev, V1, P343; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454; YAMASHITA M, 1989, VIROLOGY, V171, P458, DOI 10.1016/0042-6822(89)90615-6; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143; ZERIAL A, 1987, NUCLEIC ACIDS RES, V15, P9909, DOI 10.1093/nar/15.23.9909; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	46	51	67	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					583	587		10.1038/9893	http://dx.doi.org/10.1038/9893			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385324				2022-12-27	WOS:000080716500031
J	Liu, DTY				Liu, DTY			New blood for Taiwanese biotechnology	NATURE BIOTECHNOLOGY			English	Article									Acad Sinica, Inst Biol Chem, Taipei, Taiwan	Academia Sinica - Taiwan	Liu, DTY (corresponding author), Acad Sinica, Inst Biol Chem, Taipei, Taiwan.								0	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					440	441		10.1038/8608	http://dx.doi.org/10.1038/8608			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331798				2022-12-27	WOS:000080074500023
J	Palsson, B; Thorgeirsson, S				Palsson, B; Thorgeirsson, S			Decoding developments in Iceland	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Calif San Diego, La Jolla, CA 92093 USA; NCI, Bethesda, MD 20892 USA	University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Palsson, B (corresponding author), Univ Calif San Diego, La Jolla, CA 92093 USA.			Palsson, Bernhard/0000-0003-2357-6785				Hodgson J, 1998, NAT BIOTECHNOL, V16, P896, DOI 10.1038/nbt1098-896; Hodgson J, 1998, NAT BIOTECHNOL, V16, P1017, DOI 10.1038/3463; HODGSON J, 1998, SCI AM           FEB, P24; HODGSON J, 1998, NAT GENET, V20, P99; HODGSON J, 1998, SCIENCE, V280, P890	5	9	10	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					407	407		10.1038/8532	http://dx.doi.org/10.1038/8532			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331779	Bronze			2022-12-27	WOS:000080074500004
J	John, DCA; Watson, R; Kind, AJ; Scott, AR; Kadler, KE; Bulleid, NJ				John, DCA; Watson, R; Kind, AJ; Scott, AR; Kadler, KE; Bulleid, NJ			Expression of an engineered form of recombinant procollagen in mouse milk	NATURE BIOTECHNOLOGY			English	Article						recombinant procollagen; transgenic animals; protein engineering	HUMAN PROLYL 4-HYDROXYLASE; TRIPLE-HELIX; REQUIRES COEXPRESSION; III PROCOLLAGEN; TRANSGENIC MICE; COLLAGEN; PROTEIN; SUBUNIT; SYSTEM; ASSOCIATION	We have examined the suitability of the mouse mammary gland for expression of novel recombinant procollagens that can be used for biomedical applications. We generated transgenic mouse lines containing cDNA constructs encoding recombinant procollagen, along with the alpha and beta subunits of prolyl 4-hydroxylase, an enzyme that modifies the collagen into a form that is stable at body temperature, The lines expressed relatively high levels (50-200 mu g/ml) of recombinant procollagen in milk, As engineered, the recombinant procollagen was shortened and consisted of a pro alpha 2(I) chain capable of forming a triple-helical homotrimer not normally found in nature, Analysis of the product demonstrated that (1) the pro alpha chains formed disulphide-linked trimers, (2) the trimers contained a thermostable triple-helical domain, (3) the N-propeptides were aligned correctly, and (4) the expressed procollagen was not proteolytically processed to collagen in milk.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; PPL Therapeut Scotland Ltd, Roslin EH25 9PP, Midlothian, Scotland	University of Manchester	Bulleid, NJ (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg, Manchester M13 9PT, Lancs, England.	neil.bulleid@man.ac.uk	KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683; Bulleid, Neil/0000-0002-9839-5279	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arnold WV, 1997, MATRIX BIOL, V16, P105, DOI 10.1016/S0945-053X(97)90039-1; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; Bulleid NJ, 1996, BIOCHEM J, V317, P195, DOI 10.1042/bj3170195; CARVER AS, 1993, BIO-TECHNOL, V11, P1263; Colman A, 1998, BIOCHEM SOC SYMP, P141; DOMBROWSKI KE, 1988, J BIOL CHEM, V263, P16545; FERTALA A, 1994, BIOCHEM J, V298, P31, DOI 10.1042/bj2980031; Fichard A, 1997, J BIOL CHEM, V272, P30083, DOI 10.1074/jbc.272.48.30083; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; KADLER K, 1995, PROTEIN PROFILE, V2, P491; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1967, ANAL BIOCHEM, V19, P249, DOI 10.1016/0003-2697(67)90160-1; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; LEES JF, 1994, J BIOL CHEM, V269, P24354; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; Myllyharju J, 1997, J BIOL CHEM, V272, P21824, DOI 10.1074/jbc.272.35.21824; Paleyanda RK, 1997, NAT BIOTECHNOL, V15, P971, DOI 10.1038/nbt1097-971; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Prunkard D, 1996, NAT BIOTECHNOL, V14, P867, DOI 10.1038/nbt0796-867; Sambrock J, 1989, MOL CLONING LAB MANU, V1; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Stromqvist M, 1997, TRANSGENIC RES, V6, P271, DOI 10.1023/A:1018406611380; TEERLINK T, 1989, CLIN CHIM ACTA, V183, P309, DOI 10.1016/0009-8981(89)90365-3; TOMAN D, 1996, 6 INT C MOL BIOL PAT; VanCott KE, 1996, J MOL RECOGNIT, V9, P407, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<407::AID-JMR277>3.0.CO;2-X; Vuorela A, 1997, EMBO J, V16, P6702, DOI 10.1093/emboj/16.22.6702; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Yarus S, 1997, TRANSGENIC RES, V6, P51, DOI 10.1023/A:1018405116406	31	68	79	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1999	17	4					385	389		10.1038/7945	http://dx.doi.org/10.1038/7945			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	183VH	10207889				2022-12-27	WOS:000079574400029
J	Lane, M; Bavister, BD; Lyons, EA; Forest, KT				Lane, M; Bavister, BD; Lyons, EA; Forest, KT			Containerless vitrification of mammalian oocytes and embryos - Adapting a proven method for flash-cooling protein crystals to the cryopreservation of live cells.	NATURE BIOTECHNOLOGY			English	Article							MOUSE EMBRYOS; DEVELOPMENTAL COMPETENCE; BOVINE OOCYTES; SURVIVAL		Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Lane, M (corresponding author), Colorado Ctr Reprod Med, 799 E Hampden Ave,Suite 300, Englewood, CO 80110 USA.	mlane@colocrm.com	Lane, Michelle/D-1512-2010		NICHD NIH HHS [HD22023] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD022023] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		FOREST KT, 1998, Patent No. 104266; Gardner DK, 1998, HUM REPROD, V13, P3434, DOI 10.1093/humrep/13.12.3434; Krisher RL, 1999, BIOL REPROD, V60, P1345, DOI 10.1095/biolreprod60.6.1345; Lane M, 1998, MOL REPROD DEV, V50, P443, DOI 10.1002/(SICI)1098-2795(199808)50:4&lt;443::AID-MRD8&gt;3.0.CO;2-I; LANE M, 1999, IN PRESS FERTIL STER; LEIBO SP, 1978, CRYOBIOLOGY, V15, P257, DOI 10.1016/0011-2240(78)90036-6; LEIBO SP, 1974, EXP CELL RES, V89, P79, DOI 10.1016/0014-4827(74)90189-X; Martino A, 1996, BIOL REPROD, V54, P1059, DOI 10.1095/biolreprod54.5.1059; Martino A, 1996, MOL REPROD DEV, V45, P503, DOI 10.1002/(SICI)1098-2795(199612)45:4&lt;503::AID-MRD13&gt;3.0.CO;2-X; Menezo Y, 1997, IN VITRO FERTILIZATION AND ASSISTED REPRODUCTION, P49; Parkin S, 1998, J APPL CRYSTALLOGR, V31, P945, DOI 10.1107/S0021889898005305; RALL WF, 1985, NATURE, V313, P573, DOI 10.1038/313573a0; RALL WF, 1987, CRYOBIOLOGY, V24, P387, DOI 10.1016/0011-2240(87)90042-3; Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; Vajta G, 1998, MOL REPROD DEV, V51, P53, DOI 10.1002/(SICI)1098-2795(199809)51:1&lt;53::AID-MRD6&gt;3.0.CO;2-V; Vajta G, 1997, CRYO-LETT, V18, P191	17	164	180	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1234	1236		10.1038/70795	http://dx.doi.org/10.1038/70795			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585728				2022-12-27	WOS:000084170700038
J	Greenspan, NS; Di Cera, E				Greenspan, NS; Di Cera, E			Defining epitopes: It's not as easy as it seems	NATURE BIOTECHNOLOGY			English	Editorial Material							ALANINE-SCANNING MUTAGENESIS; ACID-BINDING PROTEIN; SPECIFICITY; RECEPTOR; RECOGNITION; THROMBIN; ENERGY		Case Western Reserve Univ, Cleveland, OH 44106 USA; Washington Univ, Sch Med, St Louis, MO 63110 USA	Case Western Reserve University; Washington University (WUSTL)	Greenspan, NS (corresponding author), Case Western Reserve Univ, Cleveland, OH 44106 USA.		Greenspan, Neil/AAJ-4795-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, R01HL058141, R01HL049413] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58141, HL49413] Funding Source: Medline; NIAID NIH HHS [AI41657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; Di Cera E, 1998, ADV PROTEIN CHEM, V51, P59; Di Cera E, 1998, CHEM REV, V98, P1563, DOI 10.1021/cr960135g; GREENSPAN NS, 1997, CONCEPTS CHEM CONT C, P383; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; Manning TC, 1998, IMMUNITY, V8, P413, DOI 10.1016/S1074-7613(00)80547-6; Richieri GV, 1997, J BIOL CHEM, V272, P16737, DOI 10.1074/jbc.272.27.16737; Rondard P, 1998, J BIOL CHEM, V273, P34753, DOI 10.1074/jbc.273.52.34753; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; Van Regenmortel MHV, 1998, J IMMUNOL METHODS, V216, P37, DOI 10.1016/S0022-1759(98)00069-6	14	58	492	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					936	937		10.1038/13590	http://dx.doi.org/10.1038/13590			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504677				2022-12-27	WOS:000083015700005
J	French, CE; Rosser, SJ; Davies, GJ; Nicklin, S; Bruce, NC				French, CE; Rosser, SJ; Davies, GJ; Nicklin, S; Bruce, NC			Biodegradation of explosives by transgenic plants expressing pentaerythritol tetranitrate reductase	NATURE BIOTECHNOLOGY			English	Article						phytoremediation; explosives; transgenic plants; PETN reductase	ENTEROBACTER-CLOACAE PB2; PHYTOREMEDIATION; DEGRADATION	Plants offer many advantages over bacteria as agents for bioremediation; however, they typically lack the degradative capabilities of specially selected bacterial strains. Transgenic plants expressing microbial degradative enzymes could combine the advantages of both systems. To investigate this possibility in the context of bioremediation of explosive residues, we generated transgenic tobacco plants expressing pentaerythritol tetranitrate reductase, an enzyme derived from an explosive-degrading bacterium that enables degradation of nitrate ester and nitroaromatic explosives. Seeds from transgenic plants were able to germinate and grow in the presence of 1 mM glycerol trinitrate (GTN) or 0.05 mM trinitrotoluene, at concentrations that inhibited germination and growth of wild-type seeds. Transgenic seedlings grown in liquid medium with 1 mM GTN showed more rapid and complete denitration of GTN than wild-type seedlings. This example suggests that transgenic plants expressing microbial degradative genes may provide a generally applicable strategy for bioremediation of organic pollutants in soil.	Univ Cambridge, Inst Biotechnol, Cambridge CB2 1QT, England	University of Cambridge	Bruce, NC (corresponding author), Univ Cambridge, Inst Biotechnol, Tennis Court Rd, Cambridge CB2 1QT, England.			Rosser, Susan/0000-0002-2560-6485				Binks PR, 1996, APPL ENVIRON MICROB, V62, P1214, DOI 10.1128/AEM.62.4.1214-1219.1996; Cunningham SD, 1996, PLANT PHYSIOL, V110, P715, DOI 10.1104/pp.110.3.715; French CE, 1998, APPL ENVIRON MICROB, V64, P2864; French CE, 1996, J BACTERIOL, V178, P6623, DOI 10.1128/jb.178.22.6623-6627.1996; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; Goel A, 1997, NAT BIOTECHNOL, V15, P174, DOI 10.1038/nbt0297-174; GUERINEAU F, 1992, PLANT MOL BIOL, V18, P815, DOI 10.1007/BF00020027; Hoeppel R. E., 1994, Hazardous waste site soil remediation: theory and application of innovative technologies., P311; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Hughes JB, 1997, ENVIRON SCI TECHNOL, V31, P266, DOI 10.1021/es960409h; OGAWA N, 1995, BIOL PHARM BULL, V18, P1352; Raskin I, 1996, P NATL ACAD SCI USA, V93, P3164, DOI 10.1073/pnas.93.8.3164; Rugh CL, 1998, NAT BIOTECHNOL, V16, P925, DOI 10.1038/nbt1098-925; Sambrook J., 2002, MOL CLONING LAB MANU; Schnoor J.L., 1995, ENV SCI TECH, V29, P318; SHANNON MJR, 1993, ANNU REV MICROBIOL, V47, P715, DOI [10.1146/annurev.micro.47.1.715, 10.1146/annurev.mi.47.100193.003435]; TAYLOR IW, 1989, INT J BIOCHEM, V21, P67, DOI 10.1016/0020-711X(89)90028-1	17	160	170	3	47	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					491	494		10.1038/8673	http://dx.doi.org/10.1038/8673			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331811				2022-12-27	WOS:000080074500036
J	Persidis, A				Persidis, A			Biotechnology 2000	NATURE BIOTECHNOLOGY			English	Editorial Material									Rheogene, Charlottesville, VA 22903 USA		Persidis, A (corresponding author), Rheogene, 706 Forest St, Charlottesville, VA 22903 USA.								0	2	2	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1239	1239		10.1038/70809	http://dx.doi.org/10.1038/70809			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585731	Bronze			2022-12-27	WOS:000084170700039
J	Cismowski, MJ; Takesono, A; Ma, CL; Lizano, JS; Xie, XB; Fuernkranz, H; Lanier, SM; Duzic, E				Cismowski, MJ; Takesono, A; Ma, CL; Lizano, JS; Xie, XB; Fuernkranz, H; Lanier, SM; Duzic, E			Genetic screens in yeast to identify mammalian nonreceptor modulators of G-protein signaling	NATURE BIOTECHNOLOGY			English	Article						functional screens; Saccharomyces cerevisiae; G alpha regulation; nonreceptor modulators; Ras-like GTPase	PHEROMONE-RESPONSE PATHWAY; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL GENOMICS; SHUTTLE VECTORS; A-FACTOR; CELLS; TRANSDUCTION; EXPRESSION; RECEPTOR; ENCODES	We describe genetic screens in Saccharomyces cerevisiae designed to identify mammalian nonreceptor modulators of G-protein signaling pathways. Strains lacking a pheromone-responsive G-protein coupled receptor and expressing a mammalian-yeast G alpha hybrid protein were made conditional for growth upon either pheromone pathway activation (activator screen) or pheromone pathway inactivation (inhibitor screen). Mammalian cDNAs that conferred plasmid-dependent growth under restrictive conditions were identified. One of the cDNAs identified from the activator screen, a human Ras-related G protein that we term AGS1 (for activator of G-protein signaling), appears to function by facilitating guanosine triphosphate (GTP) exchange on the heterotrimeric G alpha. A cDNA product identified from the inhibitor screen encodes a previously identified regulator of G-protein signaling, human RGS5.	Cadus Pharmaceut Corp, Tarrytown, NY 10591 USA; Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA	Medical University of South Carolina	Duzic, E (corresponding author), Cadus Pharmaceut Corp, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.	eduzic@cadus.com	Cismowski, Mary/E-2897-2011	Lanier, Stephen/0000-0002-2740-7607	NINDS NIH HHS [R01-NS24821] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; BEALS CR, 1987, P NATL ACAD SCI USA, V84, P7886, DOI 10.1073/pnas.84.22.7886; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROACH JR, 1983, EXPT MANIPULATION GE; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; Evans MJ, 1997, TRENDS GENET, V13, P370, DOI 10.1016/S0168-9525(97)01240-7; FOWLKES DM, 1998, Patent No. 5789184; Hicks GG, 1997, NAT GENET, V16, P338, DOI 10.1038/ng0897-338; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kemppainen RJ, 1998, J BIOL CHEM, V273, P3129, DOI 10.1074/jbc.273.6.3129; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; Klein C, 1998, NAT BIOTECHNOL, V16, P1334, DOI 10.1038/4310; KURJAN J, 1993, ANNU REV GENET, V27, P147; Law SF, 1996, MOL CELL BIOL, V16, P3327; LEE E, 1992, J BIOL CHEM, V267, P1212; Manfredi JP, 1996, MOL CELL BIOL, V16, P4700; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrock J, 1989, MOL CLONING LAB MANU, V1; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; Sato M, 1996, J BIOL CHEM, V271, P30052, DOI 10.1074/jbc.271.47.30052; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHNEIDER JC, 1991, METHOD ENZYMOL, V194, P373; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SIMONSEN H, 1994, TRENDS PHARMACOL SCI, V15, P437, DOI 10.1016/0165-6147(94)90052-3; Spence P, 1998, DRUG DISCOV TODAY, V3, P179, DOI 10.1016/S1359-6446(97)01162-8; STEVENSON BJ, 1995, GENE DEV, V9, P2949, DOI 10.1101/gad.9.23.2949; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; Whitney M, 1998, NAT BIOTECHNOL, V16, P1329, DOI 10.1038/4302	38	152	160	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					878	883		10.1038/12867	http://dx.doi.org/10.1038/12867			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471929				2022-12-27	WOS:000082365800029
J	Dove, A				Dove, A			Drug screening - Beyond the bottleneck	NATURE BIOTECHNOLOGY			English	Article							2-HYBRID											ARCHER R, 1998, J ASS LAB AUTOMAT, V3, P4; Frederickson RM, 1998, CURR OPIN BIOTECH, V9, P90, DOI 10.1016/S0958-1669(98)80090-6; Kell Douglas, 1999, Trends in Biotechnology, V17, P89, DOI 10.1016/S0167-7799(98)01273-6; Young K, 1998, NAT BIOTECHNOL, V16, P946, DOI 10.1038/nbt1098-946	4	79	82	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					859	863		10.1038/12845	http://dx.doi.org/10.1038/12845			11	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471925				2022-12-27	WOS:000082365800025
J	Persidis, A				Persidis, A			Cardiovascular disease drug discovery	NATURE BIOTECHNOLOGY			English	Article									Argonex Inc, Business Dev, Charlottesville, VA 22903 USA		Persidis, A (corresponding author), Argonex Inc, Business Dev, 706 Forest St, Charlottesville, VA 22903 USA.							Fox KAA, 1999, CARDIOVASC DRUG THER, V13, P211, DOI 10.1023/A:1007792024993; Hwang DM, 1997, CIRCULATION, V96, P4146; Li A, 1999, AM J MED GENET, V86, P57, DOI 10.1002/(SICI)1096-8628(19990903)86:1<57::AID-AJMG11>3.0.CO;2-R; Meyer BJ, 1996, EUR HEART J, V17, P1318; Persidis A, 1998, NAT BIOTECHNOL, V16, P209, DOI 10.1038/nbt0298-209; Plebani M, 1999, INT J CLIN LAB RES, V29, P56, DOI 10.1007/s005990050064; *WHO, 1995, WORLD HLTH STAT Q, V48; *WHO, 1993, WORLD HLTH STAT Q, V46	8	5	5	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					930	931		10.1038/12935	http://dx.doi.org/10.1038/12935			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471943				2022-12-27	WOS:000082365800039
J	Lee, CL; Linton, J; Soughayer, JS; Sims, CE; Allbritton, NL				Lee, CL; Linton, J; Soughayer, JS; Sims, CE; Allbritton, NL			Localized measurement of kinase activation in oocytes of Xenopus laevis	NATURE BIOTECHNOLOGY			English	Article						kinase; Xenopus laevis; oocyte; capillary electrophoresis; peptide; protein kinase C; protein kinase A; cdc2 kinase	INDUCED NEURITE RETRACTION; PROTEIN-KINASE; LYSOPHOSPHATIDIC ACID; MESSENGER-RNA; PC12 CELLS; RECEPTORS; PEPTIDES; DOMAIN	We have combined a rapid cytoplasmic sampling technique with capillary electrophoresis to measure the activation of protein kinase C (PKC) in a small region (approximately 60 mu m) of a Xenopus oocyte, The phosphorylation of a fluorescent PKC substrate was measured following addition of a pharmacological or physiological stimulus to an oocyte. When substrates for cdc2 kinase (cdc2K), PKC, and protein kinase A (PKA) were comicroinjected into an oocyte, all three substrates could be identified on the electropherogram after cytoplasmic sampling. With this new method, it should be possible to measure simultaneously the activation of multiple different kinases in a single cell, enabling the quantitative dissection of signal transduction pathways.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Natl Def Med Ctr, Inst Aerosp Med, Taipei, Taiwan	University of California System; University of California Irvine; National Defense Medical Center	Allbritton, NL (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	nlallbri@uci.edu			NCRR NIH HHS [RR13314] Funding Source: Medline; NIAID NIH HHS [K08AI01513] Funding Source: Medline; NIGMS NIH HHS [GM57015] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R55RR013314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057015] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; ERIM FB, 1995, J CHROMATOGR A, V708, P356; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Hausen P., 1991, EARLY DEV XENOPUS LA; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KLINE D, 1988, SCIENCE, V241, P464, DOI 10.1126/science.3134693; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; Luzzi V, 1997, ANAL CHEM, V69, P4761, DOI 10.1021/ac970550o; PONGRACZ J, 1995, INT J CANCER, V61, P35, DOI 10.1002/ijc.2910610107; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SRINIVASAN J, 1995, BIOCHEM J, V309, P927, DOI 10.1042/bj3090927; TIGYI G, 1990, P NATL ACAD SCI USA, V87, P1521, DOI 10.1073/pnas.87.4.1521; TIGYI G, 1992, J BIOL CHEM, V267, P21360; Tigyi G, 1996, J NEUROCHEM, V66, P549; Tigyi G, 1996, J NEUROCHEM, V66, P537; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Weinberger R., 1993, PRACTICAL CAPILLARY; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	19	39	46	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					759	762		10.1038/11691	http://dx.doi.org/10.1038/11691			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429239				2022-12-27	WOS:000081751400023
J	Facciotti, MT; Bertain, PB; Yuan, L				Facciotti, MT; Bertain, PB; Yuan, L			Improved stearate phenotype in transgenic canola expressing a modified acyl-acyl carrier protein thioesterase	NATURE BIOTECHNOLOGY			English	Article						alanine scanning; site-directed mutagenesis; stearate; transgenic plants; protein engineering	SUBSTRATE-SPECIFICITY; SCANNING MUTAGENESIS; ACP THIOESTERASES; FATTY-ACIDS; TRANSFORMATION	The engineering of crops for selected fatty acid production is one of the major goals of plant biotechnology. The Garm FatA1, an acyl-acyl carrier protein (ACP) thioesterase isolated from Garcinia mangostana, generates an elevated stearate (18:0) phenotype in transgenic Brassica plants. By site-directed mutagenesis, we generated seven mutants that showed up to a 13-fold increase in specific enzyme activity toward 18:0-ACP in vitro. The seed-specific expression of mutant S111A/V193A in Brassica plants results in transgenic plants that accumulate 55-68% more stearate than plants expressing the wild-type enzyme. Our results demonstrate that a thioesterase can be engineered to increase specific activity and that its improved function demonstrated in vitro is retained in vivo.	Calgene Inc, LLC, Davis, CA 95616 USA		Yuan, L (corresponding author), Maxygen, Redwood City, CA 94063 USA.		Facciotti, Marc/AAF-9227-2020	Facciotti, Marc/0000-0003-4453-3274				BERNATZKY R, 1986, THEOR APPL GENET, V72, P314, DOI 10.1007/BF00288567; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; Cahoon EB, 1997, P NATL ACAD SCI USA, V94, P4872, DOI 10.1073/pnas.94.10.4872; DAVIES HM, 1991, ARCH BIOCHEM BIOPHYS, V290, P37, DOI 10.1016/0003-9861(91)90588-A; DELVECCHIO AJ, 1996, INFORM, V7, P230; Facciotti MT, 1998, FETT-LIPID, V100, P167; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Hawkins DJ, 1998, PLANT J, V13, P743, DOI 10.1046/j.1365-313X.1998.00073.x; JONES A, 1995, PLANT CELL, V7, P359, DOI 10.1105/tpc.7.3.359; KATAN MB, 1995, ANNU REV NUTR, V15, P473, DOI 10.1146/annurev.nutr.15.1.473; KNUDSON DS, 1992, P NATL ACAD SCI USA, V89, P2624; Kristensen C, 1997, J BIOL CHEM, V272, P12978, DOI 10.1074/jbc.272.20.12978; Maniatis T., 1982, MOL CLONING LAB MANU; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; Nelson GJ, 1998, NUTR REV, V56, P250, DOI 10.1111/j.1753-4887.1998.tb01758.x; Nickerson DP, 1997, FEBS LETT, V405, P153, DOI 10.1016/S0014-5793(97)00174-9; RADKE SE, 1992, PLANT CELL REP, V11, P499, DOI 10.1007/BF00236265; VOLKER T, 1996, GENETIC ENG, P111; YUAN L, 1995, P NATL ACAD SCI USA, V92, P10639, DOI 10.1073/pnas.92.23.10639; Yuan L, 1996, J BIOL CHEM, V271, P3417; Yuan L, 1997, CURR OPIN BIOTECH, V8, P227, DOI 10.1016/S0958-1669(97)80107-3	21	51	82	2	21	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					593	597		10.1038/9909	http://dx.doi.org/10.1038/9909			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385326				2022-12-27	WOS:000080716500033
J	Persidis, A				Persidis, A			Agricultural biotechnology	NATURE BIOTECHNOLOGY			English	Article							TOBACCO MOSAIC-VIRUS; TRANSGENIC PLANTS; EXPRESSION; GENE		Argonex Inc, Business Dev, Charlottesville, VA 22901 USA		Persidis, A (corresponding author), Argonex Inc, Business Dev, 2044 India Rd, Charlottesville, VA 22901 USA.							ABEL PP, 1986, SCIENCE, V232, P738, DOI 10.1126/science.3457472; Abelson PH, 1998, SCIENCE, V279, P2019; Bos L, 1999, PHILOS T ROY SOC B, V354, P675, DOI 10.1098/rstb.1999.0420; Briggs SP, 1998, CURR OPIN BIOTECH, V9, P233, DOI 10.1016/S0958-1669(98)80121-3; Chaney RL, 1997, CURR OPIN BIOTECH, V8, P279, DOI 10.1016/S0958-1669(97)80004-3; Gelvin SB, 1998, CURR OPIN BIOTECH, V9, P227, DOI 10.1016/S0958-1669(98)80120-1; HIATT A, 1990, NATURE, V344, P469, DOI 10.1038/344469a0; Ma JKC, 1996, ANN NY ACAD SCI, V792, P72, DOI 10.1111/j.1749-6632.1996.tb32493.x; POWELL PA, 1989, P NATL ACAD SCI USA, V86, P6949, DOI 10.1073/pnas.86.18.6949; Scholthof HB, 1996, ANNU REV PHYTOPATHOL, V34, P299, DOI 10.1146/annurev.phyto.34.1.299; Smith G, 1997, REPROD FERT DEVELOP, V9, P85, DOI 10.1071/R96051; WARNER DT, 1964, J THEOR BIOL, V6, P118, DOI 10.1016/0022-5193(64)90068-2; Yu KF, 1999, GENOME, V42, P27, DOI 10.1139/gen-42-1-27	13	7	7	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					612	614		10.1038/9940	http://dx.doi.org/10.1038/9940			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385330				2022-12-27	WOS:000080716500037
J	Lahteenmaki, R; Michael, A; Marshall, A				Lahteenmaki, R; Michael, A; Marshall, A			Public biotech 98: the numbers	NATURE BIOTECHNOLOGY			English	Article																			0	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					429	432		10.1038/8598	http://dx.doi.org/10.1038/8598			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331795				2022-12-27	WOS:000080074500020
J	Puttaraju, M; Jamison, SF; Mansfield, SG; Garcia-Blanco, MA; Mitchell, LG				Puttaraju, M; Jamison, SF; Mansfield, SG; Garcia-Blanco, MA; Mitchell, LG			Spliceosome-mediated RNA trans-splicing as a tool for gene therapy	NATURE BIOTECHNOLOGY			English	Article						spliceosome; trans-splicing; gene therapy; RNA repair	PRE-MESSENGER-RNA; POLYMERASE CHAIN-REACTION; CHORIONIC-GONADOTROPIN; MAMMALIAN-CELLS; POLYPYRIMIDINE TRACT; SCHISTOSOMA-MANSONI; HUMAN PARASITE; BETA; SEQUENCE; EXPRESSION	We have developed RNA molecules capable of effecting spliceosome-mediated RNA trans-splicing reactions with a target messenger RNA precursor (pre-mRNA). Targeted trans-splicing was demonstrated in a HeLa nuclear extract, cultured human cells, and H1299 human lung cancer tumors in athymic mice. Trans-splicing between a cancer-associated pre-mRNA encoding the p-subunit of human chorionic gonadotropin gene 6 and pre-trans-splicing molecule (PTM) RNA was accurate both in vitro and in vivo. Comparison of targeted versus nontargeted trans-splicing revealed a moderate level of specificity, which was improved by the addition of an internal inverted repeat encompassing the PTM splice site. Competition between cis- and trans-splicing demonstrated that cis-splicing can be inhibited by transsplicing. RNA repair In a splicing model of a nonfunctional lacZ transcript was effected in cells by a PTM, which restored significant beta-galactosidase activity. These observations suggest that spliceosome-mediated RNA trans-splicing may represent a general approach for reprogramming the sequence of targeted transcripts, providing a novel approach to gene therapy.	Intronn LLC, Durham, NC 27701 USA; Duke Univ, Med Ctr, Durham, NC 27710 USA	Duke University	Garcia-Blanco, MA (corresponding author), Intronn LLC, Durham, NC 27701 USA.	garci001@mc.duke.edu; lgm@intrex.net						ACEVEDO HF, 1995, CANCER, V76, P1467, DOI 10.1002/1097-0142(19951015)76:8<1467::AID-CNCR2820760826>3.0.CO;2-A; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; Bellet D, 1997, CANCER RES, V57, P516; BERGER P, 1994, FEBS LETT, V343, P229, DOI 10.1016/0014-5793(94)80561-X; Birken S, 1996, ENDOCRINOLOGY, V137, P1402, DOI 10.1210/en.137.4.1402; BRUZIK JP, 1992, NATURE, V360, P692, DOI 10.1038/360692a0; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; Coolidge CJ, 1997, NUCLEIC ACIDS RES, V25, P888, DOI 10.1093/nar/25.4.888; DAVIS RE, 1995, J BIOL CHEM, V270, P21813, DOI 10.1074/jbc.270.37.21813; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; EUL J, 1995, EMBO J, V14, P3226, DOI 10.1002/j.1460-2075.1995.tb07325.x; Hoon DSB, 1996, INT J CANCER, V69, P369, DOI 10.1002/(SICI)1097-0215(19961021)69:5<369::AID-IJC3>3.0.CO;2-3; Jones JT, 1996, NAT MED, V2, P643, DOI 10.1038/nm0696-643; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Lan N, 1998, SCIENCE, V280, P1593, DOI 10.1126/science.280.5369.1593; Malek O, 1997, P NATL ACAD SCI USA, V94, P553, DOI 10.1073/pnas.94.2.553; MITCHELL LG, 1989, ANAL BIOCHEM, V178, P239, DOI 10.1016/0003-2697(89)90631-3; MITCHELL LG, 1994, ADV BIOMAGNETIC SEPA, P31; Moore M., 1993, RNA WORLD, P303; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; Pasman Z, 1996, NUCLEIC ACIDS RES, V24, P1638, DOI 10.1093/nar/24.9.1638; Phylactou LA, 1998, NAT GENET, V18, P378, DOI 10.1038/ng0498-378; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Sharp HM, 1997, EUR PSYCHIAT, V12, P1, DOI 10.1016/S0924-9338(97)86371-7; SHIMIZU A, 1989, P NATL ACAD SCI USA, V86, P8020, DOI 10.1073/pnas.86.20.8020; Sierakowska H, 1996, P NATL ACAD SCI USA, V93, P12840, DOI 10.1073/pnas.93.23.12840; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TALMADGE K, 1984, NUCLEIC ACIDS RES, V12, P8415, DOI 10.1093/nar/12.22.8415; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; VANDERPLOEG LHT, 1986, CELL, V47, P479, DOI 10.1016/0092-8674(86)90608-2; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511	41	150	194	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1999	17	3					246	252		10.1038/6986	http://dx.doi.org/10.1038/6986			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	173JM	10096291				2022-12-27	WOS:000078977500025
J	Deak, M; Horvath, GV; Davletova, S; Torok, K; Sass, L; Vass, I; Barna, B; Kiraly, Z; Dudits, D				Deak, M; Horvath, GV; Davletova, S; Torok, K; Sass, L; Vass, I; Barna, B; Kiraly, Z; Dudits, D			Plants ectopically expressing the iron-binding protein, ferritin, are tolerant to oxidative damage and pathogens	NATURE BIOTECHNOLOGY			English	Article						stress; reactive oxygen species; paraquat; necrosis; iron	PEA PISUM-SATIVUM; TRANSGENIC PLANTS; HYDROGEN-PEROXIDE; OXYGEN RADICALS; MAIZE FERRITIN; ABSCISIC-ACID; STRESS; DEFENSE; RESISTANCE; PARAQUAT	Transgenic tobacco plants that synthesize alfalfa ferritin in vegetative tissues-either in its processed form in chloroplasts or in the cytoplasmic nonprocessed form-retained photosynthetic function upon free radical toxicity generated by iron excess or paraquat treatment. Progeny of transgenic plants accumulating ferritin in their leaves exhibited tolerance to necrotic damage caused by viral (tobacco necrosis virus) and fungal (Alternaria alternata, Botrytis cinerea) infections. These transformants exhibited normal photosynthetic function and chlorophyll content under greenhouse conditions. We propose that by sequestering intracellular iron involved in generation of the very reactive hydroxyl radicals through a Fenton reaction, ferritin protects plant cells from oxidative damage induced by a wide range of stresses.	Hungarian Acad Sci, Biol Res Ctr, Inst Plant Biol, H-6726 Szeged, Hungary; Bay Zoltan Appl Res Fdn, Inst Biotechnol, H-6726 Szeged, Hungary; Hungarian Acad Sci, Inst Plant Protect, H-1525 Budapest, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Centre for Agricultural Research	Dudits, D (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Plant Biol, Temesvari Krt 62, H-6726 Szeged, Hungary.	dudits@nucleua.szbk.u-szeged.hu	Davletova, Sholpan/K-5764-2015; Vass, Imre/AAS-6171-2021	Davletova, Sholpan/0000-0003-4759-3256; Vass, Imre/0000-0003-4987-7842				ALLEN RD, 1995, PLANT PHYSIOL, V107, P1049, DOI 10.1104/pp.107.4.1049; ANDREWS SC, 1992, J INORG BIOCHEM, V47, P161, DOI 10.1016/0162-0134(92)84062-R; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BABBS CF, 1989, PLANT PHYSIOL, V90, P1267, DOI 10.1104/pp.90.4.1267; BAKER CJ, 1995, ANNU REV PHYTOPATHOL, V33, P299, DOI 10.1146/annurev.py.33.090195.001503; BALLA G, 1992, J BIOL CHEM, V267, P18148; BARNA B, 1993, NATURWISSENSCHAFTEN, V80, P420, DOI 10.1007/BF01168338; BAUMINGER ER, 1991, BIOCHIM BIOPHYS ACTA, V1118, P48, DOI 10.1016/0167-4838(91)90440-B; BOWLER C, 1991, EMBO J, V10, P1723, DOI 10.1002/j.1460-2075.1991.tb07696.x; Briat JF, 1997, TRENDS PLANT SCI, V2, P187, DOI 10.1016/S1360-1385(97)85225-9; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; CLAES B, 1991, PLANT J, V1, P15, DOI 10.1111/j.1365-313X.1991.00015.x; EISTNER EF, 1982, ANNU REV PLANT PHYS, V33, P73; ELSTNER EF, 1994, OXYGEN ENV STRESS PL, P131; FOBISLOISY I, 1995, EUR J BIOCHEM, V231, P609, DOI 10.1111/j.1432-1033.1995.0609d.x; FOYER CH, 1994, PLANT CELL ENVIRON, V17, P507, DOI 10.1111/j.1365-3040.1994.tb00146.x; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; JOURNET EP, 1987, METHOD ENZYMOL, V148, P234; KAMPFENKEL K, 1995, PLANT PHYSIOL, V107, P725, DOI 10.1104/pp.107.3.725; KIRALY Z, 1993, OXYGEN FREE RADICALS AND SCAVENGERS IN THE NATURAL SCIENCES, P9; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; LOBREAUX S, 1993, EMBO J, V12, P651, DOI 10.1002/j.1460-2075.1993.tb05698.x; LOBREAUX S, 1991, BIOCHEM J, V274, P601, DOI 10.1042/bj2740601; LOBREAUX S, 1992, BIOCHEM J, V288, P931, DOI 10.1042/bj2880931; Low PS, 1996, PHYSIOL PLANTARUM, V96, P533, DOI 10.1111/j.1399-3054.1996.tb00469.x; MAES M, 1992, NUCLEIC ACIDS RES, V20, P4374, DOI 10.1093/nar/20.16.4374; MITRA A, 1994, PLANT PHYSIOL, V106, P977, DOI 10.1104/pp.106.3.977; Mullineaux PM, 1996, BIOCHEM SOC T, V24, P829, DOI 10.1042/bst0240829; NECHUSHTAI R, 1985, PLANT MOL BIOL, V4, P377, DOI 10.1007/BF02418259; OUF MF, 1993, CEREAL RES COMMUN, V21, P31; PENG M, 1992, PHYTOPATHOLOGY, V82, P696, DOI 10.1094/Phyto-82-696; PERL A, 1993, THEOR APPL GENET, V85, P568, DOI 10.1007/BF00220915; Prince A. H., 1989, FREE RADICAL RES COM, V8, P61; RENNENBERG H, 1994, BIOCHEM SOC T, V22, P936, DOI 10.1042/bst0220936; REPINE JE, 1981, J BIOL CHEM, V256, P7094; Sambrook J., 2002, MOL CLONING LAB MANU; SUTHERLAND MW, 1991, PHYSIOL MOL PLANT P, V39, P79, DOI 10.1016/0885-5765(91)90020-I; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; THOMAS CE, 1986, J BIOL CHEM, V261, P3064; VANWUYTSWINKEL O, 1995, BIOCHEM J, V305, P253, DOI 10.1042/bj3050253; Vass I, 1996, BIOCHEMISTRY-US, V35, P8964, DOI 10.1021/bi9530595; VILE GF, 1993, J BIOL CHEM, V268, P14678; ZER H, 1994, PHYSIOL PLANTARUM, V92, P437, DOI 10.1111/j.1399-3054.1994.tb08833.x	45	149	182	4	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17	2					192	196		10.1038/6198	http://dx.doi.org/10.1038/6198			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165EX	10052358				2022-12-27	WOS:000078508300030
J	Mehta, V				Mehta, V			Biotechnology's future and the art of managing R & D	NATURE BIOTECHNOLOGY			English	Article									Mehta Partners, New York, NY 10012 USA		Mehta, V (corresponding author), Mehta Partners, 584 Broadway,Suite 1206, New York, NY 10012 USA.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1999	17			S			BE29	BE30		10.1038/4638	http://dx.doi.org/10.1038/4638			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	165PD	10052323	Bronze			2022-12-27	WOS:000078529400014
J	Georgiou, G; DeWitt, N				Georgiou, G; DeWitt, N			Enzyme beauty	NATURE BIOTECHNOLOGY			English	News Item									Univ Texas, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Georgiou, G (corresponding author), Univ Texas, Austin, TX 78712 USA.							1999, 15 EN ENG C UN ENG F	1	4	5	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1161	1162		10.1038/70701	http://dx.doi.org/10.1038/70701			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585709				2022-12-27	WOS:000084170700018
